Three-dimensional structure of complement receptor type 2 and uses thereof

ABSTRACT

Disclosed is a crystalline human CR2 protein in complex with C3d, and the three dimensional structure of the crystalline complex. Also disclosed are methods of use of the structure, particularly for structure-based identification of compounds that bind to CR2 and inhibit or enhance the binding of CR2 to a natural ligand, that bind to CR2 and agonize or antagonize the receptor, that bind to CR2 and inhibit or enhance CR2 dimerization, or that use the C3-binding ability of CR2 as a drug delivery vehicle. Also disclosed are therapeutic compounds obtained by such methods and uses for such compounds.

GOVERNMENT SUPPORT

This invention was made in part with government support under Grant No. NIH R0-1CA53615 awarded by the National Institutes of Health. The government has certain rights to this invention.

FIELD OF THE INVENTION

This invention relates to the crystallization and resolution of the three-dimensional structure of the human complement receptor type 2 (CR2) protein, and to methods of using such structure, particularly for structure-based drug design of regulatory compounds.

BACKGROUND OF THE INVENTION

Complement receptor type 2 (CR2 or CD21) is a key interface between innate and adaptive immunity by serving as the receptor for complement component C3d, as well as for C3 and fragments of C3 that contain the C3d domain or a portion thereof, including but not limited to C3dg, iC3b and C3b (D. T. Fearon and R. H. Carter, Annu Rev Immunol 13, 127-49 (1995); D. T. Fearon, Semin Immunol 10, 355-61 (1998)). C3d and other CR2-binding C3 fragments that contain C3d or a portion thereof are covalently attached to foreign antigens (such as invading microorganisms) through the action of the classical, alternative or lectin complement pathways (S. K. A. Law and K. B. M. Reid, Complement,. D. Male, Ed., In Focus (Oxford, UK: IRL Press., ed. second edition, 1995)). C3d- or other CR2-binding C3 fragment-bound antigens then greatly amplify B cell responses by binding to CR2 through these C3 fragments at the same time as engaging the B cell receptor (BCR) via the bound antigen (R. H. Carter and D. T. Fearon, Science 256, 105-7 (1992); J. C. Cambier, Biochem Soc Trans 25, 441-5 (1997)). The cross-linking of CR2 to the BCR by C3d, C3, or other CR2-binding fragments of C3 that contain C3d or a portion thereof greatly amplifies a signal transduction cascade through the CR2/CD19/CD81 co-activation complex (D. T. Fearon, 1995 ibid.; D. T. Fearon, 1998, ibid.; J. C. Cambier, 1997, ibid.; A. K. Matsumoto, et al., J Exp Med 173, 55-64 (1991)).

Human CR2 is also the obligate receptor for the Epstein-Barr virus (EBV) through its interactions with the gp350/220 viral membrane protein (J. D. Fingeroth, et al., Proc Natl Acad Sci USA 81, 4510-4 (1984)). EBV causes infectious mononucleosis, and is associated with Burkitt's Lymphoma and several other lymphomas and non-lymphoid tumors (M. Okano, Acta Paediatr 87, 11-8 (1998)). In addition, human CR2 serves as a receptor for CD23 (J. P. Aubry et al., Nature 358, 505-7 (1992)) and is thus a receptor for at least three biologically important ligands. Using genetically manipulated mice and animal models, CR2 has been shown to be essential for the development of normal humoral immunity to T-dependent antigens (T. Hebell et al., Science 254, 102-5 (1991); J. M. Ahearn, et al., Immunity 4, 251-62 (1996); H. Molina, et al., Proc Natl Acad Sci USA 93, 3357-61 (1996)) as well as possibly play an important role in the maintenance of B cell self-tolerance and the development of autoimmunity (A. P. Prodeus, et al., Immunity 9, 721-31 (1998)). CR2 has also been shown to mediate the interaction of C3-bound HIV-1 as an immune complex with B cells in a fashion that promotes transfer of virus and infection of CD4 T cells (S. Moir, et al., J Exp Med 192, 637-46 (2000)). CR2 also mediates direct infection of CR2-expressing T cells or other CR2-expressing cell lineages that are bound by HIV-1 immune complexes containing C3, C3d or other CR2-binding C3 fragments (including, but not limited to, HIV-1 complexed with C3d).

Interactions with all three human CR2 ligands require the first two of 15 or 16 short consensus repeat (SCR) domains (C. A. Lowell, et al., J Exp Med 170, 1931-46 (1989); J. C. Carel et al., J Biol Chem 265, 12293-9(1990)). SCR domains, like Ig domains, are found in many proteins from both complement and non-complement families, and mediate diverse biological functions (A. P. Wiles, et al., J Mol Biol 272, 253-65 (1997)). Several of the SCR proteins also serve as receptors for important human pathogens. For example, in addition to CR2, CD46 is a Measles Virus receptor (R. E. Dorig et al., Cell 75, 295-305 (1993)), and CD55 is an echovirus receptor (T. Ward, et al., EMBO J 13, 5070-4 (1994); J. M. Bergelson, et al., Proc Natl Acad Sci USA 91, 6245-9 (1994)). Previously determined structures of SCR proteins containing two or four SCR domains have revealed a conserved core structure but variable orientations between domains mediated in part by relatively short 3-8 amino acid inter-SCR linker peptides (A. P. Wiles, et al., 1997, ibid.; P. N. Barlow, et al., J Mol Biol 232, 268-84 (1993); J. M. Casasnovas et al., EMBO J 18, 2911-22 (1999); R. Schwarzenbacher, et al., EMBO J 18, 6228-39 (1999)). As one of the major functions of SCR domains is to mediate protein-protein (such as receptor-ligand) interactions, and at least two SCRs have been found to be required for these interactions, the relative angle and orientation unique to each SCR-containing protein is likely to contribute to both biologic diversity as well as specificity. However, the lack of a high-resolution structure of a receptor-ligand complex in this family has hindered the understanding of the molecular recognition mechanisms of this class of proteins. With regard to the structure of CR2 and the molecular interactions with its ligands, C3d and EBVgp350/220, variable results have been obtained using mutagenesis, monoclonal antibody, and peptide strategies (C. A. Lowell, et al.,J Exp Med 170, 1931-46 (1989); D. R. Martin et al., J Exp Med 174, 1299-311 (1991); H. Molina, et al., J Biol Chem266, 12173-9(1991); H. Molina et al., J Immunol 153, 789-95 (1994); D. R. Martin et al., J Virol 68, 4716-26 (1994); H. Molina, et al., J Immunol 154, 5426-35 (1995)).

Therefore, there is a need in the art for a three dimensional structure of CR2 in order to better understand the molecular recognition mechanisms of the protein and to enable the identification and/or design of compounds that mimic, enhance, disrupt or compete with the interactions of CR2 with its ligands.

SUMMARY OF THE INVENTION

One embodiment of the present invention relates to a method of structure-based identification of compounds which potentially bind to complement receptor type 2 (CR2) proteins or to a complex of CR2 and its ligand. This method includes the steps of: (a) providing a three dimensional structure of a CR2 short consensus repeat (SCR) 1-2 region; and, (b) identifying a candidate compound for binding to the CR2 SCR 1-2 region by performing structure based drug design with the structure of (a). The three dimensional structure of a CR2 short consensus repeat (SCR) 1-2 region is selected from: (i) a structure defined by atomic coordinates of a three dimensional structure of a crystalline CR2 SCR1-2 region in complex with C3d; (ii) a structure defined by atomic coordinates selected from: (1) atomic coordinates represented in a table selected from the group consisting of Table 2 (CR2-C3d) and Table 3 (CR2 only); and, (2) atomic coordinates that define a three dimensional structure, wherein at least 50% of the structure has an average root-mean-square deviation (RMSD) from backbone atoms in secondary structure elements in at least one domain of a three dimensional structure represented by the atomic coordinates of (1) of equal to or less than about 1.0 Å; and (ii) a structure defined by atomic coordinates derived from CR2 protein molecules arranged in a crystalline manner in a space group R32 so as to form a unit cell of dimensions a=b=170.5 Å, c=173.8 Å.

In one aspect of this embodiment, the step of identifying comprises selecting candidate compounds that potentially bind to and activate CR2.

In another aspect of this embodiment, the method further includes the step of: (c) selecting candidate compounds of (b) that inhibit the binding of CR2 to its ligand. The step (c) of selecting can include: (i) contacting the candidate compound identified in step (b) with CR2 or a fragment thereof and a CR2 ligand or a fragment thereof under conditions in which a CR2-CR2 ligand complex can form in the absence of the candidate compound; and (ii) measuring the binding affinity of the CR2 or fragment thereof to the CR2 ligand or fragment thereof; wherein a candidate inhibitor compound is selected as a compound that inhibits the binding of CR2 to its ligand when there is a decrease in the binding affinity of the CR2 or fragment thereof for the CR2 ligand or fragment thereof, as compared to in the absence of the candidate inhibitor compound. The CR2 ligand can include, but is not limited to, C3d, C3, a CR2-binding fragment of C3 containing C3d, CD23, and Epstein Barr Virus (EBV) gp350/220, or CR2-binding fragments of any of the ligands. In one aspect, the CR2 protein or fragment thereof comprises an amino acid sequence selected from the group of SEQ ID NO:4 and SEQ ID NO:6.

In another aspect of this embodiment, the method further includes the step of: (c) selecting candidate compounds that stabilizes a complex of CR2 with its ligand. Step (c) can include: (i) contacting the candidate compound identified in step (b) with a CR2-CR2 ligand complex, wherein the CR2-CR2 ligand complex comprises CR2 or a fragment thereof and a CR2 ligand, or a fragment thereof; and (ii) measuring the stability of the CR2-CR2 ligand complex of (i), wherein a candidate stabilizer compound is selected as a compound that stabilizes the CR2-CR2 ligand complex when there is an increase in the stability of the complex as compared to in the absence of the candidate stabilizer compound. In this aspect, the ligand is preferably selected from C3d, C3, a CR2-binding fragment of C3 containing C3d, CD23, and CR2-binding fragments of any of the ligands. In this aspect, the CR2 protein or fragment thereof can comprise an amino acid sequence selected from the group of SEQ ID NO:4 and SEQ ID NO:6.

In the method of identifying a compound, the step (a) of identifying can include identifying candidate compounds for binding to the SCR2 domain of the CR2. In one aspect, the step of identifying includes identifying candidate compounds for binding to the interface between the SCR1 and SCR2 domains of CR2. In another aspect, the step of identifying includes identifying candidate compounds for binding to the dimer interface between two CR2 proteins. In yet another aspect, the step of identifying includes identifying candidate compounds for binding to the interface between CR2 and C3d, C3, a CR2-binding fragment of C3 containing C3d, or a fragment thereof. In one aspect, the step of identifying includes identifying candidate compounds for binding to the B strand and the B-C loop of CR2 SCR2 comprising the segment: G79-G80-Y81-K82-I83-R84-G85-S86-T87-P88-Y89. In another aspect, the step of identifying includes identifying candidate compounds for binding to a site on the B strand of CR2 SCR2 comprising position K100. In another aspect, the step of identifying includes identifying candidate compounds for binding to a segment of CR2 SCR2 comprising V130-F131-P132-L133. In yet another aspect, the step of identifying comprises identifying candidate compounds for binding to a segment of CR2 SCR2 comprising the fragment T101-N102-F103. In one aspect of the method of identifying, the step of identifying includes identifying candidate compounds for binding to amino acid residues at positions 84 and 86 of an amino acid sequence selected from the group consisting of SEQ ID NO:4 and SEQ ID NO:6.

When the ligand is C3d, C3, or a CR2-binding fragment of C3 containing C3d, the step of identifying can include identifying candidate compounds for binding to the loop between helix 2-3 of C3d comprising the segment Q68-P69-S70-S71. In another aspect, the step of identifying can include identifying candidate compounds for binding to Helix 5 of C3d comprising the segment S104-Q105-V106-L107-C108-G109-A110-V111-K112-W113-L114-I115-L116-E117-K118-Q119-K120-P121-D122. In another aspect, the step of identifying can include identifying candidate compounds for binding to Helix 7of C3d comprising the segment N170-S171-L172-P173-G 174-S175-I176-T177-K178-A179-G180-D181-F182-L183-E184-A185.

The step of identifying a compound in the method of the present invention can include any suitable method of drug design, drug screening or identification, including, but not limited to: directed drug design, random drug design, grid-based drug design, and/or computational screening of one or more databases of chemical compounds.

Yet another embodiment of the present invention relates to a method to identify a compound that inhibits the complement receptor type 2 (CR2)-dependent infection of a host cell by Epstein Barr Virus (EBV). This method includes the steps of: (a) providing a three dimensional structure of a CR2 short consensus repeat (SCR) 1-2 region as described in detail above; (b) identifying a candidate compound for binding to the CR2 SCR 1-2 region by performing structure based drug design with the structure of (a) to identify a compound structure that binds to the three dimensional structure of the CR2 SCR 1-2 region; (c) contacting the candidate compound identified in step (b) with a cell that expresses CR2 or a ligand binding fragment thereof and an Epstein Barr Virus (EBV) particle under conditions in which the EBV particle can bind to CR2 and infect the cell in the absence of the candidate compound; and (d) measuring the intracellular EBV titer of the cell; wherein a candidate inhibitor compound is selected as a compound that inhibits the EBV titer in the cell, as compared to in the absence of the candidate inhibitor compound.

Yet another embodiment of the present invention relates to a method to identify a compound that inhibits the binding of CD23 to complement receptor type 2 (CR2). This method includes the steps of: (a) providing a three dimensional structure of a CR2 short consensus repeat (SCR) 1-2 region as described in detail above; (b) identifying a candidate compound for binding to the CR2 SCR 1-2 region by performing structure based drug design with the structure of (a) to identify a compound structure that binds to the three dimensional structure of the CR2 SCR 1-2 region; (c) contacting the candidate compound identified in step (b) with a first cell expressing CR2 or a ligand binding fragment thereof and a second cell expressing a CD23 protein or fragment thereof under conditions in which the CD23 protein or fragment thereof and the CR2 or the ligand binding fragment thereof can bind in the absence of the candidate compound; and (d) measuring a biological activity induced by the interaction of CD23 and CR2 in the first or second cell; wherein a candidate inhibitor compound is selected as a compound that inhibits the biological activity as compared to in the absence of the candidate inhibitor compound. In a preferred embodiment, the biological activity is IgE isotype switching in the first cell.

Yet another embodiment of the present invention relates to a method to identify a compound that inhibits the binding of C3d, C3 or another CR2-binding fragment of C3 containing C3d or a portion thereof, to complement receptor type 2 (CR2). This method includes the steps of: (a) providing a three dimensional structure of a CR2 short consensus repeat (SCR) 1-2 region as described in detail above; (b) identifying a candidate compound for binding to the CR2 SCR 1-2 region by performing structure based drug design with the structure of (a) to identify a compound structure that binds to the three dimensional structure of the CR2 SCR 1-2 region; (c) contacting the candidate compound identified in step (b) with a cell expressing CR2 or a fragment thereof and C3d, C3, a CR2-binding fragment of C3 containing C3d, or a fragment thereof, under conditions in which the C3d, the C3, the CR2-binding fragment of C3 containing C3d, or a fragment thereof, can bind to CR2 or the fragment thereof and enhance cell activation in the absence of the candidate compound; and (d) measuring the activation of the cell; wherein a candidate inhibitor compound is selected as a compound that inhibits cell activation, as compared to in the absence of the candidate inhibitor compound. In this embodiment, the cell in (c) can include, but is not limited to: a B cell, a T cell, a thymocyte, an epithelial cell, and a mast cell. Activation can be measured by any suitable method including, but not limited to: measurement of cytokine production by the cell, measurement of calcium mobilization in the cell, measurement of lyn tyrosine kinase activity in the cell, measurement of phosphatidylinositol 3′ kinase activity in the cell, measurement of activation of NF-κB, measurement of activation of MAP kinases, measurement of phosphorylation of CD19 in the cell, and measurement of activation of protein kinase C (PKC) in the cell.

Another embodiment of the present invention relates to a method to inhibit complement receptor type 2 (CR2)-dependent human immunodeficiency virus-1 (HIV-1) infection of cells in a patient. This method includes the steps of administering to a patient infected with HIV-1 an inhibitor compound that inhibits the binding of C3d, C3 or another CR2-binding fragment of C3 containing C3d or a portion thereof, -opsonized HIV-1 to B cells, follicular dendritic cells, T cells or macrophages in the patient. The inhibitor compound is selected by the steps of: (a) providing a three dimensional structure of a CR2 short consensus repeat (SCR) 1-2 region as described in detail above; (b) identifying a candidate compound for binding to the CR2 SCR 1-2 region by performing structure based drug design with the structure of (a) to identify a compound structure that binds to the three dimensional structure of the CR2 SCR 1-2 region; (c) contacting the candidate compound identified in step (b) with a B cell or follicular dendritic cell expressing CR2 or a fragment thereof and C3d, C3, a CR2-binding fragment of C3 containing C3d, or a fragment thereof, under conditions in which the C3d, the C3, the CR2-binding fragment of C3 containing C3d, or the fragment thereof, can bind to CR2 and enhance B cell activation or follicular dendritic cell activation in the absence of the candidate compound; and (d) measuring the activation of the B cell or the follicular dendritic cell, wherein a candidate inhibitor compound is selected as a compound that inhibits B cell activation or follicular dendritic cell activation, as compared to in the absence of the candidate inhibitor compound.

Yet another embodiment of the present invention relates to a method to prepare a vaccine. This method includes linking a compound that increases B cell activation to an antigen to form the vaccine, wherein the compound is selected by the steps of: (a) providing a three dimensional structure of a CR2 short consensus repeat (SCR) 1-2 region as described in detail above; (b) identifying a candidate compound for binding to the CR2 SCR 1-2 region by performing structure based drug design with the structure of (a) to identify a compound structure that binds to the three dimensional structure of the CR2 SCR 1-2 region; (c) contacting the candidate compound identified in step (b) with a B cell expressing CR2 or a fragment thereof and with C3d, C3, a CR2-binding fragment of C3 containing C3d, or a fragment thereof, under conditions in which the C3d, the C3, the CR2-binding fragment of C3 containing C3d, or the fragment thereof, can bind to and activate CR2 in the absence of the candidate compound; and (d) measuring the activation of the B cell; wherein a candidate compound for use in a vaccine is selected as a compound that increases B cell activation, as compared to in the absence of the candidate compound.

Yet another embodiment of the present invention relates to a drug delivery system, which includes: (a) a drug; and, (b) a portion of a CR2 protein selected from the group of: (i) positions on strand B and the B-C loop of SCR2 including: G79-G80-Y81-K82-I83-R84-G85-S86-T87-P88-Y89; (ii) position K100 on the B strand of CR2; and, (iii) positions: V130-F131-P132-L133; and (iv) combinations of (i)-(iii). The drug is linked to the portion of CR2.

Yet another embodiment of the present invention relates to an antibody that selectively binds to CR2. The antibody binds to a portion of CR2 selected from the group of: (a) the interface between the SCR1 and SCR2 domains of CR2; (b) the dimer interface between two CR2 proteins; and, (c) the interface between CR2 and C3d. Preferably, an antibody that binds to an interface between CR2 and C3d selectively binds to a site selected from: (i) the B strand and the B-C loop of CR2 SCR2 comprising the segment: G79-G80-Y81-K82-I83-R84-G85-S86-T87-P88-Y89; (ii) the B strand of CR2 SCR2 comprising position K100; (iii) a segment of CR2 SCR2 comprising V130-F131-P132-L133; and, (iv) a segment of CR2 SCR2 comprising T101-N102-F103.

Yet another embodiment of the present invention relates to a crystal comprising complement receptor type 2 (CR2) in complex with C3d. The CR2 consists of SEQ ID NO:4, and the C3d consists of SEQ ID NO:7. The crystal effectively diffracts X-rays for the determination of the atomic coordinates of the CR2 in complex with C3d to a resolution of greater than 2.0 Å, and the crystal has a space group R32 so as to form a unit cell of dimensions a=b=170.5 Å, c=173.8 Å.

Another embodiment of the present invention is a therapeutic composition that, when administered to an animal, enhances B cell responses in the animal. The therapeutic composition comprises a compound that stimulates the activity of a complement receptor type 2 (CR2). The compound is identified by the method that includes the steps of: (a) providing a three dimensional structure of a CR2 short consensus repeat (SCR) 1-2 region as described in detail herein; (b) identifying a candidate compound for binding to the CR2 SCR 1-2 region by performing structure based drug design with the structure of (a) to identify a compound structure that binds to the three dimensional structure of the CR2 SCR 1-2 region; (c) synthesizing the candidate compound; and (d) selecting candidate compounds that bind to and activate CR2.

Yet another embodiment relates to a therapeutic composition that, when administered to an animal, inhibits the biological activity of complement receptor type 2 (CR2) in the animal. The therapeutic composition includes a compound that inhibits the activity of a complement receptor type 2 (CR2). The compound is identified by the method that includes the steps of: (a) providing a three dimensional structure of a CR2 short consensus repeat (SCR) 1-2 region as described in detail above; (b) identifying a candidate compound for binding to the CR2 SCR 1-2 region by performing structure based drug design with the structure of (a) to identify a compound structure that binds to the three dimensional structure of the CR2 SCR 1-2 region; (c) synthesizing the candidate compound; and (d) selecting candidate compounds that inhibit the biological activity of CR2. Preferably, the compounds inhibit the formation of a complex between CR2 and a CR2 ligand. The ligand can include, C3d, C3, CR2-binding fragments of C3 containing C3d, CD23 and Epstein Barr Virus (EBV), and CR2-binding fragments any of the ligands. In one aspect, the compound inhibits the activation of CR2.

Yet another embodiment of the present invention relates to a method of preparing complement receptor type 2 (CR2) proteins having modified biological activity. This method includes the steps of: (a) providing a three dimensional structure of a CR2 short consensus repeat (SCR) 1-2 region as described in detail above; (b) analyzing the three dimensional structure to the three-dimensional structure of the CR2 SCR 1-2 region by performing structure based drug design with the structure of (a) to identify at least one site in the structure contributing to the biological activity of CR2; and (c) modifying the at least one site in a CR2 protein to alter the biological activity of the CR2 protein.

Yet another embodiment of the present invention relates to an isolated protein comprising a mutant C3d. The protein comprises an amino acid sequence that differs from SEQ ID NO:7 by an amino acid substitution selected from the group of: a non-asparagine amino acid residue at position 170, a non-isoleucine amino acid residue at position 115, and/or a non-leucine amino acid residue at position 116. The C3d mutant protein has reduced binding to complement receptor type 2 (CR2), as compared to a wild-type C3d protein. In one aspect, the mutant protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:8 and SEQ ID NO:9.

BRIEF DESCRIPTION OF THE DRAWINGS OF THE INVENTION

The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application with color drawing will be provided by the Office upon request and payment of the necessary fee.

FIG. 1A shows an overall view of the structure of CR2 binding to C3d, showing only SCR2 contacting one portion of the edge of 3d.

FIG. 1B shows the overall structure showing a second CR2-C3d complex (colored in light blue and grey) that dimerizes with the first one in FIG. 1A.

FIG. 2 shows the structure of CR2: A is a ribbon representation of the CR2 SCR1 (in red) and SCR2 (in yellow) structures, showing the SCR fold and the packing of the two domains to form a V shape;

B is a representation of the structure and packing interaction at the interface of CR2 SCR1 and SCR2 domains;

C is a surface representation of the two-domain arrangement of CR2;

D is a representation of the dimerization of CR2 through interactions between SCR1 of each molecule: and

E is a sequence alignment between human CR2 (hCR2) SCR1-2 domains (SEQ ID NO:4) and mouse CR2 (mCR2) SCR1-2 domains (SEQ ID NO:6).

FIG. 3 shows the structure at the CR2-C3d interface: A and B are representations of the surface features of the interface area on C3d (in cyan) and CR2 molecule (in yellow);

C shows the structure of the CR2 SCR2-C3d complex;

D and E show the detailed interactions between CR2 (in yellow) and C3d (in cyan) in two angles: and

F shows the human C3d sequence (SEQ ID NO:7) with secondary structure assigned on top of the corresponding sequences.

FIG. 4A is a digitized image of a native gel shift assay of the binding between CR2 and C3d wild type (wt) or mutants (mt).

FIG. 4B is a graphical representation showing the intensity changes of the complex bands (measured by densitometry) as CR2 concentration increases from lanes 2 to 4 (wt), or lanes 6 to 8 (mt115), or lanes 10 to 12 (mt170) in FIG. 4A.

FIG. 4C is a graphical representation of a competitive ELISA demonstrating the relative abilities of wild type versus mutant forms of C3d to block CR2-wild type C3d interactions.

FIGS. 5A and 5B are two view with a 180 degree rotation to each other showing the localization of the epitopes of anti-CR2 monoclonal antibodies (mAb) on the CR2 surface.

FIG. 6A is a surface representation of the model containing a dimer of CR2 SCR1 and SCR2 that bind to C3d on each receptor.

FIG. 6B is a diagram of C3d-antigen cross-linking CR2 (as dimers) and BCR on the cell surface.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to the discovery of the three-dimensional structure of complement receptor 2 (CR2/CD21), to crystalline CR2-C3d complexes, to models of such three-dimensional structures, to a method of structure based drug design using such structures, to the compounds identified by such methods and to the use of such compounds in therapeutic compositions and methods. Complement receptor 2 (CR2/CD21) is an important receptor bridging the innate and adaptive immune systems that greatly amplifies B lymphocyte activation. CR2 ligands include complement C3d, C3, a CR-2 binding fragment of C3 that contains C3d or a portion thereof, CD23 and Epstein-Barr virus gp350/220. The structural basis for ligand binding by short consensus repeat (SCR) containing proteins has been unknown, but CR2 interactions require the presence of a two SCR-containing domain. In an effort to understand how CR2 interacts with its cellular ligand C3d in the process of B cell activation, as well as its other natural ligands, the present inventors have determined the 2 Åcrystal structure of the CR2 SCR1 and SCR2 domain in complex with C3d. The present inventors describe herein the x-ray structure of this CR2 domain in complex with C3d, which reveals extensive main chain interactions of C3d with one SCR of CR2 and substantial SCR side-side packing. These results provide the first detailed understanding of receptor-ligand interactions in this protein family and reveal potential target sites for molecular drug design.

According to the present invention, the complement receptor 2 (CR2/CD21) is a protein that is characterized by the amino acid sequence represented by SEQ ID NO:1. SEQ ID NO:1 represents the full-length human CR2 protein sequence. The two short consensus repeat (SCR) domains of CR2 that are known to be required for CR2-ligand interactions, SCR1 and SCR2, are located, respectively, within the human CR2 amino acid sequence between positions Cys23 and Cys82 (i.e., between the first Cys and the fourth Cys residues) of SEQ ID NO:1 (SCR1, also represented herein by SEQ ID NO:2) and between positions Cys91 and Cys146 (i.e., between the fifth Cys and the eighth Cys residues) of SEQ ID NO:1 (SCR2, also represented herein by SEQ ID NO:3). The segment (fragment) of human CR2 represented in crystal structure herein contains both the SCR1 and the SCR2 domain (positions 20-153 of SEQ ID NO:1), and is represented herein by SEQ ID NO:4. SEQ ID NO:4 includes the 8 residue linker between SCR1 (SEQ ID NO:2) and SCR2 (SEQ ID NO:3). It also contains three residues at the N-terminus of SCR1 that match exactly positions Gly20-Ser22 of SEQ ID NO:1. At the C-terminus of SCR2, SEQ ID NO:4 contains seven residues that match exactly positions Val147-Glu153 of SEQ ID NO:1.

The full-length mouse CR2 protein sequence is represented herein by SEQ ID NO:5. The SCR1 and SCR2 domains of the mouse CR2 protein are located with the mouse CR2 amino sequence at positions 14-73 of SEQ ID NO:5 (SCR1) and positions 82-138 of SEQ ID NO:5 (SCR2). The segment (fragment) of mouse CR2 that contains both the SCR1 and SCR2 domains and the eight residue linker, and which is shown aligned with the human sequence in FIG. 2E, is located at positions 11-145 of SEQ ID NO:5 and is represented herein by SEQ ID NO:6. Human and mouse CR2 are approximately 66% identical over the full length amino acid sequences represented by SEQ ID NO:1 and SEQ ID NO:5 (using BLAST 2 pairwise alignment), and approximately 61% identical over the SCR1-SCR2 regions of SEQ ID NO:4 and SEQ ID NO:6 (using BLAST 2 pairwise alignment). It is noted that both mouse and human CR2 bind to C3 (in the C3d region).

According to the present invention, general reference to a complement receptor 2 (CR2/CD21) protein is a protein that, at a minimum, contains any portion of the SCR1 and SCR2 domains of a CR2 protein, and includes full-length CR2 proteins, soluble CR2 proteins, other biologically active fragments of CR2 proteins, CR2 proteins comprising SCR1 and SCR2, CR2 fusion proteins, or any homologue of a naturally occurring CR2, as described in detail below. A homologue of a CR2 protein includes proteins which differ from a naturally occurring CR2 in that at least one or a few, but not limited to one or a few, amino acids have been deleted (e.g., a truncated version of the protein, such as a peptide or fragment), inserted, inverted, substituted and/or derivatized (e.g., by glycosylation, phosphorylation, acetylation, myristoylation, prenylation, palmitation, amidation and/or addition of glycosylphosphatidyl inositol). Preferably, a CR2 homologue has an amino acid sequence that is at least about 70% identical to the amino acid sequence of a naturally occurring CR2 (e.g., SEQ ID NO:1, or SEQ ID NO:5), and more preferably, at least about 75%, and more preferably, at least about 80%, and more preferably, at least about 85%, and more preferably, at least about 90%, and more preferably, at least about 95% identical to the amino acid sequence of a naturally occurring CR2. Preferred three-dimensional structural homologues of a CR2 are described in detail below. According to the present invention, a CR2 homologue preferably has, at a minimum, the ability to bind to a naturally occurring ligand of CR2 (e.g., C3d (including any C3 fragments with CR2-binding ability), CD23, EBV). Such homologues include fragments of a full length CR2 (e.g., the SCR2 region or the SCR1-SCR2 region) and can be referred to herein as a CR2 ligand-binding fragment. In one embodiment, a CR2 homologue has the biological activity of a naturally occurring CR2. Reference to a CR2 protein can also generally refer to CR2 in complex with a ligand.

In general, the biological activity or biological action of a protein refers to any function(s) exhibited or performed by the protein that is ascribed to the naturally occurring form of the protein as measured or observed in vivo (i.e., in the natural physiological environment of the protein) or in vitro (i.e., under laboratory conditions). Modifications of a protein, such as in a homologue or mimetic (discussed below), may result in proteins having the same biological activity as the naturally occurring protein, or in proteins having decreased or increased biological activity as compared to the naturally occurring protein. Modifications which result in a decrease in protein expression or a decrease in the activity of the protein, can be referred to as inactivation (complete or partial), down-regulation, or decreased action of a protein. Similarly, modifications which result in an increase in protein expression or an increase in the activity of the protein, can be referred to as amplification, overproduction, activation, enhancement, up-regulation or increased action of a protein. As used herein, a protein that has “CR2 biological activity” or that is referred to as a CR2 refers to a protein that has an activity that can include any one, and preferably more than one, of the following characteristics: (a) binds to a natural ligand of CR2 (e.g., C3d, EBV, CD23, C3 or other CR2-binding C3 fragments); (b) mediates interactions between the natural ligands and other proteins; (c) responds to contact with a natural ligand or other agonist (i.e., stimulation) by activation of the signal transduction cascade through the CR2/CD19/CD81co-activation complex in a cell expressing such complex (D. T. Fearon, 1995 ibid.; D. T. Fearon, 1998, ibid.; J. C. Cambier, 1997, ibid.; A. K. Matsumoto, et al., J Exp Med 173, 55-64 (1991)), including activation of lyn tyrosine kinase, activations of phosphatidyl inositol 3′ kinase, activation of NF-κB, activation of MAP kinases, phosphorylation of CD19, activation of PI3 kinase, and activation of protein kinase C (PKC). Such biological activities of (c) associated with the binding and activation of CR2 can be referred to as downstream biological activities, since they occur downstream of the binding of CR2 by its ligand.

An isolated protein (e.g., an isolated CR2 protein or an isolated C3d protein, an isolated C3 protein, or other CR2-binding C3 fragment), according to the present invention, is a protein that has been removed from its natural milieu (i.e., that has been subject to human manipulation) and can include purified proteins, partially purified proteins, recombinantly produced proteins, and synthetically produced proteins, for example. As such, “isolated” does not reflect the extent to which the protein has been purified. Preferably, an isolated protein, and particularly, an isolated CR2 protein and/or an isolated C3d protein or other CR2-binding C3 fragment, is produced recombinantly. According to the present invention, a CR2-binding C3 fragment can include any portion of C3 that contains at least a portion of C3d sufficient to bind to CR2, and can include, but is not limited to, portions of C3 comprising C3dg, iC3b, and/or C3b, an isolated C3d segment or a portion thereof. The terms “fragment”, “segment” and “portion” can be used interchangeably herein with regard to referencing a part of a protein.

Reference to a protein from a specific organism, such as a “human CR2”, by way of example, refers to a CR2 (including a homologue of a naturally occurring CR2) from a human or a CR2 protein that has been otherwise produced from the knowledge of the primary structure (e.g., sequence) and/or the tertiary structure of a naturally occurring CR2 protein from a human. In other words, a human CR2 protein includes any CR2 protein that has the structure and function of a naturally occurring CR2 protein from a human or that has a structure and function that is sufficiently similar to a human CR2 protein such that the CR2 protein is a biologically active (i.e., has biological activity) homologue of a naturally occurring CR2 protein from a human. As such, a human CR2 protein can include purified, partially purified, recombinant, mutated/modified and synthetic proteins.

Proteins of the present invention are preferably retrieved, obtained, and/or used in “substantially pure” form. As used herein, “substantially pure” refers to a purity that allows for the effective use of the protein in vitro, ex vivo or in vivo according to the present invention. For a protein to be useful in an in vitro, ex vivo or in vivo method according to the present invention, it is substantially free of contaminants, other proteins and/or chemicals that might interfere or that would interfere with its use in a method disclosed by the present invention, or that at least would be undesirable for inclusion with the protein when it is used in a method disclosed by the present invention. For example, for a CR2 protein, such methods include crystallization of the protein, use of a portion of the protein as a drug delivery vehicle, antibody production, agonist/antagonist identification assays, and all other methods disclosed herein. Preferably, a “substantially pure” protein, as referenced herein, is a protein that can be produced by any method (i.e., by direct purification from a natural source, recombinantly, or synthetically), and that has been purified from other protein components such that the protein comprises at least about 80% weight/weight of the total protein in a given composition (e.g., the protein is about 80% of the protein in a solution/composition/buffer), and more preferably, at least about 85%, and more preferably at least about 90%, and more preferably at least about 91%, and more preferably at least about 92%, and more preferably at least about 93%, and more preferably at least about 94%, and more preferably at least about 95%, and more preferably at least about 96%, and more preferably at least about 97%, and more preferably at least about 98%, and more preferably at least about 99%, weight/weight of the total protein in a given composition.

As used herein, a “structure” of a protein refers to the components and the manner of arrangement of the components to constitute the protein. The “three dimensional structure” or “tertiary structure” of the protein refers to the arrangement of the components of the protein in three dimensions. Such term is well known to those of skill in the art. It is also to be noted that the terms “tertiary” and “three dimensional” can be used interchangeably.

The present invention provides the atomic coordinates that define the three dimensional structure of a CR2 protein in complex with a C3d protein. A CR2-ligand complex, such as a CR2-C3d complex, refers to the complex (e.g., interaction, binding), that forms between CR2 and any of its ligands (e.g., C3d) in the absence of a compound that interferes with the interaction between the CR2 and its ligand(s). A complex is naturally formed between at least one full length CR2 and a full length ligand, but according to the present invention, a CR2-ligand can also include complexes that minimally contain: (1) a CR2 SCR1 and/or CR2 SCR2 domain; and (2) a CR2-contacting portion of a ligand of CR2.

One embodiment of the present invention includes a CR2 protein in crystalline form. The present invention specifically exemplifies a portion of CR2 comprising the SCR1 and SCR2 domains. As used herein, the terms “crystalline CR2” and “CR2 crystal” both refer to crystallized CR2 protein and are intended to be used interchangeably. Preferably, a crystalline CR2 is produced using the crystal formation method described herein, in particular according to the method disclosed in Example 1. A CR2 crystal of the present invention can comprise any crystal structure and preferably crystallizes as an orthorhombic crystal lattice. A suitable crystalline CR2 of the present invention includes a monomer or a dimer, or a multimer of CR2 protein. One preferred crystalline CR2 comprises between one and five CR2 proteins in an asymmetric unit. A more preferred crystalline CR2 comprises a dimer of CR2 proteins. Preferably, a composition of the present invention includes CR2 protein molecules arranged in a crystalline manner in a space group R3 or R32 so as to form a unit cell of dimensions a=b=170.5 Å, c=173.8 Å. A preferred crystal of the present invention provides X-ray diffraction data for determination of atomic coordinates of the CR2 protein to a resolution of about 4.0 Å, and preferably to about 3.0 Å, and more preferably to about 2.0 Å.

One embodiment of the present invention includes a method for producing crystals of CR2, alone or in complex with a CR2 ligand, comprising combining CR2 protein with a mother liquor and inducing crystal formation to produce the CR2 crystals. Although the production of crystals of CR2 in complex with C3d are specifically described herein, it is to be understood that such processes as are described herein can be adapted by those of skill in the art to produce crystals of CR2 in complex with other CR2 ligands, such as Epstein Barr Virus (EBV) or CD23.

By way of example, crystals of CR2 and C3d in complex are formed using a solution containing about 20 mg/ml of CR2-C3d complex in a mother liquor. A suitable mother liquor of the present invention comprises an acetate buffer or a sulfate buffer. A preferred acetate buffer of the present invention comprises zinc acetate or zinc sulfate. The concentration of ammonium acetate in the buffer prior to crystallization is preferably 0.2M. The pH of the acetate buffer (pH 7.36) is controlled using 0.1 M NaCacodylate. The acetate buffer also contains any polyethylene glycol (PEG), with PEG 2000 at a concentration of about 17% being more preferred. Supersaturated solutions of CR2-C3d complex can be induced to crystallize by several methods including, but not limited to, vapor diffusion, liquid diffusion, batch crystallization, constant temperature and temperature induction or a combination thereof. Preferably, supersaturated solutions of CR2-C3d complex are induced to crystallize by hanging drop vapor diffusion. In a vapor diffusion method, a CR2-C3d complex is combined with a mother liquor of the present invention that will cause the CR2-C3d complex solution to become supersaturated and form CR2-C3d complex crystals at a constant temperature. Vapor diffusion is preferably performed under a controlled temperature and, by way of example, can be performed at 4° C.

One embodiment of the present invention includes a representation, or model, of the three dimensional structure of a CR2 protein, such as a computer model. A computer model of the present invention can be produced using any suitable software program, including, but not limited to, MOLSCRIPT 2.0 (Avatar Software AB, Heleneborgsgatan 21C, SE-11731 Stockholm, Sweden), the graphical display program O (Jones et. al., Acta Crystallography, vol. A47, p. 110, 1991), the graphical display program GRASP, or the graphical display program INSIGHT. Suitable computer hardware useful for producing an image of the present invention are known to those of skill in the art (e.g., a Silicon Graphics Workstation).

A representation, or model, of the three dimensional structure of the CR2-C3d complex structure for which a crystal has been produced can also be determined using techniques which include molecular replacement or SIR/MIR (single/multiple isomorphous replacement). Methods of molecular replacement are generally known by those of skill in the art (generally described in Brunger, Meth. Enzym., vol. 276, pp. 558-580, 1997; Navaza and Saludjian, Meth. Enzym., vol. 276, pp. 581-594, 1997; Tong and Rossmann, Meth. Enzym., vol. 276, pp. 594-611, 1997; and Bentley, Meth. Enzym., vol. 276, pp. 611-619, 1997, each of which are incorporated by this reference herein in their entirety) and are performed in a software program including, for example, AmoRe (CCP4, Acta Cryst.D50, 760-763 (1994) or XPLOR. Briefly, X-ray diffraction data is collected from the crystal of a crystallized target structure. The X-ray diffraction data is transformed to calculate a Patterson function. The Patterson function of the crystallized target structure is compared with a Patterson function calculated from a known structure (referred to herein as a search structure). The Patterson function of the crystallized target structure is rotated on the search structure Patterson function to determine the correct orientation of the crystallized target structure in the crystal. The translation function is then calculated to determine the location of the target structure with respect to the crystal axes. Once the crystallized target structure has been correctly positioned in the unit cell, initial phases for the experimental data can be calculated. These phases are necessary for calculation of an electron density map from which structural differences can be observed and for refinement of the structure. Preferably, the structural features (e.g., amino acid sequence, conserved di-sulphide bonds, and β-strands or β-sheets) of the search molecule are related to the crystallized target structure.

As used herein, the term “model” refers to a representation in a tangible medium of the three dimensional structure of a protein, polypeptide or peptide. For example, a model can be a representation of the three dimensional structure in an electronic file, on a computer screen, on a piece of paper (i.e., on a two dimensional medium), and/or as a ball-and-stick figure. Physical three-dimensional models are tangible and include, but are not limited to, stick models and space-filling models. The phrase “imaging the model on a computer screen” refers to the ability to express (or represent) and manipulate the model on a computer screen using appropriate computer hardware and software technology known to those skilled in the art. Such technology is available from a variety of sources including, for example, Evans and Sutherland, Salt Lake City, Utah, and Biosym Technologies, San Diego, Calif. The phrase “providing a picture of the model” refers to the ability to generate a “hard copy” of the model. Hard copies include both motion and still pictures. Computer screen images and pictures of the model can be visualized in a number of formats including space-filling representations, α carbon traces, ribbon diagrams and electron density maps.

Preferably, a three dimensional structure of a CR2 protein provided by the present invention includes: (a) a structure defined by atomic coordinates of a three dimensional structure of a crystalline CR2 SCR1-2 region in complex with C3d; (b) a structure defined by atomic coordinates selected from the group consisting of: (i) atomic coordinates represented in a table selected from the group consisting of Table 2 (CR2-C3d) and Table 3 (CR2 only); and, (ii) atomic coordinates that define a three dimensional structure, wherein at least 50% of the structure has an average root-mean-square deviation (RMSD) from backbone atoms in secondary structure elements in at least one domain of a three dimensional structure represented by the atomic coordinates of (1) of equal to or less than about 1.0 Å; and/or (c) a structure defined by atomic coordinates derived from CR2 protein molecules arranged in a crystalline manner in a space group R3 or R32 so as to form a unit cell of dimensions a=b=170.5 Å, c=173.8 Å.

The present inventors have provided the atomic coordinates that define the three dimensional structure of a crystalline CR2 short consensus repeat (SCR) 1-2 region (CR2 SCR1-2 region) in complex with C3d. Using the guidance provided herein, one of skill in the art will be able to reproduce such a crystalline structure and define atomic coordinates of such a structure. Example 1 demonstrates the production of a CR2-C3d complex (CR2 SCR1-2 region in complex with C3d) arranged in a crystalline manner in a space group R3 or R32 so as to form a unit cell of dimensions a=b=170.5 Å, c=173.8 Å. The atomic coordinates determined from this crystal structure are represented in Table 2. Additionally, these atomic coordinates were deposited on Jan. 11, 2001, with the Protein Data Bank (PDB), operated by the Research Collaboratory for Structural Bioinfornatics (RCSB) (H. M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissig, I. N. Shindyalov, P. E. Bourne, The Protein Data Bank; Nucleic Acids Research, 28:235-242 (2000)), under PDB Deposit No. PDB id 1GHQ. The atomic coordinates in Table 3 are the coordinates that define the three dimensional structure of just the CR2 SCR1-SCR2 domains of the CR2-C3d complex (i.e., the coordinates defining the C3d portion have been removed).

In one embodiment, a three dimensional structure of a CR2 protein provided by the present invention includes a structure represented by atomic coordinates that define a three dimensional structure, wherein at least 50% of the structure has an average root-mean-square deviation (RMSD) from backbone atoms in secondary structure elements in at least one domain of a three dimensional structure represented by the atomic coordinates of Table 2 or Table 3 of equal to or less than about 1.0 Å. Such a structure can be referred to as a structural homologue of the CR2 structures defined by Tables 2 and 3. Preferably, at least 50% of the structure has an average root-mean-square deviation (RMSD) from backbone atoms in secondary structure elements in at least one domain of a three dimensional structure represented by the atomic coordinates of Table 2 or Table 3 of equal to or less than about 0.7 Å, equal to or less than about 0.5 Å, and most preferably, equal to or less than about 0.3 Å. In a more preferred embodiment, a three dimensional structure of a CR2 protein provided by the present invention includes a structure defined by atomic coordinates that define a three dimensional structure, wherein at least about 75% of such structure has the recited average root-mean-square deviation (RMSD) value, and more preferably, at least about 90% of such structure has the recited average root-mean-square deviation (RMSD) value, and most preferably, about 100% of such structure has the recited average root-mean-square deviation (RMSD) value.

In one embodiment, RMSD of a structural homologue of CR2 can be extended to include atoms of amino acid side chains. As used herein, the phrase “common amino acid side chains” refers to amino acid side chains that are common to both the structural homologue and to the structure that is actually represented by such atomic coordinates. Preferably, at least 50% of the structure has an average root-mean-square deviation (RMSD) from common amino acid side chains in at least one domain of a three dimensional structure represented by the atomic coordinates of Table 2 or Table 3 of equal to or less than about 1.0 Å equal to or less than about 0.7 Å, equal to or less than about 0.5 Å, and most preferably, equal to or less than about 0.3 Å. In a more preferred embodiment, a three dimensional structure of a CR2 protein provided by the present invention includes a structure defined by atomic coordinates that define a three dimensional structure, wherein at least about 75% of such structure has the recited average root-mean-square deviation (RMSD) value, and more preferably, at least about 90% of such structure has the recited average root-mean-square deviation (RMSD) value, and most preferably, about 100% of such structure has the recited average root-mean-square deviation (RMSD) value.

One embodiment of the present invention relates to a method of structure-based identification of compounds which potentially bind to complement receptor type 2 (CR2) proteins or to a complex of CR2 and its ligand, comprising: (a) providing a three dimensional structure of a CR2 short consensus repeat (SCR) 1-2region; and (b) identifying a candidate compound for binding to the CR2 SCR 1-2 region by performing structure based drug design with the structure of (a) to identify a compound structure that binds to the three dimensional structure of the CR2 SCR 1-2region. The three dimensional structure of the CR2 SCR 1-2region is selected from the group of:

(i) a structure defined by atomic coordinates of a three dimensional structure of a crystalline CR2 SCR1-2 region in complex with C3d;

(ii) a structure defined by atomic coordinates selected from the group consisting of:

(1) atomic coordinates represented in a table selected from the group consisting of Table 2 (CR2-C3d) and Table 3 (CR2 only);

(2) atomic coordinates that define a three dimensional structure, wherein at least 50% of the structure has an average root-mean-square deviation (RMSD) from backbone atoms in secondary structure elements in at least one domain of a three dimensional structure represented by the atomic coordinates of (1) of equal to or less than about 1.0 Å; and

(iii) a structure defined by atomic coordinates derived from CR2 protein molecules arranged in a crystalline manner in a space group R3 or R32 so as to form a unit cell of dimensions a=b=170.5 Å, c=173.8 Å.

The structures used to perform the above-described method have been described in detail above and in the Examples section. According to the present invention, the phrase “providing a three dimensional structure of a CR2 short consensus repeat (SCR) 1-2 region” is defined as any means of providing, supplying, accessing, displaying, retrieving, or otherwise making available the three dimensional structure of the CR2 short consensus repeat (SCR) 1-2 region described herein. For example, the step of providing can include, but is not limited to, accessing the atomic coordinates for the structure from a database; importing the atomic coordinates for the structure into a computer or other database; displaying the atomic coordinates and/or a model of the structure in any manner, such as on a computer, on paper, etc.; and determining the three dimensional structure of a CR2 short consensus repeat (SCR) 1-2 region de novo using the guidance provided herein.

The second step of the method of structure based identification of compounds of the present invention includes identifying a candidate compound for binding to the CR2 SCR 1-2 region by performing structure based drug design with the structure of (a) to identify a compound structure that binds to the three dimensional structure of the CR2 SCR 1-2 region. CR2 is a receptor for at least three biologically important ligands, and has been shown to play a role in several aspects of the humoral immune response, EBV infection, and HIV-1 infection. Therefore, identification and/or design of compounds that mimic, enhance, disrupt or compete with the interactions of CR2 with its ligands are highly desirable. Such compounds can be designed using structure based drug design. Until the discovery of the three dimensional structure of the present invention, the only information available for the development of therapeutic compounds based on the CR2 protein was based on the primary sequence of the CR2 protein. Structure based drug design refers to the prediction of a conformation of a peptide, polypeptide, protein, or conformational interaction between a peptide or polypeptide, and a compound, using the three dimensional structure of the peptide, polypeptide or protein. Typically, structure based drug design is performed with a computer. For example, generally, for a protein to effectively interact with (e.g., bind to) a compound, it is necessary that the three dimensional structure of the compound assume a compatible conformation that allows the compound to bind to the protein in such a manner that a desired result is obtained upon binding. Knowledge of the three dimensional structure of the protein enables a skilled artisan to design a compound having such compatible conformation, or to select such a compound from available libraries of compounds. For example, knowledge of the three dimensional structure of the C3d binding site of CR2 enables one of skill in the art to design a compound that binds to CR2, is stable and results in, for example, inhibition of a biological response such as C3d binding to CR2, or cellular signal transduction through the CR2, upon such binding. In addition, for example, knowledge of the three dimensional structure of the C3d binding site of a CR2 enables a skilled artisan to design a substrate analog of CR2.

Suitable structures and models useful for structure based drug design are disclosed herein. Preferred target structures to use in a method of structure based drug design include any representations of structures produced by any modeling method disclosed herein, including molecular replacement and fold recognition related methods.

According to the present invention, the step of designing a compound for testing in a method of structure based identification of the present invention can include creating a new chemical compound or searching databases of libraries of known compounds (e.g., a compound listed in a computational screening database containing three dimensional structures of known compounds). Designing can also be performed by simulating chemical compounds having substitute moieties at certain structural features. The step of designing can include selecting a chemical compound based on a known function of the compound. A preferred step of designing comprises computational screening of one or more databases of compounds in which the three dimensional structure of the compound is known and is interacted (e.g., docked, aligned, matched, interfaced) with the three dimensional structure of a CR2 by computer (e.g. as described by Humblet and Dunbar, Animal Reports in Medicinal Chemistry, vol. 28, pp. 275-283, 1993, M Venuti, ed., Academic Press). Methods to synthesize suitable chemical compounds are known to those of skill in the art and depend upon the structure of the chemical being synthesized. Methods to evaluate the bioactivity of the synthesized compound depend upon the bioactivity of the compound (e.g., inhibitory or stimulatory) and are disclosed herein.

Various other methods of structure-based drug design are disclosed in Maulik et al., 1997, Molecular Biotechnology: Therapeutic Applications and Strategies, Wiley-Liss, Inc., which is incorporated herein by reference in its entirety. Maulik et al. disclose, for example, methods of directed design, in which the user directs the process of creating novel molecules from a fragment library of appropriately selected fragments; random design, in which the user uses a genetic or other algorithm to randomly mutate fragments and their combinations while simultaneously applying a selection criterion to evaluate the fitness of candidate ligands; and a grid-based approach in which the user calculates the interaction energy between three dimensional receptor structures and small fragment probes, followed by linking together of favorable probe sites.

In a molecular diversity strategy, large compound libraries are synthesized, for example, from peptides, oligonucleotides, carbohydrates and/or synthetic organic molecules, using biological, enzymatic and/or chemical approaches. The critical parameters in developing a molecular diversity strategy include subunit diversity, molecular size, and library diversity. The general goal of screening such libraries is to utilize sequential application of combinatorial selection to obtain high-affinity ligands for a desired target, and then to optimize the lead molecules by either random or directed design strategies. Methods of molecular diversity are described in detail in Maulik, et al., ibid.

Maulik et al. also disclose, for example, methods of directed design, in which the user directs the process of creating novel molecules from a fragment library of appropriately selected fragments; random design, in which the user uses a genetic or other algorithm to randomly mutate fragments and their combinations while simultaneously applying a selection criterion to evaluate the fitness of candidate ligands; and a grid-based approach in which the user calculates the interaction energy between three dimensional receptor structures and small fragment probes, followed by linking together of favorable probe sites.

In the present method of structure based drug design, it is not necessary to align a candidate chemical compound (i.e., a chemical compound being analyzed in, for example, a computational screening method of the present invention) to each residue in a target site (target sites will be discussed in detail below). Suitable candidate chemical compounds can align to a subset of residues described for a target site. Preferably, a candidate chemical compound comprises a conformation that promotes the formation of covalent or noncovalent crosslinking between the target site and the candidate chemical compound. Preferably, a candidate chemical compound binds to a surface adjacent to a target site to provide an additional site of interaction in a complex. When designing an antagonist (i.e., a chemical compound that inhibits the binding of a ligand to CR2 by blocking a binding site or interface), for example, the antagonist should bind with sufficient affinity to the binding site or to substantially prohibit a ligand (i.e., a molecule that specifically binds to the target site) from binding to a target area. It will be appreciated by one of skill in the art that it is not necessary that the complementarity between a candidate chemical compound and a target site extend over all residues specified here in order to inhibit or promote binding of a ligand.

In general, the design of a chemical compound possessing stereochemical complementarity can be accomplished by techniques that optimize, chemically or geometrically, the “fit” between a chemical compound and a target site. Such techniques are disclosed by, for example, Sheridan and Venkataraghavan, Acc. Chem Res., vol. 20, p. 322, 1987: Goodford, J. Med. Chem., vol. 27, p. 557, 1984; Beddell, Chem. Soc. Reviews, vol. 279, 1985; Hol, Angew. Chem., vol. 25, p. 767, 1986; and Verlinde and Hol, Structure, vol. 2, p. 577, 1994, each of which are incorporated by this reference herein in their entirety.

One embodiment of the present invention for structure based drug design comprises identifying a chemical compound that complements the shape of a CR2, including a portion of CR2, such as the SCR1-SCR2 region. Such method is referred to herein as a “geometric approach”. In a geometric approach, the number of internal degrees of freedom (and the corresponding local minima in the molecular conformation space) is reduced by considering only the geometric (hard-sphere) interactions of two rigid bodies, where one body (the active site) contains “pockets” or “grooves” that form binding sites for the second body (the complementing molecule, such as a ligand).

The geometric approach is described by Kuntz et al., J. Mol. Biol., vol. 161, p. 269, 1982, which is incorporated by this reference herein in its entirety. The algorithm for chemical compound design can be implemented using the software program DOCK Package, Version 1.0 (available from the Regents of the University of California). Pursuant to the Kuntz algorithm, the shape of the cavity or groove on the surface of a structure (e.g., CR2) at a binding site or interface is defined as a series of overlapping spheres of different radii. One or more extant databases of crystallographic data (e.g., the Cambridge Structural Database System maintained by University Chemical Laboratory, Cambridge University, Lensfield Road, Cambridge CB2 1EW, U.K.) or the Protein Data Bank maintained by Brookhaven National Laboratory, is then searched for chemical compounds that approximate the shape thus defined.

Chemical compounds identified by the geometric approach can be modified to satisfy criteria associated with chemical complementarity, such as hydrogen bonding, ionic interactions or Van der Waals interactions.

Another embodiment of the present invention for structure based identification of compounds comprises determining the interaction of chemical groups (“probes”) with an active site at sample positions within and around a binding site or interface, resulting in an array of energy values from which three dimensional contour surfaces at selected energy levels can be generated. This method is referred to herein as a “chemical-probe approach.” The chemical-probe approach to the design of a chemical compound of the present invention is described by, for example, Goodford, J. Med. Chem., vol. 28, p. 849, 1985, which is incorporated by this reference herein in its entirety, and is implemented using an appropriate software package, including for example, GRID (available from Molecular Discovery Ltd., Oxford OX2 9LL, U.K.). The chemical prerequisites for a site-complementing molecule can be identified at the outset, by probing the active site of a CR2, for example, (as represented by the atomic coordinates shown in Table 2 or Table 3) with different chemical probes, e.g., water, a methyl group, an amine nitrogen, a carboxyl oxygen and/or a hydroxyl. Preferred sites for interaction between an active site and a probe are determined. Putative complementary chemical compounds can be generated using the resulting three dimensional pattern of such sites.

According to the present invention, suitable candidate compounds to test using the method of the present invention include proteins, peptides or other organic molecules, and inorganic molecules. Suitable organic molecules include small organic molecules. Peptides refer to small molecular weight compounds yielding two or more amino acids upon hydrolysis. A polypeptide is comprised of two or more peptides. As used herein, a protein is comprised of one or more polypeptides. Preferred therapeutic compounds to design include peptides composed of “L” and/or “D” amino acids that are configured as normal or retroinverso peptides, peptidomimetic compounds, small organic molecules, or homo- or hetero-polymers thereof, in linear or branched configurations.

Preferably, a compound that is identified by the method of the present invention originates from a compound having chemical and/or stereochemical complementarity with CR2 and/or C3d. Such complementarity is characteristic of a compound that matches the surface of the receptor either in shape or in distribution of chemical groups and binds to CR2 to promote or inhibit CR2 ligand binding, or to induce cellular signal transduction in a cell expressing CR2 upon the binding of the compound to CR2. More preferably, a compound that binds to a ligand binding site of CR2 associates with an affinity of at least about 10⁻⁶ M, and more preferably with an affinity of at least about 10⁻⁷M, and more preferably with an affinity of at least about 10⁻⁸ M.

Preferably, three general sites of the CR2 are targets for structure based drug design (i.e., target sites), although other sites may become apparent to those of skill in the art. The three preferred sites include: (1) the interface between CR2 and C3d; (2) the interface between the SCR1 and SCR2 domains of CR2; and (3) the dimerization interface between two CR2 monomers. Combinations of any of these general sites are also suitable target sites. The interface between CR2 and C3d is depicted in FIG. 1A, and FIGS. 3A-3E. The interface between the SCR1 and SCR2 domains of CR2 is depicted in FIGS. 2A-2C. The dimer interface between CR2 monomeric proteins is depicted in FIGS. 1B, 2D and 6A. The following discussion provides specific detail on compound identification (e.g., drug design) using target sites of the CR2 based on its three-dimensional structure in complex with C3d. It is to be understood, however, that one of skill in the art, using the description of the CR2 structure provided herein, will be able to identify compounds that are potential candidates for inhibiting, stimulating or enhancing the interaction of CR2 with its other ligands.

The C3d binding site (i.e., the interface between CR2 and C3d) is targeted to directly affect the binding of CR2 to C3d, other CR2-binding C3 fragments, or another ligand (i.e., inhibition or enhancement). In the CR2-C3d complex, no continuous stretch of residues on C3d participates in the interactions. Rather, residues that are separated in the linear sequence of C3d, but come together on the folded C3d, interact with CR2. Namely, the residues on the H3-H4 loop (the loop between helix 3 and 4), as well as H5, and H7 make contact with CR2 (FIG. 3C). On the CR2 part, however, a linear stretch of residues within SCR2 domain makes the contact with C3d. The B strand and B-C loop of SCR2 constitute the majority of the interactions with C3d. The nature of the contacts involves elegant networks of hydrogen bonds, plus some hydrophobic and van der Waals interactions (FIGS. 3D & 3E). The contact site is discussed in detail in the Examples. Preferred target sites in the C3d binding interface with CR2 include, but are not limited to: (1) a site on the B strand and the B-C loop of CR2 SCR2 comprising the segment: G79-G80-Y81-K82-I83-R84-G85-S86-T87-P88-Y89; (2) a site on the B strand of CR2 SCR2 comprising position K100; (3) a segment of CR2 SCR2 comprising V130-F131-P132-L133; and (4) a segment of CR2 SCR2 comprising the fragment T101-N102-F103. In the T101-N102-F103 site, the N102 residue is glycosylated. The N-acetylglucosamine residue attached to N102 forms a hydrogen bond with C3d. The present inventors have shown that amino acid residues at positions 84 and 86 of SEQ ID NO:4 are particularly important residues in the binding of C3d to CR2 and therefore, segments of CR2 including these residues are particularly desirable target sites. Alternatively, the CR2 contact points on C3d can be targeted for the identification of compounds that specifically modify the interaction between CR2 and C3d (and potentially the interaction of CR2 with its other ligands). Such sites include, but are not limited to: (1) the loop between helix 2-3 of C3d comprising the segment Q68-P69-S70-S71; (2) Helix 5 of C3d comprising the segment S104-Q105-V106-L107-C108-G109-A110-V111-K 112-W113-L114-I115-L116-E117-K118-Q119-K120-P121-D122; and (3) Helix 7of C3d comprising the segment N170-S171-L172-P173-G174-S175-I176-T177-K178-A179-G180-D181-F182-L183-E184-A185 (all positions are given with respect to SEQ ID NO:7).

The interface between the two monomers of CR2 can also be targeted to affect the binding of CR2 to a ligand. Two CR2 molecules dimerize through SCR1-SCR 1 contacts in the crystal structure (FIG. 2D). The contact is symmetrical, with the E1 strands from different molecules running anti-parallel to each other. The C-terminus of the E1 strand also contacts the C-terminus of the D2 strand of another molecule. The nature of the interaction is hydrogen bonds. Without being bound by theory, the present inventors believe that a CR2 dimer, in contrast to a monomer, can allow a dramatic increase of cross-linked CR2/CD19/CD81 and B cell receptor molecules through binding to the antigen with two or more C3d attached, which can cause a 10,000-fold enhancement of the humoral immune response. Therefore, compounds that disrupt the dimer formation are expected to be primarily inhibitory compounds with regard to immune responses. Such compounds may also be beneficial, however, in inhibiting EBV or HIV infection mediated by CR2. Similarly, compounds that enhance or stabilize the dimer formation are expected to stimulate or enhance an immune response.

The interface between the SCR1 and SCR2 domains of CR2 is also targeted to affect the binding of CR2 to a ligand (i.e., inhibit or enhance). The packing of the two SCR domains in CR2 forms a V shape. Residues important for the tight packing between the two domains at the interface and the linker regions are shown in FIG. 2B. A very unique feature of the two domain CR2 structure is that the 8 amino acid linker makes a dramatic turn to allow the two SCR domains to pack against each other sideways (FIGS. 2A, 2B, 2C). Among the protein family containing SCR domains, the linkers connecting SCR domains are normally 3-5 amino acids in length, while an 8 amino acid linker is the longest known so far. The available structures of four SCR proteins containing two or 4 repeats (A. P. Wiles, et al.,(1997), supra; P. N. Barlow, et al., (1993), supra; J. M. Casasnovas, et al.,(1999), supra; R. Schwarzenbacher et al., (1999), supra) all have end-end packing between consecutive SCRs, and CR2 is thus the first to demonstrate extensive side-side packing. In end-end packing, the adjacent domains could, in principle, adopt different rotations and bend angles relative to each other in different environments. Indeed, a commonly held concept is that SCRs are not absolutely fixed relative to each other but rather are allowed some freedom to move about this interface (P. N. Barlow, et al., (1993), ibid.; J. M. Casasnovas, et al.,(1999), ibid.). However, the side-side packing of the CR2 SCR1 and SCR2 would not give the two domains freedom to adopt different orientations, unless some active process is involved to first separate the two domains. The interface between the two domains is mainly hydrophobic (FIG. 2B). Trp112, which is unique to CR2 SCR2 sequence and located on strand D2, plays a critical role in the packing by interacting with Ile39 and the main-chain from SCR1. Trp112 would be unfavorably exposed to the solvent if the two domains do not pack against each other sideways in this manner. In addition to Trp112, several other residues also play a role in the packing, including Pro121, His91, Leu39, and the carbon side chain of Glu64. The 8 amino acid linker, which contains mainly hydrophobic residues such as Tyr65, Phe66, Tyr69, also participates in the hydrophobic packing outside the two-domain interface, further solidifying the interactions between SCR1 and SCR2 (FIG. 2B). The area of the interface of the two SCRs is very extensive, covering almost half of the length of one SCR domain (FIG. 2C). Since the above-mentioned previous studies of other SCR proteins were performed in the absence of their ligands, it is possible that this interface may change upon binding of CR2 to its ligand. In any event, it is predicted that the binding of a compound to this site will have an effect on the ligand-binding ability of CR2.

A candidate compound for binding to a CR2 protein, including to one of the preferred target sites described above, is identified by one or more of the methods of structure-based identification discussed above. As used herein, a “candidate compound” refers to a compound that is selected by a method of structure-based identification described herein as having a potential for binding to a CR2 protein (or its ligand) on the basis of a predicted conformational interaction between the candidate compound and the target site of the CR2 protein. The ability of the candidate compound to actually bind to a CR2 protein can be determined using techniques known in the art, as discussed in some detail below. A “putative compound” is a compound with an unknown regulatory activity, at least with respect to the ability of such a compound to bind to and/or regulate CR2 as described herein. Therefore, a library of putative compounds can be screened using structure based identification methods as discussed herein, and from the putative compounds, one or more candidate compounds for binding to CR2 can be identified. Alternatively, a candidate compound for binding to CR2 can be designed de novo using structure based drug design, also as discussed above. Candidate compounds can be selected based on their predicted ability to inhibit the binding of CR2 to its ligand, to stabilize (e.g., enhance) the binding of CR2 to its ligand, to bind to and activate CR2, to bind to and inhibit the activation of CR2, to bind to and activate a ligand of CR2, to bind to and inhibit the activation of a ligand of CR2, to disrupt the dimerization of CR2 monomers, or to stabilize the dimerization of CR2 monomers.

Accordingly, in one aspect of the present invention, the method of structure-based identification of compounds that potentially bind to complement receptor type 2 (CR2) proteins or to a complex of CR2 and its ligand further includes steps which confirm whether or not a candidate compound has the predicted properties with respect to its effect on CR2 (or a ligand of CR2). In one embodiment, the candidate compound is predicted to be an inhibitor of the binding of CR2 to its ligand, and the method further includes: (c) contacting the candidate compound identified in step (b) with CR2 or a fragment thereof and a CR2 ligand or a fragment thereof under conditions in which a CR2-CR2 ligand complex can form in the absence of the candidate compound; and (d) measuring the binding affinity of the CR2 or fragment thereof to the CR2 ligand or fragment thereof. A candidate inhibitor compound is selected as a compound that inhibits the binding of CR2 to its ligand when there is a decrease in the binding affinity of the CR2 or fragment thereof for the CR2 ligand or fragment thereof, as compared to in the absence of the candidate inhibitor compound.

In another embodiment, the candidate compound is predicted to be a stabilizer of the binding of CR2 to its ligand, and the method further comprises: (c) contacting the candidate compound identified in step (b) with a CR2-CR2 ligand complex, wherein the CR2-CR2 ligand complex comprises CR2 or a fragment thereof and a CR2 ligand, or a fragment thereof, (d) measuring the stability of the CR2-CR2 ligand complex of (i). A candidate stabilizer compound is selected as a compound that stabilizes the CR2-CR2 ligand complex when there is an increase in the stability of the complex as compared to in the absence of the candidate stabilizer compound.

In another embodiment, the candidate compound is predicted to bind to and activate CR2 (i.e., an agonist), and the method further comprises: (c) contacting the candidate compound identified in step (b) with CR2 or a ligand-binding fragment thereof, under conditions wherein in the absence of the compound, CR2 is not activated; and, (d) measuring the ability of the candidate compound to bind to CR2 to activate CR2. A candidate agonist compound is selected as a compound that binds to CR2 and activates CR2 as compared to in the absence of the candidate agonist compound. A similar embodiment includes the identification of candidate compounds that bind to target sites on the CR2 ligand which are now known as a result of the present inventors' work, and the determination of the ability of the candidate compound to bind to and activate the ligand of CR2 (e.g., by mimicking the structure of CR2).

In another embodiment, the candidate compound is predicted to bind to and inhibit CR2 (i.e., an antagonist), and the method further comprises: (c) contacting the candidate compound identified in step (b) with CR2 or a ligand-binding fragment thereof, wherein in the absence of the compound, CR2 is not activated; and, (d) measuring the ability of the candidate compound to bind to CR2 and activate CR2. A candidate antagonist compound is selected as a compound that binds to CR2 but does not activate and, in some embodiments, inhibits any constitutive activation, of the CR2. A similar embodiment includes the identification of candidate compounds that bind to target sites on the CR2 ligand which are now known as a result of the present inventors' work, and the determination of the ability of the candidate compound to bind to but not activate the ligand of CR2.

In another embodiment, the candidate compound is predicted to bind to CR2 and to disrupt the dimerization of CR2 monomers, and the method further comprises: (c) contacting the candidate compound identified in step (b) with at least two CR2 monomers or ligand-binding fragments thereof, in the presence and in the absence of a CR2 ligand or fragment thereof; and, (d) measuring the ability of the candidate compound to bind to CR2, the ability of the CR2 monomers to dimerize, and/or the ability of the CR2 ligand to activate CR2. A candidate compound for the disruption of CR2 dimerization is selected as a compound that binds to CR2 but inhibits the dimerization of CR2 and in some embodiments, inhibits the activation of CR2 by its ligand. Similarly, a candidate compound for stabilizing the dimerization of CR2 is a compound that binds to CR2, prolongs the dimerization of CR2 as compared to in the absence of the candidate compound, and in some embodiments, enhances or prolongs the activation of CR2 by its ligand.

In one embodiment, the conditions under which a CR2 according to the present invention is contacted with a candidate compound, such as by mixing, are conditions in which the receptor is not stimulated (activated) or bound to a natural ligand if essentially no candidate compound is present. For example, such conditions include normal culture conditions in the absence of a stimulatory compound (a stimulatory compound being, e.g., the natural ligand for the receptor (e.g., C3d, CD23, EBV), a stimulatory antibody, or other equivalent stimulus). In this embodiment, the candidate compound is then contacted with the CR2. In this embodiment, the step of detecting is designed to indicate whether the candidate compound binds to CR2, and in some embodiments, whether the candidate compound activates CR2.

In an alternate embodiment, the conditions under which a CR2 according to the present invention is contacted with a candidate compound, such as by mixing, are conditions in which the receptor is normally bound by a ligand or additionally stimulated (activated) if essentially no candidate compound is present. Such conditions can include, for example, contact of CR2 with a stimulator molecule (a stimulatory compound being, e.g., the natural ligand for the receptor, a stimulatory antibody, or other equivalent stimulus) which binds to the receptor and causes the receptor to become activated. In this embodiment, the candidate compound can be contacted with the receptor prior to the contact of the receptor with the stimulatory compound (e.g., to determine whether the candidate compound blocks or otherwise inhibits the binding and/or stimulation of CR2 by the stimulatory compound), or after contact of the receptor with the stimulatory compound (e.g., to determine whether the candidate compound downregulates, or reduces the activation of the receptor).

The present methods involve contacting CR2 with the candidate compound being tested for a sufficient time to allow for binding to, activation or inhibition of the receptor by the candidate compound. The period of contact with the candidate compound being tested can be varied depending on the result being measured, and can be determined by one of skill in the art. For example, for binding assays, a shorter time of contact with the candidate compound being tested is typically suitable, than when activation is assessed. As used herein, the term “contact period” refers to the time period during which the CR2 molecules are in contact with the compound being tested. The term “incubation period” refers to the entire time during which cells expressing CR2, for example, are allowed to grow prior to evaluation, and can be inclusive of the contact period. Thus, the incubation period includes all of the contact period and may include a further time period during which the compound being tested is not present but during which growth is continuing (in the case of a cell based assay) prior to scoring. The incubation time for growth of cells can vary but is sufficient to allow for the binding of CR2, activation of the receptor or signal transduction pathways associated with the receptor, and/or inhibition of the receptor. It will be recognized that shorter incubation times are preferable because compounds can be more rapidly screened. A preferred incubation time is between about 1 minute to about 48 hours.

In accordance with the present invention, a cell-based assay is conducted under conditions which are effective to screen for candidate compounds useful in the method of the present invention. Effective conditions include, but are not limited to, appropriate media, temperature, pH and oxygen conditions that permit the growth of the cell that expresses the receptor. An appropriate, or effective, medium refers to any medium in which a cell that naturally or recombinantly expresses a CR2, when cultured, is capable of cell growth and expression of CR2. Such a medium is typically a solid or liquid medium comprising growth factors and assimilable carbon, nitrogen and phosphate sources, as well as appropriate salts, minerals, metals and other nutrients, such as vitamins. Culturing is carried out at a temperature, pH and oxygen content appropriate for the cell. Such culturing conditions are within the expertise of one of ordinary skill in the art.

Cells that are useful in the cell-based assays of the present invention include any cell that expresses a CR2 and particularly, other proteins that are associated with CR2 signal transduction cascades (e.g., the CR2/CD19/CD81 co-activation complex (D. T. Fearon, 1995 ibid.; D. T. Fearon, 1998, ibid.; J. C. Cambier, 1997, ibid.; A. K. Matsumoto, et al., J Exp Med 173, 55-64 (1991))). Such cells include B lymphocytes, T lymphocytes, follicular dendritic cells, thymocytes, epithelial cells, and mast cells. Additionally, certain cells may be induced to express CR2, for example, some tumor cells. Therefore, cells that express CR2 can include cells that naturally express CR2, recombinantly express CR2, or which can be induced to express CR2. Cells useful in some embodiments can also include cells that express a natural ligand of CR2, such as CD23.

The assay of the present invention can also be a non-cell based assay. In this embodiment, the candidate compound can be directly contacted with an isolated CR2, or a receptor component (e.g., an isolated extracellular portion of the receptor, or soluble receptor), and the ability of the candidate compound to bind to the receptor or receptor component can be evaluated, such as by an immunoassay or other binding assay. The assay can, if desired, additionally include the step of further analyzing whether candidate compounds which bind to a portion of the receptor are capable of increasing or decreasing the activity of CR2. Such further steps can be performed by cell-based assay, as described above, or by non-cell-based assay. For example, isolated membranes may be used to identify compounds that interact with CR2. Membranes can be harvested from cells expressing CR2 by standard techniques and used in an in vitro binding assay. ¹²⁵I-labeled (other labels can be used also) ligand (e.g., ¹²⁵I-labeled C3d) is contacted with the membranes and assayed for specific activity; specific binding is determined by comparison with binding assays performed in the presence of excess unlabeled ligand. Membranes are typically incubated with labeled ligand in the presence or absence of test compound. Compounds that bind to the receptor and compete with labeled ligand for binding to the membranes reduced the signal compared to the vehicle control samples.

Alternatively, soluble CR2 may be recombinantly expressed and utilized in non-cell based assays to identify compounds that bind to CR2. Recombinantly expressed CR2 polypeptides or fusion proteins containing one or more extracellular domains of CR2, and preferably, at least SCR1 and SCR2, can be used in the non-cell based screening assays. Alternatively, peptides corresponding to the extracellular domain of CR2 or fusion proteins containing the extracellular domain of CR2 can be used in non-cell based assay systems to identify compounds that bind to the extracellular portion of CR2. In non-cell based assays the recombinantly expressed CR2 is attached to a solid substrate by means well known to those in the art. For example, CR2 and/or cell lysates containing such receptors can be immobilized on a substrate such as: artificial membranes, organic supports, biopolymer supports and inorganic supports. The protein can be immobilized on the solid support by a variety of methods including adsorption, cross-linking (including covalent bonding), and entrapment. Adsorption can be through van del Waal's forces, hydrogen bonding, ionic bonding, or hydrophobic binding. Exemplary solid supports for adsorption immobilization include polymeric adsorbents and ion-exchange resins. Solid supports can be in any suitable form, including in a bead form, plate form, or well form. The test compounds are then assayed for their ability to bind to CR2.

In one embodiment, a BIAcore machine can be used to determine the binding constant of a complex between CR2 and a ligand (e.g., C3d) in the presence and absence of the candidate compound. For example, CR2 or a ligand binding fragment thereof can be immobilized on a substrate. A ligand, such as C3d, is contacted with the substrate to form a CR2-C3d complex. The dissociation constant for the complex can be determined by monitoring changes in the refractive index with respect to time as buffer is passed over the chip (O'Shannessy et al. Anal. Biochem. 212:457-468 (1993); Schuster et al., Nature 365:343-347 (1993)). Contacting a candidate compound at various concentrations with the CR2-ligand complex and monitoring the response function (e.g., the change in the refractive index with respect to time) allows the complex dissociation constant to be determined in the presence of the candidate compound and indicates whether the candidate compound is either an inhibitor or an agonist of the CR2-ligand complex. Alternatively, the candidate compound can be contacted with the immobilized CR2 at the same time as the ligand to see if the candidate compound inhibits or stabilizes the binding of the ligand to CR2.

Other suitable assays for measuring the binding of a candidate compound to a CR2 or CR2 ligand, and or for measuring the ability of such compound to affect the binding of a CR2 to its ligand include, for example, immunoassays such as enzyme linked immunoabsorbent assays (ELISA) and radioimmunoassays (RIA), as well as cell-based assays including, cytokine secretion assays, or intracellular signal transduction assays that determine, for example, protein or lipid phosphorylation, mediator release or intracellular Ca⁺⁺ mobilization upon CR2 binding to a cell signal transduction molecule or coreceptor.

As used herein, the phrase “agonist” refers to any compound that interacts with a CR2 and elicits an observable response. More particularly, a CR2 agonist can include, but is not limited to, a protein (including an antibody), a peptide, a nucleic acid or any suitable product of drug design (e.g., a mimetic) which is characterized by its ability to agonize (e.g., stimulate, induce, increase, enhance) the biological activity of a naturally occurring CR2 in a manner similar to a natural agonist (e.g., C3d, gp350/220, or CD23) (e.g., by interaction/binding with and/or direct or indirect activation of CR2, including by stabilizing the interaction of CR2 with a natural ligand). An “antagonist” refers to any compound which inhibits the effect of a CR2 agonist, as described above. More particularly, a CR2 antagonist is capable of associating with a CR2 such that the biological activity of the receptor is decreased (e.g., reduced, inhibited, blocked, reversed, altered) in a manner that is antagonistic (e.g., against, a reversal of, contrary to) to the action of a natural agonist on the receptor. It is noted that the three dimensional structures disclosed herein can be used to design or identify candidate compounds that agonize or antagonize the biological activity of the CR2 ligand. For example, a compound that enhances the interaction between CR2 and CD23 can also have a stimulatory effect on a cell that expresses CD23.

Preferred agonists (i.e., stimulatory compounds) to identify using the present method are compounds that exhibit improved binding to CR2 when compared with the ability of a natural CR2 ligand to bind to CR2, and also include compounds that enhance the binding of a natural ligand to CR2 or enhance signal transduction through CR2 coreceptor complexes. Preferred agonists of the present invention are identified by their ability to: (1) bind to, or otherwise interact with, CR2 at a higher level than, for example, a natural CR2 ligand; (2) enhance binding of CR2 to its ligand; (3) enhance dimer formation of CR2 by binding to CR2 or to the combination of CR2 bound to its ligand; and/or (4) enhance signal transduction through CR2. A preferred agonist of the present invention can also include a compound that binds to CR2 or a CR2 ligand, thereby enhancing the binding of CR2 to its ligand or improving cellular signal transduction during or after the binding of CR2 to its ligand, by, for example, modifying other regions of the CR2 by an allosteric interaction that modifies the ligand-binding site of CR2. Another suitable agonist compound of the present invention can include a compound that binds to CR2 in the absence of a natural ligand, in such a manner that CR2-mediated cellular signal transduction is stimulated.

Suitable antagonist (i.e., inhibitory) compounds to identify using the present method are compounds that interact directly with CR2, thereby inhibiting the binding of a natural ligand to CR2, by either blocking the ligand binding site of CR2 (referred to herein as substrate analogs) or by modifying other regions of CR2 (such as in the interface between the monomers of a CR2 dimer, or at the interface between the SCR1 and SCR2 regions of each monomer) such that the natural ligand cannot bind to CR2 (e.g., by allosteric interaction). A CR2 substrate analog refers to a compound that interacts with (e.g., binds to, associates with, modifies) the ligand binding site of a CR2 protein. A CR2 substrate analog can, for example, comprise a chemical compound that mimics the CR2 binding portion of a natural ligand, or that binds specifically to the ligand binding site of CR2 but does not mimic the CR2 binding portion of the natural ligand. An inhibitory compound of the present invention can also include a compound that essentially mimics at least a portion of CR2 that binds to a natural ligand (referred to herein as a peptidomimetic compound). Other suitable inhibitory compounds of the present invention include compounds that inhibit the binding of CR2 to a cell signal inducing molecule such as CD19.

Various specific embodiments of the present invention are described below. The description of the structure of CR2, and of structure based methods of identifying compounds that regulate CR2 are generally applicable to the methods described below, with particular modifications being noted in the specific description of the methods.

One embodiment of the present invention relates to a method to identify a compound that inhibits the complement receptor type 2 (CR2)-dependent infection of a host cell by Epstein Barr Virus (EBV). This method includes the steps of: (a) providing a three dimensional structure of a CR2 short consensus repeat (SCR) 1-2 region as previously described herein; (b) identifying a candidate compound for binding to the CR2 SCR 1-2 region by performing structure based drug design with the structure of (a) to identify a compound structure that binds to the three dimensional structure of the CR2 SCR 1-2 region; (c) contacting the candidate compound identified in step (b) with a cell that expresses CR2 or a ligand binding fragment thereof and an Epstein Barr Virus (EBV) particle under conditions in which the EBV particle can bind to CR2 and infect the cell in the absence of the candidate compound; and (d) measuring the intracellular EBV titer of the cell; wherein a candidate inhibitor compound is selected as a compound that inhibits the EBV titer in the cell, as compared to in the absence of the candidate inhibitor compound.

As discussed in the Background section, one of the naturally occurring ligand for human CR2 is Epstein-Barr virus (EBV). EBV interacts with CR2 via the gp350/220 viral membrane protein (J. D. Fingeroth, et al., Proc Natl Acad Sci USA 81, 4510-4 (1984)). EBV causes infectious mononucleosis, and is associated with Burkitt's Lymphoma and several other lymphomas and non-lymphoid tumors (M. Okano, Acta Paediatr 87, 11-8 (1998)). Therefore, the identification of compounds that inhibit the interaction between EBV and CR2 are desirable. Previous studies have suggested that two amino acid positions in CR2 Ser16 and Tyr68 to Tyr, FIG. 2E and green patch in FIGS. 5A and 5B) are likely to be involved in gp350/220 binding (D. R. Martinet al., J Virol 68, 4716-26(1994)). Given the three dimensional structure of the CR2 disclosed herein, one of skill in the art can now design or identify compounds that are predicted to bind to three dimensional face of CR2 including these residues.

In this embodiment, the steps of providing the CR2 structure and identifying a candidate compound are performed as described above generally for any candidate compound. The step of contacting the candidate can be performed under any suitable conditions for contacting a virus, or portion of the virus (e.g., gp350/220) with a receptor. Such a method preferably includes contacting (e.g., by mixing, adding, combining) EBV with a cell that expresses CR2 or a ligand binding fragment thereof (e.g., naturally, recombinantly or by induction) under conditions wherein, in the absence of the candidate compound, the EBV particle can bind to CR2 and infect the cell. The intracellular viral titer is measured in the presence and in the absence of the compound using methods well known to those of skill in the art. An inhibitor compound is selected as a compound that inhibits the EBV titer in the cell, as compared to in the absence of the candidate inhibitor compound.

Another embodiment of the present invention relates to a method to identify a compound that inhibits the binding of CD23 to complement receptor type 2 (CR2). This method includes the steps of: (a) providing a three dimensional structure of a CR2 short consensus repeat (SCR) 1-2 region as previously described herein; (b) identifying a candidate compound for binding to the CR2 SCR 1-2 region by performing structure based drug design with the structure of (a) to identify a compound structure that binds to the three dimensional structure of the CR2 SCR 1-2 region; (c) contacting the candidate compound identified in step (b) with a first cell expressing CR2 or a ligand binding fragment thereof and a second cell expressing a CD23 protein or fragment thereof under conditions in which the CD23 protein or fragment thereof and the CR2 or the ligand binding fragment thereof can bind in the absence of the candidate compound; and (d) measuring a biological activity induced by the interaction of CD23 and CR2 in the first or second cell; wherein a candidate inhibitor compound is selected as a compound that inhibits the biological activity as compared to in the absence of the candidate inhibitor compound.

CD23 is a molecule expressed on the follicular dendritic or other cell lineage surfaces which binds to B cells via CR2 (CR2/CD19/CD81 co-activation complex), thereby greatly potentiating signaling via the B cell antigen receptor. The identification of compounds that enhance the binding of CD23 to CR2 would be desirable under conditions when potentiation of the B cell antigen response is desired. However, CD23 is known to enhance IgE isotype switching in B cells. IgE is the prominent immunoglobulin isotype involved in allergic reactions. Inhibition of IgE production would reduce symptoms of allergic inflammation. Therefore, in one embodiment, it is desirable to inhibit the interaction between CR2 and CD23 to reduce IgE isotype switching in B cells.

In this embodiment, the step of contacting the candidate compound identified in step (b) with a first cell expressing CR2 or a ligand binding fragment thereof and a second cell expressing a CD23 protein or fragment thereof occurs under conditions in which the CD23 protein or fragment thereof and the CR2 or the ligand binding fragment thereof can bind in the absence of the candidate compound. Such conditions have been described above for cell-based assays. Preferably, the first cell is a B cell, although any CR2-expressing cell as described herein can be used. The CD23-expressing cell can include a follicular dendritic cell and a cell that recombinantly expresses CD23. Step (d) of measuring a biological activity induced by the interaction of CD23 and CR2 in the first or second cell can include the measurement of any suitable biological activity that is indicative of CR2 activation in the first cell and/or CD23 activation in the second cell. For example, biological activities associated with CR2 activation include, activation of lyn tyrosine kinase, activations of phosphatidyl inositol 3′ kinase, phosphorylation of CD19, activation of PI3 kinase, and activation of protein kinase C (PKC). If the CR2-expressing cell is a B cell, isotype switching to IgE can be measured, for example, by comparing the amounts of expression of IgE between cells in the presence and absence of the compound. Biological activities associated with CD23 activation include, but are not limited to, increases in IgG synthesis, phosphatidylinositol hydrolysis, cAMP synthesis, Calcium flux, protein tyrosine kinase activation, increases in IL-6 and TNF-α synthesis, nitric oxide activation, increases in CD40 and HLA Class II expression, and NF-κB activation (J. Gordon, Immunol. Today 15, 411-417 (1994); B. Heyman, Ann. Rev. Immunol. 18, 709-737(2000); V. Fremeaux-Bacchi, et al, Eur. J. Immunol. 28, 4268-4274 (1998); R. M. Ten, et al, J. Immunol. 163, 3851-3857 (1999). Methods of measuring such biological activities of both CR2 and CD23 are known in the art and include immunoassays, kinase assays, flow cytometry, and phosphorylation assays. In this embodiment of the invention, an inhibitor compound is selected as a compound that inhibits the biological activity of CR2 or CD23 as compared to in the absence of the inhibitor compound.

Yet another embodiment of the present invention relates to a method to identify a compound that inhibits the binding of C3d, C3 or other CR2-binding fragments of C3 that contain C3d or a portion thereof, to complement receptor type 2 (CR2). This method includes the steps of: (a) providing a three dimensional structure of a CR2 short consensus repeat (SCR) 1-2 region as previously described herein; (b) identifying a candidate compound for binding to the CR2 SCR 1-2 region by performing structure based drug design with the structure of (a) to identify a compound structure that binds to the three dimensional structure of the CR2 SCR 1-2 region; (c) contacting the candidate compound identified in step (b) with a cell expressing CR2 or a fragment thereof and C3d or a fragment thereof, C3 or other CR2-binding fragments of C3 that contain C3d or a portion thereof, under conditions in which the C3d or fragment thereof, C3 or other CR2-binding fragments of C3 that contain C3d or a portion thereof, can bind to CR2 and enhance cell activation in the absence of the candidate compound; and (d) measuring the activation of the cell; wherein a candidate inhibitor compound is selected as a compound that inhibits cell activation, as compared to in the absence of the candidate inhibitor compound.

C3d-bound antigens, or antigens containing CR2-binding C3 fragments that contain C3d or a portion thereof, amplify B cell responses by binding to CR2 through C3d (or other CR2-binding C3 fragments that contain C3d or a portion thereof) at the same time as engaging the B cell antigen receptor (BCR) via the bound antigen (R. H. Carter and D. T. Fearon, Science 256, 105-7 (1992); J. C. Cambier, Biochem Soc Trans 25, 441-5 (1997)). The cross-linking of CR2 to the BCR by C3d greatly amplifies a signal transduction cascade through the CR2/CD19/CD81 co-activation complex (D. T. Fearon, 1995 ibid.; D. T. Fearon, 1998, ibid.; J. C. Cambier, 1997, ibid.; A. K. Matsumoto, et al., J Exp Med 173, 55-64 (1991)). Therefore, compounds that inhibit this interaction are useful for reducing an immune response and specifically, a humoral immune response (although effects on the cellular immune response may also be achieved). Compounds that enhance or mimic the interaction between CR2 and C3d are useful for potentiating such an immune response.

In this embodiment, the step of contacting the candidate compound identified in step (b) with a cell expressing CR2 or a fragment thereof and C3d or a fragment thereof, C3 or other CR2-binding fragments of C3 that contain C3d or a portion thereof, occurs under conditions in which the C3d or fragment thereof, C3 or other CR2-binding fragments of C3 that contain C3d or a portion thereof, can bind to CR2 and enhance cell activation in the absence of the candidate compound. Such cell-based methods of contacting have been described previously herein. Preferably, the cell expressing CR2 is selected from the group of a B cell, a T cell, a thymocyte, an epithelial cell, and a mast cell. The measurement of cell activation in (d) can be accomplished by any suitable method for detecting CR2 biological activity as previously described herein, and includes, but is not limited to: the measurement of: cytokine production by the cell, calcium mobilization in the cell, lyn tyrosine kinase activity in the cell, phosphatidyl inositol 3′ kinase activity in the cell, phosphorylation of CD19 in the cell, and activation of protein kinase C (PKC) in the cell. An inhibitor compound is selected as a compound that inhibits cell activation, as compared to in the absence of the candidate inhibitor compound.

Another embodiment of the present invention relates to a method to inhibit complement receptor type 2 (CR2)-dependent human immunodeficiency virus-1 (HIV-1) infection of cells in a patient. This method includes the steps of administering to a patient infected with HIV-1 an inhibitor compound that inhibits the binding of C3d, C3 or another CR2-binding fragment of C3 containing C3d or a portion thereof, -opsonized HIV-1 to B cells, follicular dendritic cells, T cells or macrophages in the patient. The inhibitor compound is selected by the steps of: (a) providing a three dimensional structure of a CR2 short consensus repeat (SCR) 1-2 region as previously described herein; (b) identifying a candidate compound for binding to said CR2 SCR 1-2 region by performing structure based drug design with said structure of (a) to identify a compound structure that binds to said three dimensional structure of said CR2 SCR 1-2 region; (c) contacting said candidate compound identified in step (b) with a B cell, follicular dendritic cell, T cell or macrophage expressing CR2 or a fragment thereof and C3d or a fragment thereof, C3 or other CR2-binding fragments of C3 that contain C3d or a portion thereof, under conditions in which said C3d or fragment thereof, C3 or other CR2-binding fragments of C3 that contain C3d or a portion thereof, can bind to CR2 and enhance activation of the B cell, follicular dendritic cell, T cell or macrophage in the absence of said candidate compound; and (d) measuring the activation of the B cell, follicular dendritic cell, T cell or macrophage, wherein a candidate inhibitor compound is selected as a compound that inhibits activation of the B cell, follicular dendritic cell, T cell or macrophage, as compared to in the absence of said candidate inhibitor compound.

CR2 has been shown to mediate the interaction of C3d-bound HIV-1, or HIV-1 bound to other CR2-binding C3 fragments that contain C3d or a portion thereof, as an immune complex with B cells in a fashion that promotes transfer of virus and infection of CD4 T cells (S. Moir, et al., J Exp Med 192, 637-46 (2000)). Therefore, it would be desirable to design or identify compounds that inhibit the interaction of C3d, C3 or other CR2-binding fragments of C3 that contain C3d or a portion thereof with CR2 on B cells, follicular dendritic cells, T cells and macrophages to reduce the infection of CD4 T cells by HIV-1. In this embodiment, the step of contacting the candidate compound identified in step (b) with a B cell, follicular dendritic cell, T cell or macrophage, expressing CR2 or a fragment thereof and C3d or a fragment thereof, C3 or other CR2-binding fragments of C3 that contain C3d or a portion thereof, occurs under conditions in which the C3d or fragment thereof, C3 or other CR2-binding fragments of C3 that contain C3d or a portion thereof, can bind to CR2 and enhance activation of the B cell, follicular dendritic cell, T cell or macrophage in the absence of the candidate compound. Such conditions have been described in detail above. In addition, the step of measuring the activation of the B cell, follicular dendritic cell, T cell or macrophage expressing CR2 (i.e., by measuring a biological activity effected by CR2) have been described above.

Once a compound has been identified that inhibits the interaction between C3d and CR2 on B cells, follicular dendritic cells, T cells and/or macrophages, the compound is administered to a patient infected with HIV-1. A preferred patient to treat includes a patient with early-onset HIV infection. Such a patient can be defined herein as a patient that meets one or more of the following criteria: (1) the patient has a blood CD4⁺ T cell count of at least about 100 cells/mm³, and preferably, at least about 200 cells/mm³, and more preferably, at least about 300 cells/mm³, and even more preferably, at least about 400 cells/mm³ as determined within 30 days of the time of employment of the present method; and (2) the patient has an HIV serum load of less than about 400 copies/ml, and preferably, less than about 300 copies/ml, and more preferably, less than about 200 copies/ml, and even more preferably, less than about 100 copies/ml, and most preferably undetectable viral load, as determined by plasma RNA PCT within 30 days of when the method is employed. In one embodiment, the patient is characterized as having a CD4⁺ T cell count of at least about 100 cells/mm³ when the method is employed and/or an HIV viral load of less than about 400 copies/ml when the method is employed.

A composition to be administered to a patient, such as in this embodiment, generally includes the compound identified by the structure based identification method and a carrier, and preferably, a pharmaceutically acceptable carrier. According to the present invention, a “pharmaceutically acceptable carrier” includes pharmaceutically acceptable excipients and/or pharmaceutically acceptable delivery vehicles, which are suitable for use in administration of the composition to a suitable in vitro, ex vivo or in vivo site. A suitable in vitro, in vivo or ex vivo site is preferably at or near a cell that expresses a CR2, and most preferably, at or near a site of interest in the patient. Preferred pharmaceutically acceptable carriers are capable of maintaining a compound identified by the present methods in a form that, upon arrival of compound at the cell target in a culture or in patient, the compound is capable of interacting with its target (e.g., a CR2).

Suitable excipients of the present invention include excipients or formularies that transport or help transport, but do not specifically target a composition to a cell (also referred to herein as non-targeting carriers). Examples of pharmaceutically acceptable excipients include, but are not limited to water, phosphate buffered saline, Ringer's solution, dextrose solution, serum-containing solutions, Hank's solution, other aqueous physiologically balanced solutions, oils, esters and glycols. Aqueous carriers can contain suitable auxiliary substances required to approximate the physiological conditions of the recipient, for example, by enhancing chemical stability and isotonicity.

Suitable auxiliary substances include, for example, sodium acetate, sodium chloride, sodium lactate, potassium chloride, calcium chloride, and other substances used to produce phosphate buffer, Tris buffer, and bicarbonate buffer. Auxiliary substances can also include preservatives, such as thimerosal,—or o-cresol, formalin and benzol alcohol. Compositions of the present invention can be sterilized by conventional methods and/or lyophilized.

One type of pharmaceutically acceptable carrier includes a controlled release formulation that is capable of slowly releasing a composition of the present invention into a patient or culture. As used herein, a controlled release formulation comprises a compound of the present invention (e.g., a protein (including homologues), a drug, an antibody, a nucleic acid molecule, or a mimetic) in a controlled release vehicle. Suitable controlled release vehicles include, but are not limited to, biocompatible polymers, other polymeric matrices, capsules, microcapsules, microparticles, bolus preparations, osmotic pumps, diffusion devices, liposomes, lipospheres, and transdermal delivery systems. Other carriers of the present invention include liquids that, upon administration to a patient, form a solid or a gel in situ. Preferred carriers are also biodegradable (i.e., bioerodible). When the compound is a recombinant nucleic acid molecule, suitable delivery vehicles include, but are not limited to liposomes, viral vectors or other delivery vehicles, including ribozymes. Natural lipid-containing delivery vehicles include cells and cellular membranes. Artificial lipid-containing delivery vehicles include liposomes and micelles. A delivery vehicle of the present invention can be modified to target to a particular site in a patient, thereby targeting and making use of a compound of the present invention at that site. Suitable modifications include manipulating the chemical formula of the lipid portion of the delivery vehicle and/or introducing into the vehicle a targeting agent capable of specifically targeting a delivery vehicle to a preferred site, for example, a preferred cell type. Other suitable delivery vehicles include gold particles, poly-L-lysine/DNA-molecular conjugates, and artificial chromosomes.

A pharmaceutically acceptable carrier which is capable of targeting is herein referred to as a “delivery vehicle.” Delivery vehicles of the present invention are capable of delivering a composition of the present invention to a target site in a patient. A “target site” refers to a site in a patient to which one desires to deliver a composition. For example, a target site can be any cell which is targeted by direct injection or delivery using liposomes, viral vectors or other delivery vehicles, including ribozymes and antibodies. Examples of delivery vehicles include, but are not limited to, artificial and natural lipid-containing delivery vehicles, viral vectors, and ribozymes. Natural lipid-containing delivery vehicles include cells and cellular membranes. Artificial lipid-containing delivery vehicles include liposomes and micelles. A delivery vehicle of the present invention can be modified to target to a particular site in a subject, thereby targeting and making use of a compound of the present invention at that site. Suitable modifications include manipulating the chemical formula of the lipid portion of the delivery vehicle and/or introducing into the vehicle a compound capable of specifically targeting a delivery vehicle to a preferred site, for example, a preferred cell type. Specifically, targeting refers to causing a delivery vehicle to bind to a particular cell by the interaction of the compound in the vehicle to a molecule on the surface of the cell. Suitable targeting compounds include ligands capable of selectively (i.e., specifically) binding another molecule at a particular site. Examples of such ligands include antibodies, antigens, receptors and receptor ligands. Manipulating the chemical formula of the lipid portion of the delivery vehicle can modulate the extracellular or intracellular targeting of the delivery vehicle. For example, a chemical can be added to the lipid formula of a liposome that alters the charge of the lipid bilayer of the liposome so that the liposome fuses with particular cells having particular charge characteristics. In one embodiment, a targeting carrier can be a portion of a CR2 protein as described elsewhere herein, which is linked to the compound.

One preferred delivery vehicle of the present invention is a liposome. A liposome is capable of remaining stable in an animal for a sufficient amount of time to deliver a nucleic acid molecule or other compound to a preferred site in the animal. A liposome, according to the present invention, comprises a lipid composition that is capable of delivering a nucleic acid molecule or other compound to a particular, or selected, site in a patient. A liposome according to the present invention comprises a lipid composition that is capable of fusing with the plasma membrane of the targeted cell to deliver a nucleic acid molecule or other compound into a cell. Suitable liposomes for use with the present invention include any liposome. Preferred liposomes of the present invention include those liposomes commonly used in, for example, gene delivery methods known to those of skill in the art. More preferred liposomes comprise liposomes having a polycationic lipid composition and/or liposomes having a cholesterol backbone conjugated to polyethylene glycol. Complexing a liposome with a nucleic acid molecule or other compound can be achieved using methods standard in the art.

A liposome delivery vehicle is preferably capable of remaining stable in a patient for a sufficient amount of time to deliver a nucleic acid molecule or other compound of the present invention to a preferred site in the patient (i.e., a target cell). A liposome delivery vehicle of the present invention is preferably stable in the patient into which it has been administered for at least about 30 minutes, more preferably for at least about 1 hour and even more preferably for at least about 24 hours. A preferred liposome delivery vehicle of the present invention is from about 0.01 microns to about 1 microns in size.

Another preferred delivery vehicle comprises a viral vector. A viral vector includes an isolated nucleic acid molecule useful in the present invention, in which the nucleic acid molecules are packaged in a viral coat that allows entrance of DNA into a cell. A number of viral vectors can be used, including, but not limited to, those based on alphaviruses, poxviruses, adenoviruses, herpesviruses, lentiviruses, adeno-associated viruses and retroviruses.

A composition which includes an compound identified according to the present methods can be delivered to a cell culture or patient by any suitable method. Selection of such a method will vary with the type of compound being administered or delivered (i.e., protein, peptide, nucleic acid molecule, mimetic, or other type of compound), the mode of delivery (i.e., in vitro, in vivo, ex vivo) and the goal to be achieved by administration/delivery of the compound or composition. According to the present invention, an effective administration protocol (i.e., administering a composition in an effective manner) comprises suitable dose parameters and modes of administration that result in delivery of a composition to a desired site (i.e., to a desired cell) and/or in the desired regulatory event (e.g., inhibition of the binding of C3d-opsonized HIV-1 to B cells or follicular dendritic cells in the patient).

Administration routes include in vivo, in vitro and ex vivo routes. In vivo routes include, but are not limited to, oral, nasal, intratracheal injection, inhaled, transdermal, rectal, and parenteral routes. Preferred parenteral routes can include, but are not limited to, subcutaneous, intradermal, intravenous, intramuscular and intraperitoneal routes. Intravenous, intraperitoneal, intradermal, subcutaneous and intramuscular administrations can be performed using methods standard in the art. Aerosol (inhalation) delivery can also be performed using methods standard in the art (see, for example, Stribling et al., Proc. Natl. Acad. Sci. USA 189:11277-11281, 1992, which is incorporated herein by reference in its entirety). Oral delivery can be performed by complexing a therapeutic composition of the present invention to a carrier capable of withstanding degradation by digestive enzymes in the gut of an animal. Examples of such carriers, include plastic capsules or tablets, such as those known in the art. Direct injection techniques are particularly useful for suppressing graft rejection by, for example, injecting the composition into the transplanted tissue, or for site-specific administration of a compound, such as at the site of a tumor. Ex vivo refers to performing part of the regulatory step outside of the patient, such as by transfecting a population of cells removed from a patient with a recombinant molecule comprising a nucleic acid sequence encoding a protein according to the present invention under conditions such that the recombinant molecule is subsequently expressed by the transfected cell, and returning the transfected cells to the patient. In vitro and ex vivo routes of administration of a composition to a culture of host cells can be accomplished by a method including, but not limited to, transfection, transformation, electroporation, microinjection, lipofection, adsorption, protoplast fusion, use of protein carrying agents, use of ion carrying agents, use of detergents for cell permeabilization, and simply mixing (e.g., combining) a compound in culture with a target cell.

In this particular embodiment of the invention (i.e., the inhibition of HIV infection), it will be obvious to one of skill in the art that the number of doses administered to an immunodeficiency virus infected patient is dependent upon the extent of the infection and the response of an individual to the treatment. For example, in the case of HIV-infection, a patient having a high titer of HIV may require more doses than a patient having lower titers. In some cases, however, a patient having a high titer of HIV may require fewer doses than a patient having lower titers, if the patient with the high titer responds more favorably to the therapeutic composition than the patient with the lower titer. Thus, it is within the scope of the present invention that a suitable number of doses, as well as the time periods between administration, includes any number required to cause regression of a disease.

In another embodiment, this method is employed in conjunction with administration to the patient of one or more anti-retroviral therapeutic compounds. Such compounds include, but are not limited to, AZT, ddI, ddC, d4T, 3TC and/or protease inhibitors.

Another embodiment of the present invention relates to a method of preparing a vaccine, comprising linking a compound that increases B cell activation to an antigen to form the vaccine. The compound is selected by a method including the steps of: (a) providing a three dimensional structure of a CR2 short consensus repeat (SCR) 1-2 region as previously described herein; (b) identifying a candidate compound for binding to the CR2 SCR 1-2 region by performing structure based drug design with the structure of (a) to identify a compound structure that binds to the three dimensional structure of the CR2 SCR 1-2 region; (c) contacting the candidate compound identified in step (b) with a B cell expressing CR2 or a fragment thereof and with C3d or a fragment thereof, C3 or other CR2-binding fragments of C3 that contain C3d or a portion thereof, under conditions in which said C3d or fragment thereof, C3 or other CR2-binding fragments of C3 that contain C3d or a portion thereof, can bind to and activate CR2 in the absence of said candidate compound; and (d) measuring the activation of the B cell. A candidate compound for use in a vaccine is selected as a compound that increases B cell activation as compared to in the absence of the candidate compound.

Because CR2 plays a critical role as a coreceptor for B cells and is expressed on other cells as well, CR2 is a molecular target for adjuvants and can enhance the immune response to vaccines. Therefore, in this method, compounds are identified that bind to CR2 and that enhance B cell activation, either by enhancing the interaction between CR2 and a natural ligand (e.g., C3d), or by directly interacting with CR2 to enhance downstream biological activities of the receptor, as previously discussed herein. Methods for contacting a cell with the compound and measuring the activation events associated with CR2 activation have been previously described. In addition, to measure B cell activation, one can measure calcium mobilization, immunoglobulin class switching, cytokine production, activation of NF-κB, activation of MAP kinases, protein kinase activity and phosphorylation of proteins associated with B cell activation. In this embodiment, the conditions under which the B cell is contacted typically include the presence of an antigen that binds to the B cell antigen receptor, in addition to the other components. A compound for use in a vaccine, once identified, is typically associated with a protein (antigen or antigen-containing composition) or nucleic acid to be administered to a patient as part of the vaccine. The use of a compound identified by the present method will potentiate the immune response to the antigen.

Another embodiment of the present invention relates to a drug delivery system that will preferentially deliver compounds to sites of complement activation containing CR-2 binding fragments of C3 (e.g., C3 and portions thereof that contain C3d). Such a drug delivery system includes: (a) a drug; and, (b) a portion of a CR2 protein that includes one or more of: (i) a portion comprising positions on strand B and the B-C loop of SCR2 including: G79-G80-Y81-K82-I83-R84-G85-S86-T87-P88-Y89; (ii) a portion comprising position K100 on the B strand of CR2; and, (iii) a portion comprising positions: V130-F131-P132-L133 (positions given with reference to SEQ ID NO:4). In one embodiment, the portion of the CR2 protein can also contain positions T101-N102-F103 (reference again to SEQ ID NO:4). The drug is linked to the portion of CR2 by any suitable method, covalently or non-covalently, including by recombinant means or by chemical means. In this embodiment, the CR2 is not a full-length protein, or the soluble form of CR2, as it is known in the art (i.e., the natural soluble CR2 or the CR2 with the membrane portion removed), but rather, includes less of the amino acid sequence than the full-length or the soluble CR2, and preferably, just the portions of SCR1 and SCR2 that have been determined herein to be involved in the contact between CR2 and a natural ligand (e.g., C3d) and that are required to form a CR2 portion with the tertiary structure necessary to bind to C3d (or a fragment thereof). Therefore, the portion of CR2 used in the drug delivery system consists essentially of at least one or more of the above-recited segments of CR2, including a contiguous segment containing all of the segments (i.e., from positions 79-133 of SEQ ID NO:4), and has the three dimensional conformation of CR2 at the CR2-C3d interface, such that the portion will bind to C3d, C3 or other CR2-binding fragments of C3 that contain C3d or a portion thereof. Therefore, the portion of CR2 suitable for use in a drug delivery system includes the portions of CR2 that contact C3d, as well as the portions required to maintain the spatial positions of the contact residues, such that the tertiary structure of the C3d binding portion is conformationally similar to the tertiary structure of the C3d binding portion of the CR2 crystal described herein, using the parameters for structural homologues as described elsewhere herein for the structure of the CR2 complexed with C3d. According to the present invention, a CR2 fragment consisting essentially of the portions of SCR1 and SCP2 that have been determined herein to be involved in the contact between CR2 and C3d can have at least one, and up to about 20 (in whole number increments), additional heterologous amino acids flanking each of the C- and/or N-terminal end of the CR2 portion that contains the above-described segments and the sequence necessary to maintain the appropriate tertiary structure to bind to C3d (or a fragment thereof). According to the present invention, the heterologous amino acids are a sequence of amino acids that are not naturally found (i.e., not found in nature, in vivo) flanking the CR2 sequence that makes up the portion of CR2 or which would not be encoded by the nucleotides that flank the naturally occurring CR2 nucleic acid sequence as it occurs in the gene, if such nucleotides in the naturally occurring sequence were translated using standard codon usage for the organism from which the given CR2 portion is derived. Such heterologous amino acids can include a sequence that is less than about 75% similar to the natural sequence in the same positions. This embodiment also includes methods of identifying such portions of CR2.

Drugs that are desirable to deliver using the drug delivery system of the present invention include any drug that may have a beneficial effect on a subject when delivered to a site of complement activation wherein C3 and/or CR2-binding portions of C3 are present. The drugs can be protein-based, carbohydrate-based, lipid-based, nucleic acid-based, or any small molecule. Examples of such drugs include, but are not limited to, anti-inflammatory compounds, cytotoxic drugs, complement regulatory proteins, corticosteroids, and any compounds useful in ischemic, inflammatory autoimmune or vascular diseases, all of which have C3 fragments present.

In this embodiment, drug design strategies as specifically described above with regard to the identification of compounds that bind to CR2 and affect its interaction with various ligands can be similarly applied to the CR2 structure itself. CR2 proteins designed by this method can be used as drug delivery vehicles or to otherwise alter the biological activity of a CR2, such as by competing for a naturally occurring CR2 in vivo. One of ordinary skill in the art, using the art recognized modeling programs and drug design methods, many of which are described herein, to prepare portions of complement receptor type 2 (CR2) proteins that bind to their ligands, including CR2 homologues that retain ligand binding activity. In addition, one of skill in the art can produce CR2 proteins having modified biological activity. For example, such a method can include: (a) providing a three dimensional structure of a CR2 SCR1-2 domain as previously described herein; (b) analyzing the three dimensional structure to the three-dimensional structure of the CR2 SCR 1-2 region by performing structure based drug design with the structure of (a) to the sites in the structure contributing to ability of CR2 to bind to a ligand (e.g., C3d or other CR2-binding fragments of C3); and (c) producing a protein that is a portion of CR2 that includes such sites. In the method to produce a CR2 protein having modified biological activity, one can analyze the three dimensional structure of CR2 provided herein to identify at least one site that contributes to the biological activity of the protein, and then modify at least one such site to alter the biological activity of the CR2 protein. Methods to altered proteins for CR2 biological activity include testing the altered protein for any of the biological activities of CR2 previously described herein.

Another embodiment of the present invention relates to an antibody that selectively binds to CR2. The antibody binds to a portion of CR2 selected from the group consisting of: (a) the interface between the SCR1 and SCR2 domains of CR2; (b) the dimer interface between two CR2 proteins; and, (c) the interface between CR2 and C3d (where the C3d includes any CR2-binding fragments of C3 that contain C3d or a portion thereof). The portion of the CR2-C3d interface bound by the antibody preferably includes at site selected from: (a) the B strand and the B-C loop of CR2 SCR2 comprising the segment: G79-G80-Y81-K82-I83-R84-G85-S86-T87-P88-Y89; (b) the B strand of CR2 SCR2 comprising position K100; and (c) a segment of CR2 SCR2 comprising V130-F131-P132-L133. Prior to the present invention, the three dimensional structure of the CR2 interfaces set forth above were not known and therefore, it was not possible to design or identify an antibody by making use of such structural information. The present inventors have provided suitable target sites, including specific residues within such sites, for the design and identification of antibodies.

According to the present invention, the phrase “selectively binds to” refers to the ability of an antibody, antigen binding fragment or binding partner of the present invention to preferentially bind to specified proteins (e.g., the recited portions of a CR2 of the present invention). More specifically, the phrase “selectively binds” refers to the specific binding of one protein to another (e.g., an antibody, fragment thereof, or binding partner to an antigen), wherein the level of binding, as measured by any standard assay (e.g., an immunoassay), is statistically significantly higher than the background control for the assay. For example, when performing an immunoassay, controls typically include a reaction well/tube that contain antibody or antigen binding fragment alone (i.e., in the absence of antigen), wherein an amount of reactivity (e.g., non-specific binding to the well) by the antibody or antigen binding fragment thereof in the absence of the antigen is considered to be background. Binding can be measured using a variety of methods standard in the art including enzyme immunoassays (e.g., ELISA), immunoblot assays, etc.

Limited digestion of an immunoglobulin with a protease may produce two fragments. An antigen binding fragment is referred to as an Fab, an Fab′, or an F(ab′)₂ fragment. A fragment lacking the ability to bind to antigen is referred to as an Fc fragment. An Fab fragment comprises one arm of an immunoglobulin molecule containing a L chain (V_(L)+C_(L) domains) paired with the V_(H) region and a portion of the C_(H) region (CH1 domain). An Fab′ fragment corresponds to an Fab fragment with part of the hinge region attached to the CH1 domain. An F(ab′)₂ fragment corresponds to two Fab′ fragments that are normally covalently linked to each other through a di-sulfide bond, typically in the hinge regions.

Functional aspects of an immunoglobulin molecule include the valency of an immunoglobulin molecule, the affinity of an immunoglobulin molecule, and the avidity of an immunoglobulin molecule. As used herein, affinity refers to the strength with which an immunoglobulin molecule binds to an antigen at a single site on an immunoglobulin molecule (i.e., a monovalent Fab fragment binding to a monovalent antigen). Affinity differs from avidity which refers to the sum total of the strength with which an immunoglobulin binds to an antigen. Immunoglobulin binding affinity can be measured using techniques standard in the art, such as competitive binding techniques, equilibrium dialysis or BIAcore methods. As used herein, valency refers to the number of different antigen binding sites per immunoglobulin molecule (i.e., the number of antigen binding sites per antibody molecule of antigen binding fragment). For example, a monovalent immunoglobulin molecule can only bind to one antigen at one time, whereas a bivalent immunoglobulin molecule can bind to two or more antigens at one time, and so forth. Both monovalent and bivalent antibodies that selectively bind to CR2 of the present invention are encompassed herein.

In one embodiment of the present invention, a monovalent antibody can be used as a regulatory compound. Such an antibody is not capable of aggregating receptors. Divalent antibodies can also be used in the present invention.

In one embodiment, the antibody is a bi- or multi-specific antibody. A bi-specific (or multi-specific) antibody is capable of binding two (or more) antigens, as with a divalent (or multivalent) antibody, but in this case, the antigens are different antigens (i.e., the antibody exhibits dual or greater specificity). A bi-specific antibody suitable for use in the present method includes an antibody having: (a) a first portion (e.g., a first antigen binding portion) which binds to CR2; and (b) a second portion which binds to a cell surface molecule expressed by a cell which expresses CR2. In this embodiment, the second portion can bind to any cell surface molecule. In a preferred embodiment, the second portion is capable of targeting the regulatory antibody to a specific target cell (i.e., the regulatory antibody binds to a target molecule).

Isolated antibodies of the present invention can include serum containing such antibodies, or antibodies that have been purified to varying degrees. Whole antibodies of the present invention can be polyclonal or monoclonal. Alternatively, functional equivalents of whole antibodies, such as antigen binding fragments in which one or more antibody domains are truncated or absent (e.g., Fv, Fab, Fab′, or F(ab)₂ fragments), as well as genetically-engineered antibodies or antigen binding fragments thereof, including single chain antibodies or antibodies that can bind to more than one epitope (e.g., bi-specific antibodies), or antibodies that can bind to one or more different antigens (e.g., bi- or multi-specific antibodies), may also be employed in the invention.

Genetically engineered antibodies of the invention include those produced by standard recombinant DNA techniques involving the manipulation and re-expression of DNA encoding antibody variable and/or constant regions. Particular examples include, chimeric antibodies, where the V_(H) and/or V_(L) domains of the antibody come from a different source to the remainder of the antibody, and CDR grafted antibodies (and antigen binding fragments thereof), in which at least one CDR sequence and optionally at least one variable region framework amino acid is (are) derived from one source and the remaining portions of the variable and the constant regions (as appropriate) are derived from a different source.

Construction of chimeric and CDR-grafted antibodies are described, for example, in European Patent Applications: EP-A 0194276, EP-A 0239400, EP-A 0451216 and EP-A 0460617.

Alternative methods, employing, for example, phage display technology (see for example U.S. Pat. No. 5,969,108, U.S. Pat. No. 5,565,332, U.S. Pat. No. 5,871,907, U.S. Pat. No. 5,858,657) or the selected lymphocyte antibody method of U.S. Pat. No. 5,627,052 may also be used for the production of antibodies and/or antigen fragments of the invention, as will be readily apparent to the skilled individual.

Generally, in the production of an antibody, a suitable experimental animal, such as, for example, but not limited to, a rabbit, a sheep, a hamster, a guinea pig, a mouse, a rat, or a chicken, is exposed to an antigen against which an antibody is desired. Typically, an animal is immunized with an effective amount of antigen that is injected into the animal. An effective amount of antigen refers to an amount needed to induce antibody production by the animal. The animal's immune system is then allowed to respond over a pre-determined period of time. The immunization process can be repeated until the immune system is found to be producing antibodies to the antigen. In order to obtain polyclonal antibodies specific for the antigen, serum is collected from the animal that contains the desired antibodies (or in the case of a chicken, antibody can be collected from the eggs). Such serum is useful as a reagent. Polyclonal antibodies can be further purified from the serum (or eggs) by, for example, treating the serum with ammonium sulfate.

Monoclonal antibodies may be produced according to the methodology of Kohler and Milstein (Nature 256:495-497, 1975). For example, B lymphocytes are recovered from the spleen (or any suitable tissue) of an immunized animal and then fused with myeloma cells to obtain a population of hybridoma cells capable of continual growth in suitable culture medium. Hybridomas producing the desired antibody are selected by testing the ability of the antibody produced by the hybridoma to bind to the desired antigen.

Another embodiment of the present invention relates to a therapeutic composition that, when administered to an animal, enhances B cell responses in the animal. The therapeutic composition includes a compound that stimulates the activity of a complement receptor type 2 (CR2), which has been identified by a method of structure based identification of compounds of the present invention, as described in detail above. Specifically, this method includes the steps of: (a) providing a three dimensional structure of a CR2 short consensus repeat (SCR) 1-2 region as described previously herein; (b) identifying a candidate compound for binding to the CR2 SCR 1-2 region by performing structure based drug design with the structure of (a) to identify a compound structure that binds to the three dimensional structure of the CR2 SCR 1-2 region; (c) synthesizing the candidate compound; and (d) selecting candidate compounds that bind to and activate CR2 .

Another embodiment of the present invention relates to a therapeutic composition that, when administered to an animal, inhibits the biological activity of complement receptor type 2 (CR2) in the animal. The therapeutic composition comprises a compound that inhibits the activity of a complement receptor type 2 (CR2), the compound being identified by the method comprising: (a) providing a three dimensional structure of a CR2 short consensus repeat (SCR) 1-2 region as previously described herein; (b) identifying a candidate compound for binding to the CR2 SCR 1-2 region by performing structure based drug design with the structure of (a) to identify a compound structure that binds to the three dimensional structure of the CR2 SCR 1-2 region; (c) synthesizing the candidate compound; and (d) selecting candidate compounds that inhibit the biological activity of CR2. Preferably, the compounds inhibit the formation of a complex between CR2 and a CR2 ligand, such ligand including, but not limited to, C3d, CD23 and Epstein Barr Virus (EBV). In a more preferred embodiment, the compound inhibits the activation of CR2.

Methods of identifying candidate compounds and selecting compounds that bind to and activate or inhibit CR2 have been previously described herein. Candidate compounds can be synthesized using techniques known in the art, and depending on the type of compound. Synthesis techniques for the production of non-protein compounds, including organic and inorganic compounds are well known in the art.

For smaller peptides, chemical synthesis methods are preferred. For example, such methods include well known chemical procedures, such as solution or solid-phase peptide synthesis, or semi-synthesis in solution beginning with protein fragments coupled through conventional solution methods. Such methods are well known in the art and may be found in general texts and articles in the area such as: Merrifield, 1997, Methods Enzymol. 289:3-13; Wade et al., 1993,Australas Biotechnol. 3(6):332-336; Wong et al., 1991, Experientia 47(11-12):1123-1129; Carey et al., 1991, Ciba Found Symp. 158:187-203; Plaue et al., 1990, Biologicals 18(3):147-157; Bodanszky, 1985, Int. J. Pept. Protein Res. 25(5):449-474; or H. Dugas and C. Penney, BIOORGANIC CHEMISTRY, (1981) at pages 54-92, all of which are incorporated herein by reference in their entirety. For example, peptides may be synthesized by solid-phase methodology utilizing a commercially available peptide synthesizer and synthesis cycles supplied by the manufacturer. One skilled in the art recognizes that the solid phase synthesis could also be accomplished using the FMOC strategy and a TFA/scavenger cleavage mixture.

If larger quantities of a protein are desired, or if the protein is a larger polypeptide, the protein can be produced using recombinant DNA technology. A protein can be produced recombinantly by culturing a cell capable of expressing the protein (i.e., by expressing a recombinant nucleic acid molecule encoding the protein) under conditions effective to produce the protein, and recovering the protein. Effective culture conditions include, but are not limited to, effective media, bioreactor, temperature, pH and oxygen conditions that permit protein production. An effective medium refers to any medium in which a cell is cultured to produce the protein. Such medium typically comprises an aqueous medium having assimilable carbon, nitrogen and phosphate sources, and appropriate salts, minerals, metals and other nutrients, such as vitamins. Recombinant cells (i.e., cells expressing a nucleic acid molecule encoding the desired protein) can be cultured in conventional fermentation bioreactors, shake flasks, test tubes, microtiter dishes, and petri plates. Culturing can be carried out at a temperature, pH and oxygen content appropriate for a recombinant cell. Such culturing conditions are within the expertise of one of ordinary skill in the art. Such techniques are well known in the art and are described, for example, in Sambrook et al., 1988, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. or Current Protocols in Molecular Biology (1989) and supplements.

As discussed above, a composition, and particularly a therapeutic composition, of the present invention generally includes the therapeutic compound (e.g., the compound identified by the structure based identification method) and a carrier, and preferably, a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers and preferred methods of administration of therapeutic compositions of the present invention have been described in detail above with regard to the administration of an inhibitor compound to a patient infected with HIV. Such carriers and administration protocols are applicable to this embodiment.

Yet another embodiment of the present invention relates to an isolated C3d mutant protein, C3 or other CR2-binding fragments of C3 that contain a mutant C3d or a portion thereof, comprising an amino acid substitution of an non-asparagine amino acid residue at position 170 wherein said C3d mutant protein, C3 or other CR2-binding fragments of C3 that contain the mutant C3d or a portion thereof, has reduced binding to complement receptor type 2 (CR2), as compared to a wild-type C3d protein (SEQ ID NO:7), or equivalent wild-type CR2-binding fragment of C3 that contain C3d or a portion thereof. Preferably, the mutant protein is at least about 50% identical to SEQ ID NO:7, and more preferably at least about 60% identical, and more preferably at least about 70% identical, and more preferably at least about 80% identical, and more preferably at least about 90% identical, and more preferably at least about 95% identical to SEQ ID NO:7. In a preferred embodiment, the mutant protein comprises SEQ ID NO:8 (mt170 or mut2) or SEQ ID NO:9 (mut4).

Another embodiment of the present invention relates to a computer for producing a three-dimensional model of a molecule or molecular structure, wherein the molecule or molecular structure comprises a three dimensional structure defined by atomic coordinates of a complement receptor type 2 (CR2) protein, according to Table 2 or Table 3, or a three-dimensional model of a homologue of the molecule or molecular structure, wherein the homologue comprises a three dimensional structure that has an average root-mean-square deviation (RMSD) of equal to or less than about 1.0 Å for the backbone atoms in secondary structure elements in the CR2 protein, wherein the computer comprises:

a. a computer-readable medium encoded with the atomic coordinates of the CR2 protein, according to Table 2 or Table 3, to create an electronic file;

b. a working memory for storing a graphical display software program for processing the electronic file;

c. a processor coupled to the working memory and to the computer-readable medium which is capable of representing the electronic file as the three dimensional model; and,

d. a display coupled to the processor for visualizing the three dimensional model;

wherein the three dimensional structure of the CR2 protein is displayed on the computer.

The following examples are provided for the purpose of illustration and are not intended to limit the scope of the present invention.

EXAMPLES Example 1

The following example describes the crystallization and structure determination of the complex of complement receptor type 2 (CR2) and C3d.

Crystallization and Structure Determination of Structure

The crystals of the complex of CR2-C3d were obtained by co-crystallization of CR2 and C3d, at a protein ratio where no free CR2 or C3d could be detected by native gel electrophoresis. The protein concentration of 20 mg/ml was used for crystallization by the method of hanging drop vapor diffusion. The crystallization buffer contained 17% PEG 2K, 0.2 M ZnAcetate, and 0.1 M NaCacodylate (pH 7.36). Crystals reached full size after 4-6 weeks at 4° C. Crystal was frozen under liquid nitrogen in the crystallization buffer containing 20% glycerol. Synchrotron data were collected at Brookhaven National Laboratory and was indexed, integrated and reduced using D*trek (licensed through MSC Inc., Table 1). The space group is R32, with unit cell a=b=170.5 Å, c=173.8 Å. AmoRe (CCP4, Acta Cryst. D50, 760-763 (1994)) was used to do molecular replacement that was carried out using C3d (Accession No. 1C3D from the Protein Data Bank (PDB)) as a search model. The final correlation function and R factor after rotation and translation search were 50% and 45%. Initial phase improvement was carried out using solvent flattening and two fold averaging by the program DM (CCP4, Acta Cryst. D50, 760-763 (1994)) in CCP4 suit. Stepwise model building and refinement were carried out using program “O” and CNS (P. D. A. A. T. Brunger, G. M. Clore, W. L. Delano, P. Gros, R. W. Grosse-Kunstleve, J.-S. Jiang, J. Kuszewski, N. S. P. M. Nilges, R. J. Read, L. M. Rice, T. Simonson, G. L. Warren,Acta Cryst. D54, 905-921 (1998)). The final complete model was refined using simulated annealing, positional refinement, and individual B factor refinement. Water molecules were added last using CNS (Table 1).

TABLE 1 Structure determination and refinement Data collection statistics Space group R32 Unit cell length (Å) a = b = 170.5, c = 173.8 Resolution (Å) 25.0-2.04 Completeness (last bin) 94.1/83.6 Total reflections 255801 Unique reflections 63919 ¹ Rsym (last bin) % 6.7/22.3 I/δ (last bin) 10.8/3.7 Refinement statistics % of reflections for R_(free) 10 R_(work)/R_(free) 20.8/23.9 rmsd from ideality Bond length (Å) 0.006 Bond angle (°) 1.10 Dihedral angle (°) 16.8 Ramachandran plot 92.3/0 (core, disallowed) Average B factor 33.98 rmsd of B factor (Å²) 1.2 Protein atoms in the model 8878 H₂O in the model 580 ¹ Rsym = Σ_(ij) |(j) − < I(j) > | / Σ_(ij) I_(i) (j), where I_(i)(j) is the i-th measurement of reflection j and <I(j)> is the overall weighted mean of j measurements.

The atomic coordinates representing the structure of the complex of CR2 and C3d were deposited on Jan. 11, 2001, with the Protein Data Bank (PDB), operated by the Research Collaboratory for Structural Bioinformatics (RCSB) (H. M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissig, I. N. Shindyalov, P. E. Bourne, The Protein Data Bank; Nucleic Acids Research, 28:235-242 (2000)), under PDB Deposit No. PDB id 1GHQ. These atomic coordinates are also represented herein as Table 2.

Description of the Overall Structure of the CR2-C3d Complex

FIGS. 1A and 1B show the structure of the CR2-C3d complex. FIG. 1A is an overall view of the structure of CR2 binding to C3d, showing only SCR2 contacting one portion of the edge of C3d. CR2 SCR1 is colored in red and SCR2 in yellow, while C3d is in cyan. The side chain of residue Q20 of C3d that forms an ester-bond with antigen is drawn in pink and labeled. The position of residue D223 of C3d, which is the C3F form (fast migrating variant on agarose gel electrophoresis) that is associated with an increased incidence of certain diseases (M. C. Poznansky et al., J Immunol 143, 1254-8 (1989)), is also labeled. The other form of C3d, C3S (slow migration), has an N223 residue. The N and C termini of C3d (N1 and C307, respectively) are positioned next to each other. FIG. 1B shows the overall structure showing a second CR2-C3d complex (colored in light blue and grey) that dimerizes with the first one in FIG. 1A. The dimerization contact in the two-complex structure is through SCR1 of CR2 at the very top. (Prepared with the program MOLSCRIPT).

The complex contains a V-shaped CR2 receptor binding to a globular C3d ligand (FIG. 1A). The CR2 receptor portion contains two domains (SCR1 and SCR2) that pack against each other almost side to side, producing a drastic bend of 53 degrees between the two domains to give a V-shape. A well-structured linker of 8 amino acids (residues 64-71) connects the SCR1 and SCR2 domains. Both SCR1 and SCR2 domains consist of only beta-strands and coils, which is characteristic of the SCR fold that contains a beta-barrel core structure (A. P. Wiles, et al., J Mol Biol 272, 253-65 (1997); P. N. Barlow, et al., J Mol Biol 232, 268-84 (1993); J. M. Casasnovas, M. Larvie, T. Stehle, EMBO J 18, 2911-22 (1999); R. Schwarzenbacher, et al., EMBO J 18, 6228-39 (1999)). The V-shaped two-domain CR2 molecule has a span of 42.6 Å at the base of the molecule (from SCR1 to SCR2), and the height of “V” structure (from base to tip) measures 38.5 Å.

The C3d ligand, which has a dome-shaped structure that consists of mostly alpha helices (B. Nagar, R. G. Jones, R. J. Diefenbach, D. E. Isenman, J. M. Rini, Science 280, 1277-81 (1998)), interacts with the receptor using one portion of the edge of the dome. The CR2-contact edge of C3d is located on nearly the opposite side of the amino (N) and carboxyl (C) termini, which are physically proximate to each other (FIG. 1A). Binding to CR2 through this edge leaves the concave and convex surfaces free and the rest of the iC3b molecule (a form of C3 encompassing the C3d domain with which CR2 also interacts) likely oriented away from CR2 (FIG. 1A). The site of the ester-bond linkage to antigens (Q20) sits approximately half way between the receptor contact edge and the N and C termini of C3d (FIG. 1A). The site of mutation (N223 to D223, FIG. 1A) that defines an important disease-related allelic polymorphism, C3F (fast) versus C3S (slow) (M. C. Poznansky, P. M. Clissold, P. J. Lachmann, J Immunol 143, 1254-8 (1989)), is located away from the CR2 interaction site; therefore, this disease association is likely not directly related to CR2 binding but rather to other C3 functions.

Unexpectedly, a dimer of CR2 molecules is formed in the crystal through contacts between SCR1 domains (FIG. 1B). This CR2 dimer has a shape of two letter V's coming together head to head, with SCR1 facing SCR1 and SCR2 facing SCR2. No direct contacts occur between SCR2. This second CR2 is essentially a duplicate of the other CR2 molecule of the dimer that binds to C3d (FIG. 1B).

Description of the Structure of CR2

FIGS. 2A-2E show the structure of CR2. FIG. 2A is a ribbon representation of the CR2 SCR1 (in red) and SCR2 (in yellow) structures, showing the SCR fold and the packing of the two domains to form a V shape. The side chains of Cys residues that form intra-domain disulfide bonds are colored in cyan. Within each domain, the beta-strands B-E are labeled. A sugar residue GlcNAc (N-acetyl-glucosamine) is seen attached to N102 of SCR2. (Prepared using MOLSCRIPT). FIG. 2B shows the structure and packing interaction at the interface of CR2 SCR1 and SCR2 domains. Residues important for the tight packing between the two domains at the interface and the linker regions are shown. (Prepared with the program RIBBONS). FIG. 2C is a surface representation of the two-domain arrangement of CR2. (Prepared using GRASP). FIG. 2D shows the dimerization of CR2 through interactions between SCR1 of each molecule. Strand D2 and E1 of one CR2 molecule (red) packed against strand E1 and D2 of the second CR2 molecule in the dimer (blue). (Prepared using MOLSCRIPT). FIG. 2E shows a sequence alignment between human CR2 (SEQ ID NO:4) and mouse CR2 (mCR2) (SEQ ID NO:6). The first residue of CR2 (Gly) is changed to Ala in the structure due to PCR primer sequence. Secondary structure elements are shown above the corresponding aligned sequences. A black line represents coils and arrows represent beta-strands. The linker sequence between SCR1 and SCR2 is underlined. The residues whose side-chain or main-chain groups are involved in binding to C3 d are indicated by *. The symbol • indicates the two residues that, after mutating from mouse to human sequence, allow mCR2 to gain the ability to bind EBV gp350/220.

The CR2 structure described here contains residues 1-134 (SEQ ID NO:4; FIG. 2E, corresponding to residues 20-153 of the full length human CR2 (SEQ ID NO:1)) that fold into two SCR domains (FIG. 2A). Each domain shows a basic SCR fold: four anti-parallel beta-strands form a barrel-like beta-sheet. Strand D and E are separated into two segments, D1, D2 and E1, E2. In addition to the hydrogen bonds that hold together the antiparallel beta-strands, two intra-domain disulfide bonds cross-link the coiled N-terminus to strand D2, and strand C to strand E2 (FIG. 2A). A well ordered N-linked GlcNAc (N-acetyl-glucosamine) residue is linked to Asn102 that is located at the tip of SCR2. The rest of the sugar residues were digested away by EndoH.

A very unique feature of the two domain CR2 structure is that the 8 amino acid linker makes a dramatic turn to allow the two SCR domains to pack against each other sideways (FIGS. 2A, 2B, 2C). Among the protein family containing SCR domains, the linkers connecting SCR domains are normally 3-5 amino acids in length, while an 8 amino acid linker is the longest known so far. The available structures of four SCR proteins containing two or 4 repeats (A. P. Wiles, et al., (1997), supra; P. N. Barlow, et al., (1993), supra; J. M. Casasnovas, et al., (1999), supra; R. Schwarzenbacher et al., (1999), supra) all have end-end packing between consecutive SCRs, and CR2 is thus the first to demonstrate extensive side-side packing.

In end-end packing, the adjacent domains could, in principle, adopt different rotations and bend angles relative to each other in different environments. Indeed, a commonly held concept is that SCRs are not absolutely fixed relative to each other but rather are allowed some freedom to move about this interface (P. N. Barlow, et al., (1993), ibid.; J. M. Casasnovas, et al., (1999), ibid.). However, the side-side packing of the CR2 SCR1 and SCR2 would not give the two domains freedom to adopt different orientations, unless some active process is involved to first separate the two domains. The interface between the two domains is mainly hydrophobic (FIG. 2B). Trp112, which is unique to CR2 SCR2 sequence and located on strand D2, plays a critical role in the packing by interacting with Ile39 and the main-chain from SCR1. Trp112 would be unfavorably exposed to the solvent if the two domains do not pack against each other sideways in this manner. In addition to Trp112, several other residues also play a role in the packing, including Pro121, His91, Leu39, and the carbon side chain of Glu64. The 8 amino acid linker, which contains mainly hydrophobic residues such as Tyr65, Phe66, Tyr69, also participates in the hydrophobic packing outside the two-domain interface, further solidifying the interactions between SCR1 and SCR2 (FIG. 2B). The area of the interface of the two SCRs is very extensive, covering almost half of the length of one SCR domain (FIG. 2C). Because of the above mentioned observations of other SCR proteins studied in the absence of their ligands, it will be interesting to see if the packing of these two CR2 SCR domains remains the same in the unliganded crystal and solution states.

Two CR2 molecules dimerize through SCR1-SCR1 contacts in the crystal structure (FIG. 2D). The contact is symmetrical, with the E1 strands from different molecules running anti-parallel to each other. The C-terminus of the E1 strand also contacts the C-terminus of the D2 strand of another molecule. The nature of the interaction is hydrogen bonds. In solution, however, the present inventors have found that CR2 behaves like a monomer under physiological buffer condition as assayed by gel filtration chromatography, though this is a technique that can only detect strong protein-protein interaction. It is possible that the dimer interaction only occurs in the crystal packing and is not of relevance. Another possibility, though, is that the interaction plays biological roles under physiologic conditions, but it is too weak to be detected in solution. Considering that CR2 receptors are largely constrained in the cell membrane to only lateral movement, no strong interactions would be necessary to dimerize.

Description of the Structure of the CR2-C3d Interface

FIGS. 3A-3F show the structure at the CR2-C3d interface. FIGS. 3A and 3B show the surface features of the interface area on C3d (in cyan) and CR2 molecule (in yellow). The shape of the interface of one molecule complements that of the other. (Prepared using GRASP). FIG. 3C shows the structure of the CR2 SCR2-C3d complex. The strands of CR2 (yellow) and helices of C3d (cyan) near the interface are labeled to provide a sense of orientation. (Prepared using MOLSCRIPT). FIGS. 3D and 3E show the detailed interactions between CR2 (in yellow) and C3d (in cyan) in two angles. Dashed lines represent hydrogen bonds between carbonyl oxygen atoms (in red), nitrogen atoms (in blue) of amino acid side chains or main chain, and water molecules (in purple). (Prepared using RIBBONS). FIG. 3F shows the human C3d sequence (SEQ ID NO:7) with secondary structure assigned on top of the corresponding sequences. The residues involved in CR2 binding are indicated by *. The residue D223 in C3F from (vs. N223 in C3S) is in pink. The residue N170 shown to weaken C3d-CR2 interaction after being mutated to Arg (see FIG. 4) is colored in red. N170 is also the only residue among those involved in CR2 binding that has its side chain in close contact with and pointing toward CR2.

One particularly salient feature of the interface is the shape-matching between C3d and CR2 interacting surfaces, as the protrusions on one molecule exactly match the pits and cavities on the other (FIGS. 3A & 3B). The total of the buried area in the interface is 1400 Å². The contact interfaces between the receptor and C3d are neither hydrophobic nor particularly charged, but rather the well-fitted surface shapes from the two molecules come together to form the bonding contact in the complex. No major conformational difference is observed between the structures of free C3d and CR2-bound C3d, except for small movements (0.7-1.0 Å) of H3 (helix 3), H5, H7 and a few turns/loops on the surface.

In the CR2-C3d complex, no continuous stretch of residues on C3d participates in the interactions. Rather, residues that are separated in the linear sequence of C3d, but come together on the folded C3d, interact with CR2. Namely, the residues on the H3-H4 loop (the loop between helix 3 and 4), as well as H5, and H7 make contact with CR2 (FIG. 3C). On the CR2 part, however, a linear stretch of residues within SCR2 domain makes the contact with C3d. The B strand and B-C loop of SCR2 constitute the majority of the interactions with C3d. The nature of the contacts involves elegant networks of hydrogen bonds, plus some hydrophobic and van der Waals interactions (FIGS. 3D & 3E).

It is particularly intriguing that only SCR2 directly contacts C3d. Previous studies have shown that both SCR1 and SCR2 are required for binding of polymeric forms of C3d to CR2 on cell membranes (C. A. Lowell, et al., J Exp Med 170, 1931-46 (1989); J. C. Carel, et al., J Biol Chem 265, 12293-9 (1990); K. R. Kalli, et al., J Immunol 147, 590-4 (1991)). The requirement for both domains to bind C3d on the cell surface may be due to the necessity of inter-SCR packing for stabilization of the SCR2 site, or alternatively the dimerization of CR2 mediated by SCR1 plays a necessary role on cell membranes, as discussed later.

Specificity of CR2-C3d Interaction

A few features about the CR2-C3d interactions are very striking. The first of such is the extensive use of main-chain carbonyl oxygen and nitrogen atoms in forming hydrogen bonds (H-bonds) between CR2 and C3d. This is particularly true on the C3d side, where the majority of the H-bond contributors on C3d come from main-chain carbonyl groups (FIGS. 3D & 3E). No side chains other than Asn170on the C3d side are involved in the direct interaction with CR2. This observation likely explains the difficulties in previous efforts to accurately identify the residues that directly interact with CR2 by site-directed mutagenesis of C3d or by using C3d-derived inhibitory peptides. This interaction mode of CR2-C3d is reminiscent of MHC-antigen peptide recognition where MHC interacts with the main-chain atoms of the antigen peptide in order to allow the limited number of MHC to bind the unlimited variations of antigens for antigen presentation to T cells (P. J. Bjorkman, et al., Nature 329, 512-8 (1987)). However, in distinct contrast to the MHC-antigen peptide interaction, the binding between CR2 and C3d through main-chain atoms here does not sacrifice the specificity of the CR2 receptor for C3d ligand due to an additional pronounced shape-fitting requirement, as further evident in later discussion.

Another important feature concerns one of the major sites for binding CR2 on C3d at the C-terminal end of H5. Here four carbonyl groups, one each from Ile115, Leu116, Glu117 and Gln119 of C3d, are positioned in such a way that, collectively, they form an anion hole at the C-terminus of H5 (FIG. 3D). In the complex structure, this anion hole is occupied by the positively charged Arg84 of CR2 that is located on the B-C loop of SCR2 domain. In this case, CR2 Arg84 acts as a capping residue in-trans to seal the alpha-helical dipole moment at the C-terminus of H5 of C3d. This is in contrast to the usual observation in other protein-ligand interactions that involve an alpha-helical dipole moment, in which usually a negatively charged group interacts with the other protein through the positively charged N-terminus of a helix, possibly because of the easily accessible nitrogen atoms on the main-chain (C. Branden, J. Tooze, Introduction to Protein Structure(Garland Publishing, ed. second edition, 1999) pp. 16). However, for CR2 to interact with the negatively charged C-terminus of C3d H5 that is shielded by the particular conformation at the end of H5 and its neighboring structure, it requires CR2 to have a well-matched surface around the positively charged capping residue, providing specificity to the interaction. The sequences and conformation of SCR2 around Arg84 of CR2 provides such a surface that is well-matched with the complimentary part on C3d, and that provides the necessary specificity for the interaction with C3d.

The conformation of the C3d-binding region, the B-C loop of SCR2 domain on CR2, is thus also important for the specific binding of C3d (FIGS. 3C, 3D, 3E). As one means to accomplish this conformation, the B-C loop is held and presented on the surface of CR2 by strand B and C of SCR2 in such a way that Arg84 readily fits into the anion hole at the end of the C3d H5. The residue after Arg84 is Gly85, which does not have a side chain that would interfere with the CR2 and C3d interface interaction. The side chain of Ser86 forms an H-bond with a carbonyl oxygen from the H3-H4 loop of C3d through a water molecule (FIG. 3E). Other residues around Arg84 have side chains pointing away from the interface and use either their main-chain carbonyl oxygen or nitrogen atoms to form H-bonds with C3d. This mode of interaction from the CR2 side predicts that the basic capping residue Arg84, as well as Ser86, are likely the most important residues on this interaction surface, as long as they are presented in a correct conformation.

In this regard, of importance also is a sequence comparison between human CR2 and mouse CR2 (mCR2), both of which bind C3d with similar affinity (D. R. Martin et al., J Exp Med 174, 1299-311 (1991); J. D. Fingeroth et al., Proc Natl Acad Sci USA 86, 242-6 (1989)). The SCR1-2 region of human CR2 is represented herein as SEQ ID NO:4 and is compared to the corresponding SCR1-2 region of mouse CR2 (SEQ ID NO:6). At the C3d-interacting interface the B-C loop of mCR2 SCR2 has a basic residue Lys in place of Arg84, while Gly85 and Ser86 are conserved (positions given relative to SEQ ID NO:4). Five other amino acids around Arg84 on the B-C loop are not highly conserved (FIG. 3F). The complex structure reveals, however, that the side chains of these five non-conserved residues do not participate in the CR2-C3d interaction. Importantly, Lys84 in mouse (SEQ ID NO:6) could replace Arg84 (SEQ ID NO:4) as the trans-capping residue for H5. Of interest, outside of the 5 amino acids around Lys84 (SEQ ID NO:6), there are stretches of amino acids that are the most highly conserved between human CR2 and mCR2 (FIG. 2E). These highly conserved segments likely play an important role in presenting the B-C loop in a correct conformation for specific C3d binding to mCR2.

Another feature of the complex structure is the participation of several water molecules in the interaction (FIGS. 3D & 3E). Well-ordered water molecules participate in the formation of some H-bonds between CR2 and C3d, acting as water “glue” between the two proteins. Extensive participation of water molecules in mediating receptor-ligand binding is also seen in the interaction between CAR receptor (coxsacki-adenovirus receptor) and adenovirus knob protein (M. C. Bewley et al., Science 286, 1579-83 (1999)).

A six-coordinated Zn atom is present on the edge of the interface between CR2 and C3d (FIG. 3D). Glu117 of C3d is the only amino acid side chain that participates in the coordination. The other four coordinates are mediated by water molecules, through which H-bond connections are formed with CR2 main-chain. The contribution of the Zn coordination to the CR2-C3 d binding is likely to be insignificant, because no obvious change in formation of the CR2-C3d complex can be detected in buffers with/without Zn ion, or when using a C3d mutant containing a Glu117 to Ala mutation (see next section). In addition, the binding of CR2 with C3d does not demonstrate a known cation dependence.

Example 2

The following example describes the construction of C3d mutants that affect CR2 binding.

Based on the complex structure, mutagenesis of C3d around the interface to disrupt CR2 binding was predicted to be difficult. This is because the interaction between CR2 and C3 d involves mostly main-chain H-bonding, and the side chain residues play relatively small roles in the binding. However, to confirm the accuracy of the CR2-C3d interaction seen in this co-crystal structure, two informative C3d mutants were constructed. In mutant 170 (mt170; SEQ ID NO:8), residue Asn170 was changed to Arg. Asn170 is located on H7 of C3d and is the only residue on C3d that more or less points directly toward CR2 in the interface (FIG. 3E). Asn170 also packs directly with Tyr81 of CR2 as well as forms an H-bond with CR2 (Lys100) through a water molecule (FIG. 3E). In solution, this mutant protein behaved very similarly like the wild type C3d and showed the same apparent molecular weight as the wild type in gel-filtration chromatography, suggesting correct folding. In the binding experiment assayed by native gel shift, however, the interaction between mt170 protein and CR2 was clearly less strong comparing with that between wild type C3d and CR2 (FIG. 4A, lanes 1-4 versus 9-12).

Briefly, FIGS. 4A and 4B show a native gel shift assay of the binding between CR2 and C3d wild type (wt) or mutants (mt). FIG. 4A shows a 6% native polyacrylamide gel of C3d alone (lanes 1, 5, and 9) or C3d plus increasing amount of CR2 (other lanes). mt170 C3d alone (lane 9) migrated slower than both wt (lane 1) and mt115 due to the introduction of a positively charged Arg residue at N170 (lane 5). CR2 alone does not enter the gel in this system. The C3d band will be shifted to the upper part of the gel when it forms a complex with CR2. The C3d concentration (for both wt and mt) is the same throughout lanes 1-12. The CR2 added to each corresponding lanes for wt and mt C3d was also the same, e.g. same amount of CR2 was added to the C3d samples in lane 2, 6 and 10, or in lanes 4, 8 and 12. In the lanes with the highest CR2 concentration (lanes 4, 8, 12), the bands of C3d wt and mt115 were completely shifted to the complex form (lane 4, 8), while mt170 (migrated slower than the wt or mt115) still contains an obvious C3d band (lane 12). These results indicate that the interaction between mt170 and CR2 is weaker than that between the wt or mt115 with CR2. The same conclusion can be drawn by comparing the intensity of the bands of the complexes containing the wt, mt115 and mt170. FIG. 4B is a graphical representation showing the intensity changes of the complex bands (measured by densitometry) as CR2 concentration increases from lanes 2 to 4 (wt), or lanes 6 to 8 (mt115), or lanes 10 to 12 (mt170). The result clearly shows that mt170 has less apparent affinity for CR2 than wt and mt115.

The result shown in this experiment is consistent with that predicted by the interaction interface seen in the complex structure. In another mutant of C3d (mt115), although three residues: Gln105, Leu116 and Glu117, were mutated to Ala, the mutant protein has no obvious effect on CR2 binding (FIG. 4A, lanes 1-4 versus 5-8). This is consistent with the complex structure in that all these three residues, even though located within the interface area, have their side chains pointing sideways and are not involved in the direct contact with CR2. The side chain of Glu117, however, participates in the Zn coordination. This mutant showed that Zn coordination by Glu117 does not contribute significantly to CR2-C3d binding. The coordinated Zn in the structure, therefore, could simply come from the crystallization buffer which contained ZnAcetate.

FIG. 4C demonstrates the results of a competitive ELISA analysis using informative C3d mutants. In this analysis, C3d mutant Gln105Ala, Leu116Ala, Glu117Ala (designated mt115 in FIGS. 4A and 4B and mut1 in FIG. 4C) manifests an equal ability as wild type C3d to block the binding of soluble full length CR2 to plate-bound wild type C3d. Therefore, mutations of these two residues which utilize only the main-chain atoms to interact with CR2 did not have an effect, which is predicted by the X-ray structure. Two other informative mutants, one Asn170Arg (designated mt170 in FIGS. 4A and 4B and mut2 in FIG. 4C, also represented herein as SEQ ID NO:8) and the other a new mutant Asn170Ala, Ile115Arg, Leu116Arg (designated mut4 in FIG. 4C, also represented herein as SEQ ID NO:9), are both unable to effectively block soluble CR2 binding to plate-bound wild type C3d. Therefore, we conclude that two mutations of C3d involving Asn170, whose side-chain interacts with CR2 directly, result in substantially decreased binding to CR2.

Of interest, the mode of interaction seen here is very different from that previously predicted by C3d mutants and C3d-derived peptides (J. D. Lambris et al., Proc Natl Acad Sci USA 82, 4235-9 (1985); R. J. Diefenbach et al., J Immunol 154, 2303-20 (1995); L. Clemenza et al., J Immunol 165, 3839-48 (2000)). Close examination of the complex structure, however, can explain some of the previous mutagenesis results. For example, residues Asp163, Ile164, and Glu166 of C3d, which affect CR2-binding after being mutated to Ala (Clemenza et al., 2000, ibid.), are located on H6 that is juxtaposed to H5 where the major CR2-recognizing anion hole is positioned (FIG. 3D). Based on the structure, it is obvious that mutations of some of the residues on H6 (such as Ile164) of C3d will affect the relative positions of H6 and H5, which may account for the reduced interaction with CR2. The other group of mutations on C3d (Asp36, Glu37, Glu39) reported to weaken CR2 binding (Clemenza et al., 2000, ibid.) are located right next to the N and C termini, and the present inventors' findings cannot account for those results. However, it is of note that this particular site would be juxtaposed to additional large peptides derived from iC3b, and these additional peptides in iC3b would present a steric hindrance for the interaction with CR2 if these residues were to be involved in CR2 binding. The present inventors' observation that CR2 contacts C3d on the opposite side from the N and C termini removes that concern and is more consistent with the observed high affinity binding of CR2 to iC3b.

Example 3

The following example describes the inhibition of CR2-C3d interaction by CR2-derived peptides.

Based on the structure of the CR2-C3d complex, the results from previously reported CR2 peptide inhibition and monoclonal antibody assays can now be explained. In the peptide inhibition tests using short synthetic peptides covering all of CR2 SCR1 and SCR2, peptides from two regions were shown to inhibit CR2-C3 binding (H. Molina, et al., J Immunol 154, 5426-35 (1995)). One of them contains sequences that are located right on the interaction interface of CR2 seen in the complex structure, namely the sequences from the B strand and B-C loop of SCR2 (FIGS. 3D & 3E). This independent result strongly supports the complex structure described by the present invention. However, the other peptide located on the B strand of SCR1 also showed a similar inhibition effect as the first one. Close examination of this fragment on CR2 structure within the SCR1 domain revealed a very similar 3-dimensional arrangement of these residues as the one on SCR2, but the sequence is in part reversed. Part of the C3d-binding sequences on the SCR2 B-C loop is 83-IRGSTP-88. The peptide from SCR1 that also has inhibitory effects has a sequence of 11-LNGRIS-16 (H. Molina et al., 1995, ibid). Similarities are apparent between these two peptides if one of the sequences is reversed. Specifically, at the 3-dimensional structure level, the conformation of -NGRI- of the SCR1 peptide looks like a reverse duplicate of -IRGS- on SCR2. However, in a folded CR2 molecule, the structure of the neighboring residues around the peptide on SCR1 restricts the accessibility of the sequences within the peptide, especially the Arg residue. Therefore, this part of CR2 should not be able to bind C3d unless some major conformational switch occurred to expose the segment in a fashion similar to it in a short peptide state.

Example 4

The following example describes the inhibition of CR2-C3d binding by anti-CR2 monoclonal antibodies.

The previously mapped epitope positions on CR2 for inhibitory monoclonal antibodies also support the interaction sites seen in the CR2-C3d complex structure. Two inhibitory antibodies, OKB7 (P. E. Rao et al., Cell Immunol 93, 549-55 (1985)) and FE8 (W. M. Prodinger, et al., J Immunol 161, 4604-10 (1998)), have epitopes positioned right next to the C3d binding region (FIGS. 5A & 5B). The present inventors have also created three new monoclonal antibodies, denoted mAb171, mAb1048 and mAb629, that inhibit the specific binding of CR2 to C3d. All three have mapped epitopes on CR2 lying right within the C3d-interacting area (FIG. 5A, blue area).

FIGS. 5A and 5B show the localization of the epitopes of anti-CR2 monoclonal antibodies (mAb) on the CR2 surface. These figures are two views with a 180 degree rotation to each other. The C3d binding site is labeled. All of the mAbs inhibit the interactions between CR2 and C3d to some extent. mAb171, together with 1048 and 629 (colored in blue) have epitopes located within the C3d-binding area. OKB7 (Rao et al., 1985, ibid.) (colored in red) and FE8 (Prodinger et al., 1998, ibid.) (colored in pink) also have epitopes right next to the C3d-binding region. The green spots indicate the locations where mutations from mCR2 to hCR2 sequence allow mCR2 to gain the ability to bind EBV gp350/220. The surfaces around these two sites are likely located within the interface between CR2 and gp350/220.

Example 5

The following example describes a potential gp350/220 binding region in CR2.

Previous evidence suggests that CR2 binds to C3d and EBV gp350/220 with overlapping but distinct sites (D. R. Martin et al., J Exp Med 174, 1299-311 (1991); H. Molina et al., J Biol Chem 266, 12173-9 (1991); D. R. Martin et al., J Virol 68, 4716-26 (1994); H. Molina et al., J Immunol 154, 5426-35 (1995)). One instrumental result in this regard has been the ability to transform by point mutation mCR2 into a form capable of binding gp350/220. In this regard, mCR2 and CR2 both bind C3d, but mCR2 does not bind EBV or gp350/220. However, changing the sequence of mCR2 at two amino acids (Pro16 to Ser and Thr69 to Tyr, FIG. 2E) allowed mCR2 to gain the ability to bind EBV (D. R. Martin et al., J Virol 68, 4716-26 (1994)). Because of this, the locations of the two mutated residues are likely to be involved in gp350/220 binding. Of interest, these locations mapped on the CR2 surface (green patch on FIGS. 5A & 5B) are separated from the blue area that interacts with C3d in the complex structure of the present invention.

Example 6

The following example describes a structure model of CR2 in complex with C3d on the cell surface.

Based on the complex structure, the present inventors propose a model of CR2 binding to C3d or iC3b on the cell surface (FIG. 6). FIG. 6A is a surface representation of the model containing a dimer of CR2 SCR1 and SCR2 that bind to C3d on each receptor. The dimer contact is through SCR1 only, as seen in the crystal structure. FIG. 6B is a diagram of C3d-antigen cross-linking CR2 (as dimers) and BCR on the cell surface. The dimer form of CR2, as opposed to the monomer, in complex with CD19CD81 permits the cross-linking of multiple CR2 by C3d-antigen to greatly increase the local concentration of CR2/CD19/CD81.

In this model, CR2 in complex with C3d molecules exists as a dimer through SCR1-SCR1 contact (FIGS. 6A & 6B). C3d- or iC3b-bound antigen interacts with SCR2 in such a way that the site of ester-linkage with the antigen (residue Q20) is pointing in the lateral direction (FIG. 6A). This orientation allows CR2 maximum capabilities to interact with C3 bound to many shapes and sizes of antigens. In addition, though, there is also the opportunity for the antigen to cross-link a neighboring CR2 dimer with a second C3d/iC3b attached to it. Repeat of this interaction could cross-link many CR2/CD19/CD81 and BCR molecules, with the potential of greatly amplifying down-stream signal transduction. Of interest, previous reports of C3 d acting as a molecular adjuvant showed that two or three C3d attached to hen egg lysozyme (HEL) enhanced the IgG1 humoral response to HEL by 1,000 to 10,000 times, but one C3d had a suppressive effect (P. W. Dempsey et al., Science 271, 348-50 (1996)). The model in FIG. 6B provides one potential molecular explanation for this observation. Multiple CR2 dimers can be brought together by two (or more) C3d linked to an antigen, but only two (or three) CR2 monomers can be cross-linked together. Thus, the CR2 dimer model, in contrast to a monomer, allows a dramatic increase of cross-linked CR2/CD19/CD81 and BCR molecules through binding to the antigen with two or more C3d attached, which could account for the 10,000-fold enhancement of the observed immune response.

TABLE 2 ATOM 1 CB ALA A 1 113.978 74.531 51.463 1.00 24.47 A ATOM 2 C ALA A 1 113.746 72.085 52.085 1.00 26.48 A ATOM 3 O ALA A 1 112.896 72.106 52.942 1.00 30.12 A ATOM 4 N ALA A 1 115.853 72.884 51.119 1.00 42.70 A ATOM 5 CA ALA A 1 114.718 73.256 51.995 1.00 33.68 A ATOM 6 N LEU A 2 113.868 71.065 51.232 1.00 24.18 A ATOM 7 CA LEU A 2 112.952 69.905 51.320 1.00 27.55 A ATOM 8 CB LEU A 2 112.148 69.728 50.001 1.00 23.79 A ATOM 9 CG LEU A 2 110.907 68.774 50.002 1.00 26.21 A ATOM 10 CD1 LEU A 2 109.785 69.339 50.877 1.00 20.38 A ATOM 11 CD2 LEU A 2 110.365 68.568 48.562 1.00 22.09 A ATOM 12 C LEU A 2 113.635 68.549 51.642 1.00 27.27 A ATOM 13 O LEU A 2 114.746 68.266 51.172 1.00 22.30 A ATOM 14 N ASP A 3 112.963 67.734 52.455 1.00 23.38 A ATOM 15 CA ASP A 3 113.426 66.393 52.758 1.00 23.91 A ATOM 16 CB ASP A 3 114.304 66.327 54.028 1.00 20.20 A ATOM 17 CG ASP A 3 113.619 66.825 55.279 1.00 22.03 A ATOM 18 OD1 ASP A 3 112.357 66.765 55.433 1.00 20.42 A ATOM 19 OD2 ASP A 3 114.366 67.274 56.160 1.00 28.30 A ATOM 20 C ASP A 3 112.201 65.488 52.875 1.00 23.39 A ATOM 21 O ASP A 3 111.047 65.953 52.784 1.00 18.32 A ATOM 22 N ALA A 4 112.438 64.194 53.060 1.00 24.33 A ATOM 23 CA ALA A 4 111.330 63.243 53.164 1.00 23.20 A ATOM 24 CB ALA A 4 111.854 61.819 53.288 1.00 17.28 A ATOM 25 C ALA A 4 110.291 63.499 54.261 1.00 19.39 A ATOM 26 O ALA A 4 109.113 63.369 53.958 1.00 16.69 A ATOM 27 N GLU A 5 110.691 63.841 55.491 1.00 16.50 A ATOM 28 CA GLU A 5 109.701 64.065 56.548 1.00 22.14 A ATOM 29 CB GLU A 5 110.301 64.257 57.982 1.00 23.56 A ATOM 30 CG GLU A 5 110.935 65.596 58.263 1.00 38.23 A ATOM 31 CD GLU A 5 110.138 66.605 59.095 1.00 31.60 A ATOM 32 OE1 GLU A 5 109.004 66.397 59.598 1.00 31.04 A ATOM 33 OE2 GLU A 5 110.719 67.671 59.253 1.00 44.56 A ATOM 34 C GLU A 5 108.853 65.262 56.208 1.00 20.89 A ATOM 35 O GLU A 5 107.637 65.242 56.419 1.00 22.09 A ATOM 36 N ARG A 6 109.470 66.300 55.662 1.00 17.73 A ATOM 37 CA ARG A 6 108.703 67.491 55.302 1.00 23.39 A ATOM 38 CB ARG A 6 109.618 68.614 54.815 1.00 25.00 A ATOM 39 CG ARG A 6 110.433 69.194 55.948 1.00 24.66 A ATOM 40 CD ARG A 6 111.430 70.240 55.488 1.00 30.21 A ATOM 41 NE ARG A 6 112.143 70.710 56.662 1.00 31.75 A ATOM 42 CZ ARG A 6 113.044 71.686 56.675 1.00 37.88 A ATOM 43 NH1 ARG A 6 113.377 72.333 55.558 1.00 32.11 A ATOM 44 NH2 ARG A 6 113.608 72.015 57.830 1.00 38.98 A ATOM 45 C ARG A 6 107.696 67.156 54.219 1.00 25.83 A ATOM 46 O ARG A 6 106.532 67.558 54.304 1.00 20.78 A ATOM 47 N LEU A 7 108.122 66.409 53.205 1.00 19.13 A ATOM 48 CA LEU A 7 107.179 66.068 52.143 1.00 17.13 A ATOM 49 CB LEU A 7 107.916 65.488 50.945 1.00 16.82 A ATOM 50 CG LEU A 7 106.984 65.041 49.805 1.00 23.63 A ATOM 51 CD1 LEU A 7 106.086 66.207 49.303 1.00 18.87 A ATOM 52 CD2 LEU A 7 107.870 64.538 48.676 1.00 25.78 A ATOM 53 C LEU A 7 106.103 65.075 52.615 1.00 19.67 A ATOM 54 O LEU A 7 104.935 65.191 52.246 1.00 20.24 A ATOM 55 N LYS A 8 106.489 64.099 53.427 1.00 21.02 A ATOM 56 CA LYS A 8 105.521 63.110 53.928 1.00 24.15 A ATOM 57 CB LYS A 8 106.205 62.100 54.869 1.00 26.98 A ATOM 58 CG LYS A 8 105.339 60.838 55.146 1.00 29.12 A ATOM 59 CD LYS A 8 105.997 59.844 56.108 1.00 48.06 A ATOM 60 CE LYS A 8 107.390 59.397 55.608 1.00 61.21 A ATOM 61 NZ LYS A 8 108.117 58.353 56.469 1.00 69.61 A ATOM 62 C LYS A 8 104.281 63.720 54.630 1.00 22.77 A ATOM 63 O LYS A 8 103.163 63.203 54.499 1.00 16.94 A ATOM 64 N HIS A 9 104.465 64.778 55.412 1.00 17.13 A ATOM 65 CA HIS A 9 103.303 65.454 56.034 1.00 23.94 A ATOM 66 CB HIS A 9 103.759 66.675 56.838 1.00 15.51 A ATOM 67 CG HIS A 9 104.457 66.331 58.109 1.00 25.05 A ATOM 68 CD2 HIS A 9 105.755 66.445 58.478 1.00 22.49 A ATOM 69 ND1 HIS A 9 103.792 65.831 59.209 1.00 24.32 A ATOM 70 CE1 HIS A 9 104.649 65.654 60.200 1.00 26.37 A ATOM 71 NE2 HIS A 9 105.851 66.015 59.786 1.00 31.51 A ATOM 72 C HIS A 9 102.268 65.959 55.002 1.00 24.84 A ATOM 73 O HIS A 9 101.161 66.278 55.375 1.00 23.11 A ATOM 74 N LEU A 10 102.634 66.074 53.721 1.00 18.19 A ATOM 75 CA LEU A 10 101.670 66.538 52.730 1.00 22.98 A ATOM 76 CB LEU A 10 102.370 67.210 51.534 1.00 24.09 A ATOM 77 CG LEU A 10 103.171 68.492 51.885 1.00 30.55 A ATOM 78 CD1 LEU A 10 103.625 69.205 50.648 1.00 29.82 A ATOM 79 CD2 LEU A 10 102.285 69.415 52.701 1.00 39.35 A ATOM 80 C LEU A 10 100.789 65.391 52.237 1.00 30.17 A ATOM 81 O LEU A 10 99.875 65.616 51.442 1.00 31.15 A ATOM 82 N ILE A 11 101.065 64.159 52.663 1.00 20.98 A ATOM 83 CA ILE A 11 100.194 63.053 52.229 1.00 22.19 A ATOM 84 CB ILE A 11 101.002 61.747 52.060 1.00 27.01 A ATOM 85 CG2 ILE A 11 100.044 60.547 51.788 1.00 29.34 A ATOM 86 CG1 ILE A 11 101.984 61.940 50.863 1.00 21.97 A ATOM 87 CD1 ILE A 11 103.039 60.904 50.736 1.00 31.22 A ATOM 88 C ILE A 11 99.082 62.956 53.269 1.00 27.58 A ATOM 89 O ILE A 11 99.300 62.542 54.411 1.00 26.44 A ATOM 90 N VAL A 12 97.890 63.403 52.888 1.00 23.12 A ATOM 91 CA VAL A 12 96.760 63.400 53.803 1.00 22.74 A ATOM 92 CB VAL A 12 96.392 64.814 54.185 1.00 33.31 A ATOM 93 CG1 VAL A 12 97.530 65.452 55.004 1.00 34.31 A ATOM 94 CG2 VAL A 12 96.105 65.600 52.928 1.00 24.64 A ATOM 95 C VAL A 12 95.487 62.726 53.265 1.00 28.78 A ATOM 96 O VAL A 12 95.316 62.525 52.061 1.00 25.51 A ATOM 97 N THR A 13 94.577 62.396 54.174 1.00 22.73 A ATOM 98 CA THR A 13 93.348 61.747 53.787 1.00 24.33 A ATOM 99 CB THR A 13 92.824 60.893 54.947 1.00 28.46 A ATOM 100 OG1 THR A 13 93.834 59.921 55.298 1.00 37.06 A ATOM 101 CG2 THR A 13 91.503 60.186 54.540 1.00 22.36 A ATOM 102 C THR A 13 92.328 62.811 53.443 1.00 19.70 A ATOM 103 O THR A 13 92.043 63.649 54.254 1.00 18.28 A ATOM 104 N PRO A 14 91.760 62.781 52.239 1.00 23.16 A ATOM 105 CD PRO A 14 92.057 61.889 51.100 1.00 27.40 A ATOM 106 CA PRO A 14 90.765 63.803 51.883 1.00 23.69 A ATOM 107 CB PRO A 14 90.675 63.699 50.355 1.00 20.22 A ATOM 108 CG PRO A 14 90.959 62.232 50.106 1.00 26.75 A ATOM 109 C PRO A 14 89.406 63.564 52.509 1.00 22.95 A ATOM 110 O PRO A 14 89.009 62.415 52.725 1.00 20.64 A ATOM 111 N SER A 15 88.719 64.651 52.845 1.00 19.26 A ATOM 112 CA SER A 15 87.348 64.575 53.337 1.00 25.94 A ATOM 113 CB SER A 15 87.295 64.124 54.797 1.00 25.47 A ATOM 114 OG SER A 15 88.078 64.979 55.578 1.00 28.02 A ATOM 115 C SER A 15 86.638 65.928 53.187 1.00 26.13 A ATOM 116 O SER A 15 87.227 66.923 52.758 1.00 26.66 A ATOM 117 N GLY A 16 85.364 65.948 53.556 1.00 28.55 A ATOM 118 CA GLY A 16 84.593 67.167 53.481 1.00 25.28 A ATOM 119 C GLY A 16 83.748 67.259 52.225 1.00 23.22 A ATOM 120 O GLY A 16 83.667 66.314 51.428 1.00 20.49 A ATOM 121 N ALA A 17 83.122 68.421 52.072 1.00 21.03 A ATOM 122 CA ALA A 17 82.258 68.742 50.952 1.00 19.04 A ATOM 123 CB ALA A 17 81.288 69.898 51.356 1.00 17.25 A ATOM 124 C ALA A 17 83.051 69.097 49.692 1.00 19.33 A ATOM 125 O ALA A 17 84.271 68.928 49.643 1.00 22.08 A ATOM 126 N GLY A 18 82.356 69.566 48.668 1.00 17.15 A ATOM 127 CA GLY A 18 82.983 69.869 47.376 1.00 17.27 A ATOM 128 C GLY A 18 84.233 70.743 47.300 1.00 21.54 A ATOM 129 O GLY A 18 84.993 70.629 46.350 1.00 16.56 A ATOM 130 N GLU A 19 84.419 71.653 48.248 1.00 18.40 A ATOM 131 CA GLU A 19 85.629 72.488 48.258 1.00 22.07 A ATOM 132 CB GLU A 19 85.302 73.929 48.683 1.00 14.92 A ATOM 133 CG GLU A 19 84.450 74.722 47.650 1.00 18.57 A ATOM 134 CD GLU A 19 84.034 76.086 48.184 1.00 21.03 A ATOM 135 OE1 GLU A 19 84.654 76.565 49.162 1.00 20.93 A ATOM 136 OE2 GLU A 19 83.096 76.694 47.639 1.00 19.11 A ATOM 137 C GLU A 19 86.679 71.889 49.203 1.00 18.24 A ATOM 138 O GLU A 19 87.865 71.779 48.822 1.00 17.93 A ATOM 139 N GLN A 20 86.235 71.519 50.415 1.00 15.20 A ATOM 140 CA GLN A 20 87.084 70.923 51.502 1.00 23.25 A ATOM 141 CB GLN A 20 86.217 70.526 52.751 1.00 23.39 A ATOM 142 CG GLN A 20 85.294 71.692 53.342 1.00 43.73 A ATOM 143 CD GLN A 20 84.079 71.273 54.296 1.00 42.22 A ATOM 144 OE1 GLN A 20 83.301 70.366 53.989 1.00 38.04 A ATOM 145 NE2 GLN A 20 83.924 71.988 55.410 1.00 33.68 A ATOM 146 C GLN A 20 87.816 69.660 50.976 1.00 24.37 A ATOM 147 O GLN A 20 88.996 69.451 51.237 1.00 17.83 A ATOM 148 N ASN A 21 87.100 68.832 50.225 1.00 15.50 A ATOM 149 CA ASN A 21 87.677 67.616 49.677 1.00 18.10 A ATOM 150 CB ASN A 21 86.601 66.790 48.967 1.00 13.23 A ATOM 151 CG ASN A 21 87.145 65.457 48.485 1.00 23.30 A ATOM 152 OD1 ASN A 21 87.490 64.598 49.294 1.00 17.88 A ATOM 153 ND2 ASN A 21 87.251 65.294 47.168 1.00 17.44 A ATOM 154 C ASN A 21 88.847 67.891 48.721 1.00 21.18 A ATOM 155 O ASN A 21 89.789 67.088 48.658 1.00 21.46 A ATOM 156 N MET A 22 88.787 69.004 47.971 1.00 14.28 A ATOM 157 CA MET A 22 89.850 69.360 47.039 1.00 13.52 A ATOM 158 CB MET A 22 89.330 70.305 45.939 1.00 19.05 A ATOM 159 CG MET A 22 88.285 69.647 45.064 1.00 20.17 A ATOM 160 SD MET A 22 88.876 68.159 44.293 1.00 28.63 A ATOM 161 CE MET A 22 90.211 68.915 43.271 1.00 21.96 A ATOM 162 C MET A 22 91.028 69.995 47.767 1.00 15.63 A ATOM 163 O MET A 22 92.159 69.896 47.328 1.00 16.97 A ATOM 164 N ILE A 23 90.743 70.644 48.886 1.00 11.88 A ATOM 165 CA ILE A 23 91.784 71.242 49.714 1.00 19.19 A ATOM 166 CB ILE A 23 91.126 72.029 50.870 1.00 13.50 A ATOM 167 CG2 ILE A 23 92.159 72.357 51.971 1.00 13.80 A ATOM 168 CG1 ILE A 23 90.476 73.296 50.297 1.00 16.98 A ATOM 169 CD1 ILE A 23 89.807 74.203 51.351 1.00 17.93 A ATOM 170 C ILE A 23 92.597 70.046 50.235 1.00 22.66 A ATOM 171 O ILE A 23 93.843 70.053 50.257 1.00 18.47 A ATOM 172 N GLY A 24 91.892 68.990 50.628 1.00 15.67 A ATOM 173 CA GLY A 24 92.583 67.804 51.110 1.00 17.85 A ATOM 174 C GLY A 24 93.291 67.056 50.000 1.00 21.53 A ATOM 175 O GLY A 24 94.439 66.616 50.138 1.00 16.68 A ATOM 176 N MET A 25 92.631 66.918 48.864 1.00 18.50 A ATOM 177 CA MET A 25 93.234 66.170 47.767 1.00 15.73 A ATOM 178 CB MET A 25 92.153 65.985 46.703 1.00 21.35 A ATOM 179 CG MET A 25 92.469 65.151 45.529 1.00 26.92 A ATOM 180 SD MET A 25 90.966 64.905 44.498 1.00 24.37 A ATOM 181 CE MET A 25 91.718 63.617 43.360 1.00 17.81 A ATOM 182 C MET A 25 94.511 66.832 47.185 1.00 23.64 A ATOM 183 O MET A 25 95.432 66.146 46.757 1.00 17.81 A ATOM 184 N THR A 26 94.577 68.164 47.180 1.00 17.90 A ATOM 185 CA THR A 26 95.736 68.856 46.607 1.00 18.87 A ATOM 186 CB THR A 26 95.629 70.395 46.847 1.00 17.83 A ATOM 187 OG1 THR A 26 94.436 70.869 46.218 1.00 17.41 A ATOM 188 CG2 THR A 26 96.851 71.139 46.262 1.00 16.75 A ATOM 189 C THR A 26 97.149 68.423 47.052 1.00 11.10 A ATOM 190 O THR A 26 97.990 68.069 46.229 1.00 17.69 A ATOM 191 N PRO A 27 97.418 68.448 48.353 1.00 13.60 A ATOM 192 CD PRO A 27 96.664 68.937 49.532 1.00 11.14 A ATOM 193 CA PRO A 27 98.788 68.049 48.696 1.00 17.00 A ATOM 194 CB PRO A 27 98.861 68.267 50.218 1.00 12.53 A ATOM 195 CG PRO A 27 97.406 68.312 50.676 1.00 15.76 A ATOM 196 C PRO A 27 99.193 66.662 48.277 1.00 21.64 A ATOM 197 O PRO A 27 100.324 66.455 47.840 1.00 19.29 A ATOM 198 N THR A 28 98.273 65.709 48.393 1.00 16.44 A ATOM 199 CA THR A 28 98.607 64.333 48.046 1.00 17.14 A ATOM 200 CB THR A 28 97.488 63.396 48.522 1.00 18.78 A ATOM 201 OG1 THR A 28 97.290 63.620 49.926 1.00 16.04 A ATOM 202 CG2 THR A 28 97.822 61.967 48.263 1.00 20.93 A ATOM 203 C THR A 28 98.827 64.211 46.567 1.00 19.51 A ATOM 204 O THR A 28 99.799 63.572 46.116 1.00 17.24 A ATOM 205 N VAL A 29 97.957 64.844 45.781 1.00 16.43 A ATOM 206 CA VAL A 29 98.164 64.762 44.346 1.00 16.98 A ATOM 207 CB VAL A 29 97.035 65.430 43.524 1.00 21.71 A ATOM 208 CG1 VAL A 29 97.421 65.427 41.999 1.00 14.09 A ATOM 209 CG2 VAL A 29 95.731 64.619 43.708 1.00 22.05 A ATOM 210 C VAL A 29 99.474 65.393 43.939 1.00 24.43 A ATOM 211 O VAL A 29 100.260 64.768 43.179 1.00 19.52 A ATOM 212 N ILE A 30 99.767 66.608 44.420 1.00 21.18 A ATOM 213 CA ILE A 30 101.022 67.194 43.950 1.00 21.90 A ATOM 214 CB ILE A 30 101.165 68.700 44.228 1.00 25.58 A ATOM 215 CG2 ILE A 30 100.124 69.422 43.519 1.00 45.44 A ATOM 216 CG1 ILE A 30 101.109 68.995 45.713 1.00 20.88 A ATOM 217 CD1 ILE A 30 102.385 68.792 46.400 1.00 43.61 A ATOM 218 C ILE A 30 102.227 66.495 44.510 1.00 8.84 A ATOM 219 O ILE A 30 103.227 66.413 43.837 1.00 20.78 A ATOM 220 N ALA A 31 102.137 65.986 45.730 1.00 11.98 A ATOM 221 CA ALA A 31 103.289 65.247 46.282 1.00 16.32 A ATOM 222 CB ALA A 31 102.982 64.774 47.668 1.00 11.90 A ATOM 223 C ALA A 31 103.613 64.026 45.381 1.00 20.08 A ATOM 224 O ALA A 31 104.779 63.774 45.047 1.00 18.22 A ATOM 225 N VAL A 32 102.594 63.254 45.005 1.00 16.38 A ATOM 226 CA VAL A 32 102.852 62.078 44.161 1.00 18.95 A ATOM 227 CB VAL A 32 101.597 61.176 44.042 1.00 22.56 A ATOM 228 CG1 VAL A 32 101.803 60.122 42.937 1.00 22.34 A ATOM 229 CG2 VAL A 32 101.348 60.477 45.364 1.00 13.55 A ATOM 230 C VAL A 32 103.328 62.569 42.778 1.00 22.75 A ATOM 231 O VAL A 32 104.310 62.061 42.211 1.00 22.15 A ATOM 232 N HIS A 33 102.662 63.581 42.234 1.00 17.13 A ATOM 233 CA HIS A 33 103.113 64.112 40.945 1.00 15.67 A ATOM 234 CB HIS A 33 102.301 65.335 40.554 1.00 19.93 A ATOM 235 CG HIS A 33 102.849 66.078 39.380 1.00 19.22 A ATOM 236 CD2 HIS A 33 103.579 67.220 39.317 1.00 25.53 A ATOM 237 ND1 HIS A 33 102.541 65.747 38.076 1.00 24.42 A ATOM 238 CE1 HIS A 33 103.042 66.661 37.262 1.00 21.19 A ATOM 239 NE2 HIS A 33 103.674 67.567 37.992 1.00 27.74 A ATOM 240 C HIS A 33 104.580 64.549 41.036 1.00 15.68 A ATOM 241 O HIS A 33 105.364 64.348 40.108 1.00 20.03 A ATOM 242 N TYR A 34 104.944 65.179 42.144 1.00 16.97 A ATOM 243 CA TYR A 34 106.317 65.646 42.304 1.00 20.05 A ATOM 244 CB TYR A 34 106.420 66.500 43.571 1.00 19.93 A ATOM 245 CG TYR A 34 107.826 66.882 43.969 1.00 14.48 A ATOM 246 CD1 TYR A 34 108.374 68.143 43.629 1.00 19.63 A ATOM 247 CE1 TYR A 34 109.672 68.522 44.095 1.00 15.16 A ATOM 248 CD2 TYR A 34 108.597 66.021 44.746 1.00 21.63 A ATOM 249 CE2 TYR A 34 109.889 66.380 45.183 1.00 17.33 A ATOM 250 CZ TYR A 34 110.419 67.633 44.861 1.00 21.32 A ATOM 251 OH TYR A 34 111.695 67.974 45.318 1.00 20.25 A ATOM 252 C TYR A 34 107.326 64.471 42.392 1.00 21.84 A ATOM 253 O TYR A 34 108.389 64.514 41.770 1.00 20.07 A ATOM 254 N LEU A 35 107.010 63.454 43.197 1.00 19.69 A ATOM 255 CA LEU A 35 107.924 62.333 43.345 1.00 19.40 A ATOM 256 CB LEU A 35 107.451 61.435 44.478 1.00 17.56 A ATOM 257 CG LEU A 35 107.627 62.047 45.884 1.00 16.05 A ATOM 258 CD1 LEU A 35 106.927 61.165 46.915 1.00 19.26 A ATOM 259 CD2 LEU A 35 109.123 62.096 46.253 1.00 15.28 A ATOM 260 C LEU A 35 108.066 61.564 42.015 1.00 23.12 A ATOM 261 O LEU A 35 109.187 61.215 41.608 1.00 17.85 A ATOM 262 N ASP A 36 106.954 61.305 41.329 1.00 16.70 A ATOM 263 CA ASP A 36 107.009 60.614 40.024 1.00 21.87 A ATOM 264 CB ASP A 36 105.620 60.458 39.375 1.00 23.42 A ATOM 265 CG ASP A 36 104.722 59.442 40.071 1.00 19.96 A ATOM 266 OD1 ASP A 36 105.160 58.736 41.003 1.00 23.17 A ATOM 267 OD2 ASP A 36 103.556 59.366 39.646 1.00 26.39 A ATOM 268 C ASP A 36 107.830 61.430 39.021 1.00 26.32 A ATOM 269 O ASP A 36 108.750 60.927 38.360 1.00 22.51 A ATOM 270 N GLU A 37 107.505 62.709 38.909 1.00 19.41 A ATOM 271 CA GLU A 37 108.180 63.550 37.919 1.00 23.12 A ATOM 272 CB GLU A 37 107.476 64.916 37.874 1.00 31.20 A ATOM 273 CG GLU A 37 107.620 65.640 36.601 1.00 42.72 A ATOM 274 CD GLU A 37 106.461 65.412 35.676 1.00 49.79 A ATOM 275 OE1 GLU A 37 106.263 64.269 35.210 1.00 51.12 A ATOM 276 OE2 GLU A 37 105.728 66.387 35.415 1.00 58.13 A ATOM 277 C GLU A 37 109.679 63.735 38.197 1.00 28.37 A ATOM 278 O GLU A 37 110.506 63.788 37.269 1.00 19.17 A ATOM 279 N THR A 38 110.044 63.821 39.469 1.00 19.70 A ATOM 280 CA THR A 38 111.446 64.046 39.777 1.00 18.16 A ATOM 281 CB THR A 38 111.615 64.951 41.051 1.00 24.32 A ATOM 282 OG1 THR A 38 111.062 64.292 42.206 1.00 17.55 A ATOM 283 CG2 THR A 38 110.872 66.295 40.874 1.00 17.35 A ATOM 284 C THR A 38 112.173 62.725 39.992 1.00 23.12 A ATOM 285 O THR A 38 113.384 62.708 40.176 1.00 20.01 A ATOM 286 N GLU A 39 111.423 61.626 39.973 1.00 19.41 A ATOM 287 CA GLU A 39 111.997 60.298 40.178 1.00 24.05 A ATOM 288 CB GLU A 39 112.918 59.965 38.997 1.00 26.82 A ATOM 289 CG GLU A 39 112.089 59.751 37.704 1.00 27.56 A ATOM 290 CD GLU A 39 112.915 59.531 36.414 1.00 40.15 A ATOM 291 OE1 GLU A 39 113.910 58.776 36.430 1.00 32.93 A ATOM 292 OE2 GLU A 39 112.555 60.113 35.358 1.00 42.52 A ATOM 293 C GLU A 39 112.740 60.228 41.519 1.00 25.56 A ATOM 294 O GLU A 39 113.898 59.818 41.597 1.00 23.18 A ATOM 295 N GLN A 40 112.059 60.614 42.601 1.00 24.46 A ATOM 296 CA GLN A 40 112.707 60.592 43.899 1.00 18.16 A ATOM 297 CB GLN A 40 112.682 62.002 44.489 1.00 24.56 A ATOM 298 CG GLN A 40 113.517 63.012 43.708 1.00 10.67 A ATOM 299 CD GLN A 40 113.705 64.283 44.507 1.00 19.34 A ATOM 300 OE1 GLN A 40 114.594 64.350 45.334 1.00 17.51 A ATOM 301 NE2 GLN A 40 112.845 65.298 44.275 1.00 17.15 A ATOM 302 C GLN A 40 112.118 59.603 44.894 1.00 19.24 A ATOM 303 O GLN A 40 112.350 59.725 46.100 1.00 23.09 A ATOM 304 N TRP A 41 111.345 58.635 44.403 1.00 18.32 A ATOM 305 CA TRP A 41 110.700 57.670 45.311 1.00 18.31 A ATOM 306 CB TRP A 41 109.808 56.715 44.511 1.00 18.08 A ATOM 307 CG TRP A 41 108.504 57.334 44.147 1.00 16.18 A ATOM 308 CD2 TRP A 41 107.382 57.574 45.024 1.00 18.90 A ATOM 309 CE2 TRP A 41 106.376 58.204 44.257 1.00 16.03 A ATOM 310 CE3 TRP A 41 107.134 57.322 46.379 1.00 16.13 A ATOM 311 CD1 TRP A 41 108.139 57.816 42.926 1.00 20.37 A ATOM 312 NE1 TRP A 41 106.860 58.344 42.977 1.00 19.88 A ATOM 313 CZ2 TRP A 41 105.136 58.583 44.800 1.00 15.32 A ATOM 314 CZ3 TRP A 41 105.893 57.703 46.929 1.00 19.86 A ATOM 315 CH2 TRP A 41 104.908 58.330 46.127 1.00 17.50 A ATOM 316 C TRP A 41 111.717 56.895 46.152 1.00 23.10 A ATOM 317 O TRP A 41 111.457 56.555 47.312 1.00 24.58 A ATOM 318 N GLU A 42 112.886 56.633 45.587 1.00 22.30 A ATOM 319 CA GLU A 42 113.937 55.916 46.322 1.00 30.40 A ATOM 320 CB GLU A 42 115.163 55.750 45.427 1.00 36.58 A ATOM 321 CG GLU A 42 116.448 55.477 46.147 1.00 53.35 A ATOM 322 CD GLU A 42 116.751 54.016 46.210 1.00 62.20 A ATOM 323 OE1 GLU A 42 117.946 53.652 46.164 1.00 67.07 A ATOM 324 OE2 GLU A 42 115.790 53.227 46.306 1.00 71.58 A ATOM 325 C GLU A 42 114.292 56.689 47.595 1.00 26.77 A ATOM 326 O GLU A 42 114.483 56.112 48.658 1.00 25.14 A ATOM 327 N LYS A 43 114.352 58.005 47.515 1.00 24.54 A ATOM 328 CA LYS A 43 114.639 58.771 48.717 1.00 25.18 A ATOM 329 CB LYS A 43 115.106 60.173 48.344 1.00 33.24 A ATOM 330 CG LYS A 43 116.398 60.152 47.566 1.00 36.94 A ATOM 331 CD LYS A 43 117.068 61.498 47.549 1.00 39.52 A ATOM 332 CE LYS A 43 116.841 62.204 46.242 1.00 39.10 A ATOM 333 NZ LYS A 43 117.597 63.486 46.197 1.00 37.63 A ATOM 334 C LYS A 43 113.437 58.885 49.640 1.00 30.60 A ATOM 335 O LYS A 43 113.583 59.064 50.854 1.00 28.31 A ATOM 336 N PHE A 44 112.232 58.754 49.089 1.00 23.22 A ATOM 337 CA PHE A 44 111.061 58.940 49.924 1.00 22.11 A ATOM 338 CB PHE A 44 109.995 59.654 49.078 1.00 19.24 A ATOM 339 CG PHE A 44 108.732 59.989 49.809 1.00 21.27 A ATOM 340 CD1 PHE A 44 108.627 61.162 50.555 1.00 23.33 A ATOM 341 CD2 PHE A 44 107.624 59.154 49.710 1.00 22.69 A ATOM 342 CE1 PHE A 44 107.424 61.514 51.193 1.00 22.52 A ATOM 343 CE2 PHE A 44 106.405 59.486 50.344 1.00 27.02 A ATOM 344 CZ PHE A 44 106.306 60.674 51.083 1.00 27.40 A ATOM 345 C PHE A 44 110.533 57.628 50.510 1.00 24.45 A ATOM 346 O PHE A 44 110.059 57.605 51.647 1.00 18.55 A ATOM 347 N GLY A 45 110.636 56.550 49.730 1.00 20.97 A ATOM 348 CA GLY A 45 110.142 55.236 50.131 1.00 20.25 A ATOM 349 C GLY A 45 109.064 54.826 49.136 1.00 23.29 A ATOM 350 O GLY A 45 107.871 55.185 49.279 1.00 17.57 A ATOM 351 N LEU A 46 109.465 54.095 48.104 1.00 20.22 A ATOM 352 CA LEU A 46 108.525 53.666 47.089 1.00 18.57 A ATOM 353 CB LEU A 46 109.243 52.881 45.977 1.00 27.58 A ATOM 354 CG LEU A 46 108.444 52.315 44.770 1.00 35.06 A ATOM 355 CD1 LEU A 46 107.661 53.396 44.022 1.00 27.92 A ATOM 356 CD2 LEU A 46 109.443 51.614 43.809 1.00 32.82 A ATOM 357 C LEU A 46 107.322 52.884 47.611 1.00 23.74 A ATOM 358 O LEU A 46 106.255 52.927 46.995 1.00 19.46 A ATOM 359 N GLU A 47 107.450 52.190 48.738 1.00 19.11 A ATOM 360 CA GLU A 47 106.292 51.453 49.220 1.00 29.84 A ATOM 361 CB GLU A 47 106.629 50.448 50.332 1.00 30.68 A ATOM 362 CG GLU A 47 107.600 50.871 51.370 1.00 45.90 A ATOM 363 CD GLU A 47 107.135 52.019 52.226 1.00 52.96 A ATOM 364 OE1 GLU A 47 105.927 52.017 52.597 1.00 60.58 A ATOM 365 OE2 GLU A 47 107.991 52.901 52.541 1.00 47.47 A ATOM 366 C GLU A 47 105.151 52.350 49.678 1.00 27.56 A ATOM 367 O GLU A 47 104.061 51.855 49.854 1.00 24.22 A ATOM 368 N LYS A 48 105.403 53.655 49.861 1.00 26.01 A ATOM 369 CA LYS A 48 104.340 54.594 50.262 1.00 20.77 A ATOM 370 CB LYS A 48 104.924 55.863 50.888 1.00 20.15 A ATOM 371 CG LYS A 48 105.694 55.636 52.167 1.00 19.21 A ATOM 372 CD LYS A 48 106.344 56.939 52.656 1.00 20.50 A ATOM 373 CE LYS A 48 107.190 56.673 53.891 1.00 30.14 A ATOM 374 NZ LYS A 48 108.457 55.962 53.556 1.00 23.91 A ATOM 375 C LYS A 48 103.512 55.013 49.059 1.00 19.66 A ATOM 376 O LYS A 48 102.415 55.567 49.217 1.00 23.92 A ATOM 377 N ARG A 49 104.005 54.750 47.850 1.00 17.52 A ATOM 378 CA ARG A 49 103.257 55.178 46.655 1.00 21.83 A ATOM 379 CB ARG A 49 104.048 54.879 45.360 1.00 16.40 A ATOM 380 CG ARG A 49 103.443 55.612 44.111 1.00 14.73 A ATOM 381 CD ARG A 49 104.410 55.661 42.916 1.00 21.52 A ATOM 382 NE ARG A 49 103.924 56.478 41.815 1.00 16.66 A ATOM 383 CZ ARG A 49 103.062 56.056 40.889 1.00 31.21 A ATOM 384 NH1 ARG A 49 102.592 54.803 40.922 1.00 20.87 A ATOM 385 NH2 ARG A 49 102.657 56.894 39.938 1.00 21.02 A ATOM 386 C ARG A 49 101.826 54.612 46.536 1.00 24.68 A ATOM 387 O ARG A 49 100.872 55.334 46.224 1.00 20.52 A ATOM 388 N GLN A 50 101.681 53.313 46.785 1.00 31.61 A ATOM 389 CA GLN A 50 100.398 52.629 46.691 1.00 24.84 A ATOM 390 CB GLN A 50 100.531 51.187 47.168 1.00 33.17 A ATOM 391 CG GLN A 50 100.197 50.169 46.142 1.00 46.59 A ATOM 392 CD GLN A 50 98.794 50.305 45.608 1.00 42.68 A ATOM 393 OE1 GLN A 50 97.825 50.200 46.346 1.00 40.26 A ATOM 394 NE2 GLN A 50 98.684 50.542 44.308 1.00 47.02 A ATOM 395 C GLN A 50 99.381 53.289 47.577 1.00 27.71 A ATOM 396 O GLN A 50 98.257 53.562 47.157 1.00 18.05 A ATOM 397 N GLY A 51 99.795 53.504 48.822 1.00 19.41 A ATOM 398 CA GLY A 51 98.944 54.124 49.820 1.00 24.54 A ATOM 399 C GLY A 51 98.517 55.489 49.329 1.00 27.23 A ATOM 400 O GLY A 51 97.347 55.861 49.470 1.00 27.21 A ATOM 401 N ALA A 52 99.444 56.233 48.723 1.00 21.82 A ATOM 402 CA ALA A 52 99.089 57.561 48.220 1.00 21.64 A ATOM 403 CB ALA A 52 100.343 58.319 47.777 1.00 20.17 A ATOM 404 C ALA A 52 98.117 57.446 47.065 1.00 18.79 A ATOM 405 O ALA A 52 97.209 58.265 46.947 1.00 21.57 A ATOM 406 N LEU A 53 98.296 56.436 46.206 1.00 16.94 A ATOM 407 CA LEU A 53 97.379 56.279 45.079 1.00 20.49 A ATOM 408 CB LEU A 53 97.816 55.148 44.151 1.00 22.88 A ATOM 409 CG LEU A 53 99.197 55.310 43.509 1.00 27.56 A ATOM 410 CD1 LEU A 53 99.526 54.081 42.643 1.00 28.51 A ATOM 411 CD2 LEU A 53 99.207 56.557 42.665 1.00 19.40 A ATOM 412 C LEU A 53 95.966 56.027 45.571 1.00 22.20 A ATOM 413 O LEU A 53 95.014 56.559 44.996 1.00 22.74 A ATOM 414 N GLU A 54 95.838 55.241 46.643 1.00 20.38 A ATOM 415 CA GLU A 54 94.542 54.937 47.247 1.00 22.21 A ATOM 416 CB GLU A 54 94.705 53.920 48.404 1.00 22.94 A ATOM 417 CG GLU A 54 95.023 52.489 47.951 1.00 41.26 A ATOM 418 CD GLU A 54 95.587 51.579 49.071 1.00 48.52 A ATOM 419 OE1 GLU A 54 95.476 51.903 50.286 1.00 50.15 A ATOM 420 OE2 GLU A 54 96.141 50.514 48.717 1.00 50.86 A ATOM 421 C GLU A 54 93.870 56.214 47.801 1.00 24.94 A ATOM 422 O GLU A 54 92.644 56.351 47.710 1.00 21.97 A ATOM 423 N LEU A 55 94.656 57.126 48.392 1.00 18.88 A ATOM 424 CA LEU A 55 94.085 58.351 48.948 1.00 21.65 A ATOM 425 CB LEU A 55 95.099 59.091 49.809 1.00 17.30 A ATOM 426 CG LEU A 55 95.464 58.303 51.072 1.00 26.70 A ATOM 427 CD1 LEU A 55 96.576 59.072 51.841 1.00 25.33 A ATOM 428 CD2 LEU A 55 94.196 58.153 51.981 1.00 20.15 A ATOM 429 C LEU A 55 93.646 59.229 47.802 1.00 18.82 A ATOM 430 O LEU A 55 92.613 59.897 47.902 1.00 16.55 A ATOM 431 N ILE A 56 94.413 59.218 46.712 1.00 15.84 A ATOM 432 CA ILE A 56 94.065 60.024 45.513 1.00 16.74 A ATOM 433 CB ILE A 56 95.151 59.930 44.390 1.00 21.15 A ATOM 434 CG2 ILE A 56 94.710 60.691 43.120 1.00 25.29 A ATOM 435 CG1 ILE A 56 96.461 60.644 44.806 1.00 20.28 A ATOM 436 CD1 ILE A 56 96.234 61.948 45.382 1.00 40.37 A ATOM 437 C ILE A 56 92.723 59.508 44.945 1.00 25.52 A ATOM 438 O ILE A 56 91.816 60.297 44.615 1.00 18.85 A ATOM 439 N LYS A 57 92.589 58.183 44.822 1.00 20.21 A ATOM 440 CA LYS A 57 91.354 57.595 44.308 1.00 19.21 A ATOM 441 CB LYS A 57 91.496 56.088 44.221 1.00 26.24 A ATOM 442 CG LYS A 57 90.244 55.363 43.763 1.00 37.40 A ATOM 443 CD LYS A 57 90.531 53.831 43.577 1.00 39.50 A ATOM 444 CE LYS A 57 89.290 53.088 43.091 1.00 45.08 A ATOM 445 NZ LYS A 57 89.516 51.637 42.936 1.00 50.42 A ATOM 446 C LYS A 57 90.192 57.952 45.242 1.00 23.30 A ATOM 447 O LYS A 57 89.082 58.273 44.789 1.00 20.92 A ATOM 448 N LYS A 58 90.445 57.902 46.550 1.00 16.98 A ATOM 449 CA LYS A 58 89.421 58.260 47.513 1.00 17.12 A ATOM 450 CB LYS A 58 89.971 58.041 48.937 1.00 18.85 A ATOM 451 CG LYS A 58 88.973 58.307 50.047 1.00 25.94 A ATOM 452 CD LYS A 58 89.491 57.947 51.437 1.00 35.63 A ATOM 453 CE LYS A 58 88.639 58.677 52.501 1.00 42.54 A ATOM 454 NZ LYS A 58 88.728 58.038 53.858 1.00 50.94 A ATOM 455 C LYS A 58 89.011 59.749 47.300 1.00 25.76 A ATOM 456 O LYS A 58 87.808 60.095 47.288 1.00 22.91 A ATOM 457 N GLY A 59 89.999 60.629 47.099 1.00 21.23 A ATOM 458 CA GLY A 59 89.691 62.041 46.894 1.00 23.41 A ATOM 459 C GLY A 59 88.819 62.247 45.664 1.00 25.51 A ATOM 460 O GLY A 59 87.820 62.978 45.683 1.00 21.04 A ATOM 461 N TYR A 60 89.213 61.576 44.588 1.00 21.05 A ATOM 462 CA TYR A 60 88.517 61.642 43.312 1.00 23.66 A ATOM 463 CB TYR A 60 89.244 60.776 42.296 1.00 13.71 A ATOM 464 CG TYR A 60 88.456 60.499 41.039 1.00 25.98 A ATOM 465 CD1 TYR A 60 88.276 61.495 40.082 1.00 22.56 A ATOM 466 CE1 TYR A 60 87.570 61.250 38.915 1.00 26.16 A ATOM 467 CD2 TYR A 60 87.893 59.223 40.792 1.00 27.02 A ATOM 468 CE2 TYR A 60 87.180 58.966 39.610 1.00 23.07 A ATOM 469 CZ TYR A 60 87.027 59.994 38.677 1.00 27.86 A ATOM 470 OH TYR A 60 86.347 59.798 37.490 1.00 19.73 A ATOM 471 C TYR A 60 87.089 61.131 43.448 1.00 23.97 A ATOM 472 O TYR A 60 86.129 61.776 43.024 1.00 16.61 A ATOM 473 N THR A 61 86.947 59.954 44.029 1.00 22.77 A ATOM 474 CA THR A 61 85.615 59.365 44.185 1.00 22.30 A ATOM 475 CB THR A 61 85.739 58.003 44.849 1.00 30.49 A ATOM 476 OG1 THR A 61 86.448 57.145 43.960 1.00 31.94 A ATOM 477 CG2 THR A 61 84.371 57.401 45.164 1.00 42.36 A ATOM 478 C THR A 61 84.724 60.246 45.008 1.00 23.97 A ATOM 479 O THR A 61 83.554 60.480 44.668 1.00 22.40 A ATOM 480 N GLN A 62 85.267 60.743 46.108 1.00 20.42 A ATOM 481 CA GLN A 62 84.476 61.619 46.958 1.00 23.93 A ATOM 482 CB GLN A 62 85.255 61.966 48.242 1.00 24.47 A ATOM 483 CG GLN A 62 85.293 60.776 49.207 1.00 26.29 A ATOM 484 CD GLN A 62 86.265 60.940 50.385 1.00 27.78 A ATOM 485 OE1 GLN A 62 86.263 60.126 51.289 1.00 27.57 A ATOM 486 NE2 GLN A 62 87.098 61.980 50.362 1.00 22.36 A ATOM 487 C GLN A 62 84.037 62.885 46.215 1.00 19.82 A ATOM 488 O GLN A 62 82.903 63.334 46.374 1.00 21.86 A ATOM 489 N GLN A 63 84.910 63.441 45.382 1.00 20.60 A ATOM 490 CA GLN A 63 84.569 64.669 44.667 1.00 23.75 A ATOM 491 CB GLN A 63 85.772 65.168 43.862 1.00 17.42 A ATOM 492 CG GLN A 63 85.669 66.602 43.360 1.00 15.84 A ATOM 493 CD GLN A 63 85.470 67.642 44.449 1.00 18.31 A ATOM 494 OE1 GLN A 63 85.851 67.455 45.610 1.00 15.34 A ATOM 495 NE2 GLN A 63 84.900 68.779 44.062 1.00 17.92 A ATOM 496 C GLN A 63 83.371 64.460 43.721 1.00 27.22 A ATOM 497 O GLN A 63 82.590 65.388 43.471 1.00 16.84 A ATOM 498 N LEU A 64 83.223 63.249 43.201 1.00 18.15 A ATOM 499 CA LEU A 64 82.113 62.984 42.289 1.00 20.34 A ATOM 500 CB LEU A 64 82.194 61.562 41.738 1.00 20.67 A ATOM 501 CG LEU A 64 83.460 61.266 40.904 1.00 29.97 A ATOM 502 CD1 LEU A 64 83.341 59.848 40.328 1.00 28.53 A ATOM 503 CD2 LEU A 64 83.645 62.308 39.769 1.00 25.04 A ATOM 504 C LEU A 64 80.781 63.214 42.971 1.00 20.30 A ATOM 505 O LEU A 64 79.818 63.568 42.314 1.00 23.21 A ATOM 506 N ALA A 65 80.708 63.015 44.288 1.00 15.07 A ATOM 507 CA ALA A 65 79.459 63.267 44.975 1.00 19.06 A ATOM 508 CB ALA A 65 79.595 62.955 46.447 1.00 19.25 A ATOM 509 C ALA A 65 79.010 64.717 44.790 1.00 19.22 A ATOM 510 O ALA A 65 77.864 65.042 45.087 1.00 24.93 A ATOM 511 N PHE A 66 79.895 65.592 44.314 1.00 22.94 A ATOM 512 CA PHE A 66 79.533 67.015 44.134 1.00 22.02 A ATOM 513 CB PHE A 66 80.481 67.908 44.943 1.00 21.43 A ATOM 514 CG PHE A 66 80.548 67.511 46.386 1.00 24.76 A ATOM 515 CD1 PHE A 66 79.542 67.914 47.287 1.00 21.43 A ATOM 516 CD2 PHE A 66 81.573 66.657 46.840 1.00 20.02 A ATOM 517 CE1 PHE A 66 79.555 67.467 48.605 1.00 22.96 A ATOM 518 CE2 PHE A 66 81.594 66.203 48.162 1.00 18.70 A ATOM 519 CZ PHE A 66 80.584 66.611 49.049 1.00 21.49 A ATOM 520 C PHE A 66 79.511 67.461 42.693 1.00 17.64 A ATOM 521 O PHE A 66 79.405 68.673 42.389 1.00 18.14 A ATOM 522 N ARG A 67 79.606 66.481 41.796 1.00 21.16 A ATOM 523 CA ARG A 67 79.541 66.745 40.354 1.00 23.23 A ATOM 524 CB ARG A 67 79.971 65.496 39.598 1.00 18.11 A ATOM 525 CG ARG A 67 79.896 65.665 38.107 1.00 28.17 A ATOM 526 CD ARG A 67 80.315 64.386 37.363 1.00 25.25 A ATOM 527 NE ARG A 67 80.344 64.619 35.923 1.00 25.71 A ATOM 528 CZ ARG A 67 80.004 63.715 35.012 1.00 26.53 A ATOM 529 NH1 ARG A 67 79.601 62.496 35.388 1.00 23.05 A ATOM 530 NH2 ARG A 67 80.089 64.028 33.724 1.00 16.97 A ATOM 531 C ARG A 67 78.055 67.034 40.044 1.00 25.46 A ATOM 532 O ARG A 67 77.223 66.244 40.427 1.00 18.92 A ATOM 533 N GLN A 68 77.716 68.150 39.395 1.00 21.57 A ATOM 534 CA GLN A 68 76.305 68.440 39.084 1.00 20.68 A ATOM 535 CB GLN A 68 76.073 69.964 39.186 1.00 23.31 A ATOM 536 CG GLN A 68 76.532 70.448 40.570 1.00 17.98 A ATOM 537 CD GLN A 68 75.990 71.790 40.937 1.00 25.72 A ATOM 538 OE1 GLN A 68 75.464 72.528 40.084 1.00 23.05 A ATOM 539 NE2 GLN A 68 76.132 72.140 42.206 1.00 15.43 A ATOM 540 C GLN A 68 75.871 67.887 37.722 1.00 16.68 A ATOM 541 O GLN A 68 76.704 67.367 36.998 1.00 19.76 A ATOM 542 N PRO A 69 74.563 67.945 37.368 1.00 22.91 A ATOM 543 CD PRO A 69 73.385 68.286 38.198 1.00 21.74 A ATOM 544 CA PRO A 69 74.144 67.408 36.046 1.00 20.68 A ATOM 545 CB PRO A 69 72.628 67.698 35.995 1.00 17.83 A ATOM 546 CG PRO A 69 72.208 67.532 37.454 1.00 16.18 A ATOM 547 C PRO A 69 74.886 68.078 34.892 1.00 23.73 A ATOM 548 O PRO A 69 75.152 67.467 33.875 1.00 23.28 A ATOM 549 N SER A 70 75.246 69.340 35.086 1.00 24.11 A ATOM 550 CA SER A 70 75.975 70.114 34.092 1.00 23.11 A ATOM 551 CB SER A 70 76.000 71.580 34.528 1.00 20.68 A ATOM 552 OG SER A 70 76.662 71.709 35.793 1.00 27.57 A ATOM 553 C SER A 70 77.436 69.654 33.942 1.00 27.84 A ATOM 554 O SER A 70 78.127 70.080 33.021 1.00 24.67 A ATOM 555 N SER A 71 77.885 68.805 34.868 1.00 19.80 A ATOM 556 CA SER A 71 79.288 68.333 34.971 1.00 20.11 A ATOM 557 CB SER A 71 79.953 68.052 33.613 1.00 22.15 A ATOM 558 OG SER A 71 79.498 66.853 33.011 1.00 21.54 A ATOM 559 C SER A 71 80.131 69.401 35.702 1.00 20.52 A ATOM 560 O SER A 71 81.329 69.262 35.782 1.00 19.50 A ATOM 561 N ALA A 72 79.522 70.477 36.199 1.00 19.13 A ATOM 562 CA ALA A 72 80.273 71.479 36.973 1.00 21.30 A ATOM 563 CB ALA A 72 79.665 72.897 36.823 1.00 16.76 A ATOM 564 C ALA A 72 80.250 71.064 38.447 1.00 24.51 A ATOM 565 O ALA A 72 79.540 70.122 38.840 1.00 20.95 A ATOM 566 N PHE A 73 81.026 71.773 39.266 1.00 22.89 A ATOM 567 CA PHE A 73 81.113 71.484 40.695 1.00 19.84 A ATOM 568 CB PHE A 73 82.541 70.958 41.056 1.00 16.24 A ATOM 569 CG PHE A 73 82.890 69.625 40.409 1.00 17.75 A ATOM 570 CD1 PHE A 73 83.265 69.554 39.067 1.00 14.21 A ATOM 571 CD2 PHE A 73 82.791 68.439 41.140 1.00 21.80 A ATOM 572 CE1 PHE A 73 83.527 68.310 38.447 1.00 18.43 A ATOM 573 CE2 PHE A 73 83.048 67.196 40.546 1.00 20.67 A ATOM 574 CZ PHE A 73 83.418 67.115 39.190 1.00 17.64 A ATOM 575 C PHE A 73 80.846 72.708 41.561 1.00 15.55 A ATOM 576 O PHE A 73 81.079 73.846 41.134 1.00 17.42 A ATOM 577 N ALA A 74 80.392 72.437 42.787 1.00 18.86 A ATOM 578 CA ALA A 74 80.196 73.440 43.842 1.00 21.20 A ATOM 579 CB ALA A 74 78.774 74.076 43.782 1.00 14.22 A ATOM 580 C ALA A 74 80.381 72.705 45.171 1.00 19.11 A ATOM 581 O ALA A 74 80.364 71.471 45.211 1.00 23.95 A ATOM 582 N ALA A 75 80.579 73.456 46.259 1.00 17.13 A ATOM 583 CA ALA A 75 80.738 72.883 47.584 1.00 21.11 A ATOM 584 CB ALA A 75 80.813 73.959 48.592 1.00 12.54 A ATOM 585 C ALA A 75 79.600 71.944 47.961 1.00 19.04 A ATOM 586 O ALA A 75 79.821 70.901 48.589 1.00 18.22 A ATOM 587 N PHE A 76 78.386 72.317 47.591 1.00 20.53 A ATOM 588 CA PHE A 76 77.202 71.519 47.920 1.00 15.82 A ATOM 589 CB PHE A 76 76.420 72.195 49.053 1.00 17.12 A ATOM 590 CG PHE A 76 77.249 72.514 50.258 1.00 26.60 A ATOM 591 CD1 PHE A 76 77.723 71.505 51.098 1.00 27.70 A ATOM 592 CD2 PHE A 76 77.576 73.824 50.551 1.00 22.87 A ATOM 593 CE1 PHE A 76 78.512 71.807 52.212 1.00 22.16 A ATOM 594 CE2 PHE A 76 78.367 74.125 51.667 1.00 28.08 A ATOM 595 CZ PHE A 76 78.832 73.124 52.490 1.00 23.72 A ATOM 596 C PHE A 76 76.343 71.444 46.654 1.00 23.48 A ATOM 597 O PHE A 76 76.308 72.404 45.866 1.00 15.81 A ATOM 598 N VAL A 77 75.639 70.327 46.465 1.00 19.15 A ATOM 599 CA VAL A 77 74.845 70.141 45.255 1.00 23.84 A ATOM 600 CB VAL A 77 74.279 68.688 45.144 1.00 24.38 A ATOM 601 CG1 VAL A 77 75.456 67.682 44.930 1.00 20.82 A ATOM 602 CG2 VAL A 77 73.465 68.349 46.390 1.00 19.64 A ATOM 603 C VAL A 77 73.701 71.122 45.082 1.00 20.75 A ATOM 604 O VAL A 77 73.201 71.320 43.973 1.00 24.71 A ATOM 605 N LYS A 78 73.302 71.723 46.184 1.00 15.92 A ATOM 606 CA LYS A 78 72.245 72.712 46.200 1.00 28.31 A ATOM 607 CB LYS A 78 71.642 72.818 47.590 1.00 31.59 A ATOM 608 CG LYS A 78 70.888 71.559 47.898 1.00 52.94 A ATOM 609 CD LYS A 78 69.877 71.719 48.992 1.00 60.83 A ATOM 610 CE LYS A 78 68.914 70.543 48.967 1.00 61.05 A ATOM 611 NZ LYS A 78 68.246 70.353 47.672 1.00 30.69 A ATOM 612 C LYS A 78 72.755 74.071 45.823 1.00 26.47 A ATOM 613 O LYS A 78 71.956 74.971 45.569 1.00 24.70 A ATOM 614 N ARG A 79 74.080 74.223 45.818 1.00 20.39 A ATOM 615 CA ARG A 79 74.723 75.499 45.514 1.00 21.78 A ATOM 616 CB ARG A 79 76.013 75.592 46.349 1.00 19.49 A ATOM 617 CG ARG A 79 76.859 76.847 46.120 1.00 23.95 A ATOM 618 CD ARG A 79 78.098 76.897 47.058 1.00 20.40 A ATOM 619 NE ARG A 79 78.758 78.204 47.005 1.00 25.41 A ATOM 620 CZ ARG A 79 78.559 79.167 47.899 1.00 30.60 A ATOM 621 NH1 ARG A 79 77.724 78.956 48.915 1.00 29.61 A ATOM 622 NH2 ARG A 79 79.177 80.338 47.780 1.00 23.38 A ATOM 623 C ARG A 79 75.036 75.716 44.030 1.00 21.79 A ATOM 624 O ARG A 79 75.417 74.764 43.332 1.00 19.63 A ATOM 625 N ALA A 80 74.877 76.967 43.553 1.00 21.57 A ATOM 626 CA ALA A 80 75.180 77.331 42.159 1.00 26.40 A ATOM 627 CB ALA A 80 74.960 78.868 41.923 1.00 22.62 A ATOM 628 C ALA A 80 76.659 76.953 41.914 1.00 20.22 A ATOM 629 O ALA A 80 77.519 77.179 42.780 1.00 23.83 A ATOM 630 N PRO A 81 76.959 76.365 40.744 1.00 23.02 A ATOM 631 CD PRO A 81 75.984 76.235 39.641 1.00 22.02 A ATOM 632 CA PRO A 81 78.301 75.909 40.337 1.00 20.18 A ATOM 633 CB PRO A 81 78.046 75.207 38.995 1.00 23.34 A ATOM 634 CG PRO A 81 76.879 75.999 38.416 1.00 25.62 A ATOM 635 C PRO A 81 79.370 76.990 40.238 1.00 24.53 A ATOM 636 O PRO A 81 79.132 78.085 39.736 1.00 18.24 A ATOM 637 N SER A 82 80.560 76.677 40.736 1.00 18.76 A ATOM 638 CA SER A 82 81.648 77.630 40.669 1.00 15.88 A ATOM 639 CB SER A 82 82.494 77.549 41.942 1.00 19.09 A ATOM 640 OG SER A 82 83.781 78.102 41.725 1.00 15.72 A ATOM 641 C SER A 82 82.529 77.411 39.437 1.00 18.93 A ATOM 642 O SER A 82 82.981 76.286 39.114 1.00 17.23 A ATOM 643 N THR A 83 82.762 78.494 38.725 1.00 17.20 A ATOM 644 CA THR A 83 83.628 78.442 37.544 1.00 16.78 A ATOM 645 CB THR A 83 83.692 79.829 36.868 1.00 19.03 A ATOM 646 OG1 THR A 83 82.397 80.168 36.392 1.00 20.73 A ATOM 647 CG2 THR A 83 84.666 79.840 35.692 1.00 17.21 A ATOM 648 C THR A 83 85.060 78.069 38.027 1.00 20.11 A ATOM 649 O THR A 83 85.740 77.214 37.446 1.00 15.09 A ATOM 650 N TRP A 84 85.514 78.745 39.084 1.00 16.86 A ATOM 651 CA TRP A 84 86.839 78.483 39.627 1.00 24.71 A ATOM 652 CB TRP A 84 87.171 79.427 40.780 1.00 16.82 A ATOM 653 CG TRP A 84 88.624 79.255 41.247 1.00 17.86 A ATOM 654 CD2 TRP A 84 89.106 78.315 42.218 1.00 16.17 A ATOM 655 CE2 TRP A 84 90.510 78.464 42.284 1.00 22.04 A ATOM 656 CE3 TRP A 84 88.486 77.366 43.035 1.00 17.61 A ATOM 657 CD1 TRP A 84 89.727 79.915 40.783 1.00 23.03 A ATOM 658 NE1 TRP A 84 90.859 79.447 41.405 1.00 16.07 A ATOM 659 CZ2 TRP A 84 91.308 77.686 43.141 1.00 21.59 A ATOM 660 CZ3 TRP A 84 89.279 76.595 43.892 1.00 21.38 A ATOM 661 CH2 TRP A 84 90.670 76.759 43.936 1.00 17.83 A ATOM 662 C TRP A 84 87.001 77.049 40.136 1.00 22.89 A ATOM 663 O TRP A 84 87.973 76.398 39.800 1.00 18.84 A ATOM 664 N LEU A 85 86.065 76.561 40.949 1.00 23.94 A ATOM 665 CA LEU A 85 86.175 75.193 41.495 1.00 19.54 A ATOM 666 CB LEU A 85 85.011 74.891 42.475 1.00 14.42 A ATOM 667 CG LEU A 85 85.115 73.580 43.258 1.00 19.45 A ATOM 668 CD1 LEU A 85 86.371 73.566 44.197 1.00 11.14 A ATOM 669 CD2 LEU A 85 83.825 73.422 44.060 1.00 18.37 A ATOM 670 C LEU A 85 86.175 74.195 40.356 1.00 24.50 A ATOM 671 O LEU A 85 86.994 73.257 40.330 1.00 19.38 A ATOM 672 N THR A 86 85.285 74.413 39.383 1.00 16.67 A ATOM 673 CA THR A 86 85.226 73.494 38.279 1.00 18.11 A ATOM 674 CB THR A 86 84.068 73.818 37.357 1.00 17.96 A ATOM 675 OG1 THR A 86 82.871 73.696 38.127 1.00 12.56 A ATOM 676 CG2 THR A 86 84.007 72.851 36.202 1.00 14.63 A ATOM 677 C THR A 86 86.534 73.480 37.569 1.00 18.80 A ATOM 678 O THR A 86 87.057 72.395 37.283 1.00 15.97 A ATOM 679 N ALA A 87 87.111 74.657 37.315 1.00 15.61 A ATOM 680 CA ALA A 87 88.422 74.679 36.645 1.00 21.28 A ATOM 681 CB ALA A 87 88.812 76.132 36.265 1.00 17.13 A ATOM 682 C ALA A 87 89.532 74.068 37.535 1.00 21.82 A ATOM 683 O ALA A 87 90.531 73.527 37.036 1.00 18.47 A ATOM 684 N TYR A 88 89.400 74.203 38.845 1.00 16.96 A ATOM 685 CA TYR A 88 90.439 73.637 39.708 1.00 19.62 A ATOM 686 CB TYR A 88 90.324 74.155 41.140 1.00 17.51 A ATOM 687 CG TYR A 88 91.533 73.749 41.989 1.00 17.09 A ATOM 688 CD1 TYR A 88 92.843 73.975 41.528 1.00 17.38 A ATOM 689 CE1 TYR A 88 93.947 73.554 42.259 1.00 18.76 A ATOM 690 CD2 TYR A 88 91.366 73.093 43.214 1.00 20.06 A ATOM 691 CE2 TYR A 88 92.475 72.663 43.971 1.00 20.12 A ATOM 692 CZ TYR A 88 93.746 72.903 43.488 1.00 20.21 A ATOM 693 OH TYR A 88 94.817 72.537 44.255 1.00 13.27 A ATOM 694 C TYR A 88 90.318 72.119 39.706 1.00 21.43 A ATOM 695 O TYR A 88 91.316 71.390 39.776 1.00 16.93 A ATOM 696 N VAL A 89 89.092 71.625 39.636 1.00 19.57 A ATOM 697 CA VAL A 89 88.949 70.192 39.599 1.00 19.82 A ATOM 698 CB VAL A 89 87.486 69.796 39.599 1.00 18.50 A ATOM 699 CG1 VAL A 89 87.331 68.263 39.251 1.00 15.01 A ATOM 700 CG2 VAL A 89 86.918 70.101 40.995 1.00 13.83 A ATOM 701 C VAL A 89 89.659 69.678 38.349 1.00 23.95 A ATOM 702 O VAL A 89 90.348 68.656 38.395 1.00 18.30 A ATOM 703 N VAL A 90 89.491 70.382 37.232 1.00 17.40 A ATOM 704 CA VAL A 90 90.160 69.981 35.990 1.00 18.85 A ATOM 705 CB VAL A 90 89.724 70.929 34.791 1.00 19.41 A ATOM 706 CG1 VAL A 90 90.600 70.715 33.553 1.00 13.53 A ATOM 707 CG2 VAL A 90 88.248 70.648 34.399 1.00 17.29 A ATOM 708 C VAL A 90 91.703 70.043 36.175 1.00 19.91 A ATOM 709 O VAL A 90 92.452 69.188 35.696 1.00 20.47 A ATOM 710 N LYS A 91 92.181 71.075 36.858 1.00 20.83 A ATOM 711 CA LYS A 91 93.614 71.240 37.046 1.00 23.83 A ATOM 712 CB LYS A 91 93.861 72.579 37.741 1.00 21.45 A ATOM 713 CG LYS A 91 95.232 73.277 37.527 1.00 24.31 A ATOM 714 CD LYS A 91 95.603 73.978 38.817 1.00 28.86 A ATOM 715 CE LYS A 91 96.264 75.359 38.681 1.00 41.38 A ATOM 716 NZ LYS A 91 97.276 75.477 37.603 1.00 23.09 A ATOM 717 C LYS A 91 94.176 70.090 37.904 1.00 22.83 A ATOM 718 O LYS A 91 95.288 69.615 37.659 1.00 28.75 A ATOM 719 N VAL A 92 93.422 69.641 38.908 1.00 16.52 A ATOM 720 CA VAL A 92 93.938 68.571 39.767 1.00 15.54 A ATOM 721 CB VAL A 92 93.220 68.564 41.134 1.00 14.74 A ATOM 722 CG1 VAL A 92 93.669 67.333 41.957 1.00 12.97 A ATOM 723 CG2 VAL A 92 93.531 69.882 41.912 1.00 15.57 A ATOM 724 C VAL A 92 93.780 67.195 39.100 1.00 22.13 A ATOM 725 O VAL A 92 94.735 66.398 39.027 1.00 19.97 A ATOM 726 N PHE A 93 92.575 66.936 38.599 1.00 15.35 A ATOM 727 CA PHE A 93 92.262 65.649 37.986 1.00 21.59 A ATOM 728 CB PHE A 93 90.780 65.619 37.538 1.00 20.43 A ATOM 729 CG PHE A 93 89.762 65.399 38.658 1.00 21.63 A ATOM 730 CD1 PHE A 93 90.101 65.531 40.003 1.00 22.34 A ATOM 731 CD2 PHE A 93 88.435 65.083 38.327 1.00 25.57 A ATOM 732 CE1 PHE A 93 89.146 65.347 41.015 1.00 18.59 A ATOM 733 CE2 PHE A 93 87.474 64.900 39.309 1.00 16.00 A ATOM 734 CZ PHE A 93 87.827 65.034 40.660 1.00 18.70 A ATOM 735 C PHE A 93 93.183 65.348 36.778 1.00 20.69 A ATOM 736 O PHE A 93 93.572 64.201 36.582 1.00 22.65 A ATOM 737 N SER A 94 93.516 66.364 35.975 1.00 19.95 A ATOM 738 CA SER A 94 94.382 66.192 34.795 1.00 23.79 A ATOM 739 CB SER A 94 94.563 67.526 34.040 1.00 23.74 A ATOM 740 OG SER A 94 93.351 67.930 33.393 1.00 23.03 A ATOM 741 C SER A 94 95.759 65.623 35.169 1.00 29.47 A ATOM 742 O SER A 94 96.379 64.867 34.406 1.00 24.55 A ATOM 743 N LEU A 95 96.230 65.998 36.346 1.00 25.17 A ATOM 744 CA LEU A 95 97.500 65.515 36.858 1.00 29.40 A ATOM 745 CB LEU A 95 97.953 66.430 37.992 1.00 32.98 A ATOM 746 CG LEU A 95 99.047 67.438 37.643 1.00 41.49 A ATOM 747 CD1 LEU A 95 98.732 68.151 36.358 1.00 36.09 A ATOM 748 CD2 LEU A 95 99.244 68.378 38.800 1.00 40.51 A ATOM 749 C LEU A 95 97.413 64.064 37.368 1.00 31.25 A ATOM 750 O LEU A 95 98.433 63.376 37.493 1.00 24.33 A ATOM 751 N ALA A 96 96.203 63.614 37.685 1.00 28.03 A ATOM 752 CA ALA A 96 95.991 62.260 38.208 1.00 27.75 A ATOM 753 CB ALA A 96 94.901 62.301 39.286 1.00 26.88 A ATOM 754 C ALA A 96 95.629 61.204 37.157 1.00 29.48 A ATOM 755 O ALA A 96 95.529 60.013 37.479 1.00 25.41 A ATOM 756 N VAL A 97 95.447 61.639 35.910 1.00 25.39 A ATOM 757 CA VAL A 97 95.035 60.759 34.802 1.00 29.11 A ATOM 758 CB VAL A 97 95.034 61.571 33.480 1.00 28.78 A ATOM 759 CG1 VAL A 97 95.057 60.663 32.321 1.00 38.20 A ATOM 760 CG2 VAL A 97 93.748 62.496 33.422 1.00 24.13 A ATOM 761 C VAL A 97 95.813 59.424 34.636 1.00 33.92 A ATOM 762 O VAL A 97 95.222 58.381 34.289 1.00 31.47 A ATOM 763 N ASN A 98 97.124 59.457 34.848 1.00 21.59 A ATOM 764 CA ASN A 98 97.923 58.240 34.770 1.00 36.51 A ATOM 765 CB ASN A 98 99.222 58.471 33.983 1.00 36.15 A ATOM 766 CG ASN A 98 98.971 58.837 32.510 1.00 36.17 A ATOM 767 OD1 ASN A 98 98.119 58.252 31.844 1.00 38.38 A ATOM 768 ND2 ASN A 98 99.730 59.805 32.007 1.00 40.71 A ATOM 769 C ASN A 98 98.260 57.700 36.178 1.00 37.38 A ATOM 770 O ASN A 98 99.138 56.844 36.316 1.00 31.38 A ATOM 771 N LEU A 99 97.562 58.205 37.205 1.00 25.80 A ATOM 772 CA LEU A 99 97.763 57.760 38.592 1.00 34.00 A ATOM 773 CB LEU A 99 97.747 58.936 39.580 1.00 23.10 A ATOM 774 CG LEU A 99 98.867 59.966 39.407 1.00 26.85 A ATOM 775 CD1 LEU A 99 98.812 61.017 40.508 1.00 25.56 A ATOM 776 CD2 LEU A 99 100.191 59.231 39.390 1.00 29.12 A ATOM 777 C LEU A 99 96.656 56.804 38.994 1.00 34.25 A ATOM 778 O LEU A 99 96.911 55.782 39.629 1.00 29.94 A ATOM 779 N ILE A 100 95.431 57.169 38.623 1.00 24.08 A ATOM 780 CA ILE A 100 94.232 56.407 38.913 1.00 28.23 A ATOM 781 CB ILE A 100 93.446 57.007 40.119 1.00 26.92 A ATOM 782 CG2 ILE A 100 94.300 56.986 41.388 1.00 21.39 A ATOM 783 CG1 ILE A 100 93.022 58.457 39.786 1.00 22.04 A ATOM 784 CD1 ILE A 100 91.965 59.043 40.791 1.00 21.31 A ATOM 785 C ILE A 100 93.340 56.511 37.684 1.00 28.89 A ATOM 786 O ILE A 100 93.676 57.218 36.738 1.00 25.36 A ATOM 787 N ALA A 101 92.195 55.834 37.701 1.00 21.87 A ATOM 788 CA ALA A 101 91.278 55.891 36.563 1.00 25.41 A ATOM 789 CB ALA A 101 90.323 54.656 36.557 1.00 29.20 A ATOM 790 C ALA A 101 90.426 57.148 36.639 1.00 27.34 A ATOM 791 O ALA A 101 89.546 57.235 37.493 1.00 27.43 A ATOM 792 N ILE A 102 90.676 58.121 35.774 1.00 25.35 A ATOM 793 CA ILE A 102 89.837 59.308 35.794 1.00 26.53 A ATOM 794 CB ILE A 102 90.666 60.596 35.788 1.00 30.43 A ATOM 795 CG2 ILE A 102 89.775 61.805 35.343 1.00 26.72 A ATOM 796 CG1 ILE A 102 91.165 60.849 37.221 1.00 33.11 A ATOM 797 CD1 ILE A 102 92.470 61.458 37.221 1.00 45.56 A ATOM 798 C ILE A 102 88.919 59.248 34.585 1.00 22.33 A ATOM 799 O ILE A 102 89.378 59.106 33.461 1.00 26.71 A ATOM 800 N ASP A 103 87.621 59.318 34.836 1.00 26.27 A ATOM 801 CA ASP A 103 86.616 59.227 33.776 1.00 25.84 A ATOM 802 CB ASP A 103 85.231 59.056 34.425 1.00 25.81 A ATOM 803 CG ASP A 103 84.114 58.863 33.403 1.00 34.26 A ATOM 804 OD1 ASP A 103 84.361 59.023 32.187 1.00 25.53 A ATOM 805 OD2 ASP A 103 82.979 58.551 33.828 1.00 39.65 A ATOM 806 C ASP A 103 86.642 60.484 32.900 1.00 24.26 A ATOM 807 O ASP A 103 86.385 61.577 33.381 1.00 26.29 A ATOM 808 N SER A 104 86.972 60.331 31.627 1.00 24.09 A ATOM 809 CA SER A 104 87.010 61.465 30.700 1.00 30.37 A ATOM 810 CB SER A 104 87.490 60.999 29.333 1.00 35.62 A ATOM 811 OG SER A 104 88.890 60.808 29.371 1.00 42.20 A ATOM 812 C SER A 104 85.689 62.219 30.544 1.00 27.77 A ATOM 813 O SER A 104 85.679 63.399 30.237 1.00 26.73 A ATOM 814 N GLN A 105 84.576 61.534 30.741 1.00 26.58 A ATOM 815 CA GLN A 105 83.264 62.158 30.673 1.00 31.05 A ATOM 816 CB GLN A 105 82.162 61.141 30.991 1.00 33.79 A ATOM 817 CG GLN A 105 81.964 60.052 29.984 1.00 45.91 A ATOM 818 CD GLN A 105 81.570 60.627 28.655 1.00 53.89 A ATOM 819 OE1 GLN A 105 82.400 61.212 27.938 1.00 55.25 A ATOM 820 NE2 GLN A 105 80.286 60.499 28.320 1.00 55.15 A ATOM 821 C GLN A 105 83.227 63.209 31.778 1.00 30.55 A ATOM 822 O GLN A 105 82.602 64.258 31.644 1.00 26.07 A ATOM 823 N VAL A 106 83.867 62.889 32.897 1.00 26.33 A ATOM 824 CA VAL A 106 83.888 63.790 34.056 1.00 25.39 A ATOM 825 CB VAL A 106 84.395 63.046 35.315 1.00 24.50 A ATOM 826 CG1 VAL A 106 84.635 64.032 36.470 1.00 21.15 A ATOM 827 CG2 VAL A 106 83.369 61.966 35.738 1.00 18.61 A ATOM 828 C VAL A 106 84.829 64.931 33.742 1.00 22.14 A ATOM 829 O VAL A 106 84.446 66.083 33.719 1.00 25.05 A ATOM 830 N LEU A 107 86.076 64.589 33.498 1.00 20.26 A ATOM 831 CA LEU A 107 87.076 65.582 33.195 1.00 22.29 A ATOM 832 CB LEU A 107 88.416 64.907 32.888 1.00 19.77 A ATOM 833 CG LEU A 107 89.520 65.924 32.603 1.00 28.38 A ATOM 834 CD1 LEU A 107 89.898 66.617 33.883 1.00 29.44 A ATOM 835 CD2 LEU A 107 90.737 65.230 32.030 1.00 37.22 A ATOM 836 C LEU A 107 86.652 66.472 32.017 1.00 25.15 A ATOM 837 O LEU A 107 86.572 67.690 32.153 1.00 24.72 A ATOM 838 N CYS A 108 86.334 65.874 30.877 1.00 23.13 A ATOM 839 CA CYS A 108 85.959 66.654 29.711 1.00 20.45 A ATOM 840 C CYS A 108 84.576 67.314 29.811 1.00 27.92 A ATOM 841 O CYS A 108 84.319 68.330 29.156 1.00 25.68 A ATOM 842 CB CYS A 108 86.043 65.787 28.446 1.00 27.49 A ATOM 843 SG CYS A 108 87.690 65.037 28.227 1.00 28.60 A ATOM 844 N GLY A 109 83.684 66.748 30.613 1.00 29.41 A ATOM 845 CA GLY A 109 82.370 67.355 30.765 1.00 21.87 A ATOM 846 C GLY A 109 82.542 68.681 31.483 1.00 26.48 A ATOM 847 O GLY A 109 81.879 69.660 31.155 1.00 24.15 A ATOM 848 N ALA A 110 83.475 68.737 32.440 1.00 19.49 A ATOM 849 CA ALA A 110 83.684 69.970 33.184 1.00 17.06 A ATOM 850 CB ALA A 110 84.578 69.736 34.402 1.00 18.01 A ATOM 851 C ALA A 110 84.318 70.995 32.258 1.00 18.22 A ATOM 852 O ALA A 110 83.970 72.180 32.307 1.00 19.57 A ATOM 853 N VAL A 111 85.268 70.552 31.450 1.00 21.00 A ATOM 854 CA VAL A 111 85.947 71.421 30.492 1.00 19.95 A ATOM 855 CB VAL A 111 87.013 70.609 29.645 1.00 26.47 A ATOM 856 CG1 VAL A 111 87.331 71.346 28.314 1.00 19.61 A ATOM 857 CG2 VAL A 111 88.307 70.414 30.463 1.00 20.68 A ATOM 858 C VAL A 111 84.883 72.006 29.549 1.00 25.73 A ATOM 859 O VAL A 111 84.835 73.210 29.305 1.00 24.22 A ATOM 860 N LYS A 112 84.016 71.143 29.034 1.00 24.78 A ATOM 861 CA LYS A 112 82.996 71.589 28.096 1.00 29.18 A ATOM 862 CB LYS A 112 82.162 70.391 27.599 1.00 29.48 A ATOM 863 CG LYS A 112 81.141 70.772 26.507 1.00 35.04 A ATOM 864 CD LYS A 112 80.441 69.565 25.878 1.00 35.71 A ATOM 865 CE LYS A 112 81.420 68.677 25.104 1.00 41.21 A ATOM 866 NZ LYS A 112 80.780 67.431 24.529 1.00 43.02 A ATOM 867 C LYS A 112 82.088 72.660 28.688 1.00 24.46 A ATOM 868 O LYS A 112 81.776 73.643 28.024 1.00 26.79 A ATOM 869 N TRP A 113 81.672 72.470 29.939 1.00 23.58 A ATOM 870 CA TRP A 113 80.810 73.415 30.626 1.00 20.72 A ATOM 871 CB TRP A 113 80.459 72.878 32.014 1.00 25.99 A ATOM 872 CG TRP A 113 79.627 73.817 32.856 1.00 22.08 A ATOM 873 CD2 TRP A 113 80.101 74.659 33.909 1.00 24.19 A ATOM 874 CE2 TRP A 113 78.961 75.282 34.494 1.00 24.99 A ATOM 875 CE3 TRP A 113 81.379 74.945 34.426 1.00 19.23 A ATOM 876 CD1 TRP A 113 78.251 73.971 32.828 1.00 19.34 A ATOM 877 NE1 TRP A 113 77.856 74.845 33.820 1.00 20.42 A ATOM 878 CZ2 TRP A 113 79.060 76.153 35.557 1.00 22.43 A ATOM 879 CZ3 TRP A 113 81.484 75.808 35.491 1.00 26.60 A ATOM 880 CH2 TRP A 113 80.324 76.408 36.056 1.00 30.42 A ATOM 881 C TRP A 113 81.475 74.775 30.793 1.00 23.72 A ATOM 882 O TRP A 113 80.848 75.815 30.600 1.00 21.74 A ATOM 883 N LEU A 114 82.750 74.756 31.182 1.00 23.73 A ATOM 884 CA LEU A 114 83.508 75.976 31.396 1.00 19.99 A ATOM 885 CB LEU A 114 84.971 75.624 31.687 1.00 16.92 A ATOM 886 CG LEU A 114 85.231 75.166 33.138 1.00 17.13 A ATOM 887 CD1 LEU A 114 86.620 74.621 33.322 1.00 14.89 A ATOM 888 CD2 LEU A 114 85.050 76.365 34.046 1.00 17.43 A ATOM 889 C LEU A 114 83.413 76.839 30.143 1.00 24.77 A ATOM 890 O LEU A 114 83.101 78.042 30.204 1.00 20.50 A ATOM 891 N ILE A 115 83.676 76.197 29.008 1.00 23.02 A ATOM 892 CA ILE A 115 83.670 76.848 27.702 1.00 26.10 A ATOM 893 CB ILE A 115 84.191 75.920 26.552 1.00 24.85 A ATOM 894 CG2 ILE A 115 84.215 76.694 25.249 1.00 27.04 A ATOM 895 CG1 ILE A 115 85.585 75.368 26.851 1.00 32.98 A ATOM 896 CD1 ILE A 115 86.479 76.372 27.492 1.00 52.20 A ATOM 897 C ILE A 115 82.287 77.278 27.240 1.00 23.55 A ATOM 898 O ILE A 115 82.087 78.433 26.884 1.00 21.22 A ATOM 899 N LEU A 116 81.356 76.330 27.222 1.00 15.47 A ATOM 900 CA LEU A 116 80.009 76.584 26.722 1.00 23.51 A ATOM 901 CB LEU A 116 79.298 75.260 26.459 1.00 23.69 A ATOM 902 CG LEU A 116 79.986 74.298 25.494 1.00 29.79 A ATOM 903 CD1 LEU A 116 78.985 73.211 25.148 1.00 24.68 A ATOM 904 CD2 LEU A 116 80.479 75.022 24.250 1.00 26.74 A ATOM 905 C LEU A 116 79.126 77.454 27.598 1.00 22.96 A ATOM 906 O LEU A 116 78.214 78.095 27.100 1.00 23.54 A ATOM 907 N GLU A 117 79.386 77.479 28.902 1.00 26.63 A ATOM 908 CA GLU A 117 78.567 78.272 29.813 1.00 24.27 A ATOM 909 CB GLU A 117 78.033 77.403 30.936 1.00 21.64 A ATOM 910 CG GLU A 117 77.035 76.355 30.526 1.00 27.37 A ATOM 911 CD GLU A 117 75.767 76.959 29.969 1.00 26.27 A ATOM 912 OE1 GLU A 117 75.449 78.124 30.316 1.00 25.92 A ATOM 913 OE2 GLU A 117 75.090 76.260 29.191 1.00 30.37 A ATOM 914 C GLU A 117 79.257 79.457 30.470 1.00 24.39 A ATOM 915 O GLU A 117 78.611 80.460 30.753 1.00 25.44 A ATOM 916 N LYS A 118 80.561 79.373 30.706 1.00 18.78 A ATOM 917 CA LYS A 118 81.189 80.460 31.440 1.00 19.49 A ATOM 918 CB LYS A 118 81.782 79.887 32.748 1.00 25.65 A ATOM 919 CG LYS A 118 80.761 79.090 33.606 1.00 17.16 A ATOM 920 CD LYS A 118 79.665 80.070 34.058 1.00 21.32 A ATOM 921 CE LYS A 118 78.463 79.410 34.663 1.00 23.09 A ATOM 922 NZ LYS A 118 77.522 80.476 35.101 1.00 23.88 A ATOM 923 C LYS A 118 82.213 81.332 30.744 1.00 22.37 A ATOM 924 O LYS A 118 82.898 82.122 31.400 1.00 20.49 A ATOM 925 N GLN A 119 82.360 81.202 29.431 1.00 20.57 A ATOM 926 CA GLN A 119 83.332 82.060 28.748 1.00 32.06 A ATOM 927 CB GLN A 119 84.242 81.238 27.801 1.00 20.00 A ATOM 928 CG GLN A 119 85.382 82.091 27.173 1.00 20.89 A ATOM 929 CD GLN A 119 86.339 81.257 26.337 1.00 23.85 A ATOM 930 OE1 GLN A 119 85.940 80.270 25.734 1.00 18.93 A ATOM 931 NE2 GLN A 119 87.602 81.661 26.285 1.00 15.38 A ATOM 932 C GLN A 119 82.543 83.095 27.929 1.00 24.21 A ATOM 933 O GLN A 119 81.649 82.725 27.195 1.00 21.97 A ATOM 934 N LYS A 120 82.880 84.367 28.048 1.00 28.47 A ATOM 935 CA LYS A 120 82.193 85.403 27.288 1.00 33.91 A ATOM 936 CB LYS A 120 82.448 86.774 27.918 1.00 29.00 A ATOM 937 CG LYS A 120 81.948 86.897 29.337 1.00 38.95 A ATOM 938 CD LYS A 120 82.173 88.303 29.892 1.00 47.54 A ATOM 939 CE LYS A 120 81.955 88.332 31.396 1.00 56.75 A ATOM 940 NZ LYS A 120 80.623 87.776 31.790 1.00 65.69 A ATOM 941 C LYS A 120 82.673 85.434 25.818 1.00 36.89 A ATOM 942 O LYS A 120 83.700 84.864 25.460 1.00 30.22 A ATOM 943 N PRO A 121 81.926 86.120 24.949 1.00 37.55 A ATOM 944 CD PRO A 121 80.622 86.771 25.165 1.00 41.75 A ATOM 945 CA PRO A 121 82.327 86.197 23.548 1.00 31.55 A ATOM 946 CB PRO A 121 81.271 87.114 22.940 1.00 39.82 A ATOM 947 CG PRO A 121 80.041 86.762 23.756 1.00 44.17 A ATOM 948 C PRO A 121 83.724 86.780 23.443 1.00 31.58 A ATOM 949 O PRO A 121 84.489 86.388 22.568 1.00 29.41 A ATOM 950 N ASP A 122 84.076 87.693 24.342 1.00 27.25 A ATOM 951 CA ASP A 122 85.401 88.285 24.268 1.00 29.04 A ATOM 952 CB ASP A 122 85.435 89.636 24.985 1.00 28.38 A ATOM 953 CG ASP A 122 85.281 89.525 26.494 1.00 38.36 A ATOM 954 OD1 ASP A 122 84.964 88.438 27.033 1.00 39.09 A ATOM 955 OD2 ASP A 122 85.477 90.558 27.156 1.00 38.98 A ATOM 956 C ASP A 122 86.531 87.363 24.783 1.00 32.13 A ATOM 957 O ASP A 122 87.693 87.759 24.780 1.00 26.62 A ATOM 958 N GLY A 123 86.186 86.145 25.214 1.00 30.31 A ATOM 959 CA GLY A 123 87.203 85.196 25.678 1.00 30.38 A ATOM 960 C GLY A 123 87.422 85.098 27.188 1.00 30.19 A ATOM 961 O GLY A 123 88.039 84.144 27.654 1.00 29.94 A ATOM 962 N VAL A 124 86.930 86.077 27.940 1.00 24.05 A ATOM 963 CA VAL A 124 87.055 86.116 29.403 1.00 23.87 A ATOM 964 CB VAL A 124 86.546 87.473 29.951 1.00 23.70 A ATOM 965 CG1 VAL A 124 86.353 87.413 31.459 1.00 27.05 A ATOM 966 CG2 VAL A 124 87.522 88.581 29.581 1.00 24.79 A ATOM 967 C VAL A 124 86.240 85.041 30.106 1.00 29.58 A ATOM 968 O VAL A 124 85.071 84.813 29.733 1.00 26.81 A ATOM 969 N PHE A 125 86.824 84.383 31.126 1.00 24.92 A ATOM 970 CA PHE A 125 86.040 83.394 31.891 1.00 25.88 A ATOM 971 CB PHE A 125 86.893 82.228 32.352 1.00 24.21 A ATOM 972 CG PHE A 125 87.069 81.189 31.312 1.00 25.00 A ATOM 973 CD1 PHE A 125 86.059 80.277 31.059 1.00 23.52 A ATOM 974 CD2 PHE A 125 88.224 81.146 30.534 1.00 22.60 A ATOM 975 CE1 PHE A 125 86.186 79.345 30.063 1.00 23.68 A ATOM 976 CE2 PHE A 125 88.354 80.202 29.517 1.00 16.73 A ATOM 977 CZ PHE A 125 87.338 79.306 29.282 1.00 20.14 A ATOM 978 C PHE A 125 85.479 84.135 33.090 1.00 24.56 A ATOM 979 O PHE A 125 86.175 84.941 33.710 1.00 21.73 A ATOM 980 N GLN A 126 84.214 83.866 33.414 1.00 21.30 A ATOM 981 CA GLN A 126 83.558 84.549 34.530 1.00 22.03 A ATOM 982 CB GLN A 126 82.348 85.333 34.003 1.00 33.53 A ATOM 983 CG GLN A 126 81.694 86.233 35.019 1.00 46.06 A ATOM 984 CD GLN A 126 80.588 87.096 34.409 1.00 54.63 A ATOM 985 OE1 GLN A 126 79.474 86.612 34.131 1.00 56.00 A ATOM 986 NE2 GLN A 126 80.897 88.383 34.188 1.00 55.55 A ATOM 987 C GLN A 126 83.085 83.607 35.634 1.00 18.80 A ATOM 988 O GLN A 126 82.611 82.489 35.360 1.00 18.84 A ATOM 989 N GLU A 127 83.202 84.068 36.871 1.00 19.63 A ATOM 990 CA GLU A 127 82.770 83.301 38.050 1.00 18.00 A ATOM 991 CB GLU A 127 83.708 83.576 39.232 1.00 17.47 A ATOM 992 CG GLU A 127 83.190 82.969 40.556 1.00 21.51 A ATOM 993 CD GLU A 127 83.051 81.442 40.446 1.00 23.16 A ATOM 994 OE1 GLU A 127 82.025 80.930 39.942 1.00 17.83 A ATOM 995 OE2 GLU A 127 84.008 80.754 40.848 1.00 21.73 A ATOM 996 C GLU A 127 81.374 83.823 38.419 1.00 26.19 A ATOM 997 O GLU A 127 81.232 85.016 38.663 1.00 21.32 A ATOM 998 N ASP A 128 80.339 82.981 38.438 1.00 24.79 A ATOM 999 CA ASP A 128 79.015 83.486 38.837 1.00 23.86 A ATOM 1000 CB ASP A 128 77.909 83.020 37.876 1.00 28.03 A ATOM 1001 CG ASP A 128 77.970 83.709 36.523 1.00 31.99 A ATOM 1002 OD1 ASP A 128 78.166 84.944 36.495 1.00 35.60 A ATOM 1003 OD2 ASP A 128 77.807 83.018 35.492 1.00 29.56 A ATOM 1004 C ASP A 128 78.659 83.006 40.253 1.00 22.48 A ATOM 1005 O ASP A 128 77.629 83.368 40.796 1.00 23.11 A ATOM 1006 N ALA A 129 79.498 82.172 40.849 1.00 20.40 A ATOM 1007 CA ALA A 129 79.215 81.676 42.210 1.00 25.25 A ATOM 1008 CB ALA A 129 78.336 80.383 42.153 1.00 24.60 A ATOM 1009 C ALA A 129 80.531 81.385 42.926 1.00 21.47 A ATOM 1010 O ALA A 129 81.012 80.267 42.901 1.00 20.12 A ATOM 1011 N PRO A 130 81.142 82.412 43.535 1.00 22.93 A ATOM 1012 CD PRO A 130 80.707 83.830 43.484 1.00 18.89 A ATOM 1013 CA PRO A 130 82.406 82.269 44.248 1.00 20.89 A ATOM 1014 CB PRO A 130 82.610 83.637 44.868 1.00 24.77 A ATOM 1015 CG PRO A 130 81.951 84.575 43.823 1.00 29.40 A ATOM 1016 C PRO A 130 82.417 81.168 45.314 1.00 25.72 A ATOM 1017 O PRO A 130 81.421 80.932 46.010 1.00 20.76 A ATOM 1018 N VAL A 131 83.557 80.497 45.431 1.00 18.66 A ATOM 1019 CA VAL A 131 83.709 79.442 46.421 1.00 25.11 A ATOM 1020 CB VAL A 131 85.057 78.722 46.307 1.00 15.74 A ATOM 1021 CG1 VAL A 131 85.116 77.946 44.960 1.00 15.94 A ATOM 1022 CG2 VAL A 131 86.188 79.725 46.459 1.00 19.54 A ATOM 1023 C VAL A 131 83.618 80.030 47.806 1.00 19.19 A ATOM 1024 O VAL A 131 83.848 81.225 48.014 1.00 21.17 A ATOM 1025 N ILE A 132 83.251 79.169 48.747 1.00 18.82 A ATOM 1026 CA ILE A 132 83.149 79.556 50.154 1.00 23.91 A ATOM 1027 CB ILE A 132 82.332 78.512 50.929 1.00 24.37 A ATOM 1028 CG2 ILE A 132 82.271 78.876 52.417 1.00 20.00 A ATOM 1029 CG1 ILE A 132 80.941 78.425 50.306 1.00 21.42 A ATOM 1030 CD1 ILE A 132 80.142 77.180 50.747 1.00 24.98 A ATOM 1031 C ILE A 132 84.541 79.688 50.790 1.00 19.79 A ATOM 1032 O ILE A 132 84.781 80.623 51.520 1.00 17.40 A ATOM 1033 N HIS A 133 85.467 78.766 50.504 1.00 18.82 A ATOM 1034 CA HIS A 133 86.827 78.851 51.100 1.00 17.96 A ATOM 1035 CB HIS A 133 87.434 77.437 51.218 1.00 18.01 A ATOM 1036 CG HIS A 133 86.691 76.548 52.180 1.00 22.75 A ATOM 1037 CD2 HIS A 133 85.617 75.738 51.996 1.00 18.28 A ATOM 1038 ND1 HIS A 133 86.992 76.499 53.531 1.00 25.58 A ATOM 1039 CE1 HIS A 133 86.128 75.693 54.137 1.00 21.42 A ATOM 1040 NE2 HIS A 133 85.289 75.222 53.231 1.00 27.04 A ATOM 1041 C HIS A 133 87.711 79.735 50.221 1.00 14.42 A ATOM 1042 O HIS A 133 88.525 79.250 49.431 1.00 17.65 A ATOM 1043 N GLN A 134 87.517 81.039 50.373 1.00 11.52 A ATOM 1044 CA GLN A 134 88.238 82.045 49.608 1.00 21.65 A ATOM 1045 CB GLN A 134 87.689 83.424 50.025 1.00 17.09 A ATOM 1046 CG GLN A 134 86.298 83.729 49.418 1.00 22.43 A ATOM 1047 CD GLN A 134 86.376 84.059 47.908 1.00 21.78 A ATOM 1048 OE1 GLN A 134 87.129 84.944 47.522 1.00 28.45 A ATOM 1049 NE2 GLN A 134 85.604 83.340 47.061 1.00 22.37 A ATOM 1050 C GLN A 134 89.759 81.873 49.837 1.00 20.34 A ATOM 1051 O GLN A 134 90.565 82.314 49.052 1.00 26.33 A ATOM 1052 N GLU A 135 90.079 81.179 50.928 1.00 19.09 A ATOM 1053 CA GLU A 135 91.407 80.777 51.431 1.00 24.48 A ATOM 1054 CB GLU A 135 91.169 79.850 52.767 1.00 24.93 A ATOM 1055 CG GLU A 135 89.522 79.250 53.099 1.00 4.96 A ATOM 1056 CD GLU A 135 89.446 77.808 53.925 1.00 27.66 A ATOM 1057 OE1 GLU A 135 90.527 77.338 53.831 1.00 37.42 A ATOM 1058 OE2 GLU A 135 88.528 77.190 54.620 1.00 1.00 A ATOM 1059 C GLU A 135 92.140 79.938 50.318 1.00 20.82 A ATOM 1060 O GLU A 135 93.362 80.014 50.119 1.00 15.84 A ATOM 1061 N MET A 136 91.377 79.109 49.602 1.00 18.40 A ATOM 1062 CA MET A 136 91.967 78.147 48.626 1.00 17.42 A ATOM 1063 CB MET A 136 91.123 76.853 48.571 1.00 15.67 A ATOM 1064 CG MET A 136 89.868 76.961 47.675 1.00 17.99 A ATOM 1065 SD MET A 136 88.703 75.563 47.631 1.00 29.44 A ATOM 1066 CE MET A 136 89.744 74.260 47.009 1.00 11.97 A ATOM 1067 C MET A 136 92.269 78.546 47.203 1.00 15.51 A ATOM 1068 O MET A 136 92.791 77.747 46.443 1.00 14.46 A ATOM 1069 N ILE A 137 91.988 79.787 46.831 1.00 16.94 A ATOM 1070 CA ILE A 137 92.217 80.213 45.449 1.00 15.24 A ATOM 1071 CB ILE A 137 90.980 80.959 44.955 1.00 20.19 A ATOM 1072 CG2 ILE A 137 89.724 80.121 45.254 1.00 14.68 A ATOM 1073 CG1 ILE A 137 90.847 82.300 45.723 1.00 11.83 A ATOM 1074 CD1 ILE A 137 89.473 82.985 45.435 1.00 23.22 A ATOM 1075 C ILE A 137 93.446 81.121 45.287 1.00 19.40 A ATOM 1076 O ILE A 137 93.658 81.729 44.228 1.00 18.10 A ATOM 1077 N GLY A 138 94.222 81.215 46.361 1.00 15.44 A ATOM 1078 CA GLY A 138 95.438 82.007 46.314 1.00 18.65 A ATOM 1079 C GLY A 138 95.197 83.450 45.897 1.00 23.13 A ATOM 1080 O GLY A 138 94.182 84.061 46.313 1.00 15.00 A ATOM 1081 N GLY A 139 96.097 83.962 45.044 1.00 20.15 A ATOM 1082 CA GLY A 139 96.054 85.338 44.585 1.00 17.13 A ATOM 1083 C GLY A 139 94.767 85.808 43.967 1.00 29.17 A ATOM 1084 O GLY A 139 94.568 87.013 43.807 1.00 33.25 A ATOM 1085 N LEU A 140 93.875 84.890 43.618 1.00 23.37 A ATOM 1086 CA LEU A 140 92.621 85.317 43.023 1.00 24.08 A ATOM 1087 CB LEU A 140 91.930 84.142 42.322 1.00 22.29 A ATOM 1088 CG LEU A 140 92.000 84.065 40.800 1.00 36.28 A ATOM 1089 CD1 LEU A 140 93.365 84.425 40.297 1.00 39.55 A ATOM 1090 CD2 LEU A 140 91.640 82.663 40.376 1.00 31.19 A ATOM 1091 C LEU A 140 91.682 85.918 44.065 1.00 30.45 A ATOM 1092 O LEU A 140 90.698 86.572 43.697 1.00 29.82 A ATOM 1093 N ARG A 141 91.977 85.715 45.353 1.00 23.95 A ATOM 1094 CA ARG A 141 91.105 86.235 46.411 1.00 26.90 A ATOM 1095 CB ARG A 141 91.577 85.782 47.790 1.00 23.51 A ATOM 1096 CG ARG A 141 90.622 86.183 48.883 1.00 31.94 A ATOM 1097 CD ARG A 141 91.045 85.655 50.222 1.00 41.48 A ATOM 1098 NE ARG A 141 90.058 85.983 51.254 1.00 56.61 A ATOM 1099 CZ ARG A 141 89.989 85.390 52.451 1.00 62.59 A ATOM 1100 NH1 ARG A 141 90.853 84.427 52.773 1.00 61.70 A ATOM 1101 NH2 ARG A 141 89.055 85.761 53.330 1.00 64.29 A ATOM 1102 C ARG A 141 91.103 87.771 46.308 1.00 31.97 A ATOM 1103 O ARG A 141 90.112 88.440 46.571 1.00 35.29 A ATOM 1104 N ASN A 142 92.233 88.327 45.932 1.00 35.39 A ATOM 1105 CA ASN A 142 92.292 89.759 45.708 1.00 47.29 A ATOM 1106 CB ASN A 142 93.755 90.199 45.620 1.00 44.19 A ATOM 1107 CG ASN A 142 93.903 91.672 45.316 1.00 50.84 A ATOM 1108 OD1 ASN A 142 93.081 92.260 44.606 1.00 50.20 A ATOM 1109 ND2 ASN A 142 94.968 92.273 45.829 1.00 52.23 A ATOM 1110 C ASN A 142 91.588 89.889 44.342 1.00 43.41 A ATOM 1111 O ASN A 142 92.160 89.542 43.302 1.00 41.71 A ATOM 1112 N ASN A 143 90.343 90.361 44.363 1.00 49.05 A ATOM 1113 CA ASN A 143 89.511 90.522 43.151 1.00 54.92 A ATOM 1114 CB ASN A 143 88.071 90.941 43.523 1.00 58.67 A ATOM 1115 CG ASN A 143 87.097 89.762 43.556 1.00 67.74 A ATOM 1116 OD1 ASN A 143 87.173 88.843 42.721 1.00 72.16 A ATOM 1117 ND2 ASN A 143 86.159 89.795 44.510 1.00 73.35 A ATOM 1118 C ASN A 143 90.024 91.509 42.102 1.00 51.69 A ATOM 1119 O ASN A 143 89.457 91.625 41.012 1.00 52.71 A ATOM 1120 N ASN A 144 91.067 92.245 42.432 1.00 47.25 A ATOM 1121 CA ASN A 144 91.597 93.191 41.479 1.00 47.83 A ATOM 1122 CB ASN A 144 92.706 93.993 42.126 1.00 58.20 A ATOM 1123 CG ASN A 144 92.406 95.451 42.142 1.00 67.49 A ATOM 1124 OD1 ASN A 144 92.353 96.070 43.210 1.00 75.34 A ATOM 1125 ND2 ASN A 144 92.194 96.027 40.954 1.00 70.42 A ATOM 1126 C ASN A 144 92.157 92.456 40.274 1.00 42.44 A ATOM 1127 O ASN A 144 92.967 91.540 40.432 1.00 43.00 A ATOM 1128 N GLU A 145 91.740 92.866 39.081 1.00 35.72 A ATOM 1129 CA GLU A 145 92.207 92.277 37.832 1.00 30.80 A ATOM 1130 CB GLU A 145 93.751 92.269 37.777 1.00 29.82 A ATOM 1131 CG GLU A 145 94.342 93.705 37.873 1.00 34.98 A ATOM 1132 CD GLU A 145 95.866 93.839 37.711 1.00 33.90 A ATOM 1133 OE1 GLU A 145 96.311 94.948 37.366 1.00 37.12 A ATOM 1134 OE2 GLU A 145 96.641 92.890 37.938 1.00 36.12 A ATOM 1135 C GLU A 145 91.639 90.883 37.705 1.00 32.53 A ATOM 1136 O GLU A 145 92.261 89.979 37.134 1.00 29.47 A ATOM 1137 N LYS A 146 90.410 90.715 38.179 1.00 33.08 A ATOM 1138 CA LYS A 146 89.829 89.386 38.144 1.00 34.99 A ATOM 1139 CB LYS A 146 88.545 89.324 38.969 1.00 38.84 A ATOM 1140 CG LYS A 146 87.328 89.843 38.309 1.00 46.43 A ATOM 1141 CD LYS A 146 86.173 89.733 39.312 1.00 53.97 A ATOM 1142 CE LYS A 146 84.799 89.902 38.655 1.00 56.22 A ATOM 1143 NZ LYS A 146 84.630 91.185 37.909 1.00 58.13 A ATOM 1144 C LYS A 146 89.597 88.782 36.778 1.00 29.69 A ATOM 1145 O LYS A 146 89.864 87.593 36.608 1.00 22.87 A ATOM 1146 N ASP A 147 89.125 89.558 35.800 1.00 26.03 A ATOM 1147 CA ASP A 147 88.883 88.989 34.459 1.00 24.17 A ATOM 1148 CB ASP A 147 88.363 90.051 33.483 1.00 26.31 A ATOM 1149 CG ASP A 147 86.884 90.374 33.687 1.00 33.37 A ATOM 1150 OD1 ASP A 147 86.419 91.396 33.148 1.00 41.72 A ATOM 1151 OD2 ASP A 147 86.160 89.619 34.369 1.00 28.33 A ATOM 1152 C ASP A 147 90.175 88.402 33.894 1.00 29.67 A ATOM 1153 O ASP A 147 90.177 87.328 33.291 1.00 30.44 A ATOM 1154 N MET A 148 91.277 89.112 34.087 1.00 21.79 A ATOM 1155 CA MET A 148 92.562 88.631 33.567 1.00 27.79 A ATOM 1156 CB MET A 148 93.591 89.770 33.532 1.00 21.45 A ATOM 1157 CG MET A 148 93.406 90.794 32.411 1.00 16.88 A ATOM 1158 SD MET A 148 94.007 90.171 30.836 1.00 26.17 A ATOM 1159 CE MET A 148 95.843 90.114 31.224 1.00 25.36 A ATOM 1160 C MET A 148 93.097 87.466 34.431 1.00 23.06 A ATOM 1161 O MET A 148 93.502 86.433 33.902 1.00 26.32 A ATOM 1162 N ALA A 149 93.082 87.630 35.749 1.00 21.95 A ATOM 1163 CA ALA A 149 93.577 86.584 36.637 1.00 26.30 A ATOM 1164 CB ALA A 149 93.539 87.058 38.093 1.00 17.92 A ATOM 1165 C ALA A 149 92.762 85.290 36.464 1.00 24.09 A ATOM 1166 O ALA A 149 93.336 84.239 36.228 1.00 20.02 A ATOM 1167 N LEU A 150 91.441 85.357 36.578 1.00 23.60 A ATOM 1168 CA LEU A 150 90.615 84.157 36.396 1.00 21.51 A ATOM 1169 CB LEU A 150 89.141 84.431 36.708 1.00 21.03 A ATOM 1170 CG LEU A 150 88.167 83.219 36.546 1.00 31.38 A ATOM 1171 CD1 LEU A 150 88.557 82.048 37.474 1.00 23.78 A ATOM 1172 CD2 LEU A 150 86.725 83.681 36.903 1.00 28.01 A ATOM 1173 C LEU A 150 90.707 83.581 34.985 1.00 26.10 A ATOM 1174 O LEU A 150 90.700 82.351 34.794 1.00 23.93 A ATOM 1175 N THR A 151 90.777 84.442 33.978 1.00 21.82 A ATOM 1176 CA THR A 151 90.895 83.927 32.622 1.00 16.71 A ATOM 1177 CB THR A 151 90.817 85.079 31.570 1.00 24.41 A ATOM 1178 OG1 THR A 151 89.512 85.680 31.646 1.00 24.76 A ATOM 1179 CG2 THR A 151 91.004 84.529 30.144 1.00 24.82 A ATOM 1180 C THR A 151 92.199 83.146 32.466 1.00 22.41 A ATOM 1181 O THR A 151 92.214 82.096 31.853 1.00 22.92 A ATOM 1182 N ALA A 152 93.283 83.633 33.055 1.00 26.27 A ATOM 1183 CA ALA A 152 94.557 82.926 32.945 1.00 19.92 A ATOM 1184 CB ALA A 152 95.654 83.757 33.543 1.00 15.47 A ATOM 1185 C ALA A 152 94.459 81.578 33.671 1.00 19.39 A ATOM 1186 O ALA A 152 94.882 80.567 33.133 1.00 19.38 A ATOM 1187 N PHE A 153 93.884 81.603 34.877 1.00 17.38 A ATOM 1188 CA PHE A 153 93.713 80.417 35.703 1.00 14.60 A ATOM 1189 CB PHE A 153 92.970 80.716 37.004 1.00 17.50 A ATOM 1190 CG PHE A 153 92.773 79.492 37.851 1.00 22.29 A ATOM 1191 CD1 PHE A 153 93.813 79.005 38.652 1.00 10.97 A ATOM 1192 CD2 PHE A 153 91.551 78.828 37.855 1.00 15.16 A ATOM 1193 CE1 PHE A 153 93.623 77.853 39.448 1.00 20.47 A ATOM 1194 CE2 PHE A 153 91.348 77.689 38.636 1.00 22.68 A ATOM 1195 CZ PHE A 153 92.387 77.205 39.442 1.00 21.15 A ATOM 1196 C PHE A 153 92.940 79.346 34.977 1.00 19.47 A ATOM 1197 O PHE A 153 93.360 78.219 34.971 1.00 18.15 A ATOM 1198 N VAL A 154 91.805 79.687 34.388 1.00 17.18 A ATOM 1199 CA VAL A 154 91.016 78.686 33.682 1.00 14.37 A ATOM 1200 CB VAL A 154 89.598 79.241 33.313 1.00 17.63 A ATOM 1201 CG1 VAL A 154 88.830 78.188 32.527 1.00 14.29 A ATOM 1202 CG2 VAL A 154 88.835 79.585 34.588 1.00 17.52 A ATOM 1203 C VAL A 154 91.750 78.197 32.416 1.00 19.75 A ATOM 1204 O VAL A 154 91.801 77.003 32.146 1.00 15.15 A ATOM 1205 N LEU A 155 92.336 79.109 31.652 1.00 20.48 A ATOM 1206 CA LEU A 155 93.093 78.710 30.457 1.00 22.98 A ATOM 1207 CB LEU A 155 93.729 79.960 29.791 1.00 16.47 A ATOM 1208 CG LEU A 155 94.688 79.745 28.623 1.00 19.59 A ATOM 1209 CD1 LEU A 155 94.015 78.920 27.570 1.00 17.74 A ATOM 1210 CD2 LEU A 155 95.164 81.108 28.034 1.00 22.48 A ATOM 1211 C LEU A 155 94.200 77.680 30.800 1.00 16.38 A ATOM 1212 O LEU A 155 94.391 76.711 30.079 1.00 21.06 A ATOM 1213 N ILE A 156 94.926 77.903 31.897 1.00 17.56 A ATOM 1214 CA ILE A 156 96.016 76.992 32.288 1.00 21.21 A ATOM 1215 CB ILE A 156 96.769 77.543 33.538 1.00 23.70 A ATOM 1216 CG2 ILE A 156 97.704 76.490 34.155 1.00 17.82 A ATOM 1217 CG1 ILE A 156 97.584 78.768 33.108 1.00 20.22 A ATOM 1218 CD1 ILE A 156 98.096 79.593 34.297 1.00 15.17 A ATOM 1219 C ILE A 156 95.392 75.608 32.555 1.00 21.00 A ATOM 1220 O ILE A 156 95.955 74.595 32.181 1.00 18.43 A ATOM 1221 N SER A 157 94.222 75.577 33.187 1.00 14.32 A ATOM 1222 CA SER A 157 93.525 74.316 33.425 1.00 22.61 A ATOM 1223 CB SER A 157 92.244 74.564 34.218 1.00 23.22 A ATOM 1224 OG SER A 157 92.563 74.830 35.582 1.00 30.07 A ATOM 1225 C SER A 157 93.174 73.644 32.105 1.00 19.13 A ATOM 1226 O SER A 157 93.405 72.445 31.924 1.00 23.24 A ATOM 1227 N LEU A 158 92.640 74.416 31.163 1.00 23.19 A ATOM 1228 CA LEU A 158 92.268 73.872 29.859 1.00 26.55 A ATOM 1229 CB LEU A 158 91.607 74.955 28.970 1.00 23.19 A ATOM 1230 CG LEU A 158 90.330 75.603 29.537 1.00 28.10 A ATOM 1231 CD1 LEU A 158 89.618 76.320 28.444 1.00 30.58 A ATOM 1232 CD2 LEU A 158 89.378 74.573 30.117 1.00 26.46 A ATOM 1233 C LEU A 158 93.464 73.293 29.126 1.00 23.77 A ATOM 1234 O LEU A 158 93.342 72.294 28.417 1.00 20.25 A ATOM 1235 N GLN A 159 94.622 73.927 29.269 1.00 20.67 A ATOM 1236 CA GLN A 159 95.823 73.433 28.580 1.00 19.57 A ATOM 1237 CB GLN A 159 96.995 74.418 28.776 1.00 20.64 A ATOM 1238 CG GLN A 159 96.787 75.764 28.118 1.00 25.42 A ATOM 1239 CD GLN A 159 97.003 75.741 26.600 1.00 26.92 A ATOM 1240 OE1 GLN A 159 96.865 74.703 25.933 1.00 24.64 A ATOM 1241 NE2 GLN A 159 97.341 76.899 26.049 1.00 24.27 A ATOM 1242 C GLN A 159 96.195 72.047 29.136 1.00 25.83 A ATOM 1243 O GLN A 159 96.681 71.182 28.390 1.00 22.57 A ATOM 1244 N GLU A 160 95.963 71.833 30.433 1.00 18.37 A ATOM 1245 CA GLU A 160 96.275 70.533 31.010 1.00 28.44 A ATOM 1246 CB GLU A 160 96.124 70.505 32.527 1.00 18.70 A ATOM 1247 CG GLU A 160 97.204 71.226 33.289 1.00 29.07 A ATOM 1248 CD GLU A 160 97.071 71.010 34.792 1.00 37.12 A ATOM 1249 OE1 GLU A 160 96.376 70.046 35.219 1.00 29.05 A ATOM 1250 OE2 GLU A 160 97.673 71.806 35.539 1.00 41.97 A ATOM 1251 C GLU A 160 95.364 69.454 30.478 1.00 29.40 A ATOM 1252 O GLU A 160 95.782 68.316 30.357 1.00 24.26 A ATOM 1253 N ALA A 161 94.110 69.796 30.177 1.00 25.80 A ATOM 1254 CA ALA A 161 93.182 68.775 29.705 1.00 26.76 A ATOM 1255 CB ALA A 161 91.827 68.987 30.370 1.00 25.94 A ATOM 1256 C ALA A 161 93.019 68.749 28.189 1.00 29.95 A ATOM 1257 O ALA A 161 92.166 68.029 27.654 1.00 32.80 A ATOM 1258 N LYS A 162 93.848 69.514 27.492 1.00 30.99 A ATOM 1259 CA LYS A 162 93.741 69.628 26.043 1.00 37.27 A ATOM 1260 CB LYS A 162 94.762 70.671 25.553 1.00 38.61 A ATOM 1261 CG LYS A 162 94.792 70.892 24.048 1.00 50.32 A ATOM 1262 CD LYS A 162 95.668 72.093 23.628 1.00 56.78 A ATOM 1263 CE LYS A 162 97.171 71.809 23.618 1.00 58.73 A ATOM 1264 NZ LYS A 162 97.593 70.975 22.433 1.00 67.24 A ATOM 1265 C LYS A 162 93.885 68.321 25.254 1.00 37.81 A ATOM 1266 O LYS A 162 93.029 67.964 24.455 1.00 33.39 A ATOM 1267 N ASP A 163 94.968 67.601 25.475 1.00 41.14 A ATOM 1268 CA ASP A 163 95.171 66.387 24.719 1.00 42.49 A ATOM 1269 CB ASP A 163 96.576 65.858 24.965 1.00 51.70 A ATOM 1270 CG ASP A 163 97.643 66.839 24.512 1.00 57.18 A ATOM 1271 OD1 ASP A 163 97.366 67.598 23.557 1.00 62.80 A ATOM 1272 OD2 ASP A 163 98.752 66.846 25.094 1.00 64.82 A ATOM 1273 C ASP A 163 94.127 65.361 25.074 1.00 41.86 A ATOM 1274 O ASP A 163 93.582 64.687 24.214 1.00 41.54 A ATOM 1275 N ILE A 164 93.808 65.253 26.344 1.00 37.18 A ATOM 1276 CA ILE A 164 92.801 64.297 26.721 1.00 37.23 A ATOM 1277 CB ILE A 164 92.750 64.158 28.236 1.00 43.08 A ATOM 1278 CG2 ILE A 164 91.530 63.365 28.661 1.00 42.32 A ATOM 1279 CG1 ILE A 164 94.054 63.514 28.705 1.00 48.60 A ATOM 1280 CD1 ILE A 164 94.078 63.174 30.156 1.00 56.10 A ATOM 1281 C ILE A 164 91.404 64.634 26.216 1.00 39.86 A ATOM 1282 O ILE A 164 90.656 63.748 25.830 1.00 33.04 A ATOM 1283 N CYS A 165 91.060 65.914 26.183 1.00 32.76 A ATOM 1284 CA CYS A 165 89.715 66.278 25.814 1.00 34.31 A ATOM 1285 C CYS A 165 89.433 66.817 24.422 1.00 37.19 A ATOM 1286 O CYS A 165 88.287 66.818 24.011 1.00 28.15 A ATOM 1287 CB CYS A 165 89.180 67.278 26.839 1.00 29.46 A ATOM 1288 SG CYS A 165 89.010 66.566 28.503 1.00 28.08 A ATOM 1289 N GLU A 166 90.459 67.264 23.707 1.00 45.15 A ATOM 1290 CA GLU A 166 90.273 67.877 22.395 1.00 51.11 A ATOM 1291 CB GLU A 166 91.630 68.143 21.720 1.00 59.07 A ATOM 1292 CG GLU A 166 92.542 66.935 21.528 1.00 66.72 A ATOM 1293 CD GLU A 166 93.935 67.335 21.000 1.00 71.70 A ATOM 1294 OE1 GLU A 166 94.838 66.457 20.967 1.00 74.38 A ATOM 1295 OE2 GLU A 166 94.123 68.526 20.619 1.00 68.32 A ATOM 1296 C GLU A 166 89.349 67.152 21.449 1.00 50.87 A ATOM 1297 O GLU A 166 88.661 67.784 20.646 1.00 50.00 A ATOM 1298 N GLU A 167 89.314 65.833 21.559 1.00 52.19 A ATOM 1299 CA GLU A 167 88.448 65.027 20.718 1.00 52.32 A ATOM 1300 CB GLU A 167 88.840 63.559 20.838 1.00 60.45 A ATOM 1301 CG GLU A 167 89.074 62.885 19.504 1.00 68.41 A ATOM 1302 CD GLU A 167 89.979 63.713 18.605 1.00 74.42 A ATOM 1303 OE1 GLU A 167 91.048 64.161 19.082 1.00 77.67 A ATOM 1304 OE2 GLU A 167 89.621 63.917 17.421 1.00 78.62 A ATOM 1305 C GLU A 167 86.963 65.177 21.059 1.00 54.06 A ATOM 1306 O GLU A 167 86.136 65.356 20.163 1.00 52.37 A ATOM 1307 N GLN A 168 86.632 65.103 22.351 1.00 46.71 A ATOM 1308 CA GLN A 168 85.247 65.202 22.811 1.00 43.91 A ATOM 1309 CB GLN A 168 85.059 64.480 24.155 1.00 50.94 A ATOM 1310 CG GLN A 168 86.269 64.533 25.087 1.00 56.41 A ATOM 1311 CD GLN A 168 87.154 63.284 24.976 1.00 55.96 A ATOM 1312 OE1 GLN A 168 86.830 62.226 25.526 1.00 49.92 A ATOM 1313 NE2 GLN A 168 88.268 63.406 24.247 1.00 57.62 A ATOM 1314 C GLN A 168 84.752 66.620 22.959 1.00 42.37 A ATOM 1315 O GLN A 168 83.547 66.856 23.073 1.00 41.71 A ATOM 1316 N VAL A 169 85.673 67.571 22.965 1.00 33.31 A ATOM 1317 CA VAL A 169 85.281 68.962 23.112 1.00 35.06 A ATOM 1318 CB VAL A 169 85.809 69.506 24.469 1.00 27.42 A ATOM 1319 CG1 VAL A 169 85.245 70.889 24.754 1.00 25.13 A ATOM 1320 CG2 VAL A 169 85.402 68.540 25.573 1.00 24.56 A ATOM 1321 C VAL A 169 85.780 69.792 21.919 1.00 34.13 A ATOM 1322 O VAL A 169 86.866 70.376 21.962 1.00 31.73 A ATOM 1323 N ASN A 170 84.971 69.841 20.857 1.00 31.12 A ATOM 1324 CA ASN A 170 85.367 70.554 19.646 1.00 31.56 A ATOM 1325 CB ASN A 170 84.377 70.283 18.503 1.00 38.49 A ATOM 1326 CG ASN A 170 84.352 68.798 18.058 1.00 44.51 A ATOM 1327 OD1 ASN A 170 83.419 68.063 18.367 1.00 50.11 A ATOM 1328 ND2 ASN A 170 85.374 68.375 17.334 1.00 40.85 A ATOM 1329 C ASN A 170 85.562 72.052 19.838 1.00 33.38 A ATOM 1330 O ASN A 170 86.308 72.682 19.101 1.00 32.60 A ATOM 1331 N SER A 171 84.931 72.641 20.843 1.00 29.65 A ATOM 1332 CA SER A 171 85.123 74.080 21.054 1.00 27.07 A ATOM 1333 CB SER A 171 83.937 74.650 21.858 1.00 26.83 A ATOM 1334 OG SER A 171 83.675 73.861 23.020 1.00 22.03 A ATOM 1335 C SER A 171 86.434 74.410 21.776 1.00 23.40 A ATOM 1336 O SER A 171 86.829 75.571 21.868 1.00 25.17 A ATOM 1337 N LEU A 172 87.130 73.400 22.274 1.00 20.64 A ATOM 1338 CA LEU A 172 88.364 73.670 23.024 1.00 18.28 A ATOM 1339 CB LEU A 172 88.976 72.340 23.451 1.00 26.95 A ATOM 1340 CG LEU A 172 89.987 72.262 24.605 1.00 36.59 A ATOM 1341 CD1 LEU A 172 89.724 73.283 25.714 1.00 28.04 A ATOM 1342 CD2 LEU A 172 89.912 70.840 25.159 1.00 30.83 A ATOM 1343 C LEU A 172 89.420 74.540 22.325 1.00 23.79 A ATOM 1344 O LEU A 172 89.867 75.551 22.863 1.00 22.52 A ATOM 1345 N PRO A 173 89.821 74.173 21.095 1.00 28.78 A ATOM 1346 CD PRO A 173 89.392 73.036 20.258 1.00 26.81 A ATOM 1347 CA PRO A 173 90.837 74.991 20.419 1.00 28.96 A ATOM 1348 CB PRO A 173 91.001 74.308 19.054 1.00 28.65 A ATOM 1349 CG PRO A 173 90.597 72.878 19.321 1.00 33.10 A ATOM 1350 C PRO A 173 90.454 76.475 20.301 1.00 27.14 A ATOM 1351 O PRO A 173 91.259 77.366 20.599 1.00 22.88 A ATOM 1352 N GLY A 174 89.223 76.730 19.885 1.00 24.04 A ATOM 1353 CA GLY A 174 88.771 78.104 19.731 1.00 24.51 A ATOM 1354 C GLY A 174 88.667 78.805 21.071 1.00 23.82 A ATOM 1355 O GLY A 174 88.943 79.985 21.172 1.00 24.00 A ATOM 1356 N SER A 175 88.269 78.083 22.115 1.00 23.65 A ATOM 1357 CA SER A 175 88.167 78.706 23.462 1.00 25.41 A ATOM 1358 CB SER A 175 87.662 77.665 24.489 1.00 21.04 A ATOM 1359 OG SER A 175 87.648 78.213 25.791 1.00 22.86 A ATOM 1360 C SER A 175 89.534 79.224 23.917 1.00 23.64 A ATOM 1361 O SER A 175 89.691 80.347 24.440 1.00 21.39 A ATOM 1362 N ILE A 176 90.531 78.372 23.741 1.00 24.52 A ATOM 1363 CA ILE A 176 91.907 78.683 24.127 1.00 20.94 A ATOM 1364 CB ILE A 176 92.774 77.406 23.873 1.00 19.98 A ATOM 1365 CG2 ILE A 176 94.244 77.741 23.797 1.00 20.82 A ATOM 1366 CG1 ILE A 176 92.449 76.370 24.970 1.00 23.34 A ATOM 1367 CD1 ILE A 176 93.191 75.017 24.797 1.00 23.21 A ATOM 1368 C ILE A 176 92.427 79.921 23.371 1.00 23.29 A ATOM 1369 O ILE A 176 93.011 80.845 23.953 1.00 21.00 A ATOM 1370 N THR A 177 92.180 79.957 22.069 1.00 22.38 A ATOM 1371 CA THR A 177 92.622 81.096 21.280 1.00 26.70 A ATOM 1372 CB THR A 177 92.298 80.826 19.810 1.00 30.44 A ATOM 1373 OG1 THR A 177 93.142 79.754 19.352 1.00 32.66 A ATOM 1374 CG2 THR A 177 92.507 82.071 18.959 1.00 25.97 A ATOM 1375 C THR A 177 91.966 82.395 21.793 1.00 28.53 A ATOM 1376 O THR A 177 92.635 83.437 21.992 1.00 25.08 A ATOM 1377 N LYS A 178 90.665 82.320 22.058 1.00 24.69 A ATOM 1378 CA LYS A 178 89.966 83.486 22.556 1.00 22.85 A ATOM 1379 CB LYS A 178 88.458 83.212 22.647 1.00 33.69 A ATOM 1380 CG LYS A 178 87.719 83.233 21.285 1.00 37.81 A ATOM 1381 CD LYS A 178 86.260 82.880 21.478 1.00 45.50 A ATOM 1382 CE LYS A 178 85.580 82.539 20.168 1.00 55.66 A ATOM 1383 NZ LYS A 178 84.321 81.738 20.375 1.00 62.92 A ATOM 1384 C LYS A 178 90.513 83.903 23.908 1.00 27.56 A ATOM 1385 O LYS A 178 90.764 85.100 24.139 1.00 22.42 A ATOM 1386 N ALA A 179 90.708 82.945 24.818 1.00 21.82 A ATOM 1387 CA ALA A 179 91.232 83.327 26.117 1.00 22.17 A ATOM 1388 CB ALA A 179 91.326 82.107 27.056 1.00 20.58 A ATOM 1389 C ALA A 179 92.607 83.918 25.879 1.00 23.19 A ATOM 1390 O ALA A 179 92.958 84.970 26.424 1.00 21.73 A ATOM 1391 N GLY A 180 93.392 83.244 25.046 1.00 26.28 A ATOM 1392 CA GLY A 180 94.732 83.741 24.790 1.00 25.77 A ATOM 1393 C GLY A 180 94.723 85.155 24.206 1.00 29.69 A ATOM 1394 O GLY A 180 95.509 86.005 24.628 1.00 26.61 A ATOM 1395 N ASP A 181 93.869 85.403 23.215 1.00 19.22 A ATOM 1396 CA ASP A 181 93.776 86.745 22.600 1.00 24.71 A ATOM 1397 CB ASP A 181 92.670 86.781 21.544 1.00 28.40 A ATOM 1398 CG ASP A 181 93.045 86.061 20.266 1.00 24.26 A ATOM 1399 OD1 ASP A 181 94.242 85.821 20.035 1.00 26.47 A ATOM 1400 OD2 ASP A 181 92.138 85.751 19.475 1.00 31.29 A ATOM 1401 C ASP A 181 93.465 87.814 23.635 1.00 23.38 A ATOM 1402 O ASP A 181 94.051 88.897 23.619 1.00 24.92 A ATOM 1403 N PHE A 182 92.541 87.508 24.548 1.00 23.93 A ATOM 1404 CA PHE A 182 92.179 88.481 25.562 1.00 24.17 A ATOM 1405 CB PHE A 182 90.971 88.008 26.368 1.00 29.71 A ATOM 1406 CG PHE A 182 90.573 88.970 27.457 1.00 37.61 A ATOM 1407 CD1 PHE A 182 89.777 90.074 27.174 1.00 35.83 A ATOM 1408 CD2 PHE A 182 91.034 88.798 28.751 1.00 37.07 A ATOM 1409 CE1 PHE A 182 89.447 90.989 28.165 1.00 38.94 A ATOM 1410 CE2 PHE A 182 90.706 89.712 29.748 1.00 42.65 A ATOM 1411 CZ PHE A 182 89.915 90.806 29.456 1.00 41.10 A ATOM 1412 C PHE A 182 93.343 88.759 26.514 1.00 29.73 A ATOM 1413 O PHE A 182 93.610 89.911 26.877 1.00 26.64 A ATOM 1414 N LEU A 183 94.041 87.710 26.933 1.00 23.11 A ATOM 1415 CA LEU A 183 95.163 87.923 27.847 1.00 23.03 A ATOM 1416 CB LEU A 183 95.794 86.587 28.302 1.00 19.13 A ATOM 1417 CG LEU A 183 94.927 85.684 29.181 1.00 24.04 A ATOM 1418 CD1 LEU A 183 95.697 84.363 29.487 1.00 23.39 A ATOM 1419 CD2 LEU A 183 94.595 86.398 30.489 1.00 21.06 A ATOM 1420 C LEU A 183 96.237 88.742 27.140 1.00 19.58 A ATOM 1421 O LEU A 183 96.797 89.668 27.711 1.00 23.84 A ATOM 1422 N GLU A 184 96.545 88.383 25.904 1.00 19.16 A ATOM 1423 CA GLU A 184 97.584 89.114 25.190 1.00 29.47 A ATOM 1424 CB GLU A 184 97.874 88.459 23.842 1.00 27.07 A ATOM 1425 CG GLU A 184 98.874 89.217 23.010 1.00 33.26 A ATOM 1426 CD GLU A 184 99.360 88.416 21.817 1.00 36.59 A ATOM 1427 OE1 GLU A 184 98.869 87.295 21.569 1.00 37.18 A ATOM 1428 OE2 GLU A 184 100.249 88.907 21.120 1.00 40.45 A ATOM 1429 C GLU A 184 97.204 90.578 24.992 1.00 26.03 A ATOM 1430 O GLU A 184 98.004 91.471 25.273 1.00 29.51 A ATOM 1431 N ALA A 185 95.981 90.835 24.548 1.00 28.37 A ATOM 1432 CA ALA A 185 95.560 92.236 24.317 1.00 32.04 A ATOM 1433 CB ALA A 185 94.166 92.282 23.689 1.00 31.81 A ATOM 1434 C ALA A 185 95.567 93.137 25.537 1.00 36.13 A ATOM 1435 O ALA A 185 95.706 94.353 25.401 1.00 35.39 A ATOM 1436 N ASN A 186 95.448 92.555 26.730 1.00 32.84 A ATOM 1437 CA ASN A 186 95.352 93.351 27.953 1.00 29.26 A ATOM 1438 CB ASN A 186 94.035 93.004 28.640 1.00 27.88 A ATOM 1439 CG ASN A 186 92.847 93.480 27.836 1.00 33.22 A ATOM 1440 OD1 ASN A 186 92.562 94.672 27.813 1.00 34.12 A ATOM 1441 ND2 ASN A 186 92.175 92.566 27.143 1.00 25.25 A ATOM 1442 C ASN A 186 96.476 93.240 28.952 1.00 27.19 A ATOM 1443 O ASN A 186 96.444 93.890 30.003 1.00 27.97 A ATOM 1444 N TYR A 187 97.472 92.433 28.610 1.00 24.51 A ATOM 1445 CA TYR A 187 98.612 92.176 29.486 1.00 21.48 A ATOM 1446 CB TYR A 187 99.634 91.255 28.785 1.00 23.19 A ATOM 1447 CG TYR A 187 100.651 90.604 29.729 1.00 27.39 A ATOM 1448 CD1 TYR A 187 100.258 89.596 30.637 1.00 24.03 A ATOM 1449 CE1 TYR A 187 101.209 88.977 31.508 1.00 28.63 A ATOM 1450 CD2 TYR A 187 102.004 90.982 29.712 1.00 25.92 A ATOM 1451 CE2 TYR A 187 102.952 90.380 30.570 1.00 28.97 A ATOM 1452 CZ TYR A 187 102.551 89.379 31.465 1.00 31.32 A ATOM 1453 OH TYR A 187 103.498 88.788 32.293 1.00 25.25 A ATOM 1454 C TYR A 187 99.360 93.389 29.929 1.00 29.36 A ATOM 1455 O TYR A 187 99.645 93.536 31.122 1.00 26.96 A ATOM 1456 N MET A 188 99.721 94.240 28.956 1.00 25.41 A ATOM 1457 CA MET A 188 100.526 95.417 29.260 1.00 31.50 A ATOM 1458 CB MET A 188 100.794 96.215 27.981 1.00 24.85 A ATOM 1459 CG MET A 188 101.699 95.478 27.011 1.00 26.87 A ATOM 1460 SD MET A 188 103.239 94.935 27.730 1.00 33.34 A ATOM 1461 CE MET A 188 103.886 96.512 28.315 1.00 30.68 A ATOM 1462 C MET A 188 99.962 96.322 30.349 1.00 27.28 A ATOM 1463 O MET A 188 100.720 96.982 31.071 1.00 26.43 A ATOM 1464 N ASN A 189 98.645 96.288 30.495 1.00 25.67 A ATOM 1465 CA ASN A 189 97.927 97.092 31.482 1.00 40.32 A ATOM 1466 CB ASN A 189 96.499 97.323 31.000 1.00 46.12 A ATOM 1467 CG ASN A 189 96.220 98.769 30.729 1.00 58.01 A ATOM 1468 OD1 ASN A 189 95.564 99.113 29.728 1.00 63.96 A ATOM 1469 ND2 ASN A 189 96.722 99.643 31.612 1.00 54.68 A ATOM 1470 C ASN A 189 97.850 96.519 32.897 1.00 40.44 A ATOM 1471 O ASN A 189 97.220 97.109 33.770 1.00 40.07 A ATOM 1472 N LEU A 190 98.469 95.375 33.140 1.00 37.09 A ATOM 1473 CA LEU A 190 98.391 94.795 34.473 1.00 32.05 A ATOM 1474 CB LEU A 190 98.887 93.358 34.459 1.00 27.91 A ATOM 1475 CG LEU A 190 98.000 92.410 33.659 1.00 25.90 A ATOM 1476 CD1 LEU A 190 98.707 91.036 33.591 1.00 21.96 A ATOM 1477 CD2 LEU A 190 96.619 92.343 34.315 1.00 13.68 A ATOM 1478 C LEU A 190 99.186 95.549 35.485 1.00 32.08 A ATOM 1479 O LEU A 190 100.264 96.039 35.189 1.00 34.79 A ATOM 1480 N GLN A 191 98.653 95.630 36.696 1.00 24.96 A ATOM 1481 CA GLN A 191 99.359 96.299 37.771 1.00 29.96 A ATOM 1482 CB GLN A 191 98.443 97.330 38.429 1.00 37.43 A ATOM 1483 CG GLN A 191 98.000 98.434 37.486 1.00 50.78 A ATOM 1484 CD GLN A 191 99.178 99.289 37.084 1.00 58.93 A ATOM 1485 OE1 GLN A 191 99.756 99.994 37.923 1.00 65.09 A ATOM 1486 NE2 GLN A 191 99.566 99.220 35.803 1.00 65.13 A ATOM 1487 C GLN A 191 99.878 95.333 38.855 1.00 32.15 A ATOM 1488 O GLN A 191 100.893 95.610 39.464 1.00 28.48 A ATOM 1489 N ARG A 192 99.189 94.219 39.119 1.00 25.14 A ATOM 1490 CA ARG A 192 99.657 93.312 40.170 1.00 22.86 A ATOM 1491 CB ARG A 192 98.489 92.473 40.703 1.00 23.64 A ATOM 1492 CG ARG A 192 97.302 93.308 41.257 1.00 31.91 A ATOM 1493 CD ARG A 192 96.128 92.393 41.622 1.00 35.16 A ATOM 1494 NE ARG A 192 96.514 91.335 42.569 1.00 41.51 A ATOM 1495 CZ ARG A 192 95.847 90.184 42.733 1.00 44.28 A ATOM 1496 NH1 ARG A 192 94.757 89.949 41.997 1.00 39.94 A ATOM 1497 NH2 ARG A 192 96.255 89.280 43.641 1.00 30.46 A ATOM 1498 C ARG A 192 100.736 92.356 39.709 1.00 19.29 A ATOM 1499 O ARG A 192 100.658 91.822 38.596 1.00 15.56 A ATOM 1500 N SER A 193 101.735 92.114 40.557 1.00 20.51 A ATOM 1501 CA SER A 193 102.769 91.138 40.196 1.00 23.99 A ATOM 1502 CB SER A 193 103.853 91.066 41.250 1.00 25.82 A ATOM 1503 OG SER A 193 104.634 92.236 41.177 1.00 29.45 A ATOM 1504 C SER A 193 102.123 89.754 40.041 1.00 26.36 A ATOM 1505 O SER A 193 102.508 88.958 39.164 1.00 26.52 A ATOM 1506 N TYR A 194 101.123 89.479 40.877 1.00 27.26 A ATOM 1507 CA TYR A 194 100.429 88.201 40.790 1.00 22.13 A ATOM 1508 CB TYR A 194 99.303 88.108 41.823 1.00 23.41 A ATOM 1509 CG TYR A 194 98.539 86.783 41.755 1.00 16.74 A ATOM 1510 CD1 TYR A 194 99.067 85.620 42.340 1.00 19.51 A ATOM 1511 CE1 TYR A 194 98.401 84.389 42.271 1.00 17.85 A ATOM 1512 CD2 TYR A 194 97.312 86.692 41.087 1.00 20.75 A ATOM 1513 CE2 TYR A 194 96.621 85.461 41.001 1.00 25.88 A ATOM 1514 CZ TYR A 194 97.181 84.312 41.603 1.00 20.62 A ATOM 1515 OH TYR A 194 96.522 83.107 41.540 1.00 24.87 A ATOM 1516 C TYR A 194 99.843 87.959 39.398 1.00 23.17 A ATOM 1517 O TYR A 194 100.123 86.938 38.775 1.00 22.83 A ATOM 1518 N THR A 195 99.013 88.878 38.904 1.00 18.74 A ATOM 1519 CA THR A 195 98.391 88.680 37.602 1.00 16.68 A ATOM 1520 CB THR A 195 97.427 89.817 37.264 1.00 16.43 A ATOM 1521 OG1 THR A 195 96.657 90.130 38.428 1.00 21.65 A ATOM 1522 CG2 THR A 195 96.496 89.378 36.151 1.00 22.25 A ATOM 1523 C THR A 195 99.437 88.593 36.498 1.00 21.37 A ATOM 1524 O THR A 195 99.315 87.829 35.549 1.00 18.17 A ATOM 1525 N VAL A 196 100.506 89.359 36.647 1.00 23.63 A ATOM 1526 CA VAL A 196 101.531 89.334 35.639 1.00 20.64 A ATOM 1527 CB VAL A 196 102.620 90.409 35.959 1.00 26.84 A ATOM 1528 CG1 VAL A 196 103.973 90.045 35.324 1.00 25.77 A ATOM 1529 CG2 VAL A 196 102.154 91.773 35.456 1.00 25.74 A ATOM 1530 C VAL A 196 102.147 87.933 35.583 1.00 20.37 A ATOM 1531 O VAL A 196 102.451 87.439 34.503 1.00 19.78 A ATOM 1532 N ALA A 197 102.386 87.326 36.739 1.00 21.05 A ATOM 1533 CA ALA A 197 103.005 85.984 36.766 1.00 24.45 A ATOM 1534 CB ALA A 197 103.370 85.583 38.225 1.00 15.17 A ATOM 1535 C ALA A 197 102.056 84.951 36.162 1.00 15.00 A ATOM 1536 O ALA A 197 102.424 84.229 35.226 1.00 20.20 A ATOM 1537 N ILE A 198 100.809 84.911 36.648 1.00 24.78 A ATOM 1538 CA ILE A 198 99.887 83.889 36.144 1.00 20.75 A ATOM 1539 CB ILE A 198 98.569 83.723 37.056 1.00 19.12 A ATOM 1540 CG2 ILE A 198 97.602 84.931 36.915 1.00 20.52 A ATOM 1541 CG1 ILE A 198 97.855 82.438 36.658 1.00 19.50 A ATOM 1542 CD1 ILE A 198 96.670 82.071 37.553 1.00 20.96 A ATOM 1543 C ILE A 198 99.545 84.052 34.674 1.00 19.83 A ATOM 1544 O ILE A 198 99.593 83.057 33.913 1.00 21.51 A ATOM 1545 N ALA A 199 99.217 85.274 34.235 1.00 19.78 A ATOM 1546 CA ALA A 199 98.921 85.448 32.814 1.00 19.70 A ATOM 1547 CB ALA A 199 98.323 86.823 32.537 1.00 18.52 A ATOM 1548 C ALA A 199 100.226 85.268 32.049 1.00 11.15 A ATOM 1549 O ALA A 199 100.228 84.804 30.911 1.00 17.30 A ATOM 1550 N GLY A 200 101.345 85.621 32.680 1.00 17.10 A ATOM 1551 CA GLY A 200 102.617 85.447 32.002 1.00 19.39 A ATOM 1552 C GLY A 200 102.800 83.976 31.647 1.00 21.92 A ATOM 1553 O GLY A 200 103.113 83.615 30.486 1.00 19.30 A ATOM 1554 N TYR A 201 102.578 83.097 32.628 1.00 17.66 A ATOM 1555 CA TYR A 201 102.742 81.670 32.329 1.00 23.38 A ATOM 1556 CB TYR A 201 102.550 80.804 33.587 1.00 17.53 A ATOM 1557 CG TYR A 201 102.641 79.303 33.313 1.00 19.35 A ATOM 1558 CD1 TYR A 201 103.714 78.768 32.608 1.00 20.15 A ATOM 1559 CE1 TYR A 201 103.815 77.383 32.384 1.00 25.42 A ATOM 1560 CD2 TYR A 201 101.663 78.420 33.788 1.00 26.23 A ATOM 1561 CE2 TYR A 201 101.749 77.037 33.573 1.00 17.93 A ATOM 1562 CZ TYR A 201 102.816 76.528 32.883 1.00 25.37 A ATOM 1563 OH TYR A 201 102.908 75.171 32.690 1.00 24.20 A ATOM 1564 C TYR A 201 101.740 81.238 31.242 1.00 23.90 A ATOM 1565 O TYR A 201 102.098 80.503 30.312 1.00 18.43 A ATOM 1566 N ALA A 202 100.490 81.698 31.349 1.00 19.10 A ATOM 1567 CA ALA A 202 99.484 81.306 30.367 1.00 22.19 A ATOM 1568 CB ALA A 202 98.132 81.940 30.715 1.00 19.48 A ATOM 1569 C ALA A 202 99.916 81.720 28.963 1.00 23.29 A ATOM 1570 O ALA A 202 99.730 80.969 28.004 1.00 23.99 A ATOM 1571 N LEU A 203 100.487 82.919 28.832 1.00 23.24 A ATOM 1572 CA LEU A 203 100.929 83.371 27.510 1.00 23.06 A ATOM 1573 CB LEU A 203 101.178 84.894 27.514 1.00 24.75 A ATOM 1574 CG LEU A 203 99.907 85.744 27.664 1.00 23.34 A ATOM 1575 CD1 LEU A 203 100.306 87.220 27.773 1.00 27.91 A ATOM 1576 CD2 LEU A 203 98.963 85.548 26.489 1.00 21.31 A ATOM 1577 C LEU A 203 102.182 82.611 27.060 1.00 20.01 A ATOM 1578 O LEU A 203 102.321 82.260 25.892 1.00 22.51 A ATOM 1579 N ALA A 204 103.087 82.325 27.985 1.00 20.31 A ATOM 1580 CA ALA A 204 104.291 81.588 27.615 1.00 19.81 A ATOM 1581 CB ALA A 204 105.193 81.391 28.819 1.00 16.54 A ATOM 1582 C ALA A 204 103.893 80.248 27.035 1.00 22.33 A ATOM 1583 O ALA A 204 104.477 79.812 26.060 1.00 23.53 A ATOM 1584 N GLN A 205 102.881 79.588 27.607 1.00 21.05 A ATOM 1585 CA GLN A 205 102.483 78.289 27.058 1.00 21.95 A ATOM 1586 CB GLN A 205 101.309 77.717 27.840 1.00 18.19 A ATOM 1587 CG GLN A 205 101.588 77.415 29.314 1.00 25.79 A ATOM 1588 CD GLN A 205 100.431 76.681 29.929 1.00 29.43 A ATOM 1589 OE1 GLN A 205 99.299 77.200 29.967 1.00 23.15 A ATOM 1590 NE2 GLN A 205 100.685 75.451 30.399 1.00 23.34 A ATOM 1591 C GLN A 205 102.068 78.366 25.586 1.00 27.79 A ATOM 1592 O GLN A 205 102.165 77.392 24.847 1.00 24.19 A ATOM 1593 N MET A 206 101.575 79.525 25.164 1.00 26.44 A ATOM 1594 CA MET A 206 101.117 79.661 23.789 1.00 29.37 A ATOM 1595 CB MET A 206 99.802 80.452 23.771 1.00 26.17 A ATOM 1596 CG MET A 206 98.806 80.012 24.828 1.00 30.40 A ATOM 1597 SD MET A 206 97.200 80.847 24.718 1.00 29.96 A ATOM 1598 CE MET A 206 97.598 82.319 25.513 1.00 41.60 A ATOM 1599 C MET A 206 102.138 80.349 22.889 1.00 29.92 A ATOM 1600 O MET A 206 101.828 80.674 21.749 1.00 26.65 A ATOM 1601 N GLY A 207 103.345 80.586 23.394 1.00 29.43 A ATOM 1602 CA GLY A 207 104.352 81.278 22.593 1.00 26.83 A ATOM 1603 C GLY A 207 104.014 82.753 22.378 1.00 34.90 A ATOM 1604 O GLY A 207 104.534 83.393 21.464 1.00 27.87 A ATOM 1605 N ARG A 208 103.171 83.313 23.244 1.00 27.86 A ATOM 1606 CA ARG A 208 102.784 84.698 23.107 1.00 34.19 A ATOM 1607 CB ARG A 208 101.256 84.788 23.147 1.00 33.23 A ATOM 1608 CG ARG A 208 100.654 84.008 21.992 1.00 38.52 A ATOM 1609 CD ARG A 208 99.191 83.574 22.162 1.00 42.22 A ATOM 1610 NE ARG A 208 98.288 84.690 21.974 1.00 49.84 A ATOM 1611 CZ ARG A 208 97.110 84.638 21.362 1.00 42.43 A ATOM 1612 NH1 ARG A 208 96.641 83.509 20.856 1.00 38.92 A ATOM 1613 NH2 ARG A 208 96.416 85.753 21.233 1.00 48.94 A ATOM 1614 C ARG A 208 103.430 85.669 24.080 1.00 32.61 A ATOM 1615 O ARG A 208 103.113 86.839 24.056 1.00 31.15 A ATOM 1616 N LEU A 209 104.333 85.197 24.934 1.00 26.57 A ATOM 1617 CA LEU A 209 104.990 86.093 25.879 1.00 31.14 A ATOM 1618 CB LEU A 209 105.271 85.369 27.211 1.00 22.61 A ATOM 1619 CG LEU A 209 105.798 86.228 28.366 1.00 35.65 A ATOM 1620 CD1 LEU A 209 104.766 87.332 28.723 1.00 28.29 A ATOM 1621 CD2 LEU A 209 106.083 85.364 29.589 1.00 28.03 A ATOM 1622 C LEU A 209 106.285 86.516 25.178 1.00 32.66 A ATOM 1623 O LEU A 209 107.305 85.851 25.289 1.00 32.28 A ATOM 1624 N LYS A 210 106.212 87.611 24.426 1.00 32.19 A ATOM 1625 CA LYS A 210 107.337 88.134 23.658 1.00 34.10 A ATOM 1626 CB LYS A 210 107.118 87.884 22.169 1.00 39.67 A ATOM 1627 CG LYS A 210 106.844 86.472 21.772 1.00 49.14 A ATOM 1628 CD LYS A 210 106.174 86.418 20.399 1.00 51.11 A ATOM 1629 CE LYS A 210 106.928 85.462 19.474 1.00 58.79 A ATOM 1630 NZ LYS A 210 106.158 85.113 18.241 1.00 57.80 A ATOM 1631 C LYS A 210 107.421 89.644 23.793 1.00 35.59 A ATOM 1632 O LYS A 210 106.520 90.290 24.326 1.00 30.70 A ATOM 1633 N GLY A 211 108.488 90.201 23.230 1.00 37.65 A ATOM 1634 CA GLY A 211 108.675 91.642 23.212 1.00 34.24 A ATOM 1635 C GLY A 211 108.350 92.423 24.453 1.00 26.73 A ATOM 1636 O GLY A 211 108.884 92.158 25.535 1.00 31.87 A ATOM 1637 N PRO A 212 107.471 93.420 24.329 1.00 35.92 A ATOM 1638 CD PRO A 212 106.750 93.851 23.117 1.00 36.64 A ATOM 1639 CA PRO A 212 107.096 94.252 25.480 1.00 31.77 A ATOM 1640 CB PRO A 212 106.113 95.266 24.881 1.00 34.18 A ATOM 1641 CG PRO A 212 106.506 95.315 23.424 1.00 36.29 A ATOM 1642 C PRO A 212 106.456 93.397 26.585 1.00 29.56 A ATOM 1643 O PRO A 212 106.700 93.630 27.767 1.00 27.62 A ATOM 1644 N LEU A 213 105.644 92.416 26.205 1.00 26.27 A ATOM 1645 CA LEU A 213 105.036 91.569 27.232 1.00 30.09 A ATOM 1646 CB LEU A 213 104.048 90.590 26.613 1.00 28.37 A ATOM 1647 CG LEU A 213 102.726 91.280 26.223 1.00 31.49 A ATOM 1648 CD1 LEU A 213 102.970 92.306 25.101 1.00 29.76 A ATOM 1649 CD2 LEU A 213 101.738 90.239 25.745 1.00 29.45 A ATOM 1650 C LEU A 213 106.112 90.830 28.032 1.00 22.05 A ATOM 1651 O LEU A 213 106.139 90.886 29.250 1.00 25.06 A ATOM 1652 N LEU A 214 107.023 90.176 27.331 1.00 29.37 A ATOM 1653 CA LEU A 214 108.087 89.455 27.992 1.00 31.80 A ATOM 1654 CB LEU A 214 109.030 88.849 26.952 1.00 27.44 A ATOM 1655 CG LEU A 214 110.272 88.115 27.476 1.00 31.65 A ATOM 1656 CD1 LEU A 214 109.889 86.976 28.445 1.00 25.93 A ATOM 1657 CD2 LEU A 214 111.030 87.536 26.246 1.00 25.20 A ATOM 1658 C LEU A 214 108.836 90.401 28.889 1.00 28.32 A ATOM 1659 O LEU A 214 109.110 90.091 30.049 1.00 27.69 A ATOM 1660 N ASN A 215 109.176 91.576 28.365 1.00 33.16 A ATOM 1661 CA ASN A 215 109.912 92.553 29.175 1.00 30.08 A ATOM 1662 CB ASN A 215 110.205 93.829 28.383 1.00 37.16 A ATOM 1663 CG ASN A 215 110.980 94.815 29.205 1.00 39.99 A ATOM 1664 OD1 ASN A 215 112.161 94.586 29.516 1.00 38.55 A ATOM 1665 ND2 ASN A 215 110.311 95.895 29.629 1.00 39.72 A ATOM 1666 C ASN A 215 109.189 92.951 30.453 1.00 26.60 A ATOM 1667 O ASN A 215 109.789 93.055 31.522 1.00 27.99 A ATOM 1668 N LYS A 216 107.891 93.204 30.346 1.00 29.96 A ATOM 1669 CA LYS A 216 107.116 93.562 31.536 1.00 28.98 A ATOM 1670 CB LYS A 216 105.669 93.842 31.124 1.00 27.44 A ATOM 1671 CG LYS A 216 104.773 94.180 32.297 1.00 25.28 A ATOM 1672 CD LYS A 216 103.384 94.434 31.799 1.00 29.65 A ATOM 1673 CE LYS A 216 102.375 94.667 32.940 1.00 31.45 A ATOM 1674 NZ LYS A 216 102.739 95.753 33.908 1.00 33.04 A ATOM 1675 C LYS A 216 107.177 92.385 32.529 1.00 31.98 A ATOM 1676 O LYS A 216 107.459 92.549 33.758 1.00 23.57 A ATOM 1677 N PHE A 217 106.934 91.182 32.000 1.00 29.01 A ATOM 1678 CA PHE A 217 106.984 90.002 32.862 1.00 23.20 A ATOM 1679 CB PHE A 217 106.849 88.715 32.053 1.00 24.49 A ATOM 1680 CG PHE A 217 107.137 87.453 32.855 1.00 30.86 A ATOM 1681 CD1 PHE A 217 106.184 86.923 33.729 1.00 25.74 A ATOM 1682 CD2 PHE A 217 108.350 86.762 32.682 1.00 33.51 A ATOM 1683 CE1 PHE A 217 106.418 85.718 34.410 1.00 27.69 A ATOM 1684 CE2 PHE A 217 108.598 85.553 33.359 1.00 30.90 A ATOM 1685 CZ PHE A 217 107.620 85.029 34.228 1.00 26.68 A ATOM 1686 C PHE A 217 108.277 89.949 33.655 1.00 25.85 A ATOM 1687 O PHE A 217 108.255 89.888 34.892 1.00 26.90 A ATOM 1688 N LEU A 218 109.417 90.010 32.967 1.00 29.26 A ATOM 1689 CA LEU A 218 110.700 89.915 33.668 1.00 27.29 A ATOM 1690 CB LEU A 218 111.853 89.742 32.671 1.00 29.60 A ATOM 1691 CG LEU A 218 111.709 88.572 31.682 1.00 32.78 A ATOM 1692 CD1 LEU A 218 112.729 88.696 30.537 1.00 27.26 A ATOM 1693 CD2 LEU A 218 111.905 87.240 32.455 1.00 24.94 A ATOM 1694 C LEU A 218 111.016 91.071 34.609 1.00 30.13 A ATOM 1695 O LEU A 218 111.452 90.857 35.751 1.00 31.21 A ATOM 1696 N THR A 219 110.798 92.295 34.141 1.00 31.78 A ATOM 1697 CA THR A 219 111.097 93.480 34.958 1.00 35.74 A ATOM 1698 CB THR A 219 111.082 94.772 34.097 1.00 33.10 A ATOM 1699 OG1 THR A 219 109.778 94.981 33.536 1.00 31.70 A ATOM 1700 CG2 THR A 219 112.106 94.645 32.947 1.00 34.85 A ATOM 1701 C THR A 219 110.138 93.626 36.142 1.00 30.35 A ATOM 1702 O THR A 219 110.431 94.334 37.101 1.00 30.89 A ATOM 1703 N THR A 220 109.007 92.931 36.094 1.00 31.42 A ATOM 1704 CA THR A 220 108.081 93.014 37.216 1.00 29.70 A ATOM 1705 CB THR A 220 106.715 92.404 36.867 1.00 33.79 A ATOM 1706 OG1 THR A 220 106.091 93.206 35.862 1.00 29.37 A ATOM 1707 CG2 THR A 220 105.794 92.390 38.097 1.00 36.20 A ATOM 1708 C THR A 220 108.666 92.314 38.437 1.00 30.26 A ATOM 1709 O THR A 220 108.320 92.622 39.579 1.00 32.43 A ATOM 1710 N ALA A 221 109.590 91.388 38.223 1.00 30.76 A ATOM 1711 CA ALA A 221 110.140 90.711 39.383 1.00 33.31 A ATOM 1712 CB ALA A 221 111.030 89.552 38.950 1.00 29.98 A ATOM 1713 C ALA A 221 110.903 91.626 40.341 1.00 33.78 A ATOM 1714 O ALA A 221 111.664 92.480 39.932 1.00 37.00 A ATOM 1715 N LYS A 222 110.682 91.436 41.633 1.00 35.09 A ATOM 1716 CA LYS A 222 111.385 92.202 42.645 1.00 35.18 A ATOM 1717 CB LYS A 222 110.598 92.185 43.955 1.00 43.27 A ATOM 1718 CG LYS A 222 111.085 93.202 44.970 1.00 51.49 A ATOM 1719 CD LYS A 222 110.204 93.213 46.227 1.00 60.05 A ATOM 1720 CE LYS A 222 110.402 94.508 47.040 1.00 63.10 A ATOM 1721 NZ LYS A 222 111.855 94.791 47.290 1.00 63.82 A ATOM 1722 C LYS A 222 112.740 91.534 42.864 1.00 39.12 A ATOM 1723 O LYS A 222 112.811 90.313 43.020 1.00 31.62 A ATOM 1724 N ASP A 223 113.809 92.332 42.906 1.00 35.35 A ATOM 1725 CA ASP A 223 115.168 91.818 43.097 1.00 33.61 A ATOM 1726 CB ASP A 223 115.383 91.275 44.518 1.00 42.55 A ATOM 1727 CG ASP A 223 115.290 92.349 45.583 1.00 50.58 A ATOM 1728 OD1 ASP A 223 114.908 92.022 46.733 1.00 53.29 A ATOM 1729 OD2 ASP A 223 115.609 93.518 45.282 1.00 58.47 A ATOM 1730 C ASP A 223 115.448 90.696 42.115 1.00 31.36 A ATOM 1731 O ASP A 223 116.247 89.804 42.408 1.00 33.77 A ATOM 1732 N LYS A 224 114.786 90.737 40.962 1.00 30.77 A ATOM 1733 CA LYS A 224 114.964 89.706 39.940 1.00 35.01 A ATOM 1734 CB LYS A 224 116.370 89.807 39.382 1.00 36.58 A ATOM 1735 CG LYS A 224 116.683 91.208 38.878 1.00 47.96 A ATOM 1736 CD LYS A 224 118.037 91.262 38.207 1.00 52.39 A ATOM 1737 CE LYS A 224 118.284 92.622 37.573 1.00 56.76 A ATOM 1738 NZ LYS A 224 119.429 92.538 36.606 1.00 59.77 A ATOM 1739 C LYS A 224 114.720 88.268 40.446 1.00 35.05 A ATOM 1740 O LYS A 224 115.169 87.296 39.832 1.00 31.24 A ATOM 1741 N ASN A 225 114.026 88.117 41.566 1.00 27.53 A ATOM 1742 CA ASN A 225 113.811 86.756 42.053 1.00 33.64 A ATOM 1743 CB ASN A 225 114.834 86.408 43.156 1.00 24.93 A ATOM 1744 CG ASN A 225 114.614 87.203 44.456 1.00 32.88 A ATOM 1745 OD1 ASN A 225 115.462 87.178 45.355 1.00 27.17 A ATOM 1746 ND2 ASN A 225 113.477 87.896 44.563 1.00 23.33 A ATOM 1747 C ASN A 225 112.391 86.412 42.506 1.00 32.97 A ATOM 1748 O ASN A 225 112.114 85.247 42.781 1.00 29.39 A ATOM 1749 N ARG A 226 111.481 87.385 42.587 1.00 27.45 A ATOM 1750 CA ARG A 226 110.126 87.028 43.007 1.00 24.16 A ATOM 1751 CB ARG A 226 110.055 86.996 44.528 1.00 29.81 A ATOM 1752 CG ARG A 226 110.358 88.346 45.221 1.00 29.04 A ATOM 1753 CD ARG A 226 110.419 88.133 46.717 1.00 29.72 A ATOM 1754 NE ARG A 226 110.694 89.338 47.493 1.00 36.06 A ATOM 1755 CZ ARG A 226 111.862 89.992 47.530 1.00 40.98 A ATOM 1756 NH1 ARG A 226 112.909 89.572 46.818 1.00 42.69 A ATOM 1757 NH2 ARG A 226 111.994 91.066 48.310 1.00 37.88 A ATOM 1758 C ARG A 226 109.069 87.973 42.477 1.00 31.57 A ATOM 1759 O ARG A 226 109.330 89.143 42.211 1.00 25.27 A ATOM 1760 N TRP A 227 107.867 87.456 42.299 1.00 28.37 A ATOM 1761 CA TRP A 227 106.761 88.275 41.851 1.00 23.41 A ATOM 1762 CB TRP A 227 105.973 87.536 40.760 1.00 20.74 A ATOM 1763 CG TRP A 227 106.620 87.650 39.384 1.00 26.80 A ATOM 1764 CD2 TRP A 227 107.850 87.041 38.950 1.00 20.68 A ATOM 1765 CE2 TRP A 227 108.105 87.500 37.630 1.00 22.35 A ATOM 1766 CE3 TRP A 227 108.763 86.157 39.549 1.00 22.82 A ATOM 1767 CD1 TRP A 227 106.189 88.430 38.330 1.00 21.29 A ATOM 1768 NE1 TRP A 227 107.079 88.344 37.281 1.00 28.98 A ATOM 1769 CZ2 TRP A 227 109.225 87.105 36.897 1.00 24.84 A ATOM 1770 CZ3 TRP A 227 109.886 85.757 38.821 1.00 22.71 A ATOM 1771 CH2 TRP A 227 110.105 86.232 37.505 1.00 26.46 A ATOM 1772 C TRP A 227 105.918 88.521 43.097 1.00 31.42 A ATOM 1773 O TRP A 227 105.162 87.658 43.531 1.00 30.37 A ATOM 1774 N GLU A 228 106.081 89.674 43.723 1.00 30.19 A ATOM 1775 CA GLU A 228 105.278 89.914 44.897 1.00 40.90 A ATOM 1776 CB GLU A 228 106.105 89.747 46.169 1.00 43.17 A ATOM 1777 CG GLU A 228 107.143 90.767 46.430 1.00 49.83 A ATOM 1778 CD GLU A 228 107.521 90.796 47.904 1.00 51.45 A ATOM 1779 OE1 GLU A 228 107.955 89.753 48.428 1.00 41.85 A ATOM 1780 OE2 GLU A 228 107.375 91.865 48.534 1.00 56.43 A ATOM 1781 C GLU A 228 104.555 91.248 44.907 1.00 43.90 A ATOM 1782 O GLU A 228 105.015 92.225 44.320 1.00 38.10 A ATOM 1783 N ASP A 229 103.398 91.261 45.559 1.00 45.53 A ATOM 1784 CA ASP A 229 102.606 92.462 45.661 1.00 49.47 A ATOM 1785 CB ASP A 229 101.178 92.149 45.244 1.00 48.06 A ATOM 1786 CG ASP A 229 101.057 91.972 43.727 1.00 50.49 A ATOM 1787 OD1 ASP A 229 101.471 92.917 43.003 1.00 49.52 A ATOM 1788 OD2 ASP A 229 100.573 90.910 43.263 1.00 34.83 A ATOM 1789 C ASP A 229 102.716 92.944 47.097 1.00 56.94 A ATOM 1790 O ASP A 229 102.511 92.165 48.033 1.00 47.42 A ATOM 1791 N PRO A 230 103.104 94.229 47.290 1.00 64.41 A ATOM 1792 CD PRO A 230 103.414 95.217 46.238 1.00 66.97 A ATOM 1793 CA PRO A 230 103.261 94.830 48.625 1.00 64.83 A ATOM 1794 CB PRO A 230 103.783 96.239 48.322 1.00 68.61 A ATOM 1795 CG PRO A 230 103.206 96.530 46.968 1.00 71.34 A ATOM 1796 C PRO A 230 101.958 94.835 49.400 1.00 61.61 A ATOM 1797 O PRO A 230 100.886 94.963 48.819 1.00 59.14 A ATOM 1798 N GLY A 231 102.066 94.671 50.713 1.00 64.01 A ATOM 1799 CA GLY A 231 100.884 94.647 51.552 1.00 69.86 A ATOM 1800 C GLY A 231 100.197 93.305 51.447 1.00 70.74 A ATOM 1801 O GLY A 231 99.407 93.085 50.526 1.00 71.02 A ATOM 1802 N LYS A 232 100.487 92.408 52.388 1.00 74.07 A ATOM 1803 CA LYS A 232 99.899 91.068 52.345 1.00 77.87 A ATOM 1804 CB LYS A 232 98.369 91.170 52.297 1.00 80.70 A ATOM 1805 CG LYS A 232 97.722 91.539 53.624 1.00 83.42 A ATOM 1806 CD LYS A 232 97.830 90.372 54.609 1.00 85.26 A ATOM 1807 CE LYS A 232 97.028 90.622 55.884 1.00 85.21 A ATOM 1808 NZ LYS A 232 97.018 89.416 56.769 1.00 86.74 A ATOM 1809 C LYS A 232 100.443 90.345 51.087 1.00 77.00 A ATOM 1810 O LYS A 232 99.701 89.982 50.156 1.00 76.48 A ATOM 1811 N GLN A 233 101.762 90.168 51.071 1.00 70.42 A ATOM 1812 CA GLN A 233 102.447 89.508 49.971 1.00 64.94 A ATOM 1813 CB GLN A 233 103.895 89.999 49.916 1.00 65.15 A ATOM 1814 CG GLN A 233 104.660 89.787 51.211 1.00 68.22 A ATOM 1815 CD GLN A 233 105.334 91.059 51.716 1.00 73.51 A ATOM 1816 OE1 GLN A 233 106.256 91.581 51.087 1.00 79.17 A ATOM 1817 NE2 GLN A 233 104.869 91.567 52.859 1.00 73.37 A ATOM 1818 C GLN A 233 102.416 88.003 50.192 1.00 62.45 A ATOM 1819 O GLN A 233 103.423 87.332 50.007 1.00 59.36 A ATOM 1820 N LEU A 234 101.267 87.473 50.604 1.00 59.16 A ATOM 1821 CA LEU A 234 101.163 86.040 50.844 1.00 57.14 A ATOM 1822 CB LEU A 234 100.011 85.733 51.808 1.00 58.67 A ATOM 1823 CG LEU A 234 98.593 86.146 51.406 1.00 59.33 A ATOM 1824 CD1 LEU A 234 97.566 85.419 52.300 1.00 55.69 A ATOM 1825 CD2 LEU A 234 98.455 87.680 51.521 1.00 56.83 A ATOM 1826 C LEU A 234 101.004 85.222 49.548 1.00 56.11 A ATOM 1827 O LEU A 234 101.067 83.977 49.572 1.00 58.17 A ATOM 1828 N TYR A 235 100.835 85.906 48.415 1.00 43.77 A ATOM 1829 CA TYR A 235 100.694 85.205 47.142 1.00 33.72 A ATOM 1830 CB TYR A 235 99.701 85.954 46.262 1.00 29.90 A ATOM 1831 CG TYR A 235 98.416 86.253 46.982 1.00 31.05 A ATOM 1832 CD1 TYR A 235 97.805 87.505 46.872 1.00 32.37 A ATOM 1833 CE1 TYR A 235 96.614 87.785 47.530 1.00 27.48 A ATOM 1834 CD2 TYR A 235 97.799 85.273 47.779 1.00 29.78 A ATOM 1835 CE2 TYR A 235 96.615 85.533 48.437 1.00 27.57 A ATOM 1836 CZ TYR A 235 96.026 86.789 48.303 1.00 33.50 A ATOM 1837 OH TYR A 235 94.822 87.009 48.889 1.00 30.21 A ATOM 1838 C TYR A 235 102.015 85.112 46.401 1.00 31.37 A ATOM 1839 O TYR A 235 102.027 84.671 45.262 1.00 28.36 A ATOM 1840 N ASN A 236 103.130 85.519 47.023 1.00 24.27 A ATOM 1841 CA ASN A 236 104.399 85.505 46.292 1.00 20.44 A ATOM 1842 CB ASN A 236 105.472 86.335 47.017 1.00 25.88 A ATOM 1843 CG ASN A 236 105.651 85.944 48.484 1.00 30.25 A ATOM 1844 OD1 ASN A 236 104.890 85.148 49.032 1.00 39.82 A ATOM 1845 ND2 ASN A 236 106.644 86.543 49.133 1.00 28.85 A ATOM 1846 C ASN A 236 104.955 84.137 45.960 1.00 20.82 A ATOM 1847 O ASN A 236 105.588 83.968 44.919 1.00 20.31 A ATOM 1848 N VAL A 237 104.761 83.155 46.831 1.00 20.09 A ATOM 1849 CA VAL A 237 105.272 81.827 46.501 1.00 21.36 A ATOM 1850 CB VAL A 237 105.154 80.861 47.704 1.00 18.71 A ATOM 1851 CG1 VAL A 237 105.601 79.471 47.312 1.00 14.08 A ATOM 1852 CG2 VAL A 237 106.052 81.376 48.846 1.00 27.50 A ATOM 1853 C VAL A 237 104.481 81.299 45.301 1.00 18.56 A ATOM 1854 O VAL A 237 105.063 80.794 44.343 1.00 18.22 A ATOM 1855 N GLU A 238 103.162 81.479 45.323 1.00 17.79 A ATOM 1856 CA GLU A 238 102.315 80.996 44.239 1.00 16.12 A ATOM 1857 CB GLU A 238 100.824 81.147 44.601 1.00 17.19 A ATOM 1858 CG GLU A 238 99.867 80.782 43.468 1.00 14.34 A ATOM 1859 CD GLU A 238 98.471 81.420 43.650 1.00 11.06 A ATOM 1860 OE1 GLU A 238 98.241 82.107 44.686 1.00 19.48 A ATOM 1861 OE2 GLU A 238 97.621 81.200 42.783 1.00 16.80 A ATOM 1862 C GLU A 238 102.628 81.744 42.958 1.00 20.25 A ATOM 1863 O GLU A 238 102.845 81.130 41.897 1.00 18.11 A ATOM 1864 N ALA A 239 102.684 83.071 43.036 1.00 18.43 A ATOM 1865 CA ALA A 239 102.975 83.867 41.835 1.00 17.27 A ATOM 1866 CB ALA A 239 102.988 85.340 42.221 1.00 17.99 A ATOM 1867 C ALA A 239 104.334 83.488 41.251 1.00 16.91 A ATOM 1868 O ALA A 239 104.510 83.248 40.038 1.00 18.31 A ATOM 1869 N THR A 240 105.312 83.398 42.136 1.00 12.73 A ATOM 1870 CA THR A 240 106.678 83.101 41.673 1.00 16.78 A ATOM 1871 CB THR A 240 107.675 83.337 42.835 1.00 20.26 A ATOM 1872 OG1 THR A 240 107.499 84.683 43.322 1.00 20.23 A ATOM 1873 CG2 THR A 240 109.110 83.187 42.382 1.00 15.53 A ATOM 1874 C THR A 240 106.790 81.686 41.087 1.00 23.59 A ATOM 1875 O THR A 240 107.639 81.437 40.215 1.00 20.02 A ATOM 1876 N SER A 241 105.941 80.760 41.552 1.00 15.58 A ATOM 1877 CA SER A 241 105.991 79.381 41.022 1.00 17.43 A ATOM 1878 CB SER A 241 105.162 78.441 41.906 1.00 11.67 A ATOM 1879 OG SER A 241 105.715 78.363 43.233 1.00 15.93 A ATOM 1880 C SER A 241 105.438 79.442 39.595 1.00 17.10 A ATOM 1881 O SER A 241 105.980 78.810 38.675 1.00 18.31 A ATOM 1882 N TYR A 242 104.365 80.217 39.383 1.00 18.46 A ATOM 1883 CA TYR A 242 103.846 80.367 38.013 1.00 18.91 A ATOM 1884 CB TYR A 242 102.622 81.307 37.942 1.00 15.98 A ATOM 1885 CG TYR A 242 101.263 80.652 38.192 1.00 20.69 A ATOM 1886 CD1 TYR A 242 100.766 79.658 37.338 1.00 13.29 A ATOM 1887 CE1 TYR A 242 99.504 79.043 37.567 1.00 18.13 A ATOM 1888 CD2 TYR A 242 100.486 81.030 39.286 1.00 16.91 A ATOM 1889 CE2 TYR A 242 99.246 80.434 39.537 1.00 11.03 A ATOM 1890 CZ TYR A 242 98.759 79.444 38.669 1.00 19.17 A ATOM 1891 OH TYR A 242 97.505 78.916 38.898 1.00 17.62 A ATOM 1892 C TYR A 242 104.949 81.000 37.157 1.00 23.33 A ATOM 1893 O TYR A 242 105.190 80.603 35.997 1.00 22.29 A ATOM 1894 N ALA A 243 105.613 82.004 37.717 1.00 18.34 A ATOM 1895 CA ALA A 243 106.634 82.697 36.929 1.00 18.89 A ATOM 1896 CB ALA A 243 107.164 83.901 37.694 1.00 19.57 A ATOM 1897 C ALA A 243 107.772 81.717 36.608 1.00 21.61 A ATOM 1898 O ALA A 243 108.290 81.731 35.494 1.00 21.45 A ATOM 1899 N LEU A 244 108.145 80.861 37.565 1.00 16.89 A ATOM 1900 CA LEU A 244 109.239 79.899 37.309 1.00 20.89 A ATOM 1901 CB LEU A 244 109.588 79.103 38.587 1.00 16.59 A ATOM 1902 CG LEU A 244 110.578 77.933 38.379 1.00 21.10 A ATOM 1903 CD1 LEU A 244 111.844 78.449 37.632 1.00 20.05 A ATOM 1904 CD2 LEU A 244 110.974 77.326 39.777 1.00 12.73 A ATOM 1905 C LEU A 244 108.813 78.947 36.182 1.00 18.67 A ATOM 1906 O LEU A 244 109.610 78.556 35.296 1.00 19.02 A ATOM 1907 N LEU A 245 107.542 78.574 36.181 1.00 17.68 A ATOM 1908 CA LEU A 245 107.074 77.709 35.107 1.00 15.21 A ATOM 1909 CB LEU A 245 105.628 77.214 35.404 1.00 20.70 A ATOM 1910 CG LEU A 245 105.557 76.123 36.506 1.00 21.76 A ATOM 1911 CD1 LEU A 245 104.108 75.956 36.996 1.00 26.34 A ATOM 1912 CD2 LEU A 245 106.100 74.778 35.969 1.00 16.28 A ATOM 1913 C LEU A 245 107.147 78.449 33.746 1.00 19.30 A ATOM 1914 O LEU A 245 107.449 77.831 32.717 1.00 20.79 A ATOM 1915 N ALA A 246 106.874 79.759 33.724 1.00 18.12 A ATOM 1916 CA ALA A 246 106.959 80.501 32.461 1.00 18.77 A ATOM 1917 CB ALA A 246 106.367 81.944 32.622 1.00 16.45 A ATOM 1918 C ALA A 246 108.431 80.558 32.009 1.00 14.13 A ATOM 1919 O ALA A 246 108.738 80.352 30.823 1.00 19.75 A ATOM 1920 N LEU A 247 109.337 80.835 32.944 1.00 15.08 A ATOM 1921 CA LEU A 247 110.769 80.899 32.620 1.00 18.36 A ATOM 1922 CB LEU A 247 111.567 81.267 33.866 1.00 19.66 A ATOM 1923 CG LEU A 247 111.365 82.715 34.363 1.00 20.28 A ATOM 1924 CD1 LEU A 247 111.874 82.820 35.813 1.00 17.02 A ATOM 1925 CD2 LEU A 247 112.098 83.725 33.441 1.00 21.44 A ATOM 1926 C LEU A 247 111.263 79.557 32.058 1.00 23.09 A ATOM 1927 O LEU A 247 112.038 79.526 31.092 1.00 25.65 A ATOM 1928 N LEU A 248 110.796 78.447 32.624 1.00 22.19 A ATOM 1929 CA LEU A 248 111.239 77.124 32.123 1.00 28.05 A ATOM 1930 CB LEU A 248 110.815 75.977 33.081 1.00 24.02 A ATOM 1931 CG LEU A 248 111.577 75.998 34.437 1.00 25.05 A ATOM 1932 CD1 LEU A 248 110.943 75.071 35.436 1.00 24.06 A ATOM 1933 CD2 LEU A 248 113.066 75.617 34.216 1.00 15.01 A ATOM 1934 C LEU A 248 110.657 76.914 30.745 1.00 23.21 A ATOM 1935 O LEU A 248 111.313 76.391 29.847 1.00 25.42 A ATOM 1936 N GLN A 249 109.416 77.324 30.572 1.00 22.82 A ATOM 1937 CA GLN A 249 108.757 77.197 29.281 1.00 22.86 A ATOM 1938 CB GLN A 249 107.314 77.694 29.377 1.00 27.58 A ATOM 1939 CG GLN A 249 106.526 77.545 28.085 1.00 34.66 A ATOM 1940 CD GLN A 249 106.170 76.085 27.789 1.00 39.67 A ATOM 1941 OE1 GLN A 249 105.459 75.434 28.554 1.00 44.37 A ATOM 1942 NE2 GLN A 249 106.672 75.575 26.687 1.00 37.71 A ATOM 1943 C GLN A 249 109.513 78.042 28.226 1.00 27.62 A ATOM 1944 O GLN A 249 109.623 77.655 27.079 1.00 24.60 A ATOM 1945 N LEU A 250 110.009 79.207 28.618 1.00 32.08 A ATOM 1946 CA LEU A 250 110.740 80.080 27.700 1.00 30.59 A ATOM 1947 CB LEU A 250 110.736 81.501 28.247 1.00 28.66 A ATOM 1948 CG LEU A 250 109.401 82.220 28.410 1.00 30.11 A ATOM 1949 CD1 LEU A 250 109.530 83.326 29.426 1.00 29.85 A ATOM 1950 CD2 LEU A 250 108.960 82.728 27.062 1.00 28.49 A ATOM 1951 C LEU A 250 112.207 79.647 27.551 1.00 36.31 A ATOM 1952 O LEU A 250 112.938 80.189 26.708 1.00 31.07 A ATOM 1953 N LYS A 251 112.627 78.682 28.373 1.00 30.98 A ATOM 1954 CA LYS A 251 114.016 78.226 28.410 1.00 31.57 A ATOM 1955 CB LYS A 251 114.420 77.554 27.098 1.00 32.85 A ATOM 1956 CG LYS A 251 113.715 76.232 26.890 1.00 42.53 A ATOM 1957 CD LYS A 251 114.060 75.631 25.555 1.00 46.71 A ATOM 1958 CE LYS A 251 113.233 74.376 25.314 1.00 54.63 A ATOM 1959 NZ LYS A 251 113.214 73.987 23.864 1.00 58.25 A ATOM 1960 C LYS A 251 114.943 79.412 28.712 1.00 31.12 A ATOM 1961 O LYS A 251 116.102 79.442 28.301 1.00 32.07 A ATOM 1962 N ASP A 252 114.438 80.376 29.470 1.00 29.36 A ATOM 1963 CA ASP A 252 115.239 81.521 29.830 1.00 28.62 A ATOM 1964 CB ASP A 252 114.346 82.738 30.091 1.00 33.61 A ATOM 1965 CG ASP A 252 115.150 84.017 30.237 1.00 37.36 A ATOM 1966 OD1 ASP A 252 116.328 83.990 29.839 1.00 49.12 A ATOM 1967 OD2 ASP A 252 114.624 85.048 30.725 1.00 34.68 A ATOM 1968 C ASP A 252 116.097 81.183 31.046 1.00 31.99 A ATOM 1969 O ASP A 252 115.933 81.742 32.139 1.00 30.76 A ATOM 1970 N PHE A 253 117.069 80.301 30.819 1.00 31.40 A ATOM 1971 CA PHE A 253 117.935 79.818 31.873 1.00 27.03 A ATOM 1972 CB PHE A 253 118.786 78.674 31.338 1.00 33.08 A ATOM 1973 CG PHE A 253 117.995 77.601 30.649 1.00 33.23 A ATOM 1974 CD1 PHE A 253 116.815 77.109 31.205 1.00 35.86 A ATOM 1975 CD2 PHE A 253 118.460 77.032 29.463 1.00 34.30 A ATOM 1976 CE1 PHE A 253 116.115 76.061 30.593 1.00 35.38 A ATOM 1977 CE2 PHE A 253 117.762 75.987 28.853 1.00 30.02 A ATOM 1978 CZ PHE A 253 116.593 75.504 29.421 1.00 32.95 A ATOM 1979 C PHE A 253 118.823 80.800 32.619 1.00 36.01 A ATOM 1980 O PHE A 253 119.249 80.512 33.746 1.00 32.40 A ATOM 1981 N ASP A 254 119.124 81.951 32.028 1.00 33.64 A ATOM 1982 CA ASP A 254 119.986 82.905 32.728 1.00 37.81 A ATOM 1983 CB ASP A 254 120.588 83.884 31.729 1.00 49.35 A ATOM 1984 CG ASP A 254 119.539 84.520 30.871 1.00 65.34 A ATOM 1985 OD1 ASP A 254 118.936 83.793 30.046 1.00 75.38 A ATOM 1986 OD2 ASP A 254 119.293 85.740 31.023 1.00 75.70 A ATOM 1987 C ASP A 254 119.210 83.669 33.802 1.00 31.65 A ATOM 1988 O ASP A 254 119.791 84.196 34.752 1.00 30.63 A ATOM 1989 N PHE A 255 117.892 83.728 33.652 1.00 28.90 A ATOM 1990 CA PHE A 255 117.058 84.442 34.616 1.00 29.25 A ATOM 1991 CB PHE A 255 115.881 85.100 33.892 1.00 28.92 A ATOM 1992 CG PHE A 255 115.234 86.213 34.671 1.00 38.13 A ATOM 1993 CD1 PHE A 255 114.281 85.947 35.643 1.00 31.13 A ATOM 1994 CD2 PHE A 255 115.596 87.546 34.432 1.00 39.51 A ATOM 1995 CE1 PHE A 255 113.695 86.988 36.366 1.00 38.06 A ATOM 1996 CE2 PHE A 255 115.017 88.589 35.150 1.00 35.88 A ATOM 1997 CZ PHE A 255 114.063 88.313 36.120 1.00 39.10 A ATOM 1998 C PHE A 255 116.523 83.530 35.721 1.00 28.15 A ATOM 1999 O PHE A 255 116.078 83.996 36.767 1.00 27.42 A ATOM 2000 N VAL A 256 116.562 82.228 35.482 1.00 24.41 A ATOM 2001 CA VAL A 256 116.040 81.257 36.453 1.00 21.90 A ATOM 2002 CB VAL A 256 116.017 79.838 35.789 1.00 26.19 A ATOM 2003 CG1 VAL A 256 115.894 78.725 36.829 1.00 17.67 A ATOM 2004 CG2 VAL A 256 114.827 79.770 34.812 1.00 22.75 A ATOM 2005 C VAL A 256 116.666 81.130 37.848 1.00 22.10 A ATOM 2006 O VAL A 256 115.946 81.095 38.871 1.00 28.02 A ATOM 2007 N PRO A 257 118.007 81.124 37.931 1.00 21.20 A ATOM 2008 CD PRO A 257 118.995 81.442 36.886 1.00 24.71 A ATOM 2009 CA PRO A 257 118.667 80.963 39.234 1.00 24.35 A ATOM 2010 CB PRO A 257 120.169 81.097 38.899 1.00 27.97 A ATOM 2011 CG PRO A 257 120.234 80.711 37.411 1.00 23.95 A ATOM 2012 C PRO A 257 118.258 81.802 40.403 1.00 24.79 A ATOM 2013 O PRO A 257 117.988 81.266 41.468 1.00 27.34 A ATOM 2014 N PRO A 258 118.189 83.134 40.250 1.00 25.57 A ATOM 2015 CD PRO A 258 118.491 84.076 39.165 1.00 26.97 A ATOM 2016 CA PRO A 258 117.785 83.828 41.487 1.00 25.28 A ATOM 2017 CB PRO A 258 117.840 85.322 41.103 1.00 29.92 A ATOM 2018 CG PRO A 258 118.862 85.363 39.944 1.00 31.32 A ATOM 2019 C PRO A 258 116.373 83.414 41.927 1.00 25.27 A ATOM 2020 O PRO A 258 116.032 83.438 43.117 1.00 21.56 A ATOM 2021 N VAL A 259 115.552 83.013 40.963 1.00 21.83 A ATOM 2022 CA VAL A 259 114.175 82.658 41.291 1.00 22.97 A ATOM 2023 CB VAL A 259 113.339 82.571 39.988 1.00 21.99 A ATOM 2024 CG1 VAL A 259 111.917 82.096 40.294 1.00 17.20 A ATOM 2025 CG2 VAL A 259 113.271 83.961 39.346 1.00 24.31 A ATOM 2026 C VAL A 259 114.069 81.358 42.085 1.00 19.11 A ATOM 2027 O VAL A 259 113.366 81.256 43.091 1.00 22.76 A ATOM 2028 N VAL A 260 114.783 80.357 41.620 1.00 26.91 A ATOM 2029 CA VAL A 260 114.760 79.071 42.275 1.00 24.36 A ATOM 2030 CB VAL A 260 115.564 78.094 41.451 1.00 23.58 A ATOM 2031 CG1 VAL A 260 115.723 76.787 42.189 1.00 24.55 A ATOM 2032 CG2 VAL A 260 114.865 77.887 40.155 1.00 21.01 A ATOM 2033 C VAL A 260 115.340 79.231 43.657 1.00 24.01 A ATOM 2034 O VAL A 260 114.815 78.721 44.651 1.00 20.85 A ATOM 2035 N ARG A 261 116.436 79.972 43.724 1.00 24.50 A ATOM 2036 CA ARG A 261 117.084 80.219 45.002 1.00 19.29 A ATOM 2037 CB ARG A 261 118.320 81.101 44.757 1.00 26.10 A ATOM 2038 CG ARG A 261 119.216 81.291 45.956 1.00 42.29 A ATOM 2039 CD ARG A 261 120.449 82.133 45.594 1.00 48.37 A ATOM 2040 NE ARG A 261 121.239 81.474 44.553 1.00 53.77 A ATOM 2041 CZ ARG A 261 121.406 81.910 43.301 1.00 58.06 A ATOM 2042 NH1 ARG A 261 120.845 83.045 42.877 1.00 55.53 A ATOM 2043 NH2 ARG A 261 122.128 81.180 42.454 1.00 54.87 A ATOM 2044 C ARG A 261 116.114 80.883 45.999 1.00 26.55 A ATOM 2045 O ARG A 261 116.056 80.507 47.169 1.00 25.37 A ATOM 2046 N TRP A 262 115.353 81.885 45.556 1.00 21.10 A ATOM 2047 CA TRP A 262 114.423 82.526 46.469 1.00 21.13 A ATOM 2048 CB TRP A 262 113.759 83.756 45.804 1.00 27.41 A ATOM 2049 CG TRP A 262 112.747 84.440 46.710 1.00 26.23 A ATOM 2050 CD2 TRP A 262 111.344 84.176 46.770 1.00 24.38 A ATOM 2051 CE2 TRP A 262 110.809 84.949 47.839 1.00 22.85 A ATOM 2052 CE3 TRP A 262 110.479 83.359 46.027 1.00 29.17 A ATOM 2053 CD1 TRP A 262 113.008 85.351 47.715 1.00 27.15 A ATOM 2054 NE1 TRP A 262 111.844 85.659 48.397 1.00 25.55 A ATOM 2055 CZ2 TRP A 262 109.458 84.922 48.177 1.00 22.55 A ATOM 2056 CZ3 TRP A 262 109.134 83.332 46.359 1.00 22.37 A ATOM 2057 CH2 TRP A 262 108.636 84.106 47.427 1.00 27.32 A ATOM 2058 C TRP A 262 113.345 81.504 46.891 1.00 21.59 A ATOM 2059 O TRP A 262 113.003 81.383 48.077 1.00 21.98 A ATOM 2060 N LEU A 263 112.806 80.767 45.927 1.00 24.29 A ATOM 2061 CA LEU A 263 111.760 79.775 46.248 1.00 24.58 A ATOM 2062 CB LEU A 263 111.270 79.050 44.985 1.00 23.15 A ATOM 2063 CG LEU A 263 110.294 79.804 44.055 1.00 26.66 A ATOM 2064 CD1 LEU A 263 110.179 79.064 42.702 1.00 25.63 A ATOM 2065 CD2 LEU A 263 108.902 79.890 44.736 1.00 19.50 A ATOM 2066 C LEU A 263 112.280 78.754 47.252 1.00 25.46 A ATOM 2067 O LEU A 263 111.589 78.396 48.213 1.00 21.54 A ATOM 2068 N ASN A 264 113.521 78.334 47.052 1.00 27.69 A ATOM 2069 CA ASN A 264 114.138 77.339 47.923 1.00 26.89 A ATOM 2070 CB ASN A 264 115.429 76.833 47.317 1.00 30.52 A ATOM 2071 CG ASN A 264 115.869 75.523 47.906 1.00 37.07 A ATOM 2072 OD1 ASN A 264 117.047 75.355 48.181 1.00 41.85 A ATOM 2073 ND2 ASN A 264 114.936 74.576 48.093 1.00 34.54 A ATOM 2074 C ASN A 264 114.426 77.843 49.308 1.00 31.72 A ATOM 2075 O ASN A 264 114.734 77.040 50.186 1.00 29.93 A ATOM 2076 N GLU A 265 114.368 79.161 49.518 1.00 23.33 A ATOM 2077 CA GLU A 265 114.583 79.677 50.868 1.00 27.89 A ATOM 2078 CB GLU A 265 115.256 81.057 50.817 1.00 36.54 A ATOM 2079 CG GLU A 265 116.666 81.031 50.220 1.00 45.81 A ATOM 2080 CD GLU A 265 117.203 82.426 49.890 1.00 52.24 A ATOM 2081 OE1 GLU A 265 116.412 83.284 49.448 1.00 55.22 A ATOM 2082 OE2 GLU A 265 118.421 82.659 50.053 1.00 59.70 A ATOM 2083 C GLU A 265 113.240 79.794 51.617 1.00 31.76 A ATOM 2084 O GLU A 265 113.210 80.100 52.800 1.00 31.51 A ATOM 2085 N GLN A 266 112.131 79.578 50.917 1.00 25.12 A ATOM 2086 CA GLN A 266 110.823 79.682 51.534 1.00 25.11 A ATOM 2087 CB GLN A 266 109.769 80.120 50.492 1.00 22.70 A ATOM 2088 CG GLN A 266 110.160 81.344 49.619 1.00 27.84 A ATOM 2089 CD GLN A 266 110.749 82.499 50.434 1.00 30.91 A ATOM 2090 OE1 GLN A 266 110.138 82.961 51.386 1.00 29.87 A ATOM 2091 NE2 GLN A 266 111.949 82.952 50.065 1.00 23.36 A ATOM 2092 C GLN A 266 110.402 78.343 52.166 1.00 29.30 A ATOM 2093 O GLN A 266 110.826 77.247 51.730 1.00 24.87 A ATOM 2094 N ARG A 267 109.585 78.444 53.212 1.00 15.92 A ATOM 2095 CA ARG A 267 109.051 77.274 53.898 1.00 25.35 A ATOM 2096 CB ARG A 267 108.588 77.693 55.292 1.00 33.71 A ATOM 2097 CG ARG A 267 107.994 76.574 56.134 1.00 51.92 A ATOM 2098 CD ARG A 267 107.907 76.988 57.616 1.00 62.06 A ATOM 2099 NE ARG A 267 106.792 76.336 58.312 1.00 68.36 A ATOM 2100 CZ ARG A 267 105.511 76.589 58.055 1.00 69.62 A ATOM 2101 NH1 ARG A 267 105.199 77.484 57.118 1.00 71.28 A ATOM 2102 NH2 ARG A 267 104.546 75.951 58.721 1.00 63.27 A ATOM 2103 C ARG A 267 107.868 76.833 53.031 1.00 24.21 A ATOM 2104 O ARG A 267 106.740 76.727 53.500 1.00 21.31 A ATOM 2105 N TYR A 268 108.146 76.503 51.772 1.00 20.68 A ATOM 2106 CA TYR A 268 107.077 76.220 50.844 1.00 19.61 A ATOM 2107 CB TYR A 268 107.623 76.325 49.416 1.00 19.65 A ATOM 2108 CG TYR A 268 108.603 75.213 49.054 1.00 20.48 A ATOM 2109 CD1 TYR A 268 108.141 73.919 48.758 1.00 14.04 A ATOM 2110 CE1 TYR A 268 109.038 72.914 48.336 1.00 17.07 A ATOM 2111 CD2 TYR A 268 109.988 75.469 48.950 1.00 18.73 A ATOM 2112 CE2 TYR A 268 110.896 74.462 48.562 1.00 10.52 A ATOM 2113 CZ TYR A 268 110.400 73.191 48.251 1.00 18.28 A ATOM 2114 OH TYR A 268 111.270 72.207 47.849 1.00 20.44 A ATOM 2115 C TYR A 268 106.320 74.921 51.058 1.00 25.67 A ATOM 2116 O TYR A 268 105.280 74.726 50.457 1.00 20.64 A ATOM 2117 N TYR A 269 106.837 74.047 51.923 1.00 22.96 A ATOM 2118 CA TYR A 269 106.192 72.764 52.224 1.00 22.56 A ATOM 2119 CB TYR A 269 107.284 71.749 52.550 1.00 19.40 A ATOM 2120 CG TYR A 269 108.279 72.324 53.538 1.00 25.20 A ATOM 2121 CD1 TYR A 269 108.002 72.326 54.913 1.00 21.63 A ATOM 2122 CE1 TYR A 269 108.856 72.951 55.823 1.00 19.42 A ATOM 2123 CD2 TYR A 269 109.452 72.970 53.098 1.00 23.97 A ATOM 2124 CE2 TYR A 269 110.310 73.620 54.010 1.00 18.32 A ATOM 2125 CZ TYR A 269 110.002 73.600 55.359 1.00 24.42 A ATOM 2126 OH TYR A 269 110.809 74.232 56.269 1.00 30.40 A ATOM 2127 C TYR A 269 105.286 72.941 53.459 1.00 19.68 A ATOM 2128 O TYR A 269 104.703 71.986 53.943 1.00 21.53 A ATOM 2129 N GLY A 270 105.176 74.170 53.948 1.00 21.67 A ATOM 2130 CA GLY A 270 104.406 74.456 55.146 1.00 17.59 A ATOM 2131 C GLY A 270 102.977 73.953 55.184 1.00 25.69 A ATOM 2132 O GLY A 270 102.532 73.482 56.232 1.00 24.34 A ATOM 2133 N GLY A 271 102.266 73.984 54.057 1.00 19.73 A ATOM 2134 CA GLY A 271 100.868 73.577 54.104 1.00 21.41 A ATOM 2135 C GLY A 271 100.160 74.574 55.033 1.00 26.85 A ATOM 2136 O GLY A 271 100.583 75.740 55.198 1.00 40.08 A ATOM 2137 N GLY A 272 99.091 74.158 55.662 1.00 23.80 A ATOM 2138 CA GLY A 272 98.437 75.085 56.568 1.00 26.88 A ATOM 2139 C GLY A 272 97.305 75.856 55.915 1.00 23.11 A ATOM 2140 O GLY A 272 97.123 75.787 54.712 1.00 21.50 A ATOM 2141 N TYR A 273 96.567 76.618 56.710 1.00 17.15 A ATOM 2142 CA TYR A 273 95.425 77.353 56.196 1.00 19.83 A ATOM 2143 CB TYR A 273 94.836 78.198 57.313 1.00 21.62 A ATOM 2144 CG TYR A 273 93.616 78.988 56.897 1.00 23.29 A ATOM 2145 CD1 TYR A 273 92.321 78.473 57.084 1.00 20.57 A ATOM 2146 CE1 TYR A 273 91.184 79.246 56.758 1.00 23.40 A ATOM 2147 CD2 TYR A 273 93.759 80.281 56.359 1.00 23.31 A ATOM 2148 CE2 TYR A 273 92.646 81.060 56.027 1.00 22.47 A ATOM 2149 CZ TYR A 273 91.371 80.532 56.235 1.00 20.88 A ATOM 2150 OH TYR A 273 90.314 81.304 55.896 1.00 20.65 A ATOM 2151 C TYR A 273 95.747 78.224 54.976 1.00 23.07 A ATOM 2152 O TYR A 273 96.764 78.920 54.931 1.00 14.66 A ATOM 2153 N GLY A 274 94.891 78.150 53.966 1.00 23.18 A ATOM 2154 CA GLY A 274 95.092 78.955 52.768 1.00 16.12 A ATOM 2155 C GLY A 274 96.280 78.623 51.891 1.00 25.88 A ATOM 2156 O GLY A 274 96.629 79.431 51.012 1.00 20.78 A ATOM 2157 N SER A 275 96.907 77.458 52.080 1.00 14.86 A ATOM 2158 CA SER A 275 98.089 77.131 51.270 1.00 20.55 A ATOM 2159 CB SER A 275 99.074 76.297 52.077 1.00 16.52 A ATOM 2160 OG SER A 275 98.428 75.061 52.389 1.00 21.60 A ATOM 2161 C SER A 275 97.806 76.335 50.005 1.00 20.94 A ATOM 2162 O SER A 275 98.746 75.961 49.318 1.00 17.86 A ATOM 2163 N THR A 276 96.544 76.072 49.683 1.00 18.41 A ATOM 2164 CA THR A 276 96.269 75.232 48.516 1.00 19.71 A ATOM 2165 CB THR A 276 94.730 75.059 48.238 1.00 22.45 A ATOM 2166 OG1 THR A 276 94.192 76.301 47.838 1.00 51.89 A ATOM 2167 CG2 THR A 276 93.993 74.729 49.503 1.00 5.81 A ATOM 2168 C THR A 276 96.967 75.607 47.228 1.00 21.51 A ATOM 2169 O THR A 276 97.666 74.764 46.650 1.00 19.94 A ATOM 2170 N GLN A 277 96.823 76.850 46.754 1.00 13.97 A ATOM 2171 CA GLN A 277 97.463 77.189 45.485 1.00 15.27 A ATOM 2172 CB GLN A 277 96.942 78.540 44.964 1.00 15.99 A ATOM 2173 CG GLN A 277 95.421 78.529 44.563 1.00 8.40 A ATOM 2174 CD GLN A 277 95.100 77.321 43.742 1.00 20.22 A ATOM 2175 OE1 GLN A 277 95.685 77.090 42.673 1.00 16.53 A ATOM 2176 NE2 GLN A 277 94.190 76.505 44.258 1.00 18.51 A ATOM 2177 C GLN A 277 99.007 77.220 45.567 1.00 13.58 A ATOM 2178 O GLN A 277 99.689 76.791 44.620 1.00 15.16 A ATOM 2179 N ALA A 278 99.534 77.754 46.667 1.00 17.70 A ATOM 2180 CA ALA A 278 100.996 77.842 46.833 1.00 17.58 A ATOM 2181 CB ALA A 278 101.367 78.522 48.200 1.00 12.12 A ATOM 2182 C ALA A 278 101.539 76.426 46.798 1.00 20.92 A ATOM 2183 O ALA A 278 102.581 76.154 46.176 1.00 19.56 A ATOM 2184 N THR A 279 100.821 75.524 47.477 1.00 18.75 A ATOM 2185 CA THR A 279 101.254 74.136 47.553 1.00 15.04 A ATOM 2186 CB THR A 279 100.380 73.341 48.554 1.00 23.60 A ATOM 2187 OG1 THR A 279 100.574 73.865 49.873 1.00 16.00 A ATOM 2188 CG2 THR A 279 100.755 71.832 48.531 1.00 18.05 A ATOM 2189 C THR A 279 101.224 73.469 46.195 1.00 20.78 A ATOM 2190 O THR A 279 102.224 72.894 45.758 1.00 14.58 A ATOM 2191 N PHE A 280 100.080 73.544 45.514 1.00 14.85 A ATOM 2192 CA PHE A 280 99.989 72.925 44.212 1.00 15.92 A ATOM 2193 CB PHE A 280 98.601 73.198 43.604 1.00 15.13 A ATOM 2194 CG PHE A 280 98.354 72.463 42.313 1.00 19.65 A ATOM 2195 CD1 PHE A 280 97.543 71.341 42.284 1.00 19.12 A ATOM 2196 CD2 PHE A 280 98.873 72.932 41.120 1.00 17.17 A ATOM 2197 CE1 PHE A 280 97.261 70.703 41.074 1.00 21.16 A ATOM 2198 CE2 PHE A 280 98.593 72.308 39.910 1.00 22.94 A ATOM 2199 CZ PHE A 280 97.784 71.202 39.884 1.00 22.80 A ATOM 2200 C PHE A 280 101.031 73.493 43.273 1.00 22.45 A ATOM 2201 O PHE A 280 101.706 72.768 42.534 1.00 17.39 A ATOM 2202 N MET A 281 101.157 74.808 43.284 1.00 15.49 A ATOM 2203 CA MET A 281 102.061 75.445 42.339 1.00 19.30 A ATOM 2204 CB MET A 281 101.681 76.939 42.169 1.00 16.61 A ATOM 2205 CG MET A 281 100.322 77.212 41.527 1.00 18.78 A ATOM 2206 SD MET A 281 100.020 76.356 39.946 1.00 24.71 A ATOM 2207 CE MET A 281 101.567 76.615 39.056 1.00 22.61 A ATOM 2208 C MET A 281 103.576 75.321 42.559 1.00 12.99 A ATOM 2209 O MET A 281 104.316 75.044 41.593 1.00 20.36 A ATOM 2210 N VAL A 282 104.036 75.481 43.800 1.00 20.60 A ATOM 2211 CA VAL A 282 105.475 75.395 44.084 1.00 17.17 A ATOM 2212 CB VAL A 282 105.795 75.806 45.562 1.00 16.00 A ATOM 2213 CG1 VAL A 282 105.366 74.677 46.522 1.00 16.44 A ATOM 2214 CG2 VAL A 282 107.331 76.108 45.740 1.00 20.08 A ATOM 2215 C VAL A 282 105.974 73.961 43.790 1.00 16.69 A ATOM 2216 O VAL A 282 107.058 73.777 43.230 1.00 16.91 A ATOM 2217 N PHE A 283 105.184 72.943 44.134 1.00 13.38 A ATOM 2218 CA PHE A 283 105.623 71.562 43.832 1.00 20.74 A ATOM 2219 CB PHE A 283 104.821 70.541 44.684 1.00 13.63 A ATOM 2220 CG PHE A 283 105.280 70.495 46.117 1.00 21.60 A ATOM 2221 CD1 PHE A 283 104.633 71.260 47.107 1.00 18.08 A ATOM 2222 CD2 PHE A 283 106.402 69.732 46.477 1.00 17.18 A ATOM 2223 CE1 PHE A 283 105.100 71.264 48.441 1.00 21.58 A ATOM 2224 CE2 PHE A 283 106.873 69.736 47.809 1.00 19.10 A ATOM 2225 CZ PHE A 283 106.220 70.502 48.790 1.00 15.19 A ATOM 2226 C PHE A 283 105.559 71.274 42.329 1.00 17.88 A ATOM 2227 O PHE A 283 106.418 70.582 41.780 1.00 17.08 A ATOM 2228 N GLN A 284 104.572 71.859 41.642 1.00 17.15 A ATOM 2229 CA GLN A 284 104.505 71.696 40.195 1.00 15.23 A ATOM 2230 CB GLN A 284 103.258 72.375 39.570 1.00 19.08 A ATOM 2231 CG GLN A 284 103.135 72.123 38.053 1.00 18.61 A ATOM 2232 CD GLN A 284 101.834 72.642 37.446 1.00 27.56 A ATOM 2233 OE1 GLN A 284 101.215 73.561 37.957 1.00 19.72 A ATOM 2234 NE2 GLN A 284 101.419 72.040 36.358 1.00 28.76 A ATOM 2235 C GLN A 284 105.733 72.350 39.583 1.00 23.26 A ATOM 2236 O GLN A 284 106.403 71.749 38.721 1.00 19.38 A ATOM 2237 N ALA A 285 106.032 73.586 40.020 1.00 20.27 A ATOM 2238 CA ALA A 285 107.169 74.314 39.474 1.00 22.72 A ATOM 2239 CB ALA A 285 107.131 75.841 39.900 1.00 13.58 A ATOM 2240 C ALA A 285 108.525 73.704 39.796 1.00 19.56 A ATOM 2241 O ALA A 285 109.342 73.571 38.891 1.00 18.63 A ATOM 2242 N LEU A 286 108.775 73.348 41.060 1.00 17.53 A ATOM 2243 CA LEU A 286 110.059 72.729 41.426 1.00 22.71 A ATOM 2244 CB LEU A 286 110.238 72.682 42.957 1.00 20.14 A ATOM 2245 CG LEU A 286 110.337 74.074 43.563 1.00 26.93 A ATOM 2246 CD1 LEU A 286 110.528 74.003 45.093 1.00 20.46 A ATOM 2247 CD2 LEU A 286 111.470 74.793 42.896 1.00 21.22 A ATOM 2248 C LEU A 286 110.181 71.322 40.832 1.00 18.99 A ATOM 2249 O LEU A 286 111.286 70.866 40.558 1.00 23.33 A ATOM 2250 N ALA A 287 109.058 70.631 40.629 1.00 20.11 A ATOM 2251 CA ALA A 287 109.135 69.321 39.980 1.00 18.27 A ATOM 2252 CB ALA A 287 107.786 68.606 40.005 1.00 16.55 A ATOM 2253 C ALA A 287 109.519 69.613 38.530 1.00 25.56 A ATOM 2254 O ALA A 287 110.381 68.942 37.927 1.00 19.06 A ATOM 2255 N GLN A 288 108.907 70.634 37.935 1.00 18.68 A ATOM 2256 CA GLN A 288 109.249 70.877 36.536 1.00 16.52 A ATOM 2257 CB GLN A 288 108.392 71.977 35.894 1.00 23.21 A ATOM 2258 CG GLN A 288 108.681 72.106 34.390 1.00 20.99 A ATOM 2259 CD GLN A 288 108.188 70.889 33.579 1.00 29.85 A ATOM 2260 OE1 GLN A 288 108.896 70.370 32.704 1.00 29.90 A ATOM 2261 NE2 GLN A 288 106.972 70.448 33.863 1.00 16.47 A ATOM 2262 C GLN A 288 110.719 71.258 36.345 1.00 22.79 A ATOM 2263 O GLN A 288 111.330 70.907 35.335 1.00 16.55 A ATOM 2264 N TYR A 289 111.262 72.009 37.287 1.00 19.12 A ATOM 2265 CA TYR A 289 112.654 72.405 37.203 1.00 18.73 A ATOM 2266 CB TYR A 289 113.021 73.260 38.403 1.00 18.19 A ATOM 2267 CG TYR A 289 114.482 73.677 38.476 1.00 26.27 A ATOM 2268 CD1 TYR A 289 114.898 74.932 38.001 1.00 26.70 A ATOM 2269 CE1 TYR A 289 116.232 75.332 38.072 1.00 25.07 A ATOM 2270 CD2 TYR A 289 115.447 72.820 39.024 1.00 23.61 A ATOM 2271 CE2 TYR A 289 116.796 73.199 39.098 1.00 26.68 A ATOM 2272 CZ TYR A 289 117.178 74.469 38.615 1.00 31.54 A ATOM 2273 OH TYR A 289 118.491 74.859 38.678 1.00 22.55 A ATOM 2274 C TYR A 289 113.541 71.142 37.207 1.00 25.66 A ATOM 2275 O TYR A 289 114.502 71.042 36.424 1.00 21.35 A ATOM 2276 N GLN A 290 113.224 70.195 38.095 1.00 22.15 A ATOM 2277 CA GLN A 290 114.013 68.974 38.200 1.00 25.92 A ATOM 2278 CB GLN A 290 113.751 68.295 39.535 1.00 16.82 A ATOM 2279 CG GLN A 290 114.234 69.185 40.698 1.00 20.11 A ATOM 2280 CD GLN A 290 113.869 68.620 42.062 1.00 28.81 A ATOM 2281 OE1 GLN A 290 114.594 67.805 42.611 1.00 23.19 A ATOM 2282 NE2 GLN A 290 112.740 69.050 42.603 1.00 19.24 A ATOM 2283 C GLN A 290 113.792 68.037 37.053 1.00 24.56 A ATOM 2284 O GLN A 290 114.690 67.272 36.654 1.00 22.99 A ATOM 2285 N LYS A 291 112.604 68.100 36.485 1.00 28.20 A ATOM 2286 CA LYS A 291 112.340 67.233 35.349 1.00 27.92 A ATOM 2287 CB LYS A 291 110.879 67.253 34.960 1.00 25.58 A ATOM 2288 CG LYS A 291 110.640 66.179 33.951 1.00 35.43 A ATOM 2289 CD LYS A 291 109.644 66.601 32.962 1.00 47.83 A ATOM 2290 CE LYS A 291 109.438 65.497 31.950 1.00 53.06 A ATOM 2291 NZ LYS A 291 108.781 64.338 32.602 1.00 54.26 A ATOM 2292 C LYS A 291 113.128 67.716 34.138 1.00 30.13 A ATOM 2293 O LYS A 291 113.543 66.915 33.313 1.00 24.65 A ATOM 2294 N ASP A 292 113.305 69.031 34.028 1.00 21.05 A ATOM 2295 CA ASP A 292 114.016 69.633 32.891 1.00 25.19 A ATOM 2296 CB ASP A 292 113.610 71.109 32.757 1.00 23.19 A ATOM 2297 CG ASP A 292 112.222 71.299 32.158 1.00 33.23 A ATOM 2298 OD1 ASP A 292 111.626 70.308 31.703 1.00 27.34 A ATOM 2299 OD2 ASP A 292 111.737 72.452 32.131 1.00 27.83 A ATOM 2300 C ASP A 292 115.556 69.584 33.008 1.00 23.90 A ATOM 2301 O ASP A 292 116.275 69.573 32.017 1.00 22.32 A ATOM 2302 N ALA A 293 116.034 69.604 34.236 1.00 20.48 A ATOM 2303 CA ALA A 293 117.451 69.602 34.558 1.00 28.06 A ATOM 2304 CB ALA A 293 117.602 69.472 36.065 1.00 20.35 A ATOM 2305 C ALA A 293 118.355 68.564 33.838 1.00 29.15 A ATOM 2306 O ALA A 293 119.480 68.885 33.427 1.00 30.95 A ATOM 2307 N PRO A 294 117.913 67.302 33.732 1.00 29.07 A ATOM 2308 CD PRO A 294 116.811 66.630 34.437 1.00 30.66 A ATOM 2309 CA PRO A 294 118.777 66.331 33.051 1.00 28.43 A ATOM 2310 CB PRO A 294 118.013 65.019 33.196 1.00 36.12 A ATOM 2311 CG PRO A 294 117.307 65.185 34.516 1.00 34.80 A ATOM 2312 C PRO A 294 119.062 66.686 31.593 1.00 34.08 A ATOM 2313 O PRO A 294 120.059 66.245 31.042 1.00 37.55 A ATOM 2314 N SER A 295 118.206 67.496 30.970 1.00 31.59 A ATOM 2315 CA SER A 295 118.412 67.895 29.570 1.00 32.05 A ATOM 2316 CB SER A 295 117.053 68.031 28.827 1.00 37.77 A ATOM 2317 OG SER A 295 116.413 66.791 28.542 1.00 38.35 A ATOM 2318 C SER A 295 119.141 69.246 29.412 1.00 33.12 A ATOM 2319 O SER A 295 119.543 69.592 28.310 1.00 27.93 A ATOM 2320 N ASP A 296 119.310 70.014 30.490 1.00 26.80 A ATOM 2321 CA ASP A 296 119.913 71.328 30.352 1.00 30.74 A ATOM 2322 CB ASP A 296 118.782 72.415 30.256 1.00 27.90 A ATOM 2323 CG ASP A 296 117.839 72.252 28.986 1.00 41.52 A ATOM 2324 OD1 ASP A 296 118.246 72.564 27.834 1.00 38.56 A ATOM 2325 OD2 ASP A 296 116.655 71.816 29.121 1.00 44.60 A ATOM 2326 C ASP A 296 120.862 71.604 31.525 1.00 31.76 A ATOM 2327 O ASP A 296 120.426 71.809 32.661 1.00 31.22 A ATOM 2328 N HIS A 297 122.161 71.613 31.240 1.00 27.39 A ATOM 2329 CA HIS A 297 123.221 71.862 32.231 1.00 31.02 A ATOM 2330 CB HIS A 297 124.562 72.043 31.514 1.00 39.25 A ATOM 2331 CG HIS A 297 125.466 70.858 31.577 1.00 47.23 A ATOM 2332 CD2 HIS A 297 126.818 70.762 31.501 1.00 46.79 A ATOM 2333 ND1 HIS A 297 125.005 69.597 31.863 1.00 48.20 A ATOM 2334 CE1 HIS A 297 126.036 68.777 31.990 1.00 54.99 A ATOM 2335 NE2 HIS A 297 127.146 69.462 31.778 1.00 46.54 A ATOM 2336 C HIS A 297 122.999 73.125 33.043 1.00 27.48 A ATOM 2337 O HIS A 297 123.412 73.224 34.203 1.00 28.00 A ATOM 2338 N GLN A 298 122.396 74.117 32.401 1.00 22.60 A ATOM 2339 CA GLN A 298 122.174 75.396 33.046 1.00 25.08 A ATOM 2340 CB GLN A 298 121.569 76.409 32.065 1.00 30.41 A ATOM 2341 CG GLN A 298 122.332 76.669 30.783 1.00 34.42 A ATOM 2342 CD GLN A 298 121.872 75.791 29.603 1.00 37.26 A ATOM 2343 OE1 GLN A 298 121.932 76.217 28.444 1.00 36.98 A ATOM 2344 NE2 GLN A 298 121.429 74.558 29.897 1.00 32.64 A ATOM 2345 C GLN A 298 121.276 75.302 34.280 1.00 26.28 A ATOM 2346 O GLN A 298 121.322 76.182 35.129 1.00 23.86 A ATOM 2347 N GLU A 299 120.448 74.263 34.374 1.00 22.71 A ATOM 2348 CA GLU A 299 119.556 74.107 35.525 1.00 29.56 A ATOM 2349 CB GLU A 299 118.247 73.497 35.081 1.00 27.09 A ATOM 2350 CG GLU A 299 117.445 74.443 34.288 1.00 42.75 A ATOM 2351 CD GLU A 299 116.372 73.723 33.574 1.00 52.61 A ATOM 2352 OE1 GLU A 299 115.342 73.415 34.208 1.00 64.24 A ATOM 2353 OE2 GLU A 299 116.565 73.443 32.377 1.00 59.69 A ATOM 2354 C GLU A 299 120.251 73.185 36.491 1.00 30.34 A ATOM 2355 O GLU A 299 119.841 72.042 36.706 1.00 25.19 A ATOM 2356 N LEU A 300 121.289 73.724 37.099 1.00 26.72 A ATOM 2357 CA LEU A 300 122.164 72.960 37.960 1.00 26.16 A ATOM 2358 CB LEU A 300 123.621 73.384 37.693 1.00 24.26 A ATOM 2359 CG LEU A 300 124.040 74.875 37.817 1.00 23.41 A ATOM 2360 CD1 LEU A 300 122.894 75.782 38.110 1.00 13.62 A ATOM 2361 CD2 LEU A 300 125.064 75.023 38.845 1.00 23.86 A ATOM 2362 C LEU A 300 121.930 73.005 39.439 1.00 31.66 A ATOM 2363 O LEU A 300 122.685 72.360 40.165 1.00 24.27 A ATOM 2364 N ASN A 301 120.899 73.717 39.895 1.00 20.86 A ATOM 2365 CA ASN A 301 120.674 73.844 41.335 1.00 27.51 A ATOM 2366 CB ASN A 301 119.685 74.974 41.629 1.00 27.49 A ATOM 2367 CG ASN A 301 120.338 76.367 41.606 1.00 41.50 A ATOM 2368 OD1 ASN A 301 121.524 76.531 41.948 1.00 42.07 A ATOM 2369 ND2 ASN A 301 119.546 77.386 41.248 1.00 40.89 A ATOM 2370 C ASN A 301 120.139 72.561 41.946 1.00 27.36 A ATOM 2371 O ASN A 301 119.478 71.775 41.255 1.00 20.70 A ATOM 2372 N LEU A 302 120.455 72.338 43.227 1.00 28.60 A ATOM 2373 CA LEU A 302 119.962 71.168 43.945 1.00 24.52 A ATOM 2374 CB LEU A 302 121.038 70.593 44.894 1.00 29.03 A ATOM 2375 CG LEU A 302 120.446 69.605 45.935 1.00 27.91 A ATOM 2376 CD1 LEU A 302 119.494 68.711 45.254 1.00 18.13 A ATOM 2377 CD2 LEU A 302 121.464 68.809 46.627 1.00 28.47 A ATOM 2378 C LEU A 302 118.742 71.586 44.767 1.00 21.88 A ATOM 2379 O LEU A 302 118.888 72.203 45.817 1.00 20.14 A ATOM 2380 N ASP A 303 117.540 71.265 44.306 1.00 18.15 A ATOM 2381 CA ASP A 303 116.335 71.611 45.095 1.00 29.52 A ATOM 2382 CB ASP A 303 115.472 72.630 44.334 1.00 25.17 A ATOM 2383 CG ASP A 303 115.065 72.121 42.996 1.00 37.89 A ATOM 2384 OD1 ASP A 303 115.528 71.037 42.637 1.00 54.39 A ATOM 2385 OD2 ASP A 303 114.298 72.780 42.279 1.00 57.27 A ATOM 2386 C ASP A 303 115.580 70.289 45.373 1.00 22.29 A ATOM 2387 O ASP A 303 114.347 70.216 45.577 1.00 22.75 A ATOM 2388 N VAL A 304 116.382 69.240 45.425 1.00 21.19 A ATOM 2389 CA VAL A 304 115.925 67.870 45.624 1.00 25.10 A ATOM 2390 CB VAL A 304 116.935 66.930 44.914 1.00 21.32 A ATOM 2391 CG1 VAL A 304 118.001 66.444 45.851 1.00 13.87 A ATOM 2392 CG2 VAL A 304 116.235 65.842 44.282 1.00 42.05 A ATOM 2393 C VAL A 304 115.770 67.499 47.102 1.00 19.73 A ATOM 2394 O VAL A 304 116.219 68.242 47.961 1.00 19.32 A ATOM 2395 N SER A 305 115.136 66.360 47.402 1.00 21.55 A ATOM 2396 CA SER A 305 114.969 65.904 48.794 1.00 24.92 A ATOM 2397 CB SER A 305 114.202 64.572 48.838 1.00 31.82 A ATOM 2398 OG SER A 305 112.797 64.716 48.530 1.00 45.40 A ATOM 2399 C SER A 305 116.366 65.696 49.401 1.00 32.11 A ATOM 2400 O SER A 305 117.187 64.961 48.836 1.00 19.54 A ATOM 2401 N LEU A 306 116.649 66.330 50.535 1.00 25.35 A ATOM 2402 CA LEU A 306 117.962 66.173 51.161 1.00 30.33 A ATOM 2403 CB LEU A 306 118.422 67.488 51.831 1.00 35.23 A ATOM 2404 CG LEU A 306 118.886 68.694 50.987 1.00 33.58 A ATOM 2405 CD1 LEU A 306 119.870 68.352 49.838 1.00 29.73 A ATOM 2406 CD2 LEU A 306 117.665 69.257 50.434 1.00 39.98 A ATOM 2407 C LEU A 306 117.943 65.050 52.208 1.00 37.07 A ATOM 2408 O LEU A 306 116.874 64.515 52.547 1.00 34.41 A ATOM 2409 N GLN A 307 119.107 64.670 52.722 1.00 37.78 A ATOM 2410 CA GLN A 307 119.102 63.615 53.734 1.00 47.24 A ATOM 2411 CB GLN A 307 120.507 63.110 54.035 1.00 52.95 A ATOM 2412 CG GLN A 307 120.931 61.932 53.174 1.00 64.46 A ATOM 2413 CD GLN A 307 121.481 62.371 51.846 1.00 70.87 A ATOM 2414 OE1 GLN A 307 122.341 63.253 51.785 1.00 76.28 A ATOM 2415 NE2 GLN A 307 121.001 61.755 50.767 1.00 77.08 A ATOM 2416 C GLN A 307 118.482 64.115 55.021 1.00 42.93 A ATOM 2417 O GLN A 307 118.665 65.308 55.340 1.00 42.42 A ATOM 2418 OXT GLN A 307 117.838 63.294 55.699 1.00 44.41 A ATOM 2419 CB ALA B 1 64.181 107.666 4.123 1.00 39.20 B ATOM 2420 C ALA B 1 62.836 105.816 3.113 1.00 41.03 B ATOM 2421 O ALA B 1 61.659 105.713 3.477 1.00 42.08 B ATOM 2422 N ALA B 1 62.413 108.231 2.458 1.00 40.18 B ATOM 2423 CA ALA B 1 63.447 107.201 2.861 1.00 43.96 B ATOM 2424 N ILE B 2 63.636 104.759 2.923 1.00 39.63 B ATOM 2425 CA ILE B 2 63.175 103.383 3.141 1.00 37.01 B ATOM 2426 CB ILE B 2 64.245 102.349 2.700 1.00 32.57 B ATOM 2427 CG2 ILE B 2 63.775 100.936 3.064 1.00 35.80 B ATOM 2428 CG1 ILE B 2 64.457 102.422 1.178 1.00 34.01 B ATOM 2429 CD1 ILE B 2 65.479 101.372 0.650 1.00 31.21 B ATOM 2430 C ILE B 2 62.831 103.151 4.633 1.00 38.27 B ATOM 2431 O ILE B 2 63.565 103.577 5.528 1.00 32.71 B ATOM 2432 N SER B 3 61.714 102.486 4.897 1.00 30.65 B ATOM 2433 CA SER B 3 61.316 102.226 6.272 1.00 26.19 B ATOM 2434 CB SER B 3 60.245 103.236 6.689 1.00 31.79 B ATOM 2435 OG SER B 3 59.060 103.020 5.926 1.00 27.35 B ATOM 2436 C SER B 3 60.744 100.826 6.435 1.00 30.38 B ATOM 2437 O SER B 3 60.495 100.132 5.446 1.00 28.89 B ATOM 2438 N CYS B 4 60.559 100.410 7.690 1.00 27.89 B ATOM 2439 CA CYS B 4 59.941 99.127 8.003 1.00 27.29 B ATOM 2440 C CYS B 4 58.609 99.528 8.600 1.00 26.13 B ATOM 2441 O CYS B 4 58.446 100.666 9.061 1.00 29.64 B ATOM 2442 CB CYS B 4 60.731 98.328 9.056 1.00 27.46 B ATOM 2443 SG CYS B 4 62.214 97.531 8.369 1.00 27.76 B ATOM 2444 N GLY B 5 57.648 98.622 8.561 1.00 22.65 B ATOM 2445 CA GLY B 5 56.366 98.916 9.155 1.00 23.57 B ATOM 2446 C GLY B 5 56.452 98.570 10.643 1.00 24.00 B ATOM 2447 O GLY B 5 57.504 98.199 11.181 1.00 23.18 B ATOM 2448 N SER B 6 55.322 98.698 11.313 1.00 21.65 B ATOM 2449 CA SER B 6 55.204 98.441 12.733 1.00 22.23 B ATOM 2450 CB SER B 6 53.722 98.511 13.098 1.00 27.49 B ATOM 2451 OG SER B 6 53.543 98.605 14.483 1.00 33.82 B ATOM 2452 C SER B 6 55.785 97.062 13.091 1.00 26.45 B ATOM 2453 O SER B 6 55.489 96.081 12.439 1.00 22.14 B ATOM 2454 N PRO B 7 56.639 96.980 14.122 1.00 26.74 B ATOM 2455 CD PRO B 7 57.230 98.026 14.973 1.00 25.89 B ATOM 2456 CA PRO B 7 57.191 95.661 14.468 1.00 25.01 B ATOM 2457 CB PRO B 7 58.175 95.984 15.592 1.00 22.52 B ATOM 2458 CG PRO B 7 57.589 97.228 16.232 1.00 26.49 B ATOM 2459 C PRO B 7 56.133 94.627 14.894 1.00 27.04 B ATOM 2460 O PRO B 7 55.061 94.961 15.414 1.00 24.19 B ATOM 2461 N PRO B 8 56.439 93.345 14.700 1.00 24.37 B ATOM 2462 CD PRO B 8 57.540 92.754 13.936 1.00 26.75 B ATOM 2463 CA PRO B 8 55.431 92.366 15.099 1.00 25.28 B ATOM 2464 CB PRO B 8 55.974 91.048 14.538 1.00 31.15 B ATOM 2465 CG PRO B 8 57.401 91.314 14.245 1.00 33.33 B ATOM 2466 C PRO B 8 55.228 92.382 16.613 1.00 30.70 B ATOM 2467 O PRO B 8 56.180 92.527 17.364 1.00 31.22 B ATOM 2468 N PRO B 9 53.971 92.314 17.074 1.00 30.39 B ATOM 2469 CD PRO B 9 52.724 92.280 16.275 1.00 37.82 B ATOM 2470 CA PRO B 9 53.686 92.322 18.518 1.00 32.22 B ATOM 2471 CB PRO B 9 52.155 92.415 18.589 1.00 31.66 B ATOM 2472 CG PRO B 9 51.705 91.731 17.265 1.00 31.37 B ATOM 2473 C PRO B 9 54.190 91.062 19.209 1.00 26.54 B ATOM 2474 O PRO B 9 54.542 90.072 18.563 1.00 23.13 B ATOM 2475 N ILE B 10 54.214 91.111 20.526 1.00 25.96 B ATOM 2476 CA ILE B 10 54.651 89.969 21.302 1.00 34.36 B ATOM 2477 CB ILE B 10 56.150 90.068 21.770 1.00 24.92 B ATOM 2478 CG2 ILE B 10 56.398 91.363 22.562 1.00 24.04 B ATOM 2479 CG1 ILE B 10 56.491 88.795 22.581 1.00 30.43 B ATOM 2480 CD1 ILE B 10 57.991 88.536 22.813 1.00 24.83 B ATOM 2481 C ILE B 10 53.753 89.810 22.511 1.00 33.31 B ATOM 2482 O ILE B 10 53.743 90.647 23.412 1.00 32.83 B ATOM 2483 N LEU B 11 52.992 88.724 22.525 1.00 30.71 B ATOM 2484 CA LEU B 11 52.108 88.483 23.659 1.00 34.63 B ATOM 2485 CB LEU B 11 51.217 87.277 23.365 1.00 36.50 B ATOM 2486 CG LEU B 11 50.279 87.435 22.161 1.00 41.37 B ATOM 2487 CD1 LEU B 11 49.708 86.073 21.769 1.00 42.99 B ATOM 2488 CD2 LEU B 11 49.142 88.425 22.495 1.00 39.65 B ATOM 2489 C LEU B 11 52.912 88.247 24.946 1.00 33.29 B ATOM 2490 O LEU B 11 53.905 87.517 24.948 1.00 28.06 B ATOM 2491 N ASN B 12 52.463 88.872 26.032 1.00 31.32 B ATOM 2492 CA ASN B 12 53.086 88.753 27.328 1.00 30.29 B ATOM 2493 CB ASN B 12 53.025 87.303 27.802 1.00 32.27 B ATOM 2494 CG ASN B 12 51.612 86.875 28.083 1.00 38.86 B ATOM 2495 OD1 ASN B 12 50.917 87.526 28.864 1.00 38.55 B ATOM 2496 ND2 ASN B 12 51.161 85.805 27.431 1.00 34.66 B ATOM 2497 C ASN B 12 54.510 89.250 27.371 1.00 32.36 B ATOM 2498 O ASN B 12 55.277 88.858 28.239 1.00 32.55 B ATOM 2499 N GLY B 13 54.849 90.130 26.439 1.00 28.46 B ATOM 2500 CA GLY B 13 56.187 90.671 26.400 1.00 28.72 B ATOM 2501 C GLY B 13 56.147 92.166 26.169 1.00 29.82 B ATOM 2502 O GLY B 13 55.075 92.780 26.153 1.00 34.03 B ATOM 2503 N ARG B 14 57.324 92.742 25.983 1.00 28.15 B ATOM 2504 CA ARG B 14 57.486 94.166 25.739 1.00 31.15 B ATOM 2505 CB ARG B 14 58.198 94.882 26.897 1.00 34.62 B ATOM 2506 CG ARG B 14 57.388 95.196 28.116 1.00 41.44 B ATOM 2507 CD ARG B 14 58.240 95.962 29.112 1.00 42.08 B ATOM 2508 NE ARG B 14 57.526 96.080 30.373 1.00 49.55 B ATOM 2509 CZ ARG B 14 58.023 96.595 31.487 1.00 48.40 B ATOM 2510 NH1 ARG B 14 59.261 97.065 31.509 1.00 40.73 B ATOM 2511 NH2 ARG B 14 57.276 96.602 32.593 1.00 56.30 B ATOM 2512 C ARG B 14 58.409 94.342 24.567 1.00 23.56 B ATOM 2513 O ARG B 14 59.232 93.480 24.280 1.00 23.51 B ATOM 2514 N ILE B 15 58.319 95.516 23.955 1.00 27.48 B ATOM 2515 CA ILE B 15 59.171 95.893 22.841 1.00 26.75 B ATOM 2516 CB ILE B 15 58.345 96.176 21.580 1.00 26.32 B ATOM 2517 CG2 ILE B 15 59.250 96.815 20.497 1.00 29.30 B ATOM 2518 CG1 ILE B 15 57.656 94.902 21.122 1.00 30.62 B ATOM 2519 CD1 ILE B 15 56.760 95.100 19.889 1.00 35.23 B ATOM 2520 C ILE B 15 59.767 97.212 23.279 1.00 26.59 B ATOM 2521 O ILE B 15 59.050 98.050 23.818 1.00 30.94 B ATOM 2522 N SER B 16 61.055 97.409 23.036 1.00 23.15 B ATOM 2523 CA SER B 16 61.709 98.654 23.393 1.00 32.61 B ATOM 2524 CB SER B 16 63.187 98.567 23.057 1.00 29.32 B ATOM 2525 OG SER B 16 63.359 98.151 21.717 1.00 35.31 B ATOM 2526 C SER B 16 61.082 99.839 22.639 1.00 41.27 B ATOM 2527 O SER B 16 60.466 99.674 21.576 1.00 36.78 B ATOM 2528 N TYR B 17 61.260 101.035 23.193 1.00 42.89 B ATOM 2529 CA TYR B 17 60.719 102.267 22.624 1.00 46.29 B ATOM 2530 CB TYR B 17 60.932 103.436 23.623 1.00 44.99 B ATOM 2531 CG TYR B 17 60.026 103.380 24.865 1.00 47.02 B ATOM 2532 CD1 TYR B 17 60.510 103.694 26.151 1.00 49.03 B ATOM 2533 CE1 TYR B 17 59.664 103.655 27.283 1.00 48.52 B ATOM 2534 CD2 TYR B 17 58.686 103.025 24.748 1.00 51.67 B ATOM 2535 CE2 TYR B 17 57.833 102.974 25.861 1.00 53.32 B ATOM 2536 CZ TYR B 17 58.319 103.292 27.122 1.00 56.82 B ATOM 2537 OH TYR B 17 57.430 103.259 28.190 1.00 55.53 B ATOM 2538 C TYR B 17 61.397 102.551 21.285 1.00 46.15 B ATOM 2539 O TYR B 17 62.600 102.375 21.146 1.00 50.00 B ATOM 2540 N TYR B 18 60.623 102.952 20.281 1.00 46.05 B ATOM 2541 CA TYR B 18 61.204 103.270 18.975 1.00 44.93 B ATOM 2542 CB TYR B 18 61.076 102.076 18.010 1.00 37.78 B ATOM 2543 CG TYR B 18 59.645 101.669 17.711 1.00 37.10 B ATOM 2544 CD1 TYR B 18 58.890 102.343 16.750 1.00 31.24 B ATOM 2545 CE1 TYR B 18 57.573 101.980 16.501 1.00 34.43 B ATOM 2546 CD2 TYR B 18 59.040 100.622 18.415 1.00 34.57 B ATOM 2547 CE2 TYR B 18 57.730 100.255 18.184 1.00 36.06 B ATOM 2548 CZ TYR B 18 57.000 100.939 17.218 1.00 35.02 B ATOM 2549 OH TYR B 18 55.706 100.565 16.967 1.00 33.22 B ATOM 2550 C TYR B 18 60.524 104.514 18.375 1.00 40.62 B ATOM 2551 O TYR B 18 59.356 104.784 18.632 1.00 40.57 B ATOM 2552 N SER B 19 61.280 105.260 17.586 1.00 42.39 B ATOM 2553 CA SER B 19 60.786 106.464 16.931 1.00 49.17 B ATOM 2554 CB SER B 19 61.922 107.472 16.789 1.00 49.59 B ATOM 2555 OG SER B 19 63.070 106.843 16.237 1.00 54.17 B ATOM 2556 C SER B 19 60.213 106.155 15.540 1.00 51.20 B ATOM 2557 O SER B 19 60.569 105.165 14.900 1.00 42.62 B ATOM 2558 N THR B 20 59.347 107.041 15.073 1.00 48.91 B ATOM 2559 CA THR B 20 58.706 106.898 13.783 1.00 49.40 B ATOM 2560 CB THR B 20 57.166 107.002 13.991 1.00 52.73 B ATOM 2561 OG1 THR B 20 56.483 106.279 12.968 1.00 60.25 B ATOM 2562 CG2 THR B 20 56.714 108.456 13.943 1.00 51.71 B ATOM 2563 C THR B 20 59.222 108.022 12.844 1.00 47.48 B ATOM 2564 O THR B 20 59.460 109.147 13.280 1.00 50.56 B ATOM 2565 N PRO B 21 59.427 107.720 11.551 1.00 46.52 B ATOM 2566 CD PRO B 21 59.801 108.745 10.551 1.00 44.33 B ATOM 2567 CA PRO B 21 59.204 106.417 10.909 1.00 43.20 B ATOM 2568 CB PRO B 21 59.137 106.769 9.422 1.00 43.49 B ATOM 2569 CG PRO B 21 60.103 107.918 9.305 1.00 44.19 B ATOM 2570 C PRO B 21 60.342 105.456 11.248 1.00 37.71 B ATOM 2571 O PRO B 21 61.393 105.891 11.674 1.00 38.42 B ATOM 2572 N THR B 22 60.123 104.155 11.067 1.00 40.00 B ATOM 2573 CA THR B 22 61.139 103.150 11.382 1.00 37.29 B ATOM 2574 CB THR B 22 60.521 101.715 11.578 1.00 33.63 B ATOM 2575 OG1 THR B 22 59.497 101.719 12.600 1.00 36.55 B ATOM 2576 CG2 THR B 22 61.626 100.734 11.963 1.00 26.59 B ATOM 2577 C THR B 22 62.143 103.079 10.221 1.00 35.94 B ATOM 2578 O THR B 22 61.851 102.484 9.183 1.00 33.29 B ATOM 2579 N ALA B 23 63.326 103.663 10.410 1.00 33.77 B ATOM 2580 CA ALA B 23 64.367 103.677 9.380 1.00 30.19 B ATOM 2581 CB ALA B 23 65.314 104.852 9.615 1.00 28.90 B ATOM 2582 C ALA B 23 65.192 102.399 9.300 1.00 30.98 B ATOM 2583 O ALA B 23 65.331 101.693 10.284 1.00 23.97 B ATOM 2584 N VAL B 24 65.736 102.127 8.112 1.00 27.61 B ATOM 2585 CA VAL B 24 66.591 100.982 7.874 1.00 26.92 B ATOM 2586 CB VAL B 24 67.197 101.042 6.460 1.00 29.41 B ATOM 2587 CG1 VAL B 24 68.357 100.043 6.326 1.00 28.58 B ATOM 2588 CG2 VAL B 24 66.107 100.729 5.430 1.00 26.92 B ATOM 2589 C VAL B 24 67.707 101.091 8.898 1.00 32.79 B ATOM 2590 O VAL B 24 68.266 102.166 9.077 1.00 26.10 B ATOM 2591 N GLY B 25 68.026 100.000 9.586 1.00 28.01 B ATOM 2592 CA GLY B 25 69.070 100.081 10.596 1.00 31.93 B ATOM 2593 C GLY B 25 68.516 100.210 12.007 1.00 34.29 B ATOM 2594 O GLY B 25 69.251 100.080 12.966 1.00 28.44 B ATOM 2595 N THR B 26 67.227 100.486 12.148 1.00 26.99 B ATOM 2596 CA THR B 26 66.650 100.568 13.474 1.00 29.37 B ATOM 2597 CB THR B 26 65.179 100.994 13.403 1.00 30.78 B ATOM 2598 OG1 THR B 26 65.111 102.295 12.808 1.00 26.87 B ATOM 2599 CG2 THR B 26 64.524 101.000 14.833 1.00 23.56 B ATOM 2600 C THR B 26 66.713 99.183 14.136 1.00 32.07 B ATOM 2601 O THR B 26 66.462 98.171 13.473 1.00 28.44 B ATOM 2602 N VAL B 27 67.056 99.143 15.429 1.00 28.90 B ATOM 2603 CA VAL B 27 67.124 97.891 16.200 1.00 29.71 B ATOM 2604 CB VAL B 27 68.507 97.703 16.858 1.00 36.67 B ATOM 2605 CG1 VAL B 27 68.477 96.507 17.808 1.00 31.87 B ATOM 2606 CG2 VAL B 27 69.554 97.478 15.793 1.00 32.00 B ATOM 2607 C VAL B 27 66.054 97.946 17.292 1.00 26.09 B ATOM 2608 O VAL B 27 65.961 98.921 18.029 1.00 28.74 B ATOM 2609 N ILE B 28 65.230 96.913 17.349 1.00 28.74 B ATOM 2610 CA ILE B 28 64.126 96.780 18.294 1.00 34.25 B ATOM 2611 CB ILE B 28 62.802 96.400 17.552 1.00 38.10 B ATOM 2612 CG2 ILE B 28 61.752 95.929 18.516 1.00 49.78 B ATOM 2613 CG1 ILE B 28 62.260 97.598 16.808 1.00 46.71 B ATOM 2614 CD1 ILE B 28 62.252 98.826 17.612 1.00 40.93 B ATOM 2615 C ILE B 28 64.491 95.619 19.223 1.00 38.36 B ATOM 2616 O ILE B 28 65.063 94.626 18.769 1.00 29.90 B ATOM 2617 N ARG B 29 64.134 95.724 20.503 1.00 30.42 B ATOM 2618 CA ARG B 29 64.470 94.673 21.458 1.00 32.43 B ATOM 2619 CB ARG B 29 65.468 95.242 22.461 1.00 38.54 B ATOM 2620 CG ARG B 29 66.234 94.231 23.273 1.00 56.74 B ATOM 2621 CD ARG B 29 67.479 94.939 23.821 1.00 68.43 B ATOM 2622 NE ARG B 29 68.210 95.573 22.722 1.00 77.31 B ATOM 2623 CZ ARG B 29 69.134 94.960 21.983 1.00 81.82 B ATOM 2624 NH1 ARG B 29 69.454 93.693 22.237 1.00 82.00 B ATOM 2625 NH2 ARG B 29 69.723 95.603 20.976 1.00 82.81 B ATOM 2626 C ARG B 29 63.222 94.132 22.168 1.00 26.06 B ATOM 2627 O ARG B 29 62.432 94.884 22.704 1.00 20.11 B ATOM 2628 N TYR B 30 63.032 92.823 22.133 1.00 22.95 B ATOM 2629 CA TYR B 30 61.886 92.206 22.787 1.00 31.30 B ATOM 2630 CB TYR B 30 61.299 91.096 21.905 1.00 28.61 B ATOM 2631 CG TYR B 30 60.647 91.547 20.605 1.00 29.37 B ATOM 2632 CD1 TYR B 30 61.389 92.135 19.579 1.00 24.77 B ATOM 2633 CE1 TYR B 30 60.781 92.553 18.387 1.00 19.11 B ATOM 2634 CD2 TYR B 30 59.282 91.378 20.403 1.00 29.03 B ATOM 2635 CE2 TYR B 30 58.674 91.785 19.215 1.00 26.35 B ATOM 2636 CZ TYR B 30 59.429 92.379 18.216 1.00 23.41 B ATOM 2637 OH TYR B 30 58.793 92.836 17.083 1.00 26.05 B ATOM 2638 C TYR B 30 62.340 91.579 24.126 1.00 28.93 B ATOM 2639 O TYR B 30 63.497 91.168 24.283 1.00 24.49 B ATOM 2640 N SER B 31 61.418 91.488 25.067 1.00 26.50 B ATOM 2641 CA SER B 31 61.697 90.903 26.369 1.00 24.95 B ATOM 2642 CB SER B 31 62.304 91.946 27.308 1.00 21.32 B ATOM 2643 OG SER B 31 61.426 93.028 27.483 1.00 26.55 B ATOM 2644 C SER B 31 60.388 90.378 26.954 1.00 29.25 B ATOM 2645 O SER B 31 59.287 90.780 26.529 1.00 22.45 B ATOM 2646 N CYS B 32 60.515 89.484 27.930 1.00 27.99 B ATOM 2647 CA CYS B 32 59.364 88.868 28.606 1.00 32.41 B ATOM 2648 C CYS B 32 59.371 89.122 30.121 1.00 38.37 B ATOM 2649 O CYS B 32 60.431 89.311 30.719 1.00 37.82 B ATOM 2650 CB CYS B 32 59.371 87.347 28.400 1.00 30.70 B ATOM 2651 SG CYS B 32 59.450 86.770 26.677 1.00 32.11 B ATOM 2652 N SER B 33 58.178 89.101 30.717 1.00 51.37 B ATOM 2653 CA SER B 33 57.995 89.265 32.163 1.00 56.15 B ATOM 2654 CB SER B 33 56.544 89.013 32.552 1.00 60.18 B ATOM 2655 OG SER B 33 55.675 89.714 31.672 1.00 66.23 B ATOM 2656 C SER B 33 58.859 88.260 32.894 1.00 57.27 B ATOM 2657 O SER B 33 59.535 87.427 32.274 1.00 60.30 B ATOM 2658 N GLY B 34 58.805 88.290 34.219 1.00 53.29 B ATOM 2659 CA GLY B 34 59.662 87.391 34.976 1.00 47.70 B ATOM 2660 C GLY B 34 59.278 85.922 34.987 1.00 44.48 B ATOM 2661 O GLY B 34 60.129 85.033 35.135 1.00 38.34 B ATOM 2662 N THR B 35 57.993 85.660 34.818 1.00 40.51 B ATOM 2663 CA THR B 35 57.524 84.290 34.860 1.00 40.76 B ATOM 2664 CB THR B 35 56.225 84.239 35.644 1.00 41.73 B ATOM 2665 OG1 THR B 35 55.258 85.077 35.014 1.00 48.51 B ATOM 2666 CG2 THR B 35 56.468 84.761 37.057 1.00 44.89 B ATOM 2667 C THR B 35 57.369 83.691 33.470 1.00 39.51 B ATOM 2668 O THR B 35 56.786 82.613 33.286 1.00 31.97 B ATOM 2669 N PHE B 36 57.924 84.399 32.491 1.00 35.56 B ATOM 2670 CA PHE B 36 57.873 83.955 31.112 1.00 31.01 B ATOM 2671 CB PHE B 36 57.146 84.967 30.250 1.00 33.05 B ATOM 2672 CG PHE B 36 55.673 84.918 30.396 1.00 35.23 B ATOM 2673 CD1 PHE B 36 55.040 85.573 31.444 1.00 35.53 B ATOM 2674 CD2 PHE B 36 54.909 84.204 29.483 1.00 31.53 B ATOM 2675 CE1 PHE B 36 53.663 85.497 31.570 1.00 37.58 B ATOM 2676 CE2 PHE B 36 53.549 84.126 29.604 1.00 32.60 B ATOM 2677 CZ PHE B 36 52.918 84.769 30.638 1.00 32.38 B ATOM 2678 C PHE B 36 59.276 83.798 30.577 1.00 32.83 B ATOM 2679 O PHE B 36 60.212 84.347 31.125 1.00 33.40 B ATOM 2680 N ARG B 37 59.427 83.049 29.498 1.00 30.99 B ATOM 2681 CA ARG B 37 60.741 82.896 28.916 1.00 29.69 B ATOM 2682 CB ARG B 37 61.201 81.458 29.083 1.00 30.62 B ATOM 2683 CG ARG B 37 61.442 81.072 30.541 1.00 35.61 B ATOM 2684 CD ARG B 37 62.492 81.992 31.177 1.00 39.39 B ATOM 2685 NE ARG B 37 62.303 82.044 32.629 1.00 49.28 B ATOM 2686 CZ ARG B 37 62.847 81.168 33.451 1.00 47.41 B ATOM 2687 NH1 ARG B 37 63.614 80.212 32.947 1.00 53.00 B ATOM 2688 NH2 ARG B 37 62.602 81.223 34.751 1.00 44.10 B ATOM 2689 C ARG B 37 60.713 83.280 27.439 1.00 32.05 B ATOM 2690 O ARG B 37 59.809 82.874 26.700 1.00 25.63 B ATOM 2691 N LEU B 38 61.706 84.050 27.011 1.00 23.96 B ATOM 2692 CA LEU B 38 61.802 84.470 25.621 1.00 30.62 B ATOM 2693 CB LEU B 38 62.655 85.738 25.508 1.00 23.25 B ATOM 2694 CG LEU B 38 62.739 86.365 24.105 1.00 28.16 B ATOM 2695 CD1 LEU B 38 61.376 86.948 23.659 1.00 20.01 B ATOM 2696 CD2 LEU B 38 63.753 87.486 24.132 1.00 32.19 B ATOM 2697 C LEU B 38 62.386 83.361 24.745 1.00 27.63 B ATOM 2698 O LEU B 38 63.447 82.793 25.036 1.00 27.98 B ATOM 2699 N ILE B 39 61.651 83.017 23.691 1.00 30.18 B ATOM 2700 CA ILE B 39 62.073 81.983 22.743 1.00 27.37 B ATOM 2701 CB ILE B 39 60.940 80.959 22.492 1.00 30.75 B ATOM 2702 CG2 ILE B 39 61.438 79.878 21.538 1.00 29.27 B ATOM 2703 CG1 ILE B 39 60.455 80.359 23.822 1.00 30.90 B ATOM 2704 CD1 ILE B 39 61.491 79.535 24.559 1.00 26.44 B ATOM 2705 C ILE B 39 62.403 82.668 21.418 1.00 29.53 B ATOM 2706 O ILE B 39 61.510 83.256 20.797 1.00 24.87 B ATOM 2707 N GLY B 40 63.676 82.609 20.998 1.00 21.97 B ATOM 2708 CA GLY B 40 64.084 83.239 19.751 1.00 23.62 B ATOM 2709 C GLY B 40 64.957 84.450 19.975 1.00 22.85 B ATOM 2710 O GLY B 40 65.065 84.921 21.104 1.00 21.42 B ATOM 2711 N GLU B 41 65.592 84.958 18.925 1.00 27.33 B ATOM 2712 CA GLU B 41 66.472 86.133 19.065 1.00 29.50 B ATOM 2713 CB GLU B 41 67.138 86.471 17.730 1.00 33.78 B ATOM 2714 CG GLU B 41 68.634 86.193 17.721 1.00 52.17 B ATOM 2715 CD GLU B 41 69.411 87.123 18.648 1.00 57.74 B ATOM 2716 OE1 GLU B 41 70.414 86.641 19.231 1.00 66.30 B ATOM 2717 OE2 GLU B 41 69.034 88.326 18.791 1.00 53.76 B ATOM 2718 C GLU B 41 65.667 87.333 19.541 1.00 30.40 B ATOM 2719 O GLU B 41 64.601 87.619 18.995 1.00 27.22 B ATOM 2720 N LYS B 42 66.197 88.049 20.528 1.00 27.86 B ATOM 2721 CA LYS B 42 65.538 89.215 21.135 1.00 32.03 B ATOM 2722 CB LYS B 42 66.171 89.495 22.504 1.00 37.19 B ATOM 2723 CG LYS B 42 67.610 89.990 22.379 1.00 43.78 B ATOM 2724 CD LYS B 42 68.196 90.536 23.674 1.00 54.68 B ATOM 2725 CE LYS B 42 68.055 89.538 24.812 1.00 62.51 B ATOM 2726 NZ LYS B 42 68.438 88.139 24.443 1.00 69.20 B ATOM 2727 C LYS B 42 65.586 90.530 20.331 1.00 32.32 B ATOM 2728 O LYS B 42 64.771 91.432 20.555 1.00 27.61 B ATOM 2729 N SER B 43 66.547 90.680 19.422 1.00 28.99 B ATOM 2730 CA SER B 43 66.611 91.946 18.672 1.00 33.61 B ATOM 2731 CB SER B 43 68.012 92.565 18.722 1.00 29.97 B ATOM 2732 OG SER B 43 68.478 92.606 20.047 1.00 47.21 B ATOM 2733 C SER B 43 66.273 91.770 17.224 1.00 28.57 B ATOM 2734 O SER B 43 66.765 90.841 16.588 1.00 32.11 B ATOM 2735 N LEU B 44 65.443 92.661 16.697 1.00 26.09 B ATOM 2736 CA LEU B 44 65.127 92.607 15.280 1.00 25.34 B ATOM 2737 CB LEU B 44 63.620 92.609 14.987 1.00 21.75 B ATOM 2738 CG LEU B 44 62.608 91.642 15.593 1.00 33.26 B ATOM 2739 CD1 LEU B 44 61.455 91.487 14.626 1.00 24.66 B ATOM 2740 CD2 LEU B 44 63.227 90.293 15.976 1.00 19.72 B ATOM 2741 C LEU B 44 65.738 93.863 14.694 1.00 27.39 B ATOM 2742 O LEU B 44 65.759 94.919 15.334 1.00 29.07 B ATOM 2743 N LEU B 45 66.201 93.740 13.456 1.00 26.79 B ATOM 2744 CA LEU B 45 66.854 94.812 12.727 1.00 26.17 B ATOM 2745 CB LEU B 45 68.202 94.303 12.213 1.00 25.36 B ATOM 2746 CG LEU B 45 69.343 95.281 11.950 1.00 35.90 B ATOM 2747 CD1 LEU B 45 70.263 94.668 10.905 1.00 31.78 B ATOM 2748 CD2 LEU B 45 68.853 96.627 11.519 1.00 39.62 B ATOM 2749 C LEU B 45 66.016 95.198 11.516 1.00 25.11 B ATOM 2750 O LEU B 45 65.568 94.320 10.761 1.00 20.94 B ATOM 2751 N CYS B 46 65.803 96.487 11.298 1.00 24.85 B ATOM 2752 CA CYS B 46 65.057 96.887 10.097 1.00 22.87 B ATOM 2753 C CYS B 46 66.106 96.897 8.976 1.00 29.24 B ATOM 2754 O CYS B 46 67.099 97.601 9.051 1.00 28.50 B ATOM 2755 CB CYS B 46 64.446 98.284 10.251 1.00 26.50 B ATOM 2756 SG CYS B 46 63.677 98.900 8.705 1.00 27.31 B ATOM 2757 N ILE B 47 65.877 96.106 7.943 1.00 24.65 B ATOM 2758 CA ILE B 47 66.817 95.991 6.842 1.00 28.64 B ATOM 2759 CB ILE B 47 67.412 94.572 6.871 1.00 30.17 B ATOM 2760 CG2 ILE B 47 68.114 94.258 5.601 1.00 42.28 B ATOM 2761 CG1 ILE B 47 68.341 94.458 8.070 1.00 40.16 B ATOM 2762 CD1 ILE B 47 69.121 93.190 8.107 1.00 53.27 B ATOM 2763 C ILE B 47 66.098 96.188 5.504 1.00 28.32 B ATOM 2764 O ILE B 47 64.874 96.332 5.466 1.00 24.72 B ATOM 2765 N THR B 48 66.853 96.238 4.413 1.00 24.30 B ATOM 2766 CA THR B 48 66.236 96.267 3.091 1.00 27.24 B ATOM 2767 CB THR B 48 66.215 97.672 2.405 1.00 31.04 B ATOM 2768 OG1 THR B 48 65.632 97.534 1.090 1.00 26.58 B ATOM 2769 CG2 THR B 48 67.627 98.250 2.271 1.00 23.59 B ATOM 2770 C THR B 48 67.048 95.280 2.254 1.00 26.55 B ATOM 2771 O THR B 48 68.276 95.371 2.173 1.00 27.30 B ATOM 2772 N LYS B 49 66.370 94.295 1.688 1.00 24.39 B ATOM 2773 CA LYS B 49 67.031 93.309 0.837 1.00 25.65 B ATOM 2774 CB LYS B 49 66.323 91.943 0.940 1.00 27.44 B ATOM 2775 CG LYS B 49 66.358 91.351 2.368 1.00 36.21 B ATOM 2776 CD LYS B 49 67.171 90.103 2.479 1.00 40.52 B ATOM 2777 CE LYS B 49 68.570 90.294 2.025 1.00 41.63 B ATOM 2778 NZ LYS B 49 69.314 89.069 2.403 1.00 46.47 B ATOM 2779 C LYS B 49 67.041 93.752 −0.632 1.00 33.01 B ATOM 2780 O LYS B 49 67.987 93.450 −1.353 1.00 28.70 B ATOM 2781 N ASP B 50 65.994 94.451 −1.083 1.00 26.02 B ATOM 2782 CA ASP B 50 65.933 94.859 −2.495 1.00 29.77 B ATOM 2783 CB ASP B 50 64.575 94.503 −3.108 1.00 28.99 B ATOM 2784 CG ASP B 50 63.439 95.221 −2.440 1.00 26.54 B ATOM 2785 OD1 ASP B 50 63.720 96.043 −1.562 1.00 25.74 B ATOM 2786 OD2 ASP B 50 62.262 94.969 −2.779 1.00 32.42 B ATOM 2787 C ASP B 50 66.200 96.327 −2.744 1.00 30.62 B ATOM 2788 O ASP B 50 66.037 96.794 −3.858 1.00 24.13 B ATOM 2789 N LYS B 51 66.610 97.050 −1.709 1.00 27.94 B ATOM 2790 CA LYS B 51 66.889 98.473 −1.824 1.00 31.18 B ATOM 2791 CB LYS B 51 68.014 98.742 −2.819 1.00 34.46 B ATOM 2792 CG LYS B 51 69.381 98.355 −2.297 1.00 41.85 B ATOM 2793 CD LYS B 51 70.447 98.960 −3.175 1.00 49.97 B ATOM 2794 CE LYS B 51 71.826 98.869 −2.564 1.00 59.90 B ATOM 2795 NZ LYS B 51 72.754 99.713 −3.366 1.00 67.70 B ATOM 2796 C LYS B 51 65.666 99.305 −2.186 1.00 30.87 B ATOM 2797 O LYS B 51 65.786 100.430 −2.634 1.00 28.68 B ATOM 2798 N VAL B 52 64.483 98.748 −1.992 1.00 26.95 B ATOM 2799 CA VAL B 52 63.263 99.501 −2.231 1.00 26.37 B ATOM 2800 CB VAL B 52 62.456 98.945 −3.402 1.00 27.69 B ATOM 2801 CG1 VAL B 52 61.123 99.695 −3.511 1.00 32.70 B ATOM 2802 CG2 VAL B 52 63.236 99.113 −4.679 1.00 32.13 B ATOM 2803 C VAL B 52 62.375 99.437 −1.000 1.00 30.79 B ATOM 2804 O VAL B 52 61.949 100.461 −0.491 1.00 26.76 B ATOM 2805 N ASP B 53 62.102 98.232 −0.512 1.00 26.86 B ATOM 2806 CA ASP B 53 61.210 98.074 0.642 1.00 26.94 B ATOM 2807 CB ASP B 53 60.156 96.999 0.318 1.00 42.02 B ATOM 2808 CG ASP B 53 59.285 97.356 −0.871 1.00 53.53 B ATOM 2809 OD1 ASP B 53 58.878 98.540 −0.943 1.00 63.13 B ATOM 2810 OD2 ASP B 53 58.964 96.476 −1.727 1.00 64.13 B ATOM 2811 C ASP B 53 62.006 97.651 1.888 1.00 25.00 B ATOM 2812 O ASP B 53 63.063 97.038 1.773 1.00 22.23 B ATOM 2813 N GLY B 54 61.490 97.959 3.072 1.00 20.64 B ATOM 2814 CA GLY B 54 62.170 97.578 4.293 1.00 24.10 B ATOM 2815 C GLY B 54 61.441 96.397 4.919 1.00 25.17 B ATOM 2816 O GLY B 54 60.237 96.266 4.728 1.00 25.23 B ATOM 2817 N THR B 55 62.169 95.517 5.605 1.00 23.87 B ATOM 2818 CA THR B 55 61.589 94.373 6.318 1.00 20.36 B ATOM 2819 CB THR B 55 61.679 93.051 5.518 1.00 27.74 B ATOM 2820 OG1 THR B 55 61.052 92.004 6.267 1.00 24.11 B ATOM 2821 CG2 THR B 55 63.151 92.669 5.212 1.00 21.92 B ATOM 2822 C THR B 55 62.371 94.156 7.600 1.00 22.54 B ATOM 2823 O THR B 55 63.535 94.526 7.675 1.00 24.57 B ATOM 2824 N TRP B 56 61.743 93.589 8.624 1.00 23.11 B ATOM 2825 CA TRP B 56 62.513 93.285 9.827 1.00 25.54 B ATOM 2826 CB TRP B 56 61.580 92.954 10.988 1.00 23.18 B ATOM 2827 CG TRP B 56 60.874 94.202 11.420 1.00 19.51 B ATOM 2828 CD2 TRP B 56 61.456 95.282 12.147 1.00 21.91 B ATOM 2829 CE2 TRP B 56 60.473 96.302 12.247 1.00 26.89 B ATOM 2830 CE3 TRP B 56 62.722 95.491 12.729 1.00 25.30 B ATOM 2831 CD1 TRP B 56 59.595 94.578 11.119 1.00 21.93 B ATOM 2832 NE1 TRP B 56 59.343 95.849 11.617 1.00 21.49 B ATOM 2833 CZ2 TRP B 56 60.713 97.521 12.895 1.00 26.71 B ATOM 2834 CZ3 TRP B 56 62.963 96.706 13.380 1.00 29.35 B ATOM 2835 CH2 TRP B 56 61.957 97.706 13.451 1.00 28.96 B ATOM 2836 C TRP B 56 63.335 92.075 9.384 1.00 28.11 B ATOM 2837 O TRP B 56 62.882 91.296 8.535 1.00 23.54 B ATOM 2838 N ASP B 57 64.535 91.909 9.926 1.00 20.44 B ATOM 2839 CA ASP B 57 65.401 90.812 9.470 1.00 25.81 B ATOM 2840 CB ASP B 57 66.885 91.113 9.761 1.00 30.15 B ATOM 2841 CG ASP B 57 67.234 91.045 11.255 1.00 35.84 B ATOM 2842 OD1 ASP B 57 66.319 91.161 12.102 1.00 23.31 B ATOM 2843 OD2 ASP B 57 68.443 90.889 11.581 1.00 41.06 B ATOM 2844 C ASP B 57 65.058 89.433 9.963 1.00 26.11 B ATOM 2845 O ASP B 57 65.634 88.455 9.486 1.00 28.90 B ATOM 2846 N LYS B 58 64.114 89.336 10.896 1.00 29.91 B ATOM 2847 CA LYS B 58 63.687 88.032 11.411 1.00 27.97 B ATOM 2848 CB LYS B 58 64.697 87.491 12.443 1.00 30.61 B ATOM 2849 CG LYS B 58 64.884 88.378 13.650 1.00 38.23 B ATOM 2850 CD LYS B 58 65.966 87.831 14.618 1.00 41.02 B ATOM 2851 CE LYS B 58 67.406 88.063 14.115 1.00 37.73 B ATOM 2852 NZ LYS B 58 67.830 89.511 14.119 1.00 29.19 B ATOM 2853 C LYS B 58 62.319 88.105 12.045 1.00 22.71 B ATOM 2854 O LYS B 58 61.795 89.188 12.311 1.00 26.33 B ATOM 2855 N PRO B 59 61.700 86.947 12.292 1.00 25.99 B ATOM 2856 CD PRO B 59 62.084 85.584 11.885 1.00 24.09 B ATOM 2857 CA PRO B 59 60.367 86.972 12.919 1.00 22.11 B ATOM 2858 CB PRO B 59 59.902 85.515 12.845 1.00 26.86 B ATOM 2859 CG PRO B 59 60.730 84.913 11.746 1.00 29.91 B ATOM 2860 C PRO B 59 60.509 87.419 14.369 1.00 30.21 B ATOM 2861 O PRO B 59 61.593 87.307 14.968 1.00 28.15 B ATOM 2862 N ALA B 60 59.433 87.924 14.951 1.00 25.43 B ATOM 2863 CA ALA B 60 59.516 88.330 16.339 1.00 26.37 B ATOM 2864 CB ALA B 60 58.260 89.089 16.742 1.00 26.63 B ATOM 2865 C ALA B 60 59.644 87.085 17.223 1.00 21.91 B ATOM 2866 O ALA B 60 59.104 86.068 16.914 1.00 22.47 B ATOM 2867 N PRO B 61 60.358 87.173 18.350 1.00 23.37 B ATOM 2868 CD PRO B 61 61.134 88.320 18.870 1.00 22.24 B ATOM 2869 CA PRO B 61 60.476 86.007 19.227 1.00 19.99 B ATOM 2870 CB PRO B 61 61.650 86.386 20.130 1.00 21.18 B ATOM 2871 CG PRO B 61 61.458 87.876 20.314 1.00 22.73 B ATOM 2872 C PRO B 61 59.151 85.933 20.024 1.00 27.42 B ATOM 2873 O PRO B 61 58.314 86.831 19.903 1.00 27.48 B ATOM 2874 N LYS B 62 58.960 84.893 20.834 1.00 21.73 B ATOM 2875 CA LYS B 62 57.737 84.770 21.648 1.00 26.90 B ATOM 2876 CB LYS B 62 56.880 83.576 21.187 1.00 32.90 B ATOM 2877 CG LYS B 62 56.318 83.743 19.779 1.00 39.12 B ATOM 2878 CD LYS B 62 55.638 82.502 19.258 1.00 48.29 B ATOM 2879 CE LYS B 62 55.142 82.741 17.828 1.00 54.55 B ATOM 2880 NZ LYS B 62 54.620 81.478 17.213 1.00 59.87 B ATOM 2881 C LYS B 62 58.050 84.601 23.133 1.00 30.68 B ATOM 2882 O LYS B 62 59.190 84.287 23.528 1.00 24.62 B ATOM 2883 N CYS B 63 57.039 84.843 23.958 1.00 25.15 B ATOM 2884 CA CYS B 63 57.171 84.675 25.405 1.00 27.27 B ATOM 2885 C CYS B 63 56.314 83.481 25.792 1.00 30.43 B ATOM 2886 O CYS B 63 55.111 83.454 25.515 1.00 30.82 B ATOM 2887 CB CYS B 63 56.646 85.903 26.149 1.00 25.60 B ATOM 2888 SG CYS B 63 57.682 87.384 25.922 1.00 31.81 B ATOM 2889 N GLU B 64 56.934 82.486 26.414 1.00 29.14 B ATOM 2890 CA GLU B 64 56.220 81.297 26.871 1.00 27.87 B ATOM 2891 CB GLU B 64 56.938 80.043 26.393 1.00 22.54 B ATOM 2892 CG GLU B 64 56.839 79.836 24.884 1.00 30.23 B ATOM 2893 CD GLU B 64 57.354 78.472 24.471 1.00 25.42 B ATOM 2894 OE1 GLU B 64 58.146 77.879 25.221 1.00 28.63 B ATOM 2895 OE2 GLU B 64 56.993 77.994 23.396 1.00 24.45 B ATOM 2896 C GLU B 64 56.172 81.301 28.394 1.00 27.43 B ATOM 2897 O GLU B 64 57.189 81.564 29.036 1.00 28.45 B ATOM 2898 N TYR B 65 55.003 81.039 28.981 1.00 30.82 B ATOM 2899 CA TYR B 65 54.898 81.016 30.449 1.00 26.71 B ATOM 2900 CB TYR B 65 53.474 80.638 30.881 1.00 24.67 B ATOM 2901 CG TYR B 65 53.222 80.754 32.382 1.00 30.61 B ATOM 2902 CD1 TYR B 65 53.558 81.915 33.078 1.00 37.93 B ATOM 2903 CE1 TYR B 65 53.369 82.013 34.464 1.00 37.10 B ATOM 2904 CD2 TYR B 65 52.681 79.689 33.102 1.00 29.91 B ATOM 2905 CE2 TYR B 65 52.481 79.765 34.477 1.00 32.04 B ATOM 2906 CZ TYR B 65 52.829 80.927 35.149 1.00 38.91 B ATOM 2907 OH TYR B 65 52.653 81.014 36.510 1.00 40.82 B ATOM 2908 C TYR B 65 55.931 79.969 30.908 1.00 26.37 B ATOM 2909 O TYR B 65 56.022 78.891 30.339 1.00 27.39 B ATOM 2910 N PHE B 66 56.722 80.290 31.924 1.00 30.93 B ATOM 2911 CA PHE B 66 57.770 79.381 32.362 1.00 29.14 B ATOM 2912 CB PHE B 66 58.611 80.060 33.455 1.00 27.56 B ATOM 2913 CG PHE B 66 59.743 79.210 33.998 1.00 28.67 B ATOM 2914 CD1 PHE B 66 60.632 78.559 33.139 1.00 33.68 B ATOM 2915 CD2 PHE B 66 59.907 79.055 35.371 1.00 30.48 B ATOM 2916 CE1 PHE B 66 61.669 77.763 33.648 1.00 35.23 B ATOM 2917 CE2 PHE B 66 60.931 78.267 35.895 1.00 26.93 B ATOM 2918 CZ PHE B 66 61.816 77.618 35.041 1.00 31.25 B ATOM 2919 C PHE B 66 57.283 78.013 32.844 1.00 32.09 B ATOM 2920 O PHE B 66 56.382 77.924 33.671 1.00 31.84 B ATOM 2921 N ASN B 67 57.882 76.956 32.312 1.00 28.91 B ATOM 2922 CA ASN B 67 57.553 75.591 32.727 1.00 31.14 B ATOM 2923 CB ASN B 67 57.124 74.763 31.524 1.00 32.40 B ATOM 2924 CG ASN B 67 56.635 73.368 31.903 1.00 37.56 B ATOM 2925 OD1 ASN B 67 57.193 72.701 32.784 1.00 33.77 B ATOM 2926 ND2 ASN B 67 55.589 72.914 31.218 1.00 40.31 B ATOM 2927 C ASN B 67 58.844 75.009 33.318 1.00 30.31 B ATOM 2928 O ASN B 67 59.719 74.551 32.577 1.00 26.39 B ATOM 2929 N LYS B 68 58.960 75.038 34.644 1.00 28.27 B ATOM 2930 CA LYS B 68 60.148 74.535 35.329 1.00 29.00 B ATOM 2931 CB LYS B 68 60.041 74.792 36.843 1.00 35.08 B ATOM 2932 CG LYS B 68 58.984 73.906 37.518 1.00 41.56 B ATOM 2933 CD LYS B 68 59.179 73.778 39.031 1.00 52.33 B ATOM 2934 CE LYS B 68 58.907 75.077 39.764 1.00 54.82 B ATOM 2935 NZ LYS B 68 58.896 74.891 41.250 1.00 58.88 B ATOM 2936 C LYS B 68 60.398 73.039 35.087 1.00 32.74 B ATOM 2937 O LYS B 68 61.507 72.556 35.318 1.00 32.92 B ATOM 2938 N TYR B 69 59.389 72.305 34.611 1.00 33.19 B ATOM 2939 CA TYR B 69 59.559 70.867 34.354 1.00 25.62 B ATOM 2940 CB TYR B 69 58.259 70.096 34.687 1.00 30.97 B ATOM 2941 CG TYR B 69 57.801 70.349 36.107 1.00 30.82 B ATOM 2942 CD1 TYR B 69 56.774 71.266 36.378 1.00 28.48 B ATOM 2943 CE1 TYR B 69 56.444 71.623 37.697 1.00 31.73 B ATOM 2944 CD2 TYR B 69 58.486 69.776 37.192 1.00 31.64 B ATOM 2945 CE2 TYR B 69 58.174 70.118 38.507 1.00 38.99 B ATOM 2946 CZ TYR B 69 57.153 71.053 38.756 1.00 39.94 B ATOM 2947 OH TYR B 69 56.901 71.467 40.048 1.00 41.68 B ATOM 2948 C TYR B 69 60.029 70.516 32.955 1.00 31.61 B ATOM 2949 O TYR B 69 60.549 69.414 32.722 1.00 31.53 B ATOM 2950 N SER B 70 59.889 71.447 32.017 1.00 29.13 B ATOM 2951 CA SER B 70 60.328 71.162 30.649 1.00 31.79 B ATOM 2952 CB SER B 70 59.926 72.310 29.708 1.00 27.84 B ATOM 2953 OG SER B 70 58.524 72.534 29.725 1.00 38.42 B ATOM 2954 C SER B 70 61.849 70.949 30.544 1.00 34.24 B ATOM 2955 O SER B 70 62.624 71.534 31.296 1.00 31.38 B ATOM 2956 N SER B 71 62.261 70.097 29.613 1.00 33.64 B ATOM 2957 CA SER B 71 63.676 69.832 29.351 1.00 36.09 B ATOM 2958 CB SER B 71 64.265 68.809 30.324 1.00 39.34 B ATOM 2959 OG SER B 71 63.823 67.519 30.007 1.00 41.01 B ATOM 2960 C SER B 71 63.790 69.308 27.907 1.00 41.17 B ATOM 2961 O SER B 71 62.959 68.520 27.432 1.00 41.90 B ATOM 2962 N CYS B 72 64.805 69.766 27.195 1.00 32.35 B ATOM 2963 CA CYS B 72 64.970 69.351 25.816 1.00 36.35 B ATOM 2964 C CYS B 72 66.139 68.393 25.722 1.00 36.24 B ATOM 2965 O CYS B 72 67.089 68.472 26.503 1.00 34.41 B ATOM 2966 CB CYS B 72 65.205 70.586 24.920 1.00 26.09 B ATOM 2967 SG CYS B 72 63.836 71.795 24.962 1.00 32.64 B ATOM 2968 N PRO B 73 66.069 67.453 24.779 1.00 35.65 B ATOM 2969 CD PRO B 73 64.958 67.148 23.867 1.00 38.10 B ATOM 2970 CA PRO B 73 67.157 66.494 24.617 1.00 35.61 B ATOM 2971 CB PRO B 73 66.567 65.461 23.661 1.00 35.75 B ATOM 2972 CG PRO B 73 65.662 66.314 22.806 1.00 40.23 B ATOM 2973 C PRO B 73 68.355 67.203 24.011 1.00 37.18 B ATOM 2974 O PRO B 73 68.225 68.277 23.427 1.00 31.86 B ATOM 2975 N GLU B 74 69.521 66.595 24.151 1.00 30.08 B ATOM 2976 CA GLU B 74 70.726 67.168 23.594 1.00 36.66 B ATOM 2977 CB GLU B 74 71.904 66.221 23.830 1.00 40.69 B ATOM 2978 CG GLU B 74 73.123 66.500 22.972 1.00 55.61 B ATOM 2979 CD GLU B 74 74.357 66.847 23.791 1.00 65.33 B ATOM 2980 OE1 GLU B 74 75.476 66.535 23.311 1.00 68.86 B ATOM 2981 OE2 GLU B 74 74.214 67.432 24.899 1.00 67.56 B ATOM 2982 C GLU B 74 70.526 67.411 22.099 1.00 31.83 B ATOM 2983 O GLU B 74 70.179 66.517 21.347 1.00 34.92 B ATOM 2984 N PRO B 75 70.743 68.639 21.648 1.00 29.85 B ATOM 2985 CD PRO B 75 71.019 69.851 22.431 1.00 29.21 B ATOM 2986 CA PRO B 75 70.573 68.944 20.227 1.00 31.16 B ATOM 2987 CB PRO B 75 70.349 70.441 20.235 1.00 30.77 B ATOM 2988 CG PRO B 75 71.310 70.872 21.362 1.00 28.27 B ATOM 2989 C PRO B 75 71.855 68.552 19.507 1.00 37.41 B ATOM 2990 O PRO B 75 72.949 68.998 19.877 1.00 35.98 B ATOM 2991 N ILE B 76 71.728 67.726 18.474 1.00 37.41 B ATOM 2992 CA ILE B 76 72.904 67.277 17.757 1.00 41.40 B ATOM 2993 CB ILE B 76 73.069 65.755 17.912 1.00 47.80 B ATOM 2994 CG2 ILE B 76 74.385 65.302 17.272 1.00 48.99 B ATOM 2995 CG1 ILE B 76 73.078 65.396 19.404 1.00 48.44 B ATOM 2996 CD1 ILE B 76 72.926 63.918 19.671 1.00 55.08 B ATOM 2997 C ILE B 76 72.874 67.654 16.294 1.00 38.62 B ATOM 2998 O ILE B 76 71.874 67.480 15.625 1.00 39.69 B ATOM 2999 N VAL B 77 73.984 68.195 15.813 1.00 36.89 B ATOM 3000 CA VAL B 77 74.107 68.610 14.433 1.00 38.30 B ATOM 3001 CB VAL B 77 74.290 70.119 14.331 1.00 39.19 B ATOM 3002 CG1 VAL B 77 74.483 70.519 12.871 1.00 39.16 B ATOM 3003 CG2 VAL B 77 73.081 70.826 14.946 1.00 40.99 B ATOM 3004 C VAL B 77 75.307 67.939 13.761 1.00 40.36 B ATOM 3005 O VAL B 77 76.457 68.351 13.948 1.00 41.17 B ATOM 3006 N PRO B 78 75.057 66.893 12.966 1.00 40.75 B ATOM 3007 CD PRO B 78 73.785 66.267 12.590 1.00 37.39 B ATOM 3008 CA PRO B 78 76.183 66.228 12.303 1.00 40.96 B ATOM 3009 CB PRO B 78 75.506 65.195 11.412 1.00 41.91 B ATOM 3010 CG PRO B 78 74.119 65.745 11.229 1.00 45.49 B ATOM 3011 C PRO B 78 76.997 67.232 11.525 1.00 37.80 B ATOM 3012 O PRO B 78 76.447 68.140 10.913 1.00 37.38 B ATOM 3013 N GLY B 79 78.312 67.083 11.590 1.00 32.94 B ATOM 3014 CA GLY B 79 79.186 68.002 10.900 1.00 36.40 B ATOM 3015 C GLY B 79 79.427 69.261 11.712 1.00 34.31 B ATOM 3016 O GLY B 79 80.209 70.109 11.304 1.00 42.13 B ATOM 3017 N GLY B 80 78.760 69.404 12.855 1.00 36.96 B ATOM 3018 CA GLY B 80 78.960 70.608 13.664 1.00 39.25 B ATOM 3019 C GLY B 80 79.072 70.348 15.164 1.00 35.08 B ATOM 3020 O GLY B 80 78.994 69.202 15.609 1.00 40.28 B ATOM 3021 N TYR B 81 79.225 71.410 15.953 1.00 37.65 B ATOM 3022 CA TYR B 81 79.345 71.271 17.408 1.00 33.04 B ATOM 3023 CB TYR B 81 80.800 71.019 17.799 1.00 29.39 B ATOM 3024 CG TYR B 81 81.745 72.112 17.331 1.00 31.26 B ATOM 3025 CD1 TYR B 81 82.169 73.116 18.199 1.00 28.35 B ATOM 3026 CE1 TYR B 81 82.992 74.143 17.766 1.00 28.17 B ATOM 3027 CD2 TYR B 81 82.181 72.163 16.004 1.00 28.62 B ATOM 3028 CE2 TYR B 81 83.006 73.188 15.559 1.00 31.47 B ATOM 3029 CZ TYR B 81 83.401 74.174 16.449 1.00 30.40 B ATOM 3030 OH TYR B 81 84.172 75.207 16.012 1.00 32.87 B ATOM 3031 C TYR B 81 78.847 72.536 18.095 1.00 33.96 B ATOM 3032 O TYR B 81 78.696 73.581 17.454 1.00 30.79 B ATOM 3033 N LYS B 82 78.600 72.431 19.398 1.00 23.56 B ATOM 3034 CA LYS B 82 78.114 73.557 20.195 1.00 29.94 B ATOM 3035 CB LYS B 82 77.348 73.034 21.428 1.00 25.29 B ATOM 3036 CG LYS B 82 76.140 72.144 21.057 1.00 27.67 B ATOM 3037 CD LYS B 82 75.335 71.652 22.266 1.00 33.47 B ATOM 3038 CE LYS B 82 76.215 71.041 23.365 1.00 44.83 B ATOM 3039 NZ LYS B 82 77.091 69.944 22.837 1.00 45.24 B ATOM 3040 C LYS B 82 79.205 74.526 20.629 1.00 29.85 B ATOM 3041 O LYS B 82 80.270 74.110 21.099 1.00 31.44 B ATOM 3042 N ILE B 83 78.980 75.822 20.428 1.00 25.93 B ATOM 3043 CA ILE B 83 79.959 76.795 20.887 1.00 21.30 B ATOM 3044 CB ILE B 83 80.449 77.771 19.800 1.00 29.03 B ATOM 3045 CG2 ILE B 83 81.296 77.004 18.799 1.00 23.68 B ATOM 3046 CG1 ILE B 83 79.278 78.514 19.155 1.00 24.89 B ATOM 3047 CD1 ILE B 83 79.722 79.571 18.148 1.00 27.44 B ATOM 3048 C ILE B 83 79.362 77.581 22.027 1.00 26.62 B ATOM 3049 O ILE B 83 80.038 78.408 22.636 1.00 32.15 B ATOM 3050 N ARG B 84 78.092 77.330 22.324 1.00 24.60 B ATOM 3051 CA ARG B 84 77.471 77.981 23.469 1.00 25.74 B ATOM 3052 CB ARG B 84 77.047 79.396 23.131 1.00 34.80 B ATOM 3053 CG ARG B 84 76.583 80.160 24.348 1.00 45.89 B ATOM 3054 CD ARG B 84 76.518 81.629 24.027 1.00 56.25 B ATOM 3055 NE ARG B 84 77.801 82.302 24.217 1.00 62.31 B ATOM 3056 CZ ARG B 84 78.276 82.707 25.397 1.00 64.61 B ATOM 3057 NH1 ARG B 84 77.581 82.496 26.512 1.00 65.21 B ATOM 3058 NH2 ARG B 84 79.421 83.386 25.454 1.00 61.85 B ATOM 3059 C ARG B 84 76.278 77.199 23.984 1.00 27.61 B ATOM 3060 O ARG B 84 75.487 76.687 23.189 1.00 24.27 B ATOM 3061 N GLY B 85 76.166 77.105 25.314 1.00 25.11 B ATOM 3062 CA GLY B 85 75.074 76.374 25.959 1.00 23.64 B ATOM 3063 C GLY B 85 75.394 74.877 26.115 1.00 32.13 B ATOM 3064 O GLY B 85 75.961 74.257 25.200 1.00 25.66 B ATOM 3065 N SER B 86 75.094 74.293 27.281 1.00 24.97 B ATOM 3066 CA SER B 86 75.347 72.859 27.473 1.00 34.32 B ATOM 3067 CB SER B 86 76.755 72.588 28.034 1.00 31.54 B ATOM 3068 OG SER B 86 76.964 73.322 29.223 1.00 42.05 B ATOM 3069 C SER B 86 74.315 72.304 28.415 1.00 27.65 B ATOM 3070 O SER B 86 73.536 73.064 28.979 1.00 24.75 B ATOM 3071 N THR B 87 74.294 70.982 28.573 1.00 27.03 B ATOM 3072 CA THR B 87 73.325 70.314 29.454 1.00 29.87 B ATOM 3073 CB THR B 87 73.532 68.806 29.450 1.00 34.20 B ATOM 3074 OG1 THR B 87 73.876 68.395 28.125 1.00 54.47 B ATOM 3075 CG2 THR B 87 72.263 68.107 29.856 1.00 36.26 B ATOM 3076 C THR B 87 73.420 70.767 30.903 1.00 30.09 B ATOM 3077 O THR B 87 74.501 71.113 31.381 1.00 30.94 B ATOM 3078 N PRO B 88 72.293 70.771 31.626 1.00 26.03 B ATOM 3079 CD PRO B 88 72.370 71.088 33.060 1.00 30.64 B ATOM 3080 CA PRO B 88 70.921 70.406 31.240 1.00 33.13 B ATOM 3081 CB PRO B 88 70.225 70.211 32.585 1.00 28.86 B ATOM 3082 CG PRO B 88 70.903 71.248 33.440 1.00 31.91 B ATOM 3083 C PRO B 88 70.228 71.482 30.388 1.00 31.83 B ATOM 3084 O PRO B 88 70.495 72.668 30.535 1.00 29.33 B ATOM 3085 N TYR B 89 69.340 71.059 29.503 1.00 27.84 B ATOM 3086 CA TYR B 89 68.613 71.990 28.641 1.00 29.55 B ATOM 3087 CB TYR B 89 68.553 71.414 27.239 1.00 27.73 B ATOM 3088 CG TYR B 89 69.938 71.078 26.722 1.00 29.87 B ATOM 3089 CD1 TYR B 89 70.326 69.759 26.501 1.00 33.12 B ATOM 3090 CE1 TYR B 89 71.605 69.456 26.036 1.00 26.70 B ATOM 3091 CD2 TYR B 89 70.865 72.086 26.467 1.00 32.19 B ATOM 3092 CE2 TYR B 89 72.134 71.795 26.007 1.00 28.60 B ATOM 3093 CZ TYR B 89 72.492 70.482 25.802 1.00 27.81 B ATOM 3094 OH TYR B 89 73.770 70.211 25.415 1.00 32.86 B ATOM 3095 C TYR B 89 67.212 72.242 29.176 1.00 25.88 B ATOM 3096 O TYR B 89 66.333 71.400 29.025 1.00 25.96 B ATOM 3097 N ARG B 90 67.015 73.405 29.790 1.00 25.05 B ATOM 3098 CA ARG B 90 65.732 73.778 30.386 1.00 21.94 B ATOM 3099 CB ARG B 90 65.950 74.306 31.802 1.00 25.43 B ATOM 3100 CG ARG B 90 66.836 73.368 32.650 1.00 35.30 B ATOM 3101 CD ARG B 90 66.308 71.933 32.684 1.00 30.92 B ATOM 3102 NE ARG B 90 65.162 71.857 33.578 1.00 38.77 B ATOM 3103 CZ ARG B 90 64.577 70.721 33.950 1.00 43.50 B ATOM 3104 NH1 ARG B 90 65.038 69.562 33.500 1.00 42.19 B ATOM 3105 NH2 ARG B 90 63.529 70.750 34.771 1.00 39.16 B ATOM 3106 C ARG B 90 65.001 74.823 29.580 1.00 26.84 B ATOM 3107 O ARG B 90 65.540 75.372 28.606 1.00 21.63 B ATOM 3108 N HIS B 91 63.767 75.095 29.999 1.00 24.57 B ATOM 3109 CA HIS B 91 62.903 76.057 29.318 1.00 28.69 B ATOM 3110 CB HIS B 91 61.570 76.143 30.062 1.00 26.54 B ATOM 3111 CG HIS B 91 60.516 76.909 29.326 1.00 34.66 B ATOM 3112 CD2 HIS B 91 59.414 77.563 29.770 1.00 26.97 B ATOM 3113 ND1 HIS B 91 60.513 77.035 27.952 1.00 29.34 B ATOM 3114 CE1 HIS B 91 59.457 77.735 27.582 1.00 27.63 B ATOM 3115 NE2 HIS B 91 58.775 78.066 28.666 1.00 34.45 B ATOM 3116 C HIS B 91 63.546 77.445 29.177 1.00 30.22 B ATOM 3117 O HIS B 91 63.937 78.069 30.161 1.00 23.98 B ATOM 3118 N GLY B 92 63.663 77.915 27.941 1.00 26.25 B ATOM 3119 CA GLY B 92 64.260 79.209 27.702 1.00 20.48 B ATOM 3120 C GLY B 92 65.752 79.118 27.458 1.00 24.40 B ATOM 3121 O GLY B 92 66.310 80.102 27.019 1.00 24.34 B ATOM 3122 N ASP B 93 66.407 77.974 27.724 1.00 20.35 B ATOM 3123 CA ASP B 93 67.857 77.884 27.472 1.00 19.73 B ATOM 3124 CB ASP B 93 68.487 76.575 27.992 1.00 23.61 B ATOM 3125 CG ASP B 93 68.579 76.504 29.504 1.00 20.60 B ATOM 3126 OD1 ASP B 93 68.336 77.522 30.167 1.00 23.89 B ATOM 3127 OD2 ASP B 93 68.884 75.401 30.020 1.00 25.06 B ATOM 3128 C ASP B 93 68.138 77.911 25.981 1.00 25.02 B ATOM 3129 O ASP B 93 67.362 77.415 25.170 1.00 24.06 B ATOM 3130 N SER B 94 69.298 78.422 25.625 1.00 21.77 B ATOM 3131 CA SER B 94 69.641 78.511 24.229 1.00 27.05 B ATOM 3132 CB SER B 94 69.779 79.972 23.834 1.00 28.57 B ATOM 3133 OG SER B 94 70.417 80.035 22.587 1.00 38.84 B ATOM 3134 C SER B 94 70.935 77.815 23.908 1.00 25.71 B ATOM 3135 O SER B 94 71.833 77.727 24.753 1.00 26.52 B ATOM 3136 N VAL B 95 71.051 77.331 22.678 1.00 27.36 B ATOM 3137 CA VAL B 95 72.291 76.689 22.245 1.00 26.56 B ATOM 3138 CB VAL B 95 72.096 75.178 22.088 1.00 26.82 B ATOM 3139 CG1 VAL B 95 73.282 74.581 21.344 1.00 34.06 B ATOM 3140 CG2 VAL B 95 71.908 74.549 23.460 1.00 30.69 B ATOM 3141 C VAL B 95 72.729 77.273 20.908 1.00 30.07 B ATOM 3142 O VAL B 95 71.903 77.496 20.019 1.00 26.03 B ATOM 3143 N THR B 96 74.026 77.526 20.758 1.00 27.23 B ATOM 3144 CA THR B 96 74.540 78.058 19.503 1.00 23.14 B ATOM 3145 CB THR B 96 75.242 79.419 19.687 1.00 32.77 B ATOM 3146 OG1 THR B 96 74.292 80.383 20.163 1.00 26.94 B ATOM 3147 CG2 THR B 96 75.845 79.896 18.329 1.00 26.13 B ATOM 3148 C THR B 96 75.550 77.071 18.915 1.00 33.62 B ATOM 3149 O THR B 96 76.445 76.614 19.618 1.00 26.19 B ATOM 3150 N PHE B 97 75.381 76.732 17.638 1.00 28.29 B ATOM 3151 CA PHE B 97 76.249 75.788 16.922 1.00 27.82 B ATOM 3152 CB PHE B 97 75.409 74.849 16.039 1.00 27.23 B ATOM 3153 CG PHE B 97 74.598 73.858 16.796 1.00 30.99 B ATOM 3154 CD1 PHE B 97 73.325 74.183 17.257 1.00 28.10 B ATOM 3155 CD2 PHE B 97 75.149 72.633 17.153 1.00 24.15 B ATOM 3156 CE1 PHE B 97 72.608 73.310 18.081 1.00 29.54 B ATOM 3157 CE2 PHE B 97 74.434 71.756 17.975 1.00 26.96 B ATOM 3158 CZ PHE B 97 73.155 72.101 18.444 1.00 28.76 B ATOM 3159 C PHE B 97 77.247 76.479 15.980 1.00 33.87 B ATOM 3160 O PHE B 97 77.088 77.663 15.628 1.00 30.90 B ATOM 3161 N ALA B 98 78.274 75.725 15.582 1.00 33.98 B ATOM 3162 CA ALA B 98 79.266 76.152 14.574 1.00 34.14 B ATOM 3163 CB ALA B 98 80.551 76.651 15.211 1.00 38.55 B ATOM 3164 C ALA B 98 79.544 74.880 13.785 1.00 36.15 B ATOM 3165 O ALA B 98 79.370 73.775 14.312 1.00 35.98 B ATOM 3166 N CYS B 99 79.953 75.018 12.527 1.00 38.50 B ATOM 3167 CA CYS B 99 80.266 73.843 11.711 1.00 39.15 B ATOM 3168 C CYS B 99 81.747 73.512 11.779 1.00 36.00 B ATOM 3169 O CYS B 99 82.573 74.408 11.865 1.00 32.17 B ATOM 3170 CB CYS B 99 79.901 74.086 10.251 1.00 42.12 B ATOM 3171 SG CYS B 99 78.108 74.162 9.949 1.00 40.52 B ATOM 3172 N LYS B 100 82.089 72.229 11.749 1.00 35.70 B ATOM 3173 CA LYS B 100 83.498 71.842 11.770 1.00 40.35 B ATOM 3174 CB LYS B 100 83.632 70.319 11.848 1.00 43.13 B ATOM 3175 CG LYS B 100 83.185 69.707 13.148 1.00 38.59 B ATOM 3176 CD LYS B 100 82.771 68.263 12.966 1.00 44.87 B ATOM 3177 CE LYS B 100 82.689 67.562 14.314 1.00 48.06 B ATOM 3178 NZ LYS B 100 82.353 66.122 14.196 1.00 53.59 B ATOM 3179 C LYS B 100 84.190 72.329 10.482 1.00 45.56 B ATOM 3180 O LYS B 100 83.532 72.770 9.525 1.00 42.57 B ATOM 3181 N THR B 101 85.519 72.239 10.456 1.00 47.39 B ATOM 3182 CA THR B 101 86.286 72.651 9.282 1.00 48.55 B ATOM 3183 CB THR B 101 87.794 72.408 9.497 1.00 48.03 B ATOM 3184 OG1 THR B 101 88.281 73.285 10.521 1.00 47.14 B ATOM 3185 CG2 THR B 101 88.557 72.683 8.212 1.00 51.80 B ATOM 3186 C THR B 101 85.816 71.876 8.042 1.00 47.72 B ATOM 3187 O THR B 101 85.523 70.681 8.127 1.00 43.56 B ATOM 3188 N ASN B 102 85.747 72.555 6.901 1.00 47.11 B ATOM 3189 CA ASN B 102 85.294 71.943 5.647 1.00 48.36 B ATOM 3190 CB ASN B 102 85.961 70.594 5.375 1.00 53.67 B ATOM 3191 CG ASN B 102 87.461 70.703 5.219 1.00 58.65 B ATOM 3192 OD1 ASN B 102 87.980 71.763 4.856 1.00 59.24 B ATOM 3193 ND2 ASN B 102 88.171 69.599 5.484 1.00 61.19 B ATOM 3194 C ASN B 102 83.797 71.728 5.632 1.00 49.36 B ATOM 3195 O ASN B 102 83.284 70.965 4.814 1.00 51.85 B ATOM 3196 N PHE B 103 83.097 72.378 6.555 1.00 48.85 B ATOM 3197 CA PHE B 103 81.641 72.294 6.617 1.00 44.54 B ATOM 3198 CB PHE B 103 81.179 71.539 7.855 1.00 44.01 B ATOM 3199 CG PHE B 103 81.335 70.067 7.740 1.00 45.42 B ATOM 3200 CD1 PHE B 103 82.554 69.461 8.037 1.00 47.36 B ATOM 3201 CD2 PHE B 103 80.270 69.274 7.323 1.00 44.68 B ATOM 3202 CE1 PHE B 103 82.715 68.064 7.921 1.00 44.91 B ATOM 3203 CE2 PHE B 103 80.413 67.883 7.202 1.00 46.13 B ATOM 3204 CZ PHE B 103 81.638 67.276 7.503 1.00 44.51 B ATOM 3205 C PHE B 103 81.103 73.700 6.663 1.00 43.79 B ATOM 3206 O PHE B 103 81.736 74.577 7.239 1.00 41.42 B ATOM 3207 N SER B 104 79.939 73.908 6.052 1.00 46.45 B ATOM 3208 CA SER B 104 79.306 75.216 6.007 1.00 47.47 B ATOM 3209 CB SER B 104 79.176 75.706 4.570 1.00 53.61 B ATOM 3210 OG SER B 104 77.886 75.379 4.057 1.00 61.85 B ATOM 3211 C SER B 104 77.921 75.051 6.596 1.00 46.27 B ATOM 3212 O SER B 104 77.285 74.007 6.425 1.00 46.36 B ATOM 3213 N MET B 105 77.435 76.089 7.269 1.00 47.80 B ATOM 3214 CA MET B 105 76.129 75.998 7.913 1.00 50.16 B ATOM 3215 CB MET B 105 76.114 76.848 9.184 1.00 42.24 B ATOM 3216 CG MET B 105 74.783 76.829 9.931 1.00 39.50 B ATOM 3217 SD MET B 105 74.951 77.585 11.559 1.00 31.98 B ATOM 3218 CE MET B 105 76.153 76.456 12.300 1.00 32.14 B ATOM 3219 C MET B 105 74.948 76.398 7.046 1.00 52.75 B ATOM 3220 O MET B 105 75.066 77.234 6.147 1.00 52.67 B ATOM 3221 N ASN B 106 73.807 75.787 7.343 1.00 57.15 B ATOM 3222 CA ASN B 106 72.560 76.072 6.664 1.00 56.25 B ATOM 3223 CB ASN B 106 72.186 74.950 5.722 1.00 63.78 B ATOM 3224 CG ASN B 106 72.678 75.210 4.332 1.00 72.25 B ATOM 3225 OD1 ASN B 106 72.787 76.372 3.916 1.00 78.63 B ATOM 3226 ND2 ASN B 106 72.995 74.141 3.597 1.00 74.20 B ATOM 3227 C ASN B 106 71.504 76.200 7.727 1.00 54.17 B ATOM 3228 O ASN B 106 71.303 75.277 8.508 1.00 56.24 B ATOM 3229 N GLY B 107 70.833 77.342 7.762 1.00 50.67 B ATOM 3230 CA GLY B 107 69.805 77.552 8.763 1.00 44.02 B ATOM 3231 C GLY B 107 70.334 78.414 9.886 1.00 42.66 B ATOM 3232 O GLY B 107 71.478 78.864 9.854 1.00 41.68 B ATOM 3233 N ASN B 108 69.500 78.646 10.889 1.00 46.24 B ATOM 3234 CA ASN B 108 69.878 79.464 12.032 1.00 47.08 B ATOM 3235 CB ASN B 108 68.613 79.910 12.751 1.00 55.35 B ATOM 3236 CG ASN B 108 67.793 80.851 11.903 1.00 63.30 B ATOM 3237 OD1 ASN B 108 68.164 82.013 11.722 1.00 67.44 B ATOM 3238 ND2 ASN B 108 66.691 80.352 11.346 1.00 68.11 B ATOM 3239 C ASN B 108 70.808 78.723 12.981 1.00 39.04 B ATOM 3240 O ASN B 108 70.560 77.577 13.347 1.00 33.47 B ATOM 3241 N LYS B 109 71.858 79.406 13.402 1.00 34.53 B ATOM 3242 CA LYS B 109 72.859 78.806 14.280 1.00 35.55 B ATOM 3243 CB LYS B 109 74.138 79.632 14.217 1.00 35.53 B ATOM 3244 CG LYS B 109 73.909 81.037 14.698 1.00 37.21 B ATOM 3245 CD LYS B 109 75.176 81.691 15.171 1.00 43.67 B ATOM 3246 CE LYS B 109 74.913 83.141 15.501 1.00 53.84 B ATOM 3247 NZ LYS B 109 76.079 83.848 16.124 1.00 67.33 B ATOM 3248 C LYS B 109 72.456 78.639 15.753 1.00 33.59 B ATOM 3249 O LYS B 109 73.116 77.900 16.490 1.00 32.99 B ATOM 3250 N SER B 110 71.409 79.337 16.198 1.00 29.02 B ATOM 3251 CA SER B 110 70.972 79.239 17.597 1.00 31.62 B ATOM 3252 CB SER B 110 71.068 80.588 18.298 1.00 28.39 B ATOM 3253 OG SER B 110 72.395 81.073 18.276 1.00 35.28 B ATOM 3254 C SER B 110 69.547 78.730 17.734 1.00 33.04 B ATOM 3255 O SER B 110 68.665 79.049 16.935 1.00 28.18 B ATOM 3256 N VAL B 111 69.336 77.927 18.761 1.00 32.94 B ATOM 3257 CA VAL B 111 68.028 77.360 19.032 1.00 28.12 B ATOM 3258 CB VAL B 111 67.998 75.911 18.507 1.00 34.53 B ATOM 3259 CG1 VAL B 111 69.117 75.074 19.143 1.00 27.59 B ATOM 3260 CG2 VAL B 111 66.694 75.304 18.785 1.00 41.47 B ATOM 3261 C VAL B 111 67.729 77.488 20.539 1.00 26.65 B ATOM 3262 O VAL B 111 68.631 77.621 21.359 1.00 27.71 B ATOM 3263 N TRP B 112 66.447 77.496 20.866 1.00 26.33 B ATOM 3264 CA TRP B 112 65.932 77.654 22.205 1.00 21.46 B ATOM 3265 CB TRP B 112 65.023 78.895 22.287 1.00 27.43 B ATOM 3266 CG TRP B 112 65.772 80.142 22.392 1.00 28.72 B ATOM 3267 CD2 TRP B 112 66.455 80.818 21.323 1.00 27.13 B ATOM 3268 CE2 TRP B 112 67.130 81.922 21.894 1.00 23.65 B ATOM 3269 CE3 TRP B 112 66.560 80.595 19.944 1.00 27.06 B ATOM 3270 CD1 TRP B 112 66.053 80.849 23.542 1.00 29.24 B ATOM 3271 NE1 TRP B 112 66.875 81.916 23.242 1.00 22.18 B ATOM 3272 CZ2 TRP B 112 67.896 82.804 21.132 1.00 24.55 B ATOM 3273 CZ3 TRP B 112 67.328 81.476 19.179 1.00 32.51 B ATOM 3274 CH2 TRP B 112 67.985 82.570 19.782 1.00 28.74 B ATOM 3275 C TRP B 112 65.113 76.462 22.622 1.00 24.09 B ATOM 3276 O TRP B 112 64.348 75.924 21.826 1.00 23.03 B ATOM 3277 N CYS B 113 65.257 76.065 23.886 1.00 16.00 B ATOM 3278 CA CYS B 113 64.507 74.942 24.421 1.00 22.66 B ATOM 3279 C CYS B 113 63.090 75.442 24.775 1.00 27.37 B ATOM 3280 O CYS B 113 62.892 76.248 25.702 1.00 23.71 B ATOM 3281 CB CYS B 113 65.230 74.386 25.636 1.00 24.38 B ATOM 3282 SG CYS B 113 64.295 73.084 26.474 1.00 25.70 B ATOM 3283 N GLN B 114 62.105 74.973 24.014 1.00 22.77 B ATOM 3284 CA GLN B 114 60.704 75.406 24.190 1.00 27.53 B ATOM 3285 CB GLN B 114 59.993 75.312 22.852 1.00 23.87 B ATOM 3286 CG GLN B 114 60.669 76.101 21.776 1.00 25.80 B ATOM 3287 CD GLN B 114 59.934 75.957 20.455 1.00 34.33 B ATOM 3288 OE1 GLN B 114 59.540 74.850 20.084 1.00 40.82 B ATOM 3289 NE2 GLN B 114 59.749 77.062 19.744 1.00 28.51 B ATOM 3290 C GLN B 114 59.918 74.632 25.242 1.00 24.17 B ATOM 3291 O GLN B 114 60.324 73.557 25.638 1.00 24.70 B ATOM 3292 N ALA B 115 58.806 75.187 25.704 1.00 28.17 B ATOM 3293 CA ALA B 115 57.984 74.520 26.720 1.00 32.79 B ATOM 3294 CB ALA B 115 56.769 75.392 27.068 1.00 30.00 B ATOM 3295 C ALA B 115 57.523 73.107 26.316 1.00 34.03 B ATOM 3296 O ALA B 115 57.338 72.237 27.170 1.00 33.21 B ATOM 3297 N ASN B 116 57.343 72.881 25.020 1.00 36.70 B ATOM 3298 CA ASN B 116 56.913 71.573 24.526 1.00 38.02 B ATOM 3299 CB ASN B 116 56.230 71.728 23.168 1.00 34.90 B ATOM 3300 CG ASN B 116 57.198 72.144 22.087 1.00 33.42 B ATOM 3301 OD1 ASN B 116 58.359 72.454 22.364 1.00 28.93 B ATOM 3302 ND2 ASN B 116 56.728 72.167 20.853 1.00 30.98 B ATOM 3303 C ASN B 116 58.104 70.608 24.392 1.00 34.77 B ATOM 3304 O ASN B 116 58.017 69.612 23.695 1.00 37.59 B ATOM 3305 N ASN B 117 59.219 70.937 25.044 1.00 36.92 B ATOM 3306 CA ASN B 117 60.425 70.094 25.072 1.00 31.01 B ATOM 3307 CB ASN B 117 60.095 68.728 25.699 1.00 35.95 B ATOM 3308 CG ASN B 117 59.327 68.855 27.022 1.00 41.69 B ATOM 3309 OD1 ASN B 117 58.165 68.448 27.116 1.00 48.82 B ATOM 3310 ND2 ASN B 117 59.966 69.428 28.041 1.00 38.48 B ATOM 3311 C ASN B 117 61.155 69.913 23.753 1.00 35.04 B ATOM 3312 O ASN B 117 61.989 69.010 23.584 1.00 30.97 B ATOM 3313 N MET B 118 60.877 70.804 22.814 1.00 32.90 B ATOM 3314 CA MET B 118 61.544 70.747 21.539 1.00 30.69 B ATOM 3315 CB MET B 118 60.533 70.486 20.426 1.00 39.19 B ATOM 3316 CG MET B 118 60.143 69.004 20.284 1.00 45.35 B ATOM 3317 SD MET B 118 58.844 68.904 19.065 1.00 61.98 B ATOM 3318 CE MET B 118 57.379 68.930 20.152 1.00 59.12 B ATOM 3319 C MET B 118 62.299 72.033 21.290 1.00 32.74 B ATOM 3320 O MET B 118 61.958 73.093 21.820 1.00 31.41 B ATOM 3321 N TRP B 119 63.322 71.913 20.460 1.00 30.27 B ATOM 3322 CA TRP B 119 64.197 73.007 20.122 1.00 32.04 B ATOM 3323 CB TRP B 119 65.519 72.477 19.556 1.00 29.45 B ATOM 3324 CG TRP B 119 66.377 71.888 20.618 1.00 34.08 B ATOM 3325 CD2 TRP B 119 67.091 72.613 21.638 1.00 29.55 B ATOM 3326 CE2 TRP B 119 67.641 71.653 22.514 1.00 32.16 B ATOM 3327 CE3 TRP B 119 67.309 73.974 21.891 1.00 27.61 B ATOM 3328 CD1 TRP B 119 66.533 70.563 20.907 1.00 27.66 B ATOM 3329 NE1 TRP B 119 67.287 70.419 22.045 1.00 29.97 B ATOM 3330 CZ2 TRP B 119 68.401 72.018 23.634 1.00 33.69 B ATOM 3331 CZ3 TRP B 119 68.067 74.333 23.002 1.00 28.67 B ATOM 3332 CH2 TRP B 119 68.603 73.356 23.860 1.00 29.17 B ATOM 3333 C TRP B 119 63.672 74.059 19.188 1.00 35.37 B ATOM 3334 O TRP B 119 62.946 73.750 18.264 1.00 34.01 B ATOM 3335 N GLY B 120 64.129 75.279 19.507 1.00 44.82 B ATOM 3336 CA GLY B 120 63.928 76.577 18.868 1.00 40.39 B ATOM 3337 C GLY B 120 62.736 76.818 18.037 1.00 45.27 B ATOM 3338 O GLY B 120 61.922 75.920 17.884 1.00 54.52 B ATOM 3339 N PRO B 121 62.570 78.049 17.525 1.00 39.72 B ATOM 3340 CD PRO B 121 63.331 79.268 17.805 1.00 34.64 B ATOM 3341 CA PRO B 121 61.411 78.339 16.678 1.00 40.69 B ATOM 3342 CB PRO B 121 61.355 79.869 16.674 1.00 33.54 B ATOM 3343 CG PRO B 121 62.781 80.221 16.775 1.00 38.11 B ATOM 3344 C PRO B 121 61.717 77.733 15.294 1.00 38.17 B ATOM 3345 O PRO B 121 60.817 77.305 14.591 1.00 40.16 B ATOM 3346 N THR B 122 62.994 77.693 14.930 1.00 33.84 B ATOM 3347 CA THR B 122 63.424 77.113 13.660 1.00 38.91 B ATOM 3348 CB THR B 122 64.548 77.939 12.988 1.00 42.26 B ATOM 3349 OG1 THR B 122 65.803 77.671 13.634 1.00 39.47 B ATOM 3350 CG2 THR B 122 64.259 79.431 13.106 1.00 40.58 B ATOM 3351 C THR B 122 63.968 75.708 13.874 1.00 40.61 B ATOM 3352 O THR B 122 64.163 75.266 14.999 1.00 43.52 B ATOM 3353 N ARG B 123 64.220 75.005 12.784 1.00 42.70 B ATOM 3354 CA ARG B 123 64.762 73.656 12.870 1.00 46.43 B ATOM 3355 CB ARG B 123 64.505 72.912 11.549 1.00 48.19 B ATOM 3356 CG ARG B 123 64.849 71.433 11.600 1.00 63.34 B ATOM 3357 CD ARG B 123 64.109 70.638 10.517 1.00 71.72 B ATOM 3358 NE ARG B 123 62.664 70.564 10.762 1.00 75.72 B ATOM 3359 CZ ARG B 123 61.734 70.934 9.881 1.00 77.53 B ATOM 3360 NH1 ARG B 123 62.096 71.410 8.690 1.00 78.13 B ATOM 3361 NH2 ARG B 123 60.444 70.820 10.184 1.00 75.29 B ATOM 3362 C ARG B 123 66.270 73.774 13.141 1.00 36.14 B ATOM 3363 O ARG B 123 66.861 74.816 12.880 1.00 34.06 B ATOM 3364 N LEU B 124 66.888 72.714 13.659 1.00 36.62 B ATOM 3365 CA LEU B 124 68.326 72.743 13.939 1.00 35.68 B ATOM 3366 CB LEU B 124 68.818 71.410 14.509 1.00 37.22 B ATOM 3367 CG LEU B 124 68.399 71.019 15.933 1.00 38.68 B ATOM 3368 CD1 LEU B 124 69.008 69.670 16.342 1.00 37.12 B ATOM 3369 CD2 LEU B 124 68.860 72.097 16.874 1.00 34.15 B ATOM 3370 C LEU B 124 69.081 73.029 12.656 1.00 37.07 B ATOM 3371 O LEU B 124 68.701 72.584 11.583 1.00 35.87 B ATOM 3372 N PRO B 125 70.168 73.787 12.750 1.00 40.36 B ATOM 3373 CD PRO B 125 70.832 74.306 13.962 1.00 38.05 B ATOM 3374 CA PRO B 125 70.933 74.085 11.538 1.00 35.47 B ATOM 3375 CB PRO B 125 71.993 75.069 12.029 1.00 35.51 B ATOM 3376 CG PRO B 125 72.224 74.641 13.460 1.00 35.57 B ATOM 3377 C PRO B 125 71.535 72.794 11.002 1.00 40.45 B ATOM 3378 O PRO B 125 71.432 71.739 11.640 1.00 33.92 B ATOM 3379 N THR B 126 72.131 72.867 9.814 1.00 41.58 B ATOM 3380 CA THR B 126 72.765 71.704 9.217 1.00 41.03 B ATOM 3381 CB THR B 126 71.929 71.137 8.006 1.00 42.99 B ATOM 3382 OG1 THR B 126 71.625 72.182 7.075 1.00 45.10 B ATOM 3383 CG2 THR B 126 70.628 70.529 8.503 1.00 40.83 B ATOM 3384 C THR B 126 74.157 72.116 8.777 1.00 41.16 B ATOM 3385 O THR B 126 74.415 73.299 8.544 1.00 40.35 B ATOM 3386 N CYS B 127 75.074 71.158 8.716 1.00 42.86 B ATOM 3387 CA CYS B 127 76.433 71.468 8.279 1.00 48.44 B ATOM 3388 C CYS B 127 76.774 70.561 7.098 1.00 53.76 B ATOM 3389 O CYS B 127 76.711 69.336 7.219 1.00 55.59 B ATOM 3390 CB CYS B 127 77.440 71.249 9.422 1.00 49.29 B ATOM 3391 SG CYS B 127 77.365 72.471 10.779 1.00 41.21 B ATOM 3392 N VAL B 128 77.117 71.159 5.960 1.00 52.99 B ATOM 3393 CA VAL B 128 77.466 70.386 4.764 1.00 58.11 B ATOM 3394 CB VAL B 128 76.479 70.674 3.612 1.00 60.17 B ATOM 3395 CG1 VAL B 128 76.356 72.179 3.395 1.00 59.61 B ATOM 3396 CG2 VAL B 128 76.974 70.005 2.322 1.00 62.78 B ATOM 3397 C VAL B 128 78.881 70.738 4.290 1.00 55.96 B ATOM 3398 O VAL B 128 79.307 71.875 4.427 1.00 56.76 B ATOM 3399 N SER B 129 79.604 69.763 3.747 1.00 58.88 B ATOM 3400 CA SER B 129 80.976 69.974 3.241 1.00 63.04 B ATOM 3401 CB SER B 129 81.489 68.685 2.616 1.00 64.42 B ATOM 3402 OG SER B 129 80.566 68.249 1.633 1.00 74.77 B ATOM 3403 C SER B 129 81.061 71.092 2.194 1.00 60.01 B ATOM 3404 O SER B 129 82.054 71.856 2.166 1.00 59.63 B ATOM 3405 OXT SER B 129 80.121 71.165 1.381 1.00 61.43 B END

TABLE 3 ATOM 2419 CB ALA B 1 64.181 107.666 4.123 1.00 39.20 B ATOM 2420 C ALA B 1 62.836 105.816 3.113 1.00 41.03 B ATOM 2421 O ALA B 1 61.659 105.713 3.477 1.00 42.08 B ATOM 2422 N ALA B 1 62.413 108.231 2.458 1.00 40.18 B ATOM 2423 CA ALA B 1 63.447 107.201 2.861 1.00 43.96 B ATOM 2424 N ILE B 2 63.636 104.759 2.923 1.00 39.63 B ATOM 2425 CA ILE B 2 63.175 103.383 3.141 1.00 37.01 B ATOM 2426 CB ILE B 2 64.245 102.349 2.700 1.00 32.57 B ATOM 2427 CG2 ILE B 2 63.775 100.936 3.064 1.00 35.80 B ATOM 2428 CG1 ILE B 2 64.457 102.422 1.178 1.00 34.01 B ATOM 2429 CD1 ILE B 2 65.479 101.372 0.650 1.00 31.21 B ATOM 2430 C ILE B 2 62.831 103.151 4.633 1.00 38.27 B ATOM 2431 O ILE B 2 63.565 103.577 5.528 1.00 32.71 B ATOM 2432 N SER B 3 61.714 102.486 4.897 1.00 30.65 B ATOM 2433 CA SER B 3 61.316 102.226 6.272 1.00 26.19 B ATOM 2434 CB SER B 3 60.245 103.236 6.689 1.00 31.79 B ATOM 2435 OG SER B 3 59.060 103.020 5.926 1.00 27.35 B ATOM 2436 C SER B 3 60.744 100.826 6.435 1.00 30.38 B ATOM 2437 O SER B 3 60.495 100.132 5.446 1.00 28.89 B ATOM 2438 N CYS B 4 60.559 100.410 7.690 1.00 27.89 B ATOM 2439 CA CYS B 4 59.941 99.127 8.003 1.00 27.29 B ATOM 2440 C CYS B 4 58.609 99.528 8.600 1.00 26.13 B ATOM 2441 O CYS B 4 58.446 100.666 9.061 1.00 29.64 B ATOM 2442 CB CYS B 4 60.731 98.328 9.056 1.00 27.46 B ATOM 2443 SG CYS B 4 62.214 97.531 8.369 1.00 27.76 B ATOM 2444 N GLY B 5 57.648 98.622 8.561 1.00 22.65 B ATOM 2445 CA GLY B 5 56.366 98.916 9.155 1.00 23.57 B ATOM 2446 C GLY B 5 56.452 98.570 10.643 1.00 24.00 B ATOM 2447 O GLY B 5 57.504 98.199 11.181 1.00 23.18 B ATOM 2448 N SER B 6 55.322 98.698 11.313 1.00 21.65 B ATOM 2449 CA SER B 6 55.204 98.441 12.733 1.00 22.23 B ATOM 2450 CB SER B 6 53.722 98.511 13.098 1.00 27.49 B ATOM 2451 OG SER B 6 53.543 98.605 14.483 1.00 33.82 B ATOM 2452 C SER B 6 55.785 97.062 13.091 1.00 26.45 B ATOM 2453 O SER B 6 55.489 96.081 12.439 1.00 22.14 B ATOM 2454 N PRO B 7 56.639 96.980 14.122 1.00 26.74 B ATOM 2455 CD PRO B 7 57.230 98.026 14.973 1.00 25.89 B ATOM 2456 CA PRO B 7 57.191 95.661 14.468 1.00 25.01 B ATOM 2457 CB PRO B 7 58.175 95.984 15.592 1.00 22.52 B ATOM 2458 CG PRO B 7 57.589 97.228 16.232 1.00 26.49 B ATOM 2459 C PRO B 7 56.133 94.627 14.894 1.00 27.04 B ATOM 2460 O PRO B 7 55.061 94.961 15.414 1.00 24.19 B ATOM 2461 N PRO B 8 56.439 93.345 14.700 1.00 24.37 B ATOM 2462 CD PRO B 8 57.540 92.754 13.936 1.00 26.75 B ATOM 2463 CA PRO B 8 55.431 92.366 15.099 1.00 25.28 B ATOM 2464 CB PRO B 8 55.974 91.048 14.538 1.00 31.15 B ATOM 2465 CG PRO B 8 57.401 91.314 14.245 1.00 33.33 B ATOM 2466 C PRO B 8 55.228 92.382 16.613 1.00 30.70 B ATOM 2467 O PRO B 8 56.180 92.527 17.364 1.00 31.22 B ATOM 2468 N PRO B 9 53.971 92.314 17.074 1.00 30.39 B ATOM 2469 CD PRO B 9 52.724 92.280 16.275 1.00 37.82 B ATOM 2470 CA PRO B 9 53.686 92.322 18.518 1.00 32.22 B ATOM 2471 CB PRO B 9 52.155 92.415 18.589 1.00 31.66 B ATOM 2472 CG PRO B 9 51.705 91.731 17.265 1.00 31.37 B ATOM 2473 C PRO B 9 54.190 91.062 19.209 1.00 26.54 B ATOM 2474 O PRO B 9 54.542 90.072 18.563 1.00 23.13 B ATOM 2475 N ILE B 10 54.214 91.111 20.526 1.00 25.96 B ATOM 2476 CA ILE B 10 54.651 89.969 21.302 1.00 34.36 B ATOM 2477 CB ILE B 10 56.150 90.068 21.770 1.00 24.92 B ATOM 2478 CG2 ILE B 10 56.398 91.363 22.562 1.00 24.04 B ATOM 2479 CG1 ILE B 10 56.491 88.795 22.581 1.00 30.43 B ATOM 2480 CD1 ILE B 10 57.991 88.536 22.813 1.00 24.83 B ATOM 2481 C ILE B 10 53.753 89.810 22.511 1.00 33.31 B ATOM 2482 O ILE B 10 53.743 90.647 23.412 1.00 32.83 B ATOM 2483 N LEU B 11 52.992 88.724 22.525 1.00 30.71 B ATOM 2484 CA LEU B 11 52.108 88.483 23.659 1.00 34.63 B ATOM 2485 CB LEU B 11 51.217 87.277 23.365 1.00 36.50 B ATOM 2486 CG LEU B 11 50.279 87.435 22.161 1.00 41.37 B ATOM 2487 CD1 LEU B 11 49.708 86.073 21.769 1.00 42.99 B ATOM 2488 CD2 LEU B 11 49.142 88.425 22.495 1.00 39.65 B ATOM 2489 C LEU B 11 52.912 88.247 24.946 1.00 33.29 B ATOM 2490 O LEU B 11 53.905 87.517 24.948 1.00 28.06 B ATOM 2491 N ASN B 12 52.463 88.872 26.032 1.00 31.32 B ATOM 2492 CA ASN B 12 53.086 88.753 27.328 1.00 30.29 B ATOM 2493 CB ASN B 12 53.025 87.303 27.802 1.00 32.27 B ATOM 2494 CG ASN B 12 51.612 86.875 28.083 1.00 38.86 B ATOM 2495 OD1 ASN B 12 50.917 87.526 28.864 1.00 38.55 B ATOM 2496 ND2 ASN B 12 51.161 85.805 27.431 1.00 34.66 B ATOM 2497 C ASN B 12 54.510 89.250 27.371 1.00 32.36 B ATOM 2498 O ASN B 12 55.277 88.858 28.239 1.00 32.55 B ATOM 2499 N GLY B 13 54.849 90.130 26.439 1.00 28.46 B ATOM 2500 CA GLY B 13 56.187 90.671 26.400 1.00 28.72 B ATOM 2501 C GLY B 13 56.147 92.166 26.169 1.00 29.82 B ATOM 2502 O GLY B 13 55.075 92.780 26.153 1.00 34.03 B ATOM 2503 N ARG B 14 57.324 92.742 25.983 1.00 28.15 B ATOM 2504 CA ARG B 14 57.486 94.166 25.739 1.00 31.15 B ATOM 2505 CB ARG B 14 58.198 94.882 26.897 1.00 34.62 B ATOM 2506 CG ARG B 14 57.388 95.196 28.116 1.00 41.44 B ATOM 2507 CD ARG B 14 58.240 95.962 29.112 1.00 42.08 B ATOM 2508 NE ARG B 14 57.526 96.080 30.373 1.00 49.55 B ATOM 2509 CZ ARG B 14 58.023 96.595 31.487 1.00 48.40 B ATOM 2510 NH1 ARG B 14 59.261 97.065 31.509 1.00 40.73 B ATOM 2511 NH2 ARG B 14 57.276 96.602 32.593 1.00 56.30 B ATOM 2512 C ARG B 14 58.409 94.342 24.567 1.00 23.56 B ATOM 2513 O ARG B 14 59.232 93.480 24.280 1.00 23.51 B ATOM 2514 N ILE B 15 58.319 95.516 23.955 1.00 27.48 B ATOM 2515 CA ILE B 15 59.171 95.893 22.841 1.00 26.75 B ATOM 2516 CB ILE B 15 58.345 96.176 21.580 1.00 26.32 B ATOM 2517 CG2 ILE B 15 59.250 96.815 20.497 1.00 29.30 B ATOM 2518 CG1 ILE B 15 57.656 94.902 21.122 1.00 30.62 B ATOM 2519 CD1 ILE B 15 56.760 95.100 19.889 1.00 35.23 B ATOM 2520 C ILE B 15 59.767 97.212 23.279 1.00 26.59 B ATOM 2521 O ILE B 15 59.050 98.050 23.818 1.00 30.94 B ATOM 2522 N SER B 16 61.055 97.409 23.036 1.00 23.15 B ATOM 2523 CA SER B 16 61.709 98.654 23.393 1.00 32.61 B ATOM 2524 CB SER B 16 63.187 98.567 23.057 1.00 29.32 B ATOM 2525 OG SER B 16 63.359 98.151 21.717 1.00 35.31 B ATOM 2526 C SER B 16 61.082 99.839 22.639 1.00 41.27 B ATOM 2527 O SER B 16 60.466 99.674 21.576 1.00 36.78 B ATOM 2528 N TYR B 17 61.260 101.035 23.193 1.00 42.89 B ATOM 2529 CA TYR B 17 60.719 102.267 22.624 1.00 46.29 B ATOM 2530 CB TYR B 17 60.932 103.436 23.623 1.00 44.99 B ATOM 2531 CG TYR B 17 60.026 103.380 24.865 1.00 47.02 B ATOM 2532 CD1 TYR B 17 60.510 103.694 26.151 1.00 49.03 B ATOM 2533 CE1 TYR B 17 59.664 103.655 27.283 1.00 48.52 B ATOM 2534 CD2 TYR B 17 58.686 103.025 24.748 1.00 51.67 B ATOM 2535 CE2 TYR B 17 57.833 102.974 25.861 1.00 53.32 B ATOM 2536 CZ TYR B 17 58.319 103.292 27.122 1.00 56.82 B ATOM 2537 OH TYR B 17 57.430 103.259 28.190 1.00 55.53 B ATOM 2538 C TYR B 17 61.397 102.551 21.285 1.00 46.15 B ATOM 2539 O TYR B 17 62.600 102.375 21.146 1.00 50.00 B ATOM 2540 N TYR B 18 60.623 102.952 20.281 1.00 46.05 B ATOM 2541 CA TYR B 18 61.204 103.270 18.975 1.00 44.93 B ATOM 2542 CB TYR B 18 61.076 102.076 18.010 1.00 37.78 B ATOM 2543 CG TYR B 18 59.645 101.669 17.711 1.00 37.10 B ATOM 2544 CD1 TYR B 18 58.890 102.343 16.750 1.00 31.24 B ATOM 2545 CE1 TYR B 18 57.573 101.980 16.501 1.00 34.43 B ATOM 2546 CD2 TYR B 18 59.040 100.622 18.415 1.00 34.57 B ATOM 2547 CE2 TYR B 18 57.730 100.255 18.184 1.00 36.06 B ATOM 2548 CZ TYR B 18 57.000 100.939 17.218 1.00 35.02 B ATOM 2549 OH TYR B 18 55.706 100.565 16.967 1.00 33.22 B ATOM 2550 C TYR B 18 60.524 104.514 18.375 1.00 40.62 B ATOM 2551 O TYR B 18 59.356 104.784 18.632 1.00 40.57 B ATOM 2552 N SER B 19 61.280 105.260 17.586 1.00 42.39 B ATOM 2553 CA SER B 19 60.786 106.464 16.931 1.00 49.17 B ATOM 2554 CB SER B 19 61.922 107.472 16.789 1.00 49.59 B ATOM 2555 OG SER B 19 63.070 106.843 16.237 1.00 54.17 B ATOM 2556 C SER B 19 60.213 106.155 15.540 1.00 51.20 B ATOM 2557 O SER B 19 60.569 105.165 14.900 1.00 42.62 B ATOM 2558 N THR B 20 59.347 107.041 15.073 1.00 48.91 B ATOM 2559 CA THR B 20 58.706 106.898 13.783 1.00 49.40 B ATOM 2560 CB THR B 20 57.166 107.002 13.991 1.00 52.73 B ATOM 2561 OG1 THR B 20 56.483 106.279 12.968 1.00 60.25 B ATOM 2562 CG2 THR B 20 56.714 108.456 13.943 1.00 51.71 B ATOM 2563 C THR B 20 59.222 108.022 12.844 1.00 47.48 B ATOM 2564 O THR B 20 59.460 109.147 13.280 1.00 50.56 B ATOM 2565 N PRO B 21 59.427 107.720 11.551 1.00 46.52 B ATOM 2566 CD PRO B 21 59.801 108.745 10.551 1.00 44.33 B ATOM 2567 CA PRO B 21 59.204 106.417 10.909 1.00 43.20 B ATOM 2568 CB PRO B 21 59.137 106.769 9.422 1.00 43.49 B ATOM 2569 CG PRO B 21 60.103 107.918 9.305 1.00 44.19 B ATOM 2570 C PRO B 21 60.342 105.456 11.248 1.00 37.71 B ATOM 2571 O PRO B 21 61.393 105.891 11.674 1.00 38.42 B ATOM 2572 N THR B 22 60.123 104.155 11.067 1.00 40.00 B ATOM 2573 CA THR B 22 61.139 103.150 11.382 1.00 37.29 B ATOM 2574 CB THR B 22 60.521 101.715 11.578 1.00 33.63 B ATOM 2575 OG1 THR B 22 59.497 101.719 12.600 1.00 36.55 B ATOM 2576 CG2 THR B 22 61.626 100.734 11.963 1.00 26.59 B ATOM 2577 C THR B 22 62.143 103.079 10.221 1.00 35.94 B ATOM 2578 O THR B 22 61.851 102.484 9.183 1.00 33.29 B ATOM 2579 N ALA B 23 63.326 103.663 10.410 1.00 33.77 B ATOM 2580 CA ALA B 23 64.367 103.677 9.380 1.00 30.19 B ATOM 2581 CB ALA B 23 65.314 104.852 9.615 1.00 28.90 B ATOM 2582 C ALA B 23 65.192 102.399 9.300 1.00 30.98 B ATOM 2583 O ALA B 23 65.331 101.693 10.284 1.00 23.97 B ATOM 2584 N VAL B 24 65.736 102.127 8.112 1.00 27.61 B ATOM 2585 CA VAL B 24 66.591 100.982 7.874 1.00 26.92 B ATOM 2586 CB VAL B 24 67.197 101.042 6.460 1.00 29.41 B ATOM 2587 CG1 VAL B 24 68.357 100.043 6.326 1.00 28.58 B ATOM 2588 CG2 VAL B 24 66.107 100.729 5.430 1.00 26.92 B ATOM 2589 C VAL B 24 67.707 101.091 8.898 1.00 32.79 B ATOM 2590 O VAL B 24 68.266 102.166 9.077 1.00 26.10 B ATOM 2591 N GLY B 25 68.026 100.000 9.586 1.00 28.01 B ATOM 2592 CA GLY B 25 69.070 100.081 10.596 1.00 31.93 B ATOM 2593 C GLY B 25 68.516 100.210 12.007 1.00 34.29 B ATOM 2594 O GLY B 25 69.251 100.080 12.966 1.00 28.44 B ATOM 2595 N THR B 26 67.227 100.486 12.148 1.00 26.99 B ATOM 2596 CA THR B 26 66.650 100.568 13.474 1.00 29.37 B ATOM 2597 CB THR B 26 65.179 100.994 13.403 1.00 30.78 B ATOM 2598 OG1 THR B 26 65.111 102.295 12.808 1.00 26.87 B ATOM 2599 CG2 THR B 26 64.524 101.000 14.833 1.00 23.56 B ATOM 2600 C THR B 26 66.713 99.183 14.136 1.00 32.07 B ATOM 2601 O THR B 26 66.462 98.171 13.473 1.00 28.44 B ATOM 2602 N VAL B 27 67.056 99.143 15.429 1.00 28.90 B ATOM 2603 CA VAL B 27 67.124 97.891 16.200 1.00 29.71 B ATOM 2604 CB VAL B 27 68.507 97.703 16.858 1.00 36.67 B ATOM 2605 CG1 VAL B 27 68.477 96.507 17.808 1.00 31.87 B ATOM 2606 CG2 VAL B 27 69.554 97.478 15.793 1.00 32.00 B ATOM 2607 C VAL B 27 66.054 97.946 17.292 1.00 26.09 B ATOM 2608 O VAL B 27 65.961 98.921 18.029 1.00 28.74 B ATOM 2609 N ILE B 28 65.230 96.913 17.349 1.00 28.74 B ATOM 2610 CA ILE B 28 64.126 96.780 18.294 1.00 34.25 B ATOM 2611 CB ILE B 28 62.802 96.400 17.552 1.00 38.10 B ATOM 2612 CG2 ILE B 28 61.752 95.929 18.516 1.00 49.78 B ATOM 2613 CG1 ILE B 28 62.260 97.598 16.808 1.00 46.71 B ATOM 2614 CD1 ILE B 28 62.252 98.826 17.612 1.00 40.93 B ATOM 2615 C ILE B 28 64.491 95.619 19.223 1.00 38.36 B ATOM 2616 O ILE B 28 65.063 94.626 18.769 1.00 29.90 B ATOM 2617 N ARG B 29 64.134 95.724 20.503 1.00 30.42 B ATOM 2618 CA ARG B 29 64.470 94.673 21.458 1.00 32.43 B ATOM 2619 CB ARG B 29 65.468 95.242 22.461 1.00 38.54 B ATOM 2620 CG ARG B 29 66.234 94.231 23.273 1.00 56.74 B ATOM 2621 CD ARG B 29 67.479 94.939 23.821 1.00 68.43 B ATOM 2622 NE ARG B 29 68.210 95.573 22.722 1.00 77.31 B ATOM 2623 CZ ARG B 29 69.134 94.960 21.983 1.00 81.82 B ATOM 2624 NH1 ARG B 29 69.454 93.693 22.237 1.00 82.00 B ATOM 2625 NH2 ARG B 29 69.723 95.603 20.976 1.00 82.81 B ATOM 2626 C ARG B 29 63.222 94.132 22.168 1.00 26.06 B ATOM 2627 O ARG B 29 62.432 94.884 22.704 1.00 20.11 B ATOM 2628 N TYR B 30 63.032 92.823 22.133 1.00 22.95 B ATOM 2629 CA TYR B 30 61.886 92.206 22.787 1.00 31.30 B ATOM 2630 CB TYR B 30 61.299 91.096 21.905 1.00 28.61 B ATOM 2631 CG TYR B 30 60.647 91.547 20.605 1.00 29.37 B ATOM 2632 CD1 TYR B 30 61.389 92.135 19.579 1.00 24.77 B ATOM 2633 CE1 TYR B 30 60.781 92.553 18.387 1.00 19.11 B ATOM 2634 CD2 TYR B 30 59.282 91.378 20.403 1.00 29.03 B ATOM 2635 CE2 TYR B 30 58.674 91.785 19.215 1.00 26.35 B ATOM 2636 CZ TYR B 30 59.429 92.379 18.216 1.00 23.41 B ATOM 2637 OH TYR B 30 58.793 92.836 17.083 1.00 26.05 B ATOM 2638 C TYR B 30 62.340 91.579 24.126 1.00 28.93 B ATOM 2639 O TYR B 30 63.497 91.168 24.283 1.00 24.49 B ATOM 2640 N SER B 31 61.418 91.488 25.067 1.00 26.50 B ATOM 2641 CA SER B 31 61.697 90.903 26.369 1.00 24.95 B ATOM 2642 CB SER B 31 62.304 91.946 27.308 1.00 21.32 B ATOM 2643 OG SER B 31 61.426 93.028 27.483 1.00 26.55 B ATOM 2644 C SER B 31 60.388 90.378 26.954 1.00 29.25 B ATOM 2645 O SER B 31 59.287 90.780 26.529 1.00 22.45 B ATOM 2646 N CYS B 32 60.515 89.484 27.930 1.00 27.99 B ATOM 2647 CA CYS B 32 59.364 88.868 28.606 1.00 32.41 B ATOM 2648 C CYS B 32 59.371 89.122 30.121 1.00 38.37 B ATOM 2649 O CYS B 32 60.431 89.311 30.719 1.00 37.82 B ATOM 2650 CB CYS B 32 59.371 87.347 28.400 1.00 30.70 B ATOM 2651 SG CYS B 32 59.450 86.770 26.677 1.00 32.11 B ATOM 2652 N SER B 33 58.178 89.101 30.717 1.00 51.37 B ATOM 2653 CA SER B 33 57.995 89.265 32.163 1.00 56.15 B ATOM 2654 CB SER B 33 56.544 89.013 32.552 1.00 60.18 B ATOM 2655 OG SER B 33 55.675 89.714 31.672 1.00 66.23 B ATOM 2656 C SER B 33 58.859 88.260 32.894 1.00 57.27 B ATOM 2657 O SER B 33 59.535 87.427 32.274 1.00 60.30 B ATOM 2658 N GLY B 34 58.805 88.290 34.219 1.00 53.29 B ATOM 2659 CA GLY B 34 59.662 87.391 34.976 1.00 47.70 B ATOM 2660 C GLY B 34 59.278 85.922 34.987 1.00 44.48 B ATOM 2661 O GLY B 34 60.129 85.033 35.135 1.00 38.34 B ATOM 2662 N THR B 35 57.993 85.660 34.818 1.00 40.51 B ATOM 2663 CA THR B 35 57.524 84.290 34.860 1.00 40.76 B ATOM 2664 CB THR B 35 56.225 84.239 35.644 1.00 41.73 B ATOM 2665 OG1 THR B 35 55.258 85.077 35.014 1.00 48.51 B ATOM 2666 CG2 THR B 35 56.468 84.761 37.057 1.00 44.89 B ATOM 2667 C THR B 35 57.369 83.691 33.470 1.00 39.51 B ATOM 2668 O THR B 35 56.786 82.613 33.286 1.00 31.97 B ATOM 2669 N PHE B 36 57.924 84.399 32.491 1.00 35.56 B ATOM 2670 CA PHE B 36 57.873 83.955 31.112 1.00 31.01 B ATOM 2671 CB PHE B 36 57.146 84.967 30.250 1.00 33.05 B ATOM 2672 CG PHE B 36 55.673 84.918 30.396 1.00 35.23 B ATOM 2673 CD1 PHE B 36 55.040 85.573 31.444 1.00 35.53 B ATOM 2674 CD2 PHE B 36 54.909 84.204 29.483 1.00 31.53 B ATOM 2675 CE1 PHE B 36 53.663 85.497 31.570 1.00 37.58 B ATOM 2676 CE2 PHE B 36 53.549 84.126 29.604 1.00 32.60 B ATOM 2677 CZ PHE B 36 52.918 84.769 30.638 1.00 32.38 B ATOM 2678 C PHE B 36 59.276 83.798 30.577 1.00 32.83 B ATOM 2679 O PHE B 36 60.212 84.347 31.125 1.00 33.40 B ATOM 2680 N ARG B 37 59.427 83.049 29.498 1.00 30.99 B ATOM 2681 CA ARG B 37 60.741 82.896 28.916 1.00 29.69 B ATOM 2682 CB ARG B 37 61.201 81.458 29.083 1.00 30.62 B ATOM 2683 CG ARG B 37 61.442 81.072 30.541 1.00 35.61 B ATOM 2684 CD ARG B 37 62.492 81.992 31.177 1.00 39.39 B ATOM 2685 NE ARG B 37 62.303 82.044 32.629 1.00 49.28 B ATOM 2686 CZ ARG B 37 62.847 81.168 33.451 1.00 47.41 B ATOM 2687 NH1 ARG B 37 63.614 80.212 32.947 1.00 53.00 B ATOM 2688 NH2 AEG B 37 62.602 81.223 34.751 1.00 44.10 B ATOM 2689 C ARG B 37 60.713 83.280 27.439 1.00 32.05 B ATOM 2690 O ARG B 37 59.809 82.874 26.700 1.00 25.63 B ATOM 2691 N LEU B 38 61.706 84.050 27.011 1.00 23.96 B ATOM 2692 CA LEU B 38 61.802 84.470 25.621 1.00 30.62 B ATOM 2693 CB LEU B 38 62.655 85.738 25.508 1.00 23.25 B ATOM 2694 CG LEU B 38 62.739 86.365 24.105 1.00 28.16 B ATOM 2695 CD1 LEU B 38 61.376 86.948 23.659 1.00 20.01 B ATOM 2696 CD2 LEU B 38 63.753 87.486 24.132 1.00 32.19 B ATOM 2697 C LEU B 38 62.386 83.361 24.745 1.00 27.63 B ATOM 2698 O LEU B 38 63.447 82.793 25.036 1.00 27.98 B ATOM 2699 N ILE B 39 61.651 83.017 23.691 1.00 30.18 B ATOM 2700 CA ILE B 39 62.073 81.983 22.743 1.00 27.37 B ATOM 2701 CB ILE B 39 60.940 80.959 22.492 1.00 30.75 B ATOM 2702 CG2 ILE B 39 61.438 79.878 21.538 1.00 29.27 B ATOM 2703 CG1 ILE B 39 60.455 80.359 23.822 1.00 30.90 B ATOM 2704 CD1 ILE B 39 61.491 79.535 24.559 1.00 26.44 B ATOM 2705 C ILE B 39 62.403 82.668 21.418 1.00 29.53 B ATOM 2706 O ILE B 39 61.510 83.256 20.797 1.00 24.87 B ATOM 2707 N GLY B 40 63.676 82.609 20.998 1.00 21.97 B ATOM 2708 CA GLY B 40 64.084 83.239 19.751 1.00 23.62 B ATOM 2709 C GLY B 40 64.957 84.450 19.975 1.00 22.85 B ATOM 2710 O GLY B 40 65.065 84.921 21.104 1.00 21.42 B ATOM 2711 N GLU B 41 65.592 84.958 18.925 1.00 27.33 B ATOM 2712 CA GLU B 41 66.472 86.133 19.065 1.00 29.50 B ATOM 2713 CB GLU B 41 67.138 86.471 17.730 1.00 33.78 B ATOM 2714 CG GLU B 41 68.634 86.193 17.721 1.00 52.17 B ATOM 2715 CD GLU B 41 69.411 87.123 18.648 1.00 57.74 B ATOM 2716 OE1 GLU B 41 70.414 86.641 19.231 1.00 66.30 B ATOM 2717 OE2 GLU B 41 69.034 88.326 18.791 1.00 53.76 B ATOM 2718 C GLU B 41 65.667 87.333 19.541 1.00 30.40 B ATOM 2719 O GLU B 41 64.601 87.619 18.995 1.00 27.22 B ATOM 2720 N LYS B 42 66.197 88.049 20.528 1.00 27.86 B ATOM 2721 CA LYS B 42 65.538 89.215 21.135 1.00 32.03 B ATOM 2722 CB LYS B 42 66.171 89.495 22.504 1.00 37.19 B ATOM 2723 CG LYS B 42 67.610 89.990 22.379 1.00 43.78 B ATOM 2724 CD LYS B 42 68.196 90.536 23.674 1.00 54.68 B ATOM 2725 CE LYS B 42 68.055 89.538 24.812 1.00 62.51 B ATOM 2726 NZ LYS B 42 68.438 88.139 24.443 1.00 69.20 B ATOM 2727 C LYS B 42 65.586 90.530 20.331 1.00 32.32 B ATOM 2728 O LYS B 42 64.771 91.432 20.555 1.00 27.61 B ATOM 2729 N SER B 43 66.547 90.680 19.422 1.00 28.99 B ATOM 2730 CA SER B 43 66.611 91.946 18.672 1.00 33.61 B ATOM 2731 CB SER B 43 68.012 92.565 18.722 1.00 29.97 B ATOM 2732 OG SER B 43 68.478 92.606 20.047 1.00 47.21 B ATOM 2733 C SER B 43 66.273 91.770 17.224 1.00 28.57 B ATOM 2734 O SER B 43 66.765 90.841 16.588 1.00 32.11 B ATOM 2735 N LEU B 44 65.443 92.661 16.697 1.00 26.09 B ATOM 2736 CA LEU B 44 65.127 92.607 15.280 1.00 25.34 B ATOM 2737 CB LEU B 44 63.620 92.609 14.987 1.00 21.75 B ATOM 2738 CG LEU B 44 62.608 91.642 15.593 1.00 33.26 B ATOM 2739 CD1 LEU B 44 61.455 91.487 14.626 1.00 24.66 B ATOM 2740 CD2 LEU B 44 63.227 90.293 15.976 1.00 19.72 B ATOM 2741 C LEU B 44 65.738 93.863 14.694 1.00 27.39 B ATOM 2742 O LEU B 44 65.759 94.919 15.334 1.00 29.07 B ATOM 2743 N LEU B 45 66.201 93.740 13.456 1.00 26.79 B ATOM 2744 CA LEU B 45 66.854 94.812 12.727 1.00 26.17 B ATOM 2745 CB LEU B 45 68.202 94.303 12.213 1.00 25.36 B ATOM 2746 CG LEU B 45 69.343 95.281 11.950 1.00 35.90 B ATOM 2747 CD1 LEU B 45 70.263 94.668 10.905 1.00 31.78 B ATOM 2748 CD2 LEU B 45 68.853 96.627 11.519 1.00 39.62 B ATOM 2749 C LEU B 45 66.016 95.198 11.516 1.00 25.11 B ATOM 2750 O LEU B 45 65.568 94.320 10.761 1.00 20.94 B ATOM 2751 N CYS B 46 65.803 96.487 11.298 1.00 24.85 B ATOM 2752 CA CYS B 46 65.057 96.887 10.097 1.00 22.87 B ATOM 2753 C CYS B 46 66.106 96.897 8.976 1.00 29.24 B ATOM 2754 O CYS B 46 67.099 97.601 9.051 1.00 28.50 B ATOM 2755 CB CYS B 46 64.446 98.284 10.251 1.00 26.50 B ATOM 2756 SG CYS B 46 63.677 98.900 8.705 1.00 27.31 B ATOM 2757 N ILE B 47 65.877 96.106 7.943 1.00 24.65 B ATOM 2758 CA ILE B 47 66.817 95.991 6.842 1.00 28.64 B ATOM 2759 CB ILE B 47 67.412 94.572 6.871 1.00 30.17 B ATOM 2760 CG2 ILE B 47 68.114 94.258 5.601 1.00 42.28 B ATOM 2761 CG1 ILE B 47 68.341 94.458 8.070 1.00 40.16 B ATOM 2762 CD1 ILE B 47 69.121 93.190 8.107 1.00 53.27 B ATOM 2763 C ILE B 47 66.098 96.188 5.504 1.00 28.32 B ATOM 2764 O ILE B 47 64.874 96.332 5.466 1.00 24.72 B ATOM 2765 N THR B 48 66.853 96.238 4.413 1.00 24.30 B ATOM 2766 CA THR B 48 66.236 96.267 3.091 1.00 27.24 B ATOM 2767 CB THR B 48 66.215 97.672 2.405 1.00 31.04 B ATOM 2768 OG1 THR B 48 65.632 97.534 1.090 1.00 26.58 B ATOM 2769 CG2 THR B 48 67.627 98.250 2.271 1.00 23.59 B ATOM 2770 C THR B 48 67.048 95.280 2.254 1.00 26.55 B ATOM 2771 O THR B 48 68.276 95.371 2.173 1.00 27.30 B ATOM 2772 N LYS B 49 66.370 94.295 1.688 1.00 24.39 B ATOM 2773 CA LYS B 49 67.031 93.309 0.837 1.00 25.65 B ATOM 2774 CB LYS B 49 66.323 91.943 0.940 1.00 27.44 B ATOM 2775 CG LYS B 49 66.358 91.351 2.368 1.00 36.21 B ATOM 2776 CD LYS B 49 67.171 90.103 2.479 1.00 40.52 B ATOM 2777 CE LYS B 49 68.570 90.294 2.025 1.00 41.63 B ATOM 2778 NZ LYS B 49 69.314 89.069 2.403 1.00 46.47 B ATOM 2779 C LYS B 49 67.041 93.752 −0.632 1.00 33.01 B ATOM 2780 O LYS B 49 67.987 93.450 −1.353 1.00 28.70 B ATOM 2781 N ASP B 50 65.994 94.451 −1.083 1.00 26.02 B ATOM 2782 CA ASP B 50 65.933 94.859 −2.495 1.00 29.77 B ATOM 2783 CB ASP B 50 64.575 94.503 −3.108 1.00 28.99 B ATOM 2784 CG ASP B 50 63.439 95.221 −2.440 1.00 26.54 B ATOM 2785 OD1 ASP B 50 63.720 96.043 −1.562 1.00 25.74 B ATOM 2786 OD2 ASP B 50 62.262 94.969 −2.779 1.00 32.42 B ATOM 2787 C ASP B 50 66.200 96.327 −2.744 1.00 30.62 B ATOM 2788 O ASP B 50 66.037 96.794 −3.858 1.00 24.13 B ATOM 2789 N LYS B 51 66.610 97.050 −1.709 1.00 27.94 B ATOM 2790 CA LYS B 51 66.889 98.473 −1.824 1.00 31.18 B ATOM 2791 CB LYS B 51 68.014 98.742 −2.819 1.00 34.46 B ATOM 2792 CG LYS B 51 69.381 98.355 −2.297 1.00 41.85 B ATOM 2793 CD LYS B 51 70.447 98.960 −3.175 1.00 49.97 B ATOM 2794 CE LYS B 51 71.826 98.869 −2.564 1.00 59.90 B ATOM 2795 NZ LYS B 51 72.754 99.713 −3.366 1.00 67.70 B ATOM 2796 C LYS B 51 65.666 99.305 −2.186 1.00 30.87 B ATOM 2797 O LYS B 51 65.786 100.430 −2.634 1.00 28.68 B ATOM 2798 N VAL B 52 64.483 98.748 −1.992 1.00 26.95 B ATOM 2799 CA VAL B 52 63.263 99.501 −2.231 1.00 26.37 B ATOM 2800 CB VAL B 52 62.456 98.945 −3.402 1.00 27.69 B ATOM 2801 CG1 VAL B 52 61.123 99.695 −3.511 1.00 32.70 B ATOM 2802 CG2 VAL B 52 63.236 99.113 −4.679 1.00 32.13 B ATOM 2803 C VAL B 52 62.375 99.437 −1.000 1.00 30.79 B ATOM 2804 O VAL B 52 61.949 100.461 −0.491 1.00 26.76 B ATOM 2805 N ASP B 53 62.102 98.232 −0.512 1.00 26.86 B ATOM 2806 CA ASP B 53 61.210 98.074 0.642 1.00 26.94 B ATOM 2807 CB ASP B 53 60.156 96.999 0.318 1.00 42.02 B ATOM 2808 CG ASP B 53 59.285 97.356 −0.871 1.00 53.53 B ATOM 2809 OD1 ASP B 53 58.878 98.540 −0.943 1.00 63.13 B ATOM 2810 OD2 ASP B 53 58.964 96.476 −1.727 1.00 64.13 B ATOM 2811 C ASP B 53 62.006 97.651 1.888 1.00 25.00 B ATOM 2812 O ASP B 53 63.063 97.038 1.773 1.00 22.23 B ATOM 2813 N GLY B 54 61.490 97.959 3.072 1.00 20.64 B ATOM 2814 CA GLY B 54 62.170 97.578 4.293 1.00 24.10 B ATOM 2815 C GLY B 54 61.441 96.397 4.919 1.00 25.17 B ATOM 2816 O GLY B 54 60.237 96.266 4.728 1.00 25.23 B ATOM 2817 N THR B 55 62.169 95.517 5.605 1.00 23.87 B ATOM 2818 CA THR B 55 61.589 94.373 6.318 1.00 20.36 B ATOM 2819 CB THR B 55 61.679 93.051 5.518 1.00 27.74 B ATOM 2820 OG1 THR B 55 61.052 92.004 6.267 1.00 24.11 B ATOM 2821 CG2 THR B 55 63.151 92.669 5.212 1.00 21.92 B ATOM 2822 C THR B 55 62.371 94.156 7.600 1.00 22.54 B ATOM 2823 O THR B 55 63.535 94.526 7.675 1.00 24.57 B ATOM 2824 N TRP B 56 61.743 93.589 8.624 1.00 23.11 B ATOM 2825 CA TRP B 56 62.513 93.285 9.827 1.00 25.54 B ATOM 2826 CB TRP B 56 61.580 92.954 10.988 1.00 23.18 B ATOM 2827 CG TRP B 56 60.874 94.202 11.420 1.00 19.51 B ATOM 2828 CD2 TRP B 56 61.456 95.282 12.147 1.00 21.91 B ATOM 2829 CE2 TRP B 56 60.473 96.302 12.247 1.00 26.89 B ATOM 2830 CE3 TRP B 56 62.722 95.491 12.729 1.00 25.30 B ATOM 2831 CD1 TRP B 56 59.595 94.578 11.119 1.00 21.93 B ATOM 2832 NE1 TRP B 56 59.343 95.849 11.617 1.00 21.49 B ATOM 2833 CZ2 TRP B 56 60.713 97.521 12.895 1.00 26.71 B ATOM 2834 CZ3 TRP B 56 62.963 96.706 13.380 1.00 29.35 B ATOM 2835 CH2 TRP B 56 61.957 97.706 13.451 1.00 28.96 B ATOM 2836 C TRP B 56 63.335 92.075 9.384 1.00 28.11 B ATOM 2837 O TRP B 56 62.882 91.296 8.535 1.00 23.54 B ATOM 2838 N ASP B 57 64.535 91.909 9.926 1.00 20.44 B ATOM 2839 CA ASP B 57 65.401 90.812 9.470 1.00 25.81 B ATOM 2840 CB ASP B 57 66.885 91.113 9.761 1.00 30.15 B ATOM 2841 CG ASP B 57 67.234 91.045 11.255 1.00 35.84 B ATOM 2842 OD1 ASP B 57 66.319 91.161 12.102 1.00 23.31 B ATOM 2843 OD2 ASP B 57 68.443 90.889 11.581 1.00 41.06 B ATOM 2844 C ASP B 57 65.058 89.433 9.963 1.00 26.11 B ATOM 2845 O ASP B 57 65.634 88.455 9.486 1.00 28.90 B ATOM 2846 N LYS B 58 64.114 89.336 10.896 1.00 29.91 B ATOM 2847 CA LYS B 58 63.687 88.032 11.411 1.00 27.97 B ATOM 2848 CB LYS B 58 64.697 87.491 12.443 1.00 30.61 B ATOM 2849 CG LYS B 58 64.884 88.378 13.650 1.00 38.23 B ATOM 2850 CD LYS B 58 65.966 87.831 14.618 1.00 41.02 B ATOM 2851 CE LYS B 58 67.406 88.063 14.115 1.00 37.73 B ATOM 2852 NZ LYS B 58 67.830 89.511 14.119 1.00 29.19 B ATOM 2853 C LYS B 58 62.319 88.105 12.045 1.00 22.71 B ATOM 2854 O LYS B 58 61.795 89.188 12.311 1.00 26.33 B ATOM 2855 N PRO B 59 61.700 86.947 12.292 1.00 25.99 B ATOM 2856 CD PRO B 59 62.084 85.584 11.885 1.00 24.09 B ATOM 2857 CA PRO B 59 60.367 86.972 12.919 1.00 22.11 B ATOM 2858 CB PRO B 59 59.902 85.515 12.845 1.00 26.86 B ATOM 2859 CG PRO B 59 60.730 84.913 11.746 1.00 29.91 B ATOM 2860 C PRO B 59 60.509 87.419 14.369 1.00 30.21 B ATOM 2861 O PRO B 59 61.593 87.307 14.968 1.00 28.15 B ATOM 2862 N ALA B 60 59.433 87.924 14.951 1.00 25.43 B ATOM 2863 CA ALA B 60 59.516 88.330 16.339 1.00 26.37 B ATOM 2864 CB ALA B 60 58.260 89.089 16.742 1.00 26.63 B ATOM 2865 C ALA B 60 59.644 87.085 17.223 1.00 21.91 B ATOM 2866 O ALA B 60 59.104 86.068 16.914 1.00 22.47 B ATOM 2867 N PRO B 61 60.358 87.173 18.350 1.00 23.37 B ATOM 2868 CD PRO B 61 61.134 88.320 18.870 1.00 22.24 B ATOM 2869 CA PRO B 61 60.476 86.007 19.227 1.00 19.99 B ATOM 2870 CB PRO B 61 61.650 86.386 20.130 1.00 21.18 B ATOM 2871 CG PRO B 61 61.458 87.876 20.314 1.00 22.73 B ATOM 2872 C PRO B 61 59.151 85.933 20.024 1.00 27.42 B ATOM 2873 O PRO B 61 58.314 86.831 19.903 1.00 27.48 B ATOM 2874 N LYS B 62 58.960 84.893 20.834 1.00 21.73 B ATOM 2875 CA LYS B 62 57.737 84.770 21.648 1.00 26.90 B ATOM 2876 CB LYS B 62 56.880 83.576 21.187 1.00 32.90 B ATOM 2877 CG LYS B 62 56.318 83.743 19.779 1.00 39.12 B ATOM 2878 CD LYS B 62 55.638 82.502 19.258 1.00 48.29 B ATOM 2879 CE LYS B 62 55.142 82.741 17.828 1.00 54.55 B ATOM 2880 NZ LYS B 62 54.620 81.478 17.213 1.00 59.87 B ATOM 2881 C LYS B 62 58.050 84.601 23.133 1.00 30.68 B ATOM 2882 O LYS B 62 59.190 84.287 23.528 1.00 24.62 B ATOM 2883 N CYS B 63 57.039 84.843 23.958 1.00 25.15 B ATOM 2884 CA CYS B 63 57.171 84.675 25.405 1.00 27.27 B ATOM 2885 C CYS B 63 56.314 83.481 25.792 1.00 30.43 B ATOM 2886 O CYS B 63 55.111 83.454 25.515 1.00 30.82 B ATOM 2887 CB CYS B 63 56.646 85.903 26.149 1.00 25.60 B ATOM 2888 SG CYS B 63 57.682 87.384 25.922 1.00 31.81 B ATOM 2889 N GLU B 64 56.934 82.486 26.414 1.00 29.14 B ATOM 2890 CA GLU B 64 56.220 81.297 26.871 1.00 27.87 B ATOM 2891 CB GLU B 64 56.938 80.043 26.393 1.00 22.54 B ATOM 2892 CG GLU B 64 56.839 79.836 24.884 1.00 30.23 B ATOM 2893 CD GLU B 64 57.354 78.472 24.471 1.00 25.42 B ATOM 2894 OE1 GLU B 64 58.146 77.879 25.221 1.00 28.63 B ATOM 2895 OE2 GLU B 64 56.993 77.994 23.396 1.00 24.45 B ATOM 2896 C GLU B 64 56.172 81.301 28.394 1.00 27.43 B ATOM 2897 O GLU B 64 57.189 81.564 29.036 1.00 28.45 B ATOM 2898 N TYR B 65 55.003 81.039 28.981 1.00 30.82 B ATOM 2899 CA TYR B 65 54.898 81.016 30.449 1.00 26.71 B ATOM 2900 CB TYR B 65 53.474 80.638 30.881 1.00 24.67 B ATOM 2901 CG TYR B 65 53.222 80.754 32.382 1.00 30.61 B ATOM 2902 CD1 TYR B 65 53.558 81.915 33.078 1.00 37.93 B ATOM 2903 CE1 TYR B 65 53.369 82.013 34.464 1.00 37.10 B ATOM 2904 CD2 TYR B 65 52.681 79.689 33.102 1.00 29.91 B ATOM 2905 CE2 TYR B 65 52.481 79.765 34.477 1.00 32.04 B ATOM 2906 CZ TYR B 65 52.829 80.927 35.149 1.00 38.91 B ATOM 2907 OH TYR B 65 52.653 81.014 36.510 1.00 40.82 B ATOM 2908 C TYR B 65 55.931 79.969 30.908 1.00 26.37 B ATOM 2909 O TYR B 65 56.022 78.891 30.339 1.00 27.39 B ATOM 2910 N PHE B 66 56.722 80.290 31.924 1.00 30.93 B ATOM 2911 CA PHE B 66 57.770 79.381 32.362 1.00 29.14 B ATOM 2912 CB PHE B 66 58.611 80.060 33.455 1.00 27.56 B ATOM 2913 CG PHE B 66 59.743 79.210 33.998 1.00 28.67 B ATOM 2914 CD1 PHE B 66 60.632 78.559 33.139 1.00 33.68 B ATOM 2915 CD2 PHE B 66 59.907 79.055 35.371 1.00 30.48 B ATOM 2916 CE1 PHE B 66 61.669 77.763 33.648 1.00 35.23 B ATOM 2917 CE2 PHE B 66 60.931 78.267 35.895 1.00 26.93 B ATOM 2918 CZ PHE B 66 61.816 77.618 35.041 1.00 31.25 B ATOM 2919 C PHE B 66 57.283 78.013 32.844 1.00 32.09 B ATOM 2920 O PHE B 66 56.382 77.924 33.671 1.00 31.84 B ATOM 2921 N ASN B 67 57.882 76.956 32.312 1.00 28.91 B ATOM 2922 CA ASN B 67 57.553 75.591 32.727 1.00 31.14 B ATOM 2923 CB ASN B 67 57.124 74.763 31.524 1.00 32.40 B ATOM 2924 CG ASN B 67 56.635 73.368 31.903 1.00 37.56 B ATOM 2925 OD1 ASN B 67 57.193 72.701 32.784 1.00 33.77 B ATOM 2926 ND2 ASN B 67 55.589 72.914 31.218 1.00 40.31 B ATOM 2927 C ASN B 67 58.844 75.009 33.318 1.00 30.31 B ATOM 2928 O ASN B 67 59.719 74.551 32.577 1.00 26.39 B ATOM 2929 N LYS B 68 58.960 75.038 34.644 1.00 28.27 B ATOM 2930 CA LYS B 68 60.148 74.535 35.329 1.00 29.00 B ATOM 2931 CB LYS B 68 60.041 74.792 36.843 1.00 35.08 B ATOM 2932 CG LYS B 68 58.984 73.906 37.518 1.00 41.56 B ATOM 2933 CD LYS B 68 59.179 73.778 39.031 1.00 52.33 B ATOM 2934 CE LYS B 68 58.907 75.077 39.764 1.00 54.82 B ATOM 2935 NZ LYS B 68 58.896 74.891 41.250 1.00 58.88 B ATOM 2936 C LYS B 68 60.398 73.039 35.087 1.00 32.74 B ATOM 2937 O LYS B 68 61.507 72.556 35.318 1.00 32.92 B ATOM 2938 N TYR B 69 59.389 72.305 34.611 1.00 33.19 B ATOM 2939 CA TYR B 69 59.559 70.867 34.354 1.00 25.62 B ATOM 2940 CB TYR B 69 58.259 70.096 34.687 1.00 30.97 B ATOM 2941 CG TYR B 69 57.801 70.349 36.107 1.00 30.82 B ATOM 2942 CD1 TYR B 69 56.774 71.266 36.378 1.00 28.48 B ATOM 2943 CE1 TYR B 69 56.444 71.623 37.697 1.00 31.73 B ATOM 2944 CD2 TYR B 69 58.486 69.776 37.192 1.00 31.64 B ATOM 2945 CE2 TYR B 69 58.174 70.118 38.507 1.00 38.99 B ATOM 2946 CZ TYR B 69 57.153 71.053 38.756 1.00 39.94 B ATOM 2947 OH TYR B 69 56.901 71.467 40.048 1.00 41.68 B ATOM 2948 C TYR B 69 60.029 70.516 32.955 1.00 31.61 B ATOM 2949 O TYR B 69 60.549 69.414 32.722 1.00 31.53 B ATOM 2950 N SER B 70 59.889 71.447 32.017 1.00 29.13 B ATOM 2951 CA SER B 70 60.328 71.162 30.649 1.00 31.79 B ATOM 2952 CB SER B 70 59.926 72.310 29.708 1.00 27.84 B ATOM 2953 OG SER B 70 58.524 72.534 29.725 1.00 38.42 B ATOM 2954 C SER B 70 61.849 70.949 30.544 1.00 34.24 B ATOM 2955 O SER B 70 62.624 71.534 31.296 1.00 31.38 B ATOM 2956 N SER B 71 62.261 70.097 29.613 1.00 33.64 B ATOM 2957 CA SER B 71 63.676 69.832 29.351 1.00 36.09 B ATOM 2958 CB SER B 71 64.265 68.809 30.324 1.00 39.34 B ATOM 2959 OG SER B 71 63.823 67.519 30.007 1.00 41.01 B ATOM 2960 C SER B 71 63.790 69.308 27.907 1.00 41.17 B ATOM 2961 O SER B 71 62.959 68.520 27.432 1.00 41.90 B ATOM 2962 N CYS B 72 64.805 69.766 27.195 1.00 32.35 B ATOM 2963 CA CYS B 72 64.970 69.351 25.816 1.00 36.35 B ATOM 2964 C CYS B 72 66.139 68.393 25.722 1.00 36.24 B ATOM 2965 O CYS B 72 67.089 68.472 26.503 1.00 34.41 B ATOM 2966 CB CYS B 72 65.205 70.586 24.920 1.00 26.09 B ATOM 2967 SG CYS B 72 63.836 71.795 24.962 1.00 32.64 B ATOM 2968 N PRO B 73 66.069 67.453 24.779 1.00 35.65 B ATOM 2969 CD PRO B 73 64.958 67.148 23.867 1.00 38.10 B ATOM 2970 CA PRO B 73 67.157 66.494 24.617 1.00 35.61 B ATOM 2971 CB PRO B 73 66.567 65.461 23.661 1.00 35.75 B ATOM 2972 CG PRO B 73 65.662 66.314 22.806 1.00 40.23 B ATOM 2973 C PRO B 73 68.355 67.203 24.011 1.00 37.18 B ATOM 2974 O PRO B 73 68.225 68.277 23.427 1.00 31.86 B ATOM 2975 N GLU B 74 69.521 66.595 24.151 1.00 30.08 B ATOM 2976 CA GLU B 74 70.726 67.168 23.594 1.00 36.66 B ATOM 2977 CB GLU B 74 71.904 66.221 23.830 1.00 40.69 B ATOM 2978 CG GLU B 74 73.123 66.500 22.972 1.00 55.61 B ATOM 2979 CD GLU B 74 74.357 66.847 23.791 1.00 65.33 B ATOM 2980 OE1 GLU B 74 75.476 66.535 23.311 1.00 68.86 B ATOM 2981 OE2 GLU B 74 74.214 67.432 24.899 1.00 67.56 B ATOM 2982 C GLU B 74 70.526 67.411 22.099 1.00 31.83 B ATOM 2983 O GLU B 74 70.179 66.517 21.347 1.00 34.92 B ATOM 2984 N PRO B 75 70.743 68.639 21.648 1.00 29.85 B ATOM 2985 CD PRO B 75 71.019 69.851 22.431 1.00 29.21 B ATOM 2986 CA PRO B 75 70.573 68.944 20.227 1.00 31.16 B ATOM 2987 CB PRO B 75 70.349 70.441 20.235 1.00 30.77 B ATOM 2988 CG PRO B 75 71.310 70.872 21.362 1.00 28.27 B ATOM 2989 C PRO B 75 71.855 68.552 19.507 1.00 37.41 B ATOM 2990 O PRO B 75 72.949 68.998 19.877 1.00 35.98 B ATOM 2991 N ILE B 76 71.728 67.726 18.474 1.00 37.41 B ATOM 2992 CA ILE B 76 72.904 67.277 17.757 1.00 41.40 B ATOM 2993 CB ILE B 76 73.069 65.755 17.912 1.00 47.80 B ATOM 2994 CG2 ILE B 76 74.385 65.302 17.272 1.00 48.99 B ATOM 2995 CG1 ILE B 76 73.078 65.396 19.404 1.00 48.44 B ATOM 2996 CD1 ILE B 76 72.926 63.918 19.671 1.00 55.08 B ATOM 2997 C ILE B 76 72.874 67.654 16.294 1.00 38.62 B ATOM 2998 O ILE B 76 71.874 67.480 15.625 1.00 39.69 B ATOM 2999 N VAL B 77 73.984 68.195 15.813 1.00 36.89 B ATOM 3000 CA VAL B 77 74.107 68.610 14.433 1.00 38.30 B ATOM 3001 CB VAL B 77 74.290 70.119 14.331 1.00 39.19 B ATOM 3002 CG1 VAL B 77 74.483 70.519 12.871 1.00 39.16 B ATOM 3003 CG2 VAL B 77 73.081 70.826 14.946 1.00 40.99 B ATOM 3004 C VAL B 77 75.307 67.939 13.761 1.00 40.36 B ATOM 3005 O VAL B 77 76.457 68.351 13.948 1.00 41.17 B ATOM 3006 N PRO B 78 75.057 66.893 12.966 1.00 40.75 B ATOM 3007 CD PRO B 78 73.785 66.267 12.590 1.00 37.39 B ATOM 3008 CA PRO B 78 76.183 66.228 12.303 1.00 40.96 B ATOM 3009 CB PRO B 78 75.506 65.195 11.412 1.00 41.91 B ATOM 3010 CG PRO B 78 74.119 65.745 11.229 1.00 45.49 B ATOM 3011 C PRO B 78 76.997 67.232 11.525 1.00 37.80 B ATOM 3012 O PRO B 78 76.447 68.140 10.913 1.00 37.38 B ATOM 3013 N GLY B 79 78.312 67.083 11.590 1.00 32.94 B ATOM 3014 CA GLY B 79 79.186 68.002 10.900 1.00 36.40 B ATOM 3015 C GLY B 79 79.427 69.261 11.712 1.00 34.31 B ATOM 3016 O GLY B 79 80.209 70.109 11.304 1.00 42.13 B ATOM 3017 N GLY B 80 78.760 69.404 12.855 1.00 36.96 B ATOM 3018 CA GLY B 80 78.960 70.608 13.664 1.00 39.25 B ATOM 3019 C GLY B 80 79.072 70.348 15.164 1.00 35.08 B ATOM 3020 O GLY B 80 78.994 69.202 15.609 1.00 40.28 B ATOM 3021 N TYR B 81 79.225 71.410 15.953 1.00 37.65 B ATOM 3022 CA TYR B 81 79.345 71.271 17.408 1.00 33.04 B ATOM 3023 CB TYR B 81 80.800 71.019 17.799 1.00 29.39 B ATOM 3024 CG TYR B 81 81.745 72.112 17.331 1.00 31.26 B ATOM 3025 CD1 TYR B 81 82.169 73.116 18.199 1.00 28.35 B ATOM 3026 CE1 TYR B 81 82.992 74.143 17.766 1.00 28.17 B ATOM 3027 CD2 TYR B 81 82.181 72.163 16.004 1.00 28.62 B ATOM 3028 CE2 TYR B 81 83.006 73.188 15.559 1.00 31.47 B ATOM 3029 CZ TYR B 81 83.401 74.174 16.449 1.00 30.40 B ATOM 3030 OH TYR B 81 84.172 75.207 16.012 1.00 32.87 B ATOM 3031 C TYR B 81 78.847 72.536 18.095 1.00 33.96 B ATOM 3032 O TYR B 81 78.696 73.581 17.454 1.00 30.79 B ATOM 3033 N LYS B 82 78.600 72.431 19.398 1.00 23.56 B ATOM 3034 CA LYS B 82 78.114 73.557 20.195 1.00 29.94 B ATOM 3035 CB LYS B 82 77.348 73.034 21.428 1.00 25.29 B ATOM 3036 CG LYS B 82 76.140 72.144 21.057 1.00 27.67 B ATOM 3037 CD LYS B 82 75.335 71.652 22.266 1.00 33.47 B ATOM 3038 CE LYS B 82 76.215 71.041 23.365 1.00 44.83 B ATOM 3039 NZ LYS B 82 77.091 69.944 22.837 1.00 45.24 B ATOM 3040 C LYS B 82 79.205 74.526 20.629 1.00 29.85 B ATOM 3041 O LYS B 82 80.270 74.110 21.099 1.00 31.44 B ATOM 3042 N ILE B 83 78.980 75.822 20.428 1.00 25.93 B ATOM 3043 CA ILE B 83 79.959 76.795 20.887 1.00 21.30 B ATOM 3044 CB ILE B 83 80.449 77.771 19.800 1.00 29.03 B ATOM 3045 CG2 ILE B 83 81.296 77.004 18.799 1.00 23.68 B ATOM 3046 CG1 ILE B 83 79.278 78.514 19.155 1.00 24.89 B ATOM 3047 CD1 ILE B 83 79.722 79.571 18.148 1.00 27.44 B ATOM 3048 C ILE B 83 79.362 77.581 22.027 1.00 26.62 B ATOM 3049 O ILE B 83 80.038 78.408 22.636 1.00 32.15 B ATOM 3050 N ARG B 84 78.092 77.330 22.324 1.00 24.60 B ATOM 3051 CA ARG B 84 77.471 77.981 23.469 1.00 25.74 B ATOM 3052 CB ARG B 84 77.047 79.396 23.131 1.00 34.80 B ATOM 3053 CG ARG B 84 76.583 80.160 24.348 1.00 45.89 B ATOM 3054 CD ARG B 84 76.518 81.629 24.027 1.00 56.25 B ATOM 3055 NE ARG B 84 77.801 82.302 24.217 1.00 62.31 B ATOM 3056 CZ ARG B 84 78.276 82.707 25.397 1.00 64.61 B ATOM 3057 NH1 ARG B 84 77.581 82.496 26.512 1.00 65.21 B ATOM 3058 NH2 ARG B 84 79.421 83.386 25.454 1.00 61.85 B ATOM 3059 C ARG B 84 76.278 77.199 23.984 1.00 27.61 B ATOM 3060 O ARG B 84 75.487 76.687 23.189 1.00 24.27 B ATOM 3061 N GLY B 85 76.166 77.105 25.314 1.00 25.11 B ATOM 3062 CA GLY B 85 75.074 76.374 25.959 1.00 23.64 B ATOM 3063 C GLY B 85 75.394 74.877 26.115 1.00 32.13 B ATOM 3064 O GLY B 85 75.961 74.257 25.200 1.00 25.66 B ATOM 3065 N SER B 86 75.094 74.293 27.281 1.00 24.97 B ATOM 3066 CA SER B 86 75.347 72.859 27.473 1.00 34.32 B ATOM 3067 CB SER B 86 76.755 72.588 28.034 1.00 31.54 B ATOM 3068 OG SER B 86 76.964 73.322 29.223 1.00 42.05 B ATOM 3069 C SER B 86 74.315 72.304 28.415 1.00 27.65 B ATOM 3070 O SER B 86 73.536 73.064 28.979 1.00 24.75 B ATOM 3071 N THR B 87 74.294 70.982 28.573 1.00 27.03 B ATOM 3072 CA THR B 87 73.325 70.314 29.454 1.00 29.87 B ATOM 3073 CB THR B 87 73.532 68.806 29.450 1.00 34.20 B ATOM 3074 OG1 THR B 87 73.876 68.395 28.125 1.00 54.47 B ATOM 3075 CG2 THR B 87 72.263 68.107 29.856 1.00 36.26 B ATOM 3076 C THR B 87 73.420 70.767 30.903 1.00 30.09 B ATOM 3077 O THR B 87 74.501 71.113 31.381 1.00 30.94 B ATOM 3078 N PRO B 88 72.293 70.771 31.626 1.00 26.03 B ATOM 3079 CD PRO B 88 72.370 71.088 33.060 1.00 30.64 B ATOM 3080 CA PRO B 88 70.921 70.406 31.240 1.00 33.13 B ATOM 3081 CB PRO B 88 70.225 70.211 32.585 1.00 28.86 B ATOM 3082 CG PRO B 88 70.903 71.248 33.440 1.00 31.91 B ATOM 3083 C PRO B 88 70.228 71.482 30.388 1.00 31.83 B ATOM 3084 O PRO B 88 70.495 72.668 30.535 1.00 29.33 B ATOM 3085 N TYR B 89 69.340 71.059 29.503 1.00 27.84 B ATOM 3086 CA TYR B 89 68.613 71.990 28.641 1.00 29.55 B ATOM 3087 CB TYR B 89 68.553 71.414 27.239 1.00 27.73 B ATOM 3088 CG TYR B 89 69.938 71.078 26.722 1.00 29.87 B ATOM 3089 CD1 TYR B 89 70.326 69.759 26.501 1.00 33.12 B ATOM 3090 CE1 TYR B 89 71.605 69.456 26.036 1.00 26.70 B ATOM 3091 CD2 TYR B 89 70.865 72.086 26.467 1.00 32.19 B ATOM 3092 CE2 TYR B 89 72.134 71.795 26.007 1.00 28.60 B ATOM 3093 CZ TYR B 89 72.492 70.482 25.802 1.00 27.81 B ATOM 3094 OH TYR B 89 73.770 70.211 25.415 1.00 32.86 B ATOM 3095 C TYR B 89 67.212 72.242 29.176 1.00 25.88 B ATOM 3096 O TYR B 89 66.333 71.400 29.025 1.00 25.96 B ATOM 3097 N ARG B 90 67.015 73.405 29.790 1.00 25.05 B ATOM 3098 CA ARG B 90 65.732 73.778 30.386 1.00 21.94 B ATOM 3099 CB ARG B 90 65.950 74.306 31.802 1.00 25.43 B ATOM 3100 CG ARG B 90 66.836 73.368 32.650 1.00 35.30 B ATOM 3101 CD ARG B 90 66.308 71.933 32.684 1.00 30.92 B ATOM 3102 NE ARG B 90 65.162 71.857 33.578 1.00 38.77 B ATOM 3103 CZ ARG B 90 64.577 70.721 33.950 1.00 43.50 B ATOM 3104 NH1 ARG B 90 65.038 69.562 33.500 1.00 42.19 B ATOM 3105 NH2 ARG B 90 63.529 70.750 34.771 1.00 39.16 B ATOM 3106 C ARG B 90 65.001 74.823 29.580 1.00 26.84 B ATOM 3107 O ARG B 90 65.540 75.372 28.606 1.00 21.63 B ATOM 3108 N HIS B 91 63.767 75.095 29.999 1.00 24.57 B ATOM 3109 CA HIS B 91 62.903 76.057 29.318 1.00 28.69 B ATOM 3110 CB HIS B 91 61.570 76.143 30.062 1.00 26.54 B ATOM 3111 CG HIS B 91 60.516 76.909 29.326 1.00 34.66 B ATOM 3112 CD2 HIS B 91 59.414 77.563 29.770 1.00 26.97 B ATOM 3113 ND1 HIS B 91 60.513 77.035 27.952 1.00 29.34 B ATOM 3114 CE1 HIS B 91 59.457 77.735 27.582 1.00 27.63 B ATOM 3115 NE2 HIS B 91 58.775 78.066 28.666 1.00 34.45 B ATOM 3116 C HIS B 91 63.546 77.445 29.177 1.00 30.22 B ATOM 3117 O HIS B 91 63.937 78.069 30.161 1.00 23.98 B ATOM 3118 N GLY B 92 63.663 77.915 27.941 1.00 26.25 B ATOM 3119 CA GLY B 92 64.260 79.209 27.702 1.00 20.48 B ATOM 3120 C GLY B 92 65.752 79.118 27.458 1.00 24.40 B ATOM 3121 O GLY B 92 66.310 80.102 27.019 1.00 24.34 B ATOM 3122 N ASP B 93 66.407 77.974 27.724 1.00 20.35 B ATOM 3123 CA ASP B 93 67.857 77.884 27.472 1.00 19.73 B ATOM 3124 CB ASP B 93 68.487 76.575 27.992 1.00 23.61 B ATOM 3125 CG ASP B 93 68.579 76.504 29.504 1.00 20.60 B ATOM 3126 OD1 ASP B 93 68.336 77.522 30.167 1.00 23.89 B ATOM 3127 OD2 ASP B 93 68.884 75.401 30.020 1.00 25.06 B ATOM 3128 C ASP B 93 68.138 77.911 25.981 1.00 25.02 B ATOM 3129 O ASP B 93 67.362 77.415 25.170 1.00 24.06 B ATOM 3130 N SER B 94 69.298 78.422 25.625 1.00 21.77 B ATOM 3131 CA SER B 94 69.641 78.511 24.229 1.00 27.05 B ATOM 3132 CB SER B 94 69.779 79.972 23.834 1.00 28.57 B ATOM 3133 OG SER B 94 70.417 80.035 22.587 1.00 38.84 B ATOM 3134 C SER B 94 70.935 77.815 23.908 1.00 25.71 B ATOM 3135 O SER B 94 71.833 77.727 24.753 1.00 26.52 B ATOM 3136 N VAL B 95 71.051 77.331 22.678 1.00 27.36 B ATOM 3137 CA VAL B 95 72.291 76.689 22.245 1.00 26.56 B ATOM 3138 CB VAL B 95 72.096 75.178 22.088 1.00 26.82 B ATOM 3139 CG1 VAL B 95 73.282 74.581 21.344 1.00 34.06 B ATOM 3140 CG2 VAL B 95 71.908 74.549 23.460 1.00 30.69 B ATOM 3141 C VAL B 95 72.729 77.273 20.908 1.00 30.07 B ATOM 3142 O VAL B 95 71.903 77.496 20.019 1.00 26.03 B ATOM 3143 N THR B 96 74.026 77.526 20.758 1.00 27.23 B ATOM 3144 CA THR B 96 74.540 78.058 19.503 1.00 23.14 B ATOM 3145 CB THR B 96 75.242 79.419 19.687 1.00 32.77 B ATOM 3146 OG1 THR B 96 74.292 80.383 20.163 1.00 26.94 B ATOM 3147 CG2 THR B 96 75.845 79.896 18.329 1.00 26.13 B ATOM 3148 C THR B 96 75.550 77.071 18.915 1.00 33.62 B ATOM 3149 O THR B 96 76.445 76.614 19.618 1.00 26.19 B ATOM 3150 N PHE B 97 75.381 76.732 17.638 1.00 28.29 B ATOM 3151 CA PHE B 97 76.249 75.788 16.922 1.00 27.82 B ATOM 3152 CB PHE B 97 75.409 74.849 16.039 1.00 27.23 B ATOM 3153 CG PHE B 97 74.598 73.858 16.796 1.00 30.99 B ATOM 3154 CD1 PHE B 97 73.325 74.183 17.257 1.00 28.10 B ATOM 3155 CD2 PHE B 97 75.149 72.633 17.153 1.00 24.15 B ATOM 3156 CE1 PHE B 97 72.608 73.310 18.081 1.00 29.54 B ATOM 3157 CE2 PHE B 97 74.434 71.756 17.975 1.00 26.96 B ATOM 3158 CZ PHE B 97 73.155 72.101 18.444 1.00 28.76 B ATOM 3159 C PHE B 97 77.247 76.479 15.980 1.00 33.87 B ATOM 3160 O PHE B 97 77.088 77.663 15.628 1.00 30.90 B ATOM 3161 N ALA B 98 78.274 75.725 15.582 1.00 33.98 B ATOM 3162 CA ALA B 98 79.266 76.152 14.574 1.00 34.14 B ATOM 3163 CB ALA B 98 80.551 76.651 15.211 1.00 38.55 B ATOM 3164 C ALA B 98 79.544 74.880 13.785 1.00 36.15 B ATOM 3165 O ALA B 98 79.370 73.775 14.312 1.00 35.98 B ATOM 3166 N CYS B 99 79.953 75.018 12.527 1.00 38.50 B ATOM 3167 CA CYS B 99 80.266 73.843 11.711 1.00 39.15 B ATOM 3168 C CYS B 99 81.747 73.512 11.779 1.00 36.00 B ATOM 3169 O CYS B 99 82.573 74.408 11.865 1.00 32.17 B ATOM 3170 CB CYS B 99 79.901 74.086 10.251 1.00 42.12 B ATOM 3171 SG CYS B 99 78.108 74.162 9.949 1.00 40.52 B ATOM 3172 N LYS B 100 82.089 72.229 11.749 1.00 35.70 B ATOM 3173 CA LYS B 100 83.498 71.842 11.770 1.00 40.35 B ATOM 3174 CB LYS B 100 83.632 70.319 11.848 1.00 43.13 B ATOM 3175 CG LYS B 100 83.185 69.707 13.148 1.00 38.59 B ATOM 3176 CD LYS B 100 82.771 68.263 12.966 1.00 44.87 B ATOM 3177 CE LYS B 100 82.689 67.562 14.314 1.00 48.06 B ATOM 3178 NZ LYS B 100 82.353 66.122 14.196 1.00 53.59 B ATOM 3179 C LYS B 100 84.190 72.329 10.482 1.00 45.56 B ATOM 3180 O LYS B 100 83.532 72.770 9.525 1.00 42.57 B ATOM 3181 N THR B 101 85.519 72.239 10.456 1.00 47.39 B ATOM 3182 CA THR B 101 86.286 72.651 9.282 1.00 48.55 B ATOM 3183 CB THR B 101 87.794 72.408 9.497 1.00 48.03 B ATOM 3184 OG1 THR B 101 88.281 73.285 10.521 1.00 47.14 B ATOM 3185 CG2 THR B 101 88.557 72.683 8.212 1.00 51.80 B ATOM 3186 C THR B 101 85.816 71.876 8.042 1.00 47.72 B ATOM 3187 O THR B 101 85.523 70.681 8.127 1.00 43.56 B ATOM 3188 N ASN B 102 85.747 72.555 6.901 1.00 47.11 B ATOM 3189 CA ASN B 102 85.294 71.943 5.647 1.00 48.36 B ATOM 3190 CB ASN B 102 85.961 70.594 5.375 1.00 53.67 B ATOM 3191 CG ASN B 102 87.461 70.703 5.219 1.00 58.65 B ATOM 3192 OD1 ASN B 102 87.980 71.763 4.856 1.00 59.24 B ATOM 3193 ND2 ASN B 102 88.171 69.599 5.484 1.00 61.19 B ATOM 3194 C ASN B 102 83.797 71.728 5.632 1.00 49.36 B ATOM 3195 O ASN B 102 83.284 70.965 4.814 1.00 51.85 B ATOM 3196 N PHE B 103 83.097 72.378 6.555 1.00 48.85 B ATOM 3197 CA PHE B 103 81.641 72.294 6.617 1.00 44.54 B ATOM 3198 CB PHE B 103 81.179 71.539 7.855 1.00 44.01 B ATOM 3199 CG PHE B 103 81.335 70.067 7.740 1.00 45.42 B ATOM 3200 CD1 PHE B 103 82.554 69.461 8.037 1.00 47.36 B ATOM 3201 CD2 PHE B 103 80.270 69.274 7.323 1.00 44.68 B ATOM 3202 CE1 PHE B 103 82.715 68.064 7.921 1.00 44.91 B ATOM 3203 CE2 PHE B 103 80.413 67.883 7.202 1.00 46.13 B ATOM 3204 CZ PHE B 103 81.638 67.276 7.503 1.00 44.51 B ATOM 3205 C PHE B 103 81.103 73.700 6.663 1.00 43.79 B ATOM 3206 O PHE B 103 81.736 74.577 7.239 1.00 41.42 B ATOM 3207 N SER B 104 79.939 73.908 6.052 1.00 46.45 B ATOM 3208 CA SER B 104 79.306 75.216 6.007 1.00 47.47 B ATOM 3209 CB SER B 104 79.176 75.706 4.570 1.00 53.61 B ATOM 3210 OG SER B 104 77.886 75.379 4.057 1.00 61.85 B ATOM 3211 C SER B 104 77.921 75.051 6.596 1.00 46.27 B ATOM 3212 O SER B 104 77.285 74.007 6.425 1.00 46.36 B ATOM 3213 N MET B 105 77.435 76.089 7.269 1.00 47.80 B ATOM 3214 CA MET B 105 76.129 75.998 7.913 1.00 50.16 B ATOM 3215 CB MET B 105 76.114 76.848 9.184 1.00 42.24 B ATOM 3216 CG MET B 105 74.783 76.829 9.931 1.00 39.50 B ATOM 3217 SD MET B 105 74.951 77.585 11.559 1.00 31.98 B ATOM 3218 CE MET B 105 76.153 76.456 12.300 1.00 32.14 B ATOM 3219 C MET B 105 74.948 76.398 7.046 1.00 52.75 B ATOM 3220 O MET B 105 75.066 77.234 6.147 1.00 52.67 B ATOM 3221 N ASN B 106 73.807 75.787 7.343 1.00 57.15 B ATOM 3222 CA ASN B 106 72.560 76.072 6.664 1.00 56.25 B ATOM 3223 CB ASN B 106 72.186 74.950 5.722 1.00 63.78 B ATOM 3224 CG ASN B 106 72.678 75.210 4.332 1.00 72.25 B ATOM 3225 OD1 ASN B 106 72.787 76.372 3.916 1.00 78.63 B ATOM 3226 ND2 ASN B 106 72.995 74.141 3.597 1.00 74.20 B ATOM 3227 C ASN B 106 71.504 76.200 7.727 1.00 54.17 B ATOM 3228 O ASN B 106 71.303 75.277 8.508 1.00 56.24 B ATOM 3229 N GLY B 107 70.833 77.342 7.762 1.00 50.67 B ATOM 3230 CA GLY B 107 69.805 77.552 8.763 1.00 44.02 B ATOM 3231 C GLY B 107 70.334 78.414 9.886 1.00 42.66 B ATOM 3232 O GLY B 107 71.478 78.864 9.854 1.00 41.68 B ATOM 3233 N ASN B 108 69.500 78.646 10.889 1.00 46.24 B ATOM 3234 CA ASN B 108 69.878 79.464 12.032 1.00 47.08 B ATOM 3235 CB ASN B 108 68.613 79.910 12.751 1.00 55.35 B ATOM 3236 CG ASN B 108 67.793 80.851 11.903 1.00 63.30 B ATOM 3237 OD1 ASN B 108 68.164 82.013 11.722 1.00 67.44 B ATOM 3238 ND2 ASN B 108 66.691 80.352 11.346 1.00 68.11 B ATOM 3239 C ASN B 108 70.808 78.723 12.981 1.00 39.04 B ATOM 3240 O ASN B 108 70.560 77.577 13.347 1.00 33.47 B ATOM 3241 N LYS B 109 71.858 79.406 13.402 1.00 34.53 B ATOM 3242 CA LYS B 109 72.859 78.806 14.280 1.00 35.55 B ATOM 3243 CB LYS B 109 74.138 79.632 14.217 1.00 35.53 B ATOM 3244 CG LYS B 109 73.909 81.037 14.698 1.00 37.21 B ATOM 3245 CD LYS B 109 75.176 81.691 15.171 1.00 43.67 B ATOM 3246 CE LYS B 109 74.913 83.141 15.501 1.00 53.84 B ATOM 3247 NZ LYS B 109 76.079 83.848 16.124 1.00 67.33 B ATOM 3248 C LYS B 109 72.456 78.639 15.753 1.00 33.59 B ATOM 3249 O LYS B 109 73.116 77.900 16.490 1.00 32.99 B ATOM 3250 N SER B 110 71.409 79.337 16.198 1.00 29.02 B ATOM 3251 CA SER B 110 70.972 79.239 17.597 1.00 31.62 B ATOM 3252 CB SER B 110 71.068 80.588 18.298 1.00 28.39 B ATOM 3253 OG SER B 110 72.395 81.073 18.276 1.00 35.28 B ATOM 3254 C SER B 110 69.547 78.730 17.734 1.00 33.04 B ATOM 3255 O SER B 110 68.665 79.049 16.935 1.00 28.18 B ATOM 3256 N VAL B 111 69.336 77.927 18.761 1.00 32.94 B ATOM 3257 CA VAL B 111 68.028 77.360 19.032 1.00 28.12 B ATOM 3258 CB VAL B 111 67.998 75.911 18.507 1.00 34.53 B ATOM 3259 CG1 VAL B 111 69.117 75.074 19.143 1.00 27.59 B ATOM 3260 CG2 VAL B 111 66.694 75.304 18.785 1.00 41.47 B ATOM 3261 C VAL B 111 67.729 77.488 20.539 1.00 26.65 B ATOM 3262 O VAL B 111 68.631 77.621 21.359 1.00 27.71 B ATOM 3263 N TRP B 112 66.447 77.496 20.866 1.00 26.33 B ATOM 3264 CA TRP B 112 65.932 77.654 22.205 1.00 21.46 B ATOM 3265 CB TRP B 112 65.023 78.895 22.287 1.00 27.43 B ATOM 3266 CG TRP B 112 65.772 80.142 22.392 1.00 28.72 B ATOM 3267 CD2 TRP B 112 66.455 80.818 21.323 1.00 27.13 B ATOM 3268 CE2 TRP B 112 67.130 81.922 21.894 1.00 23.65 B ATOM 3269 CE3 TRP B 112 66.560 80.595 19.944 1.00 27.06 B ATOM 3270 CD1 TRP B 112 66.053 80.849 23.542 1.00 29.24 B ATOM 3271 NE1 TRP B 112 66.875 81.916 23.242 1.00 22.18 B ATOM 3272 CZ2 TRP B 112 67.896 82.804 21.132 1.00 24.55 B ATOM 3273 CZ3 TRP B 112 67.328 81.476 19.179 1.00 32.51 B ATOM 3274 CH2 TRP B 112 67.985 82.570 19.782 1.00 28.74 B ATOM 3275 C TRP B 112 65.113 76.462 22.622 1.00 24.09 B ATOM 3276 O TRP B 112 64.348 75.924 21.826 1.00 23.03 B ATOM 3277 N CYS B 113 65.257 76.065 23.886 1.00 16.00 B ATOM 3278 CA CYS B 113 64.507 74.942 24.421 1.00 22.66 B ATOM 3279 C CYS B 113 63.090 75.442 24.775 1.00 27.37 B ATOM 3280 O CYS B 113 62.892 76.248 25.702 1.00 23.71 B ATOM 3281 CB CYS B 113 65.230 74.386 25.636 1.00 24.38 B ATOM 3282 SG CYS B 113 64.295 73.084 26.474 1.00 25.70 B ATOM 3283 N GLN B 114 62.105 74.973 24.014 1.00 22.77 B ATOM 3284 CA GLN B 114 60.704 75.406 24.190 1.00 27.53 B ATOM 3285 CB GLN B 114 59.993 75.312 22.852 1.00 23.87 B ATOM 3286 CG GLN B 114 60.669 76.101 21.776 1.00 25.80 B ATOM 3287 CD GLN B 114 59.934 75.957 20.455 1.00 34.33 B ATOM 3288 OE1 GLN B 114 59.540 74.850 20.084 1.00 40.82 B ATOM 3289 NE2 GLN B 114 59.749 77.062 19.744 1.00 28.51 B ATOM 3290 C GLN B 114 59.918 74.632 25.242 1.00 24.17 B ATOM 3291 O GLN B 114 60.324 73.557 25.638 1.00 24.70 B ATOM 3292 N ALA B 115 58.806 75.187 25.704 1.00 28.17 B ATOM 3293 CA ALA B 115 57.984 74.520 26.720 1.00 32.79 B ATOM 3294 CB ALA B 115 56.769 75.392 27.068 1.00 30.00 B ATOM 3295 C ALA B 115 57.523 73.107 26.316 1.00 34.03 B ATOM 3296 O ALA B 115 57.338 72.237 27.170 1.00 33.21 B ATOM 3297 N ASN B 116 57.343 72.881 25.020 1.00 36.70 B ATOM 3298 CA ASN B 116 56.913 71.573 24.526 1.00 38.02 B ATOM 3299 CB ASN B 116 56.230 71.728 23.168 1.00 34.90 B ATOM 3300 CG ASN B 116 57.198 72.144 22.087 1.00 33.42 B ATOM 3301 OD1 ASN B 116 58.359 72.454 22.364 1.00 28.93 B ATOM 3302 ND2 ASN B 116 56.728 72.167 20.853 1.00 30.98 B ATOM 3303 C ASN B 116 58.104 70.608 24.392 1.00 34.77 B ATOM 3304 O ASN B 116 58.017 69.612 23.695 1.00 37.59 B ATOM 3305 N ASN B 117 59.219 70.937 25.044 1.00 36.92 B ATOM 3306 CA ASN B 117 60.425 70.094 25.072 1.00 31.01 B ATOM 3307 CB ASN B 117 60.095 68.728 25.699 1.00 35.95 B ATOM 3308 CG ASN B 117 59.327 68.855 27.022 1.00 41.69 B ATOM 3309 OD1 ASN B 117 58.165 68.448 27.116 1.00 48.82 B ATOM 3310 ND2 ASN B 117 59.966 69.428 28.041 1.00 38.48 B ATOM 3311 C ASN B 117 61.155 69.913 23.753 1.00 35.04 B ATOM 3312 O ASN B 117 61.989 69.010 23.584 1.00 30.97 B ATOM 3313 N MET B 118 60.877 70.804 22.814 1.00 32.90 B ATOM 3314 CA MET B 118 61.544 70.747 21.539 1.00 30.69 B ATOM 3315 CB MET B 118 60.533 70.486 20.426 1.00 39.19 B ATOM 3316 CG MET B 118 60.143 69.004 20.284 1.00 45.35 B ATOM 3317 SD MET B 118 58.844 68.904 19.065 1.00 61.98 B ATOM 3318 CE MET B 118 57.379 68.930 20.152 1.00 59.12 B ATOM 3319 C MET B 118 62.299 72.033 21.290 1.00 32.74 B ATOM 3320 O MET B 118 61.958 73.093 21.820 1.00 31.41 B ATOM 3321 N TRP B 119 63.322 71.913 20.460 1.00 30.27 B ATOM 3322 CA TRP B 119 64.197 73.007 20.122 1.00 32.04 B ATOM 3323 CB TRP B 119 65.519 72.477 19.556 1.00 29.45 B ATOM 3324 CG TRP B 119 66.377 71.888 20.618 1.00 34.08 B ATOM 3325 CD2 TRP B 119 67.091 72.613 21.638 1.00 29.55 B ATOM 3326 CE2 TRP B 119 67.641 71.653 22.514 1.00 32.16 B ATOM 3327 CE3 TRP B 119 67.309 73.974 21.891 1.00 27.61 B ATOM 3328 CD1 TRP B 119 66.533 70.563 20.907 1.00 27.66 B ATOM 3329 NE1 TRP B 119 67.287 70.419 22.045 1.00 29.97 B ATOM 3330 CZ2 TRP B 119 68.401 72.018 23.634 1.00 33.69 B ATOM 3331 CZ3 TRP B 119 68.067 74.333 23.002 1.00 28.67 B ATOM 3332 CH2 TRP B 119 68.603 73.356 23.860 1.00 29.17 B ATOM 3333 C TRP B 119 63.672 74.059 19.188 1.00 35.37 B ATOM 3334 O TRP B 119 62.946 73.750 18.264 1.00 34.01 B ATOM 3335 N GLY B 120 64.129 75.279 19.507 1.00 44.82 B ATOM 3336 CA GLY B 120 63.928 76.577 18.868 1.00 40.39 B ATOM 3337 C GLY B 120 62.736 76.818 18.037 1.00 45.27 B ATOM 3338 O GLY B 120 61.922 75.920 17.884 1.00 54.52 B ATOM 3339 N PRO B 121 62.570 78.049 17.525 1.00 39.72 B ATOM 3340 CD PRO B 121 63.331 79.268 17.805 1.00 34.64 B ATOM 3341 CA PRO B 121 61.411 78.339 16.678 1.00 40.69 B ATOM 3342 CB PRO B 121 61.355 79.869 16.674 1.00 33.54 B ATOM 3343 CG PRO B 121 62.781 80.221 16.775 1.00 38.11 B ATOM 3344 C PRO B 121 61.717 77.733 15.294 1.00 38.17 B ATOM 3345 O PRO B 121 60.817 77.305 14.591 1.00 40.16 B ATOM 3346 N THR B 122 62.994 77.693 14.930 1.00 33.84 B ATOM 3347 CA THR B 122 63.424 77.113 13.660 1.00 38.91 B ATOM 3348 CB THR B 122 64.548 77.939 12.988 1.00 42.26 B ATOM 3349 OG1 THR B 122 65.803 77.671 13.634 1.00 39.47 B ATOM 3350 CG2 THR B 122 64.259 79.431 13.106 1.00 40.58 B ATOM 3351 C THR B 122 63.968 75.708 13.874 1.00 40.61 B ATOM 3352 O THR B 122 64.163 75.266 14.999 1.00 43.52 B ATOM 3353 N ARG B 123 64.220 75.005 12.784 1.00 42.70 B ATOM 3354 CA ARG B 123 64.762 73.656 12.870 1.00 46.43 B ATOM 3355 CB ARG B 123 64.505 72.912 11.549 1.00 48.19 B ATOM 3356 CG ARG B 123 64.849 71.433 11.600 1.00 63.34 B ATOM 3357 CD ARG B 123 64.109 70.638 10.517 1.00 71.72 B ATOM 3358 NE ARG B 123 62.664 70.564 10.762 1.00 75.72 B ATOM 3359 CZ ARG B 123 61.734 70.934 9.881 1.00 77.53 B ATOM 3360 NH1 ARG B 123 62.096 71.410 8.690 1.00 78.13 B ATOM 3361 NH2 ARG B 123 60.444 70.820 10.184 1.00 75.29 B ATOM 3362 C ARG B 123 66.270 73.774 13.141 1.00 36.14 B ATOM 3363 O ARG B 123 66.861 74.816 12.880 1.00 34.06 B ATOM 3364 N LEU B 124 66.888 72.714 13.659 1.00 36.62 B ATOM 3365 CA LEU B 124 68.326 72.743 13.939 1.00 35.68 B ATOM 3366 CB LEU B 124 68.818 71.410 14.509 1.00 37.22 B ATOM 3367 CG LEU B 124 68.399 71.019 15.933 1.00 38.68 B ATOM 3368 CD1 LEU B 124 69.008 69.670 16.342 1.00 37.12 B ATOM 3369 CD2 LEU B 124 68.860 72.097 16.874 1.00 34.15 B ATOM 3370 C LEU B 124 69.081 73.029 12.656 1.00 37.07 B ATOM 3371 O LEU B 124 68.701 72.584 11.583 1.00 35.87 B ATOM 3372 N PRO B 125 70.168 73.787 12.750 1.00 40.36 B ATOM 3373 CD PRO B 125 70.832 74.306 13.962 1.00 38.05 B ATOM 3374 CA PRO B 125 70.933 74.085 11.538 1.00 35.47 B ATOM 3375 CB PRO B 125 71.993 75.069 12.029 1.00 35.51 B ATOM 3376 CG PRO B 125 72.224 74.641 13.460 1.00 35.57 B ATOM 3377 C PRO B 125 71.535 72.794 11.002 1.00 40.45 B ATOM 3378 O PRO B 125 71.432 71.739 11.640 1.00 33.92 B ATOM 3379 N THR B 126 72.131 72.867 9.814 1.00 41.58 B ATOM 3380 CA THR B 126 72.765 71.704 9.217 1.00 41.03 B ATOM 3381 CB THR B 126 71.929 71.137 8.006 1.00 42.99 B ATOM 3382 OG1 THR B 126 71.625 72.182 7.075 1.00 45.10 B ATOM 3383 CG2 THR B 126 70.628 70.529 8.503 1.00 40.83 B ATOM 3384 C THR B 126 74.157 72.116 8.777 1.00 41.16 B ATOM 3385 O THR B 126 74.415 73.299 8.544 1.00 40.35 B ATOM 3386 N CYS B 127 75.074 71.158 8.716 1.00 42.86 B ATOM 3387 CA CYS B 127 76.433 71.468 8.279 1.00 48.44 B ATOM 3388 C CYS B 127 76.774 70.561 7.098 1.00 53.76 B ATOM 3389 O CYS B 127 76.711 69.336 7.219 1.00 55.59 B ATOM 3390 CB CYS B 127 77.440 71.249 9.422 1.00 49.29 B ATOM 3391 SG CYS B 127 77.365 72.471 10.779 1.00 41.21 B ATOM 3392 N VAL B 128 77.117 71.159 5.960 1.00 52.99 B ATOM 3393 CA VAL B 128 77.466 70.386 4.764 1.00 58.11 B ATOM 3394 CB VAL B 128 76.479 70.674 3.612 1.00 60.17 B ATOM 3395 CG1 VAL B 128 76.356 72.179 3.395 1.00 59.61 B ATOM 3396 CG2 VAL B 128 76.974 70.005 2.322 1.00 62.78 B ATOM 3397 C VAL B 128 78.881 70.738 4.290 1.00 55.96 B ATOM 3398 O VAL B 128 79.307 71.875 4.427 1.00 56.76 B ATOM 3399 N SER B 129 79.604 69.763 3.747 1.00 58.88 B ATOM 3400 CA SER B 129 80.976 69.974 3.241 1.00 63.04 B ATOM 3401 CB SER B 129 81.489 68.685 2.616 1.00 64.42 B ATOM 3402 OG SER B 129 80.566 68.249 1.633 1.00 74.77 B ATOM 3403 C SER B 129 81.061 71.092 2.194 1.00 60.01 B ATOM 3404 O SER B 129 82.054 71.856 2.166 1.00 59.63 B ATOM 3405 OXT SER B 129 80.121 71.165 1.381 1.00 61.43 B ATOM 3406 CB ALA C 1 51.630 81.929 2.879 1.00 35.79 C ATOM 3407 C ALA C 1 50.853 84.288 2.366 1.00 35.46 C ATOM 3408 O ALA C 1 50.053 85.212 2.282 1.00 40.99 C ATOM 3409 N ALA C 1 49.558 82.473 1.552 1.00 39.80 C ATOM 3410 CA ALA C 1 50.392 82.883 2.708 1.00 38.04 C ATOM 3411 N ILE C 2 52.138 84.436 2.113 1.00 25.56 C ATOM 3412 CA ILE C 2 52.684 85.736 1.810 1.00 32.00 C ATOM 3413 CB ILE C 2 53.982 85.933 2.591 1.00 24.33 C ATOM 3414 CG2 ILE C 2 54.794 87.063 1.974 1.00 24.84 C ATOM 3415 CG1 ILE C 2 53.647 86.140 4.085 1.00 31.72 C ATOM 3416 CD1 ILE C 2 54.875 86.286 5.004 1.00 28.23 C ATOM 3417 C ILE C 2 52.955 85.930 0.331 1.00 29.98 C ATOM 3418 O ILE C 2 53.280 84.966 −0.364 1.00 24.28 C ATOM 3419 N SER C 3 52.816 87.164 −0.156 1.00 25.13 C ATOM 3420 CA SER C 3 53.130 87.453 −1.564 1.00 24.56 C ATOM 3421 CB SER C 3 51.848 87.773 −2.360 1.00 23.32 C ATOM 3422 OG SER C 3 51.206 88.949 −1.866 1.00 28.18 C ATOM 3423 C SER C 3 54.111 88.630 −1.651 1.00 28.79 C ATOM 3424 O SER C 3 54.240 89.413 −0.703 1.00 25.00 C ATOM 3425 N CYS C 4 54.834 88.720 −2.766 1.00 24.82 C ATOM 3426 CA CYS C 4 55.760 89.824 −3.003 1.00 23.87 C ATOM 3427 C CYS C 4 55.114 90.751 −4.020 1.00 26.63 C ATOM 3428 O CYS C 4 54.488 90.277 −4.974 1.00 24.86 C ATOM 3429 CB CYS C 4 57.075 89.341 −3.595 1.00 26.41 C ATOM 3430 SG CYS C 4 58.182 88.516 −2.412 1.00 26.19 C ATOM 3431 N GLY C 5 55.270 92.056 −3.843 1.00 25.01 C ATOM 3432 CA GLY C 5 54.697 93.002 −4.800 1.00 23.78 C ATOM 3433 C GLY C 5 55.467 93.100 −6.115 1.00 33.19 C ATOM 3434 O GLY C 5 56.444 92.346 −6.350 1.00 24.73 C ATOM 3435 N SER C 6 55.020 94.068 −6.975 1.00 24.24 C ATOM 3436 CA SER C 6 55.654 94.257 −8.285 1.00 31.29 C ATOM 3437 CB SER C 6 54.994 95.528 −8.834 1.00 28.12 C ATOM 3438 OG SER C 6 53.739 95.485 −9.097 1.00 30.57 C ATOM 3439 C SER C 6 57.187 94.422 −8.106 1.00 28.51 C ATOM 3440 O SER C 6 57.681 95.162 −7.262 1.00 27.78 C ATOM 3441 N PRO C 7 57.921 93.562 −8.849 1.00 24.89 C ATOM 3442 CD PRO C 7 57.432 92.669 −9.919 1.00 29.34 C ATOM 3443 CA PRO C 7 59.391 93.554 −8.765 1.00 29.21 C ATOM 3444 CB PRO C 7 59.778 92.308 −9.570 1.00 30.50 C ATOM 3445 CG PRO C 7 58.721 92.286 −10.660 1.00 34.19 C ATOM 3446 C PRO C 7 60.066 94.829 −9.286 1.00 25.82 C ATOM 3447 O PRO C 7 59.490 95.586 −10.054 1.00 30.82 C ATOM 3448 N PRO C 8 61.312 95.071 −8.879 1.00 25.55 C ATOM 3449 CD PRO C 8 62.239 94.221 −8.107 1.00 22.99 C ATOM 3450 CA PRO C 8 61.972 96.293 −9.360 1.00 27.11 C ATOM 3451 CB PRO C 8 63.315 96.292 −8.613 1.00 23.33 C ATOM 3452 CG PRO C 8 63.116 95.255 −7.464 1.00 30.29 C ATOM 3453 C PRO C 8 62.162 96.260 −10.877 1.00 27.57 C ATOM 3454 O PRO C 8 62.478 95.206 −11.457 1.00 27.35 C ATOM 3455 N PRO C 9 61.945 97.401 −11.552 1.00 28.23 C ATOM 3456 CD PRO C 9 61.527 98.718 −11.049 1.00 30.53 C ATOM 3457 CA PRO C 9 62.116 97.415 −13.009 1.00 29.41 C ATOM 3458 CB PRO C 9 61.430 98.714 −13.417 1.00 30.12 C ATOM 3459 CG PRO C 9 61.742 99.607 −12.272 1.00 31.67 C ATOM 3460 C PRO C 9 63.607 97.389 −13.404 1.00 37.14 C ATOM 3461 O PRO C 9 64.487 97.661 −12.572 1.00 30.31 C ATOM 3462 N ILE C 10 63.883 97.070 −14.669 1.00 30.28 C ATOM 3463 CA ILE C 10 65.252 97.015 −15.166 1.00 29.72 C ATOM 3464 CB ILE C 10 65.704 95.533 −15.351 1.00 30.40 C ATOM 3465 CG2 ILE C 10 64.708 94.766 −16.273 1.00 30.23 C ATOM 3466 CG1 ILE C 10 67.121 95.474 −15.931 1.00 28.32 C ATOM 3467 CD1 ILE C 10 67.729 94.058 −15.907 1.00 27.53 C ATOM 3468 C ILE C 10 65.380 97.792 −16.488 1.00 36.89 C ATOM 3469 O ILE C 10 64.732 97.472 −17.491 1.00 34.25 C ATOM 3470 N LEU C 11 66.219 98.822 −16.483 1.00 38.68 C ATOM 3471 CA LEU C 11 66.436 99.629 −17.678 1.00 36.69 C ATOM 3472 CB LEU C 11 67.269 100.846 −17.320 1.00 40.95 C ATOM 3473 CG LEU C 11 66.804 102.189 −17.855 1.00 45.07 C ATOM 3474 CD1 LEU C 11 65.484 102.575 −17.199 1.00 43.54 C ATOM 3475 CD2 LEU C 11 67.875 103.215 −17.565 1.00 43.98 C ATOM 3476 C LEU C 11 67.176 98.837 −18.758 1.00 39.52 C ATOM 3477 O LEU C 11 68.193 98.204 −18.475 1.00 37.78 C ATOM 3478 N ASN C 12 66.680 98.899 −19.988 1.00 30.25 C ATOM 3479 CA ASN C 12 67.284 98.227 −21.121 1.00 28.03 C ATOM 3480 CB ASN C 12 68.705 98.746 −21.351 1.00 38.34 C ATOM 3481 CG ASN C 12 68.739 100.231 −21.653 1.00 42.68 C ATOM 3482 OD1 ASN C 12 69.139 101.036 −20.813 1.00 47.15 C ATOM 3483 ND2 ASN C 12 68.318 100.596 −22.859 1.00 44.31 C ATOM 3484 C ASN C 12 67.294 96.721 −20.910 1.00 36.66 C ATOM 3485 O ASN C 12 68.253 96.075 −21.417 1.00 38.52 C ATOM 3486 N GLY C 13 66.330 96.216 −20.179 1.00 37.43 C ATOM 3487 CA GLY C 13 66.219 94.783 −19.993 1.00 37.37 C ATOM 3488 C GLY C 13 64.776 94.380 −19.800 1.00 34.87 C ATOM 3489 O GLY C 13 63.859 95.180 −19.928 1.00 37.34 C ATOM 3490 N ARG C 14 64.557 93.119 −19.493 1.00 35.59 C ATOM 3491 CA ARG C 14 63.201 92.681 −19.259 1.00 36.84 C ATOM 3492 CB ARG C 14 62.562 92.191 −20.558 1.00 41.62 C ATOM 3493 CG ARG C 14 63.338 91.087 −21.221 1.00 51.45 C ATOM 3494 CD ARG C 14 63.739 91.505 −22.634 1.00 65.10 C ATOM 3495 NE ARG C 14 64.692 92.626 −22.649 1.00 73.47 C ATOM 3496 CZ ARG C 14 64.669 93.630 −23.528 1.00 76.84 C ATOM 3497 NH1 ARG C 14 63.736 93.667 −24.477 1.00 76.76 C ATOM 3498 NH2 ARG C 14 65.576 94.600 −23.457 1.00 76.89 C ATOM 3499 C ARG C 14 63.179 91.573 −18.224 1.00 34.90 C ATOM 3500 O ARG C 14 64.211 90.974 −17.875 1.00 30.74 C ATOM 3501 N ILE C 15 61.985 91.308 −17.725 1.00 32.52 C ATOM 3502 CA ILE C 15 61.809 90.274 −16.740 1.00 35.90 C ATOM 3503 CB ILE C 15 61.048 90.814 −15.525 1.00 31.54 C ATOM 3504 CG2 ILE C 15 60.749 89.677 −14.553 1.00 25.41 C ATOM 3505 CG1 ILE C 15 61.862 91.952 −14.893 1.00 30.46 C ATOM 3506 CD1 ILE C 15 61.086 92.836 −13.959 1.00 28.46 C ATOM 3507 C ILE C 15 61.013 89.156 −17.357 1.00 39.71 C ATOM 3508 O ILE C 15 60.004 89.403 −18.022 1.00 39.51 C ATOM 3509 N SER C 16 61.469 87.932 −17.136 1.00 39.22 C ATOM 3510 CA SER C 16 60.762 86.750 −17.623 1.00 50.26 C ATOM 3511 CB SER C 16 61.410 85.472 −17.077 1.00 53.90 C ATOM 3512 OG SER C 16 61.213 85.384 −15.655 1.00 59.12 C ATOM 3513 C SER C 16 59.326 86.801 −17.091 1.00 50.15 C ATOM 3514 O SER C 16 59.097 87.096 −15.911 1.00 46.35 C ATOM 3515 N TYR C 17 58.377 86.475 −17.961 1.00 54.91 C ATOM 3516 CA TYR C 17 56.951 86.453 −17.629 1.00 50.96 C ATOM 3517 CB TYR C 17 56.154 85.806 −18.765 1.00 56.78 C ATOM 3518 CG TYR C 17 54.665 86.055 −18.678 1.00 58.05 C ATOM 3519 CD1 TYR C 17 54.109 87.224 −19.209 1.00 59.99 C ATOM 3520 CE1 TYR C 17 52.751 87.509 −19.071 1.00 61.22 C ATOM 3521 CD2 TYR C 17 53.822 85.163 −18.004 1.00 55.94 C ATOM 3522 CE2 TYR C 17 52.457 85.438 −17.854 1.00 58.29 C ATOM 3523 CZ TYR C 17 51.926 86.620 −18.395 1.00 61.48 C ATOM 3524 OH TYR C 17 50.577 86.917 −18.272 1.00 63.66 C ATOM 3525 C TYR C 17 56.708 85.652 −16.360 1.00 49.21 C ATOM 3526 O TYR C 17 57.228 84.555 −16.189 1.00 51.47 C ATOM 3527 N TYR C 18 55.921 86.212 −15.459 1.00 49.68 C ATOM 3528 CA TYR C 18 55.600 85.528 −14.218 1.00 46.63 C ATOM 3529 CB TYR C 18 56.361 86.154 −13.033 1.00 42.78 C ATOM 3530 CG TYR C 18 56.242 87.663 −12.969 1.00 35.46 C ATOM 3531 CD1 TYR C 18 57.129 88.488 −13.678 1.00 36.33 C ATOM 3532 CE1 TYR C 18 56.996 89.880 −13.663 1.00 33.08 C ATOM 3533 CD2 TYR C 18 55.220 88.270 −12.243 1.00 29.58 C ATOM 3534 CE2 TYR C 18 55.083 89.665 −12.218 1.00 29.35 C ATOM 3535 CZ TYR C 18 55.968 90.465 −12.921 1.00 27.89 C ATOM 3536 OH TYR C 18 55.863 91.850 −12.860 1.00 32.49 C ATOM 3537 C TYR C 18 54.100 85.695 −14.022 1.00 43.03 C ATOM 3538 O TYR C 18 53.496 86.659 −14.513 1.00 41.84 C ATOM 3539 N SER C 19 53.496 84.758 −13.314 1.00 44.03 C ATOM 3540 CA SER C 19 52.067 84.849 −13.068 1.00 49.05 C ATOM 3541 CB SER C 19 51.430 83.455 −13.036 1.00 48.59 C ATOM 3542 OG SER C 19 52.115 82.585 −12.147 1.00 50.14 C ATOM 3543 C SER C 19 51.823 85.584 −11.749 1.00 50.35 C ATOM 3544 O SER C 19 52.661 85.567 −10.839 1.00 46.39 C ATOM 3545 N THR C 20 50.607 86.109 −11.537 1.00 52.04 C ATOM 3546 CA THR C 20 50.099 86.975 −10.488 1.00 53.58 C ATOM 3547 CB THR C 20 49.571 88.293 −11.054 1.00 55.84 C ATOM 3548 OG1 THR C 20 48.476 88.030 −11.940 1.00 60.69 C ATOM 3549 CG2 THR C 20 50.671 89.029 −11.802 1.00 52.60 C ATOM 3550 C THR C 20 49.003 86.277 −9.703 1.00 56.21 C ATOM 3551 O THR C 20 48.037 85.783 −10.339 1.00 59.04 C ATOM 3552 N PRO C 21 49.034 86.244 −8.386 1.00 47.82 C ATOM 3553 CD PRO C 21 48.004 85.901 −7.826 1.00 47.40 C ATOM 3554 CA PRO C 21 50.027 86.916 −7.519 1.00 42.99 C ATOM 3555 CB PRO C 21 49.335 86.932 −6.151 1.00 43.36 C ATOM 3556 CG PRO C 21 48.022 86.266 −6.380 1.00 47.21 C ATOM 3557 C PRO C 21 51.356 86.153 −7.464 1.00 39.76 C ATOM 3558 O PRO C 21 51.481 85.058 −8.071 1.00 37.13 C ATOM 3559 N ILE C 22 52.324 86.813 −6.805 1.00 33.73 C ATOM 3560 CA ILE C 22 53.646 86.216 −6.676 1.00 31.36 C ATOM 3561 CB ILE C 22 54.766 87.216 −6.985 1.00 33.33 C ATOM 3562 CG2 ILE C 22 56.125 86.572 −6.755 1.00 33.08 C ATOM 3563 CG1 ILE C 22 54.641 87.724 −8.423 1.00 24.06 C ATOM 3564 CD1 ILE C 22 55.565 88.876 −8.747 1.00 24.35 C ATOM 3565 C ILE C 22 53.824 85.628 −5.269 1.00 34.54 C ATOM 3566 O ILE C 22 53.977 86.348 −4.285 1.00 28.13 C ATOM 3567 N ALA C 23 53.864 84.299 −5.155 1.00 28.78 C ATOM 3568 CA ALA C 23 54.048 83.695 −3.836 1.00 30.59 C ATOM 3569 CB ALA C 23 53.437 82.316 −3.834 1.00 31.70 C ATOM 3570 C ALA C 23 55.517 83.599 −3.412 1.00 30.12 C ATOM 3571 O ALA C 23 56.399 83.517 −4.266 1.00 25.80 C ATOM 3572 N VAL C 24 55.784 83.613 −2.102 1.00 32.21 C ATOM 3573 CA VAL C 24 57.165 83.456 −1.625 1.00 30.00 C ATOM 3574 CB VAL C 24 57.272 83.290 −0.087 1.00 35.52 C ATOM 3575 CG1 VAL C 24 56.808 84.568 0.597 1.00 35.78 C ATOM 3576 CG2 VAL C 24 56.459 82.108 0.378 1.00 39.11 C ATOM 3577 C VAL C 24 57.673 82.175 −2.253 1.00 31.34 C ATOM 3578 O VAL C 24 56.918 81.231 −2.413 1.00 28.53 C ATOM 3579 N GLY C 25 58.947 82.128 −2.603 1.00 30.39 C ATOM 3580 CA GLY C 25 59.456 80.936 −3.249 1.00 32.92 C ATOM 3581 C GLY C 25 59.526 81.119 −4.764 1.00 34.28 C ATOM 3582 O GLY C 25 60.245 80.389 −5.443 1.00 37.66 C ATOM 3583 N THR C 26 58.785 82.086 −5.296 1.00 25.38 C ATOM 3584 CA THR C 26 58.791 82.337 −6.735 1.00 33.97 C ATOM 3585 CB THR C 26 57.652 83.304 −7.169 1.00 27.23 C ATOM 3586 OG1 THR C 26 56.390 82.761 −6.784 1.00 35.09 C ATOM 3587 CG2 THR C 26 57.650 83.514 −8.696 1.00 27.35 C ATOM 3588 C THR C 26 60.113 82.985 −7.132 1.00 35.06 C ATOM 3589 O THR C 26 60.614 83.888 −6.441 1.00 32.34 C ATOM 3590 N VAL C 27 60.662 82.523 −8.246 1.00 27.52 C ATOM 3591 CA VAL C 27 61.914 83.046 −8.795 1.00 30.48 C ATOM 3592 CB VAL C 27 62.901 81.912 −9.116 1.00 35.60 C ATOM 3593 CG1 VAL C 27 64.064 82.451 −9.936 1.00 34.59 C ATOM 3594 CG2 VAL C 27 63.398 81.269 −7.830 1.00 34.12 C ATOM 3595 C VAL C 27 61.632 83.751 −10.114 1.00 32.83 C ATOM 3596 O VAL C 27 60.908 83.216 −10.953 1.00 31.75 C ATOM 3597 N ILE C 28 62.168 84.956 −10.310 1.00 31.95 C ATOM 3598 CA ILE C 28 61.967 85.628 −11.600 1.00 25.76 C ATOM 3599 CB ILE C 28 61.234 86.962 −11.482 1.00 25.19 C ATOM 3600 CG2 ILE C 28 59.782 86.710 −11.057 1.00 27.07 C ATOM 3601 CG1 ILE C 28 61.981 87.915 −10.530 1.00 20.91 C ATOM 3602 CD1 ILE C 28 61.363 89.345 −10.512 1.00 24.89 C ATOM 3603 C ILE C 28 63.341 85.870 −12.187 1.00 29.97 C ATOM 3604 O ILE C 28 64.341 85.934 −11.450 1.00 24.78 C ATOM 3605 N ARG C 29 63.394 86.015 −13.505 1.00 31.68 C ATOM 3606 CA ARG C 29 64.673 86.191 −14.185 1.00 33.25 C ATOM 3607 CB ARG C 29 64.962 84.984 −15.093 1.00 43.21 C ATOM 3608 CG ARG C 29 65.539 83.751 −14.395 1.00 55.79 C ATOM 3609 CD ARG C 29 64.795 82.458 −14.794 1.00 63.30 C ATOM 3610 NE ARG C 29 63.873 82.000 −13.745 1.00 66.73 C ATOM 3611 CZ ARG C 29 62.570 81.762 −13.917 1.00 68.37 C ATOM 3612 NH1 ARG C 29 62.003 81.935 −15.119 1.00 66.91 C ATOM 3613 NH2 ARG C 29 61.831 81.353 −12.883 1.00 61.65 C ATOM 3614 C ARG C 29 64.794 87.444 −15.020 1.00 30.28 C ATOM 3615 O ARG C 29 63.956 87.732 −15.872 1.00 29.65 C ATOM 3616 N TYR C 30 65.867 88.181 −14.778 1.00 32.96 C ATOM 3617 CA TYR C 30 66.159 89.400 −15.527 1.00 31.51 C ATOM 3618 CB TYR C 30 66.759 90.437 −14.590 1.00 27.74 C ATOM 3619 CG TYR C 30 65.773 91.001 −13.617 1.00 23.76 C ATOM 3620 CD1 TYR C 30 65.257 90.224 −12.571 1.00 28.24 C ATOM 3621 CE1 TYR C 30 64.350 90.773 −11.631 1.00 28.16 C ATOM 3622 CD2 TYR C 30 65.360 92.327 −13.718 1.00 27.82 C ATOM 3623 CE2 TYR C 30 64.456 92.879 −12.793 1.00 28.53 C ATOM 3624 CZ TYR C 30 63.971 92.097 −11.758 1.00 22.02 C ATOM 3625 OH TYR C 30 63.160 92.703 −10.848 1.00 24.79 C ATOM 3626 C TYR C 30 67.161 89.133 −16.641 1.00 25.91 C ATOM 3627 O TYR C 30 68.007 88.254 −16.520 1.00 26.19 C ATOM 3628 N SER C 31 67.065 89.883 −17.731 1.00 28.15 C ATOM 3629 CA SER C 31 68.027 89.740 −18.811 1.00 28.99 C ATOM 3630 CB SER C 31 67.611 88.643 −19.795 1.00 25.70 C ATOM 3631 OG SER C 31 66.381 88.981 −20.380 1.00 32.21 C ATOM 3632 C SER C 31 68.124 91.082 −19.518 1.00 30.27 C ATOM 3633 O SER C 31 67.213 91.910 −19.437 1.00 31.27 C ATOM 3634 N CYS C 32 69.238 91.304 −20.192 1.00 27.74 C ATOM 3635 CA CYS C 32 69.457 92.558 −20.890 1.00 32.43 C ATOM 3636 C CYS C 32 69.378 92.286 −22.369 1.00 36.47 C ATOM 3637 O CYS C 32 69.611 91.146 −22.819 1.00 33.53 C ATOM 3638 CB CYS C 32 70.840 93.110 −20.530 1.00 30.11 C ATOM 3639 SG CYS C 32 70.999 93.505 −18.757 1.00 30.29 C ATOM 3640 N SER C 33 68.922 93.383 −23.026 1.00 41.81 C ATOM 3641 CA SER C 33 69.024 93.272 −24.485 1.00 48.46 C ATOM 3642 CB SER C 33 68.136 94.544 −24.975 1.00 51.34 C ATOM 3643 OG SER C 33 68.752 95.734 −24.524 1.00 57.23 C ATOM 3644 C SER C 33 70.449 92.848 −24.842 1.00 54.01 C ATOM 3645 O SER C 33 71.347 92.852 −23.989 1.00 61.22 C ATOM 3646 N GLY C 34 70.633 92.487 −26.096 1.00 55.17 C ATOM 3647 CA GLY C 34 71.928 91.989 −26.558 1.00 49.56 C ATOM 3648 C GLY C 34 73.161 92.877 −26.748 1.00 47.38 C ATOM 3649 O GLY C 34 74.279 92.377 −26.942 1.00 46.07 C ATOM 3650 N THR C 35 72.832 94.184 −26.690 1.00 41.74 C ATOM 3651 CA THR C 35 73.932 95.134 −26.777 1.00 46.36 C ATOM 3652 CB THR C 35 73.603 96.329 −27.720 1.00 51.23 C ATOM 3653 OG1 THR C 35 72.301 96.848 −27.419 1.00 57.47 C ATOM 3654 CG2 THR C 35 73.641 95.881 −29.190 1.00 54.03 C ATOM 3655 C THR C 35 74.305 95.658 −25.383 1.00 43.55 C ATOM 3656 O THR C 35 75.001 96.655 −25.258 1.00 40.41 C ATOM 3657 N PHE C 36 73.840 94.969 −24.342 1.00 34.64 C ATOM 3658 CA PHE C 36 74.133 95.342 −22.965 1.00 31.17 C ATOM 3659 CB PHE C 36 72.888 95.857 −22.253 1.00 30.28 C ATOM 3660 CG PHE C 36 72.414 97.176 −22.750 1.00 32.70 C ATOM 3661 CD1 PHE C 36 71.692 97.266 −23.944 1.00 36.40 C ATOM 3662 CD2 PHE C 36 72.729 98.343 −22.054 1.00 33.13 C ATOM 3663 CE1 PHE C 36 71.301 98.500 −24.427 1.00 37.59 C ATOM 3664 CE2 PHE C 36 72.345 99.588 −22.528 1.00 32.44 C ATOM 3665 CZ PHE C 36 71.629 99.673 −23.718 1.00 38.52 C ATOM 3666 C PHE C 36 74.612 94.107 −22.239 1.00 34.05 C ATOM 3667 O PHE C 36 74.432 93.001 −22.727 1.00 31.93 C ATOM 3668 N ARG C 37 75.236 94.292 −21.079 1.00 28.78 C ATOM 3669 CA ARG C 37 75.703 93.167 −20.295 1.00 27.36 C ATOM 3670 CB ARG C 37 77.233 93.140 −20.235 1.00 27.49 C ATOM 3671 CG ARG C 37 77.871 92.816 −21.587 1.00 21.08 C ATOM 3672 CD ARG C 37 77.403 91.440 −22.049 1.00 27.97 C ATOM 3673 NE ARG C 37 78.050 91.042 −23.301 1.00 35.17 C ATOM 3674 CZ ARG C 37 77.641 91.427 −24.503 1.00 36.96 C ATOM 3675 NH1 ARG C 37 76.572 92.213 −24.620 1.00 32.52 C ATOM 3676 NH2 ARG C 37 78.308 91.039 −25.581 1.00 37.15 C ATOM 3677 C ARG C 37 75.091 93.309 −18.913 1.00 29.60 C ATOM 3678 O ARG C 37 75.060 94.400 −18.336 1.00 25.97 C ATOM 3679 N LEU C 38 74.614 92.193 −18.383 1.00 25.39 C ATOM 3680 CA LEU C 38 73.952 92.202 −17.083 1.00 27.27 C ATOM 3681 CB LEU C 38 73.038 90.984 −16.980 1.00 27.65 C ATOM 3682 CG LEU C 38 72.221 90.971 −15.692 1.00 35.28 C ATOM 3683 CD1 LEU C 38 70.799 91.354 −16.019 1.00 33.06 C ATOM 3684 CD2 LEU C 38 72.278 89.589 −15.051 1.00 40.58 C ATOM 3685 C LEU C 38 74.951 92.203 −15.926 1.00 24.03 C ATOM 3686 O LEU C 38 75.851 91.376 −15.892 1.00 27.79 C ATOM 3687 N ILE C 39 74.794 93.146 −15.001 1.00 25.30 C ATOM 3688 CA ILE C 39 75.654 93.264 −13.819 1.00 26.06 C ATOM 3689 CB ILE C 39 76.255 94.707 −13.686 1.00 31.18 C ATOM 3690 CG2 ILE C 39 77.130 94.813 −12.455 1.00 28.29 C ATOM 3691 CG1 ILE C 39 77.057 95.071 −14.955 1.00 37.49 C ATOM 3692 CD1 ILE C 39 78.059 94.022 −15.415 1.00 46.78 C ATOM 3693 C ILE C 39 74.787 92.979 −12.590 1.00 27.54 C ATOM 3694 O ILE C 39 73.807 93.683 −12.327 1.00 21.11 C ATOM 3695 N GLY C 40 75.140 91.950 −11.829 1.00 28.46 C ATOM 3696 CA GLY C 40 74.351 91.619 −10.654 1.00 28.45 C ATOM 3697 C GLY C 40 73.691 90.275 −10.901 1.00 31.11 C ATOM 3698 O GLY C 40 73.762 89.752 −12.008 1.00 27.47 C ATOM 3699 N GLU C 41 73.057 89.713 −9.876 1.00 32.89 C ATOM 3700 CA GLU C 41 72.395 88.411 −9.994 1.00 37.70 C ATOM 3701 CB GLU C 41 72.006 87.900 −8.597 1.00 35.85 C ATOM 3702 CG GLU C 41 71.217 86.601 −8.624 1.00 47.53 C ATOM 3703 CD GLU C 41 71.983 85.447 −9.235 1.00 48.84 C ATOM 3704 OE1 GLU C 41 71.419 84.733 −10.088 1.00 44.21 C ATOM 3705 OE2 GLU C 41 73.153 85.252 −8.842 1.00 56.76 C ATOM 3706 C GLU C 41 71.161 88.510 −10.893 1.00 32.10 C ATOM 3707 O GLU C 41 70.336 89.404 −10.718 1.00 31.37 C ATOM 3708 N LYS C 42 71.033 87.604 −11.857 1.00 33.31 C ATOM 3709 CA LYS C 42 69.879 87.647 −12.760 1.00 33.67 C ATOM 3710 CB LYS C 42 70.207 86.955 −14.069 1.00 33.01 C ATOM 3711 CG LYS C 42 70.550 85.515 −13.891 1.00 39.88 C ATOM 3712 CD LYS C 42 70.862 84.895 −15.238 1.00 43.23 C ATOM 3713 CE LYS C 42 71.922 83.820 −15.105 1.00 48.14 C ATOM 3714 NZ LYS C 42 71.648 82.872 −13.965 1.00 52.44 C ATOM 3715 C LYS C 42 68.591 87.038 −12.185 1.00 34.36 C ATOM 3716 O LYS C 42 67.509 87.306 −12.687 1.00 37.69 C ATOM 3717 N SER C 43 68.685 86.265 −11.117 1.00 25.52 C ATOM 3718 CA SER C 43 67.472 85.664 −10.565 1.00 31.67 C ATOM 3719 CB SER C 43 67.668 84.155 −10.331 1.00 28.31 C ATOM 3720 OG SER C 43 67.869 83.464 −11.537 1.00 39.90 C ATOM 3721 C SER C 43 67.099 86.274 −9.233 1.00 29.32 C ATOM 3722 O SER C 43 67.945 86.318 −8.342 1.00 31.30 C ATOM 3723 N LEU C 44 65.853 86.735 −9.087 1.00 27.40 C ATOM 3724 CA LEU C 44 65.393 87.267 −7.808 1.00 28.37 C ATOM 3725 CB LEU C 44 64.744 88.638 −7.931 1.00 27.60 C ATOM 3726 CG LEU C 44 65.498 89.876 −8.393 1.00 38.75 C ATOM 3727 CD1 LEU C 44 64.700 91.149 −7.896 1.00 26.06 C ATOM 3728 CD2 LEU C 44 66.913 89.846 −7.907 1.00 39.16 C ATOM 3729 C LEU C 44 64.352 86.315 −7.218 1.00 29.49 C ATOM 3730 O LEU C 44 63.469 85.796 −7.914 1.00 35.15 C ATOM 3731 N LEU C 45 64.434 86.137 −5.919 1.00 25.55 C ATOM 3732 CA LEU C 45 63.560 85.222 −5.230 1.00 28.43 C ATOM 3733 CB LEU C 45 64.412 84.210 −4.469 1.00 28.67 C ATOM 3734 CG LEU C 45 63.709 83.269 −3.493 1.00 30.62 C ATOM 3735 CD1 LEU C 45 62.896 82.195 −4.244 1.00 32.56 C ATOM 3736 CD2 LEU C 45 64.798 82.623 −2.649 1.00 31.55 C ATOM 3737 C LEU C 45 62.664 85.961 −4.263 1.00 28.71 C ATOM 3738 O LEU C 45 63.094 86.894 −3.558 1.00 21.68 C ATOM 3739 N CYS C 46 61.410 85.547 −4.238 1.00 25.91 C ATOM 3740 CA CYS C 46 60.455 86.152 −3.343 1.00 26.90 C ATOM 3741 C CYS C 46 60.610 85.392 −2.032 1.00 30.25 C ATOM 3742 O CYS C 46 60.448 84.173 −1.980 1.00 28.51 C ATOM 3743 CB CYS C 46 59.021 86.026 −3.908 1.00 28.02 C ATOM 3744 SG CYS C 46 57.741 86.546 −2.696 1.00 28.63 C ATOM 3745 N ILE C 47 60.925 86.115 −0.971 1.00 21.11 C ATOM 3746 CA ILE C 47 61.120 85.484 0.314 1.00 24.65 C ATOM 3747 CB ILE C 47 62.619 85.501 0.722 1.00 32.62 C ATOM 3748 CG2 ILE C 47 63.505 84.878 −0.358 1.00 27.06 C ATOM 3749 CG1 ILE C 47 63.050 86.958 0.959 1.00 25.64 C ATOM 3750 CD1 ILE C 47 64.429 87.119 1.592 1.00 32.03 C ATOM 3751 C ILE C 47 60.431 86.274 1.421 1.00 31.05 C ATOM 3752 O ILE C 47 59.931 87.399 1.226 1.00 22.58 C ATOM 3753 N THR C 48 60.421 85.669 2.596 1.00 27.58 C ATOM 3754 CA THR C 48 59.964 86.388 3.764 1.00 27.51 C ATOM 3755 CB THR C 48 58.584 85.987 4.273 1.00 28.85 C ATOM 3756 OG1 THR C 48 58.303 86.778 5.426 1.00 25.48 C ATOM 3757 CG2 THR C 48 58.490 84.526 4.619 1.00 26.50 C ATOM 3758 C THR C 48 61.001 86.164 4.839 1.00 29.22 C ATOM 3759 O THR C 48 61.455 85.049 5.060 1.00 29.40 C ATOM 3760 N LYS C 49 61.445 87.243 5.463 1.00 27.29 C ATOM 3761 CA LYS C 49 62.425 87.112 6.522 1.00 31.22 C ATOM 3762 CB LYS C 49 63.478 88.220 6.427 1.00 26.53 C ATOM 3763 CG LYS C 49 64.229 88.239 5.134 1.00 35.41 C ATOM 3764 CD LYS C 49 65.703 88.351 5.346 1.00 40.12 C ATOM 3765 CE LYS C 49 66.262 87.134 6.055 1.00 42.32 C ATOM 3766 NZ LYS C 49 67.729 87.262 6.166 1.00 46.64 C ATOM 3767 C LYS C 49 61.745 87.219 7.877 1.00 33.53 C ATOM 3768 O LYS C 49 62.249 86.692 8.856 1.00 30.36 C ATOM 3769 N ASP C 50 60.596 87.896 7.952 1.00 25.34 C ATOM 3770 CA ASP C 50 59.978 88.083 9.253 1.00 26.98 C ATOM 3771 CB ASP C 50 59.961 89.579 9.597 1.00 25.16 C ATOM 3772 CG ASP C 50 59.154 90.397 8.607 1.00 27.41 C ATOM 3773 OD1 ASP C 50 58.459 89.768 7.749 1.00 22.49 C ATOM 3774 OD2 ASP C 50 59.207 91.664 8.693 1.00 26.37 C ATOM 3775 C ASP C 50 58.598 87.492 9.365 1.00 25.28 C ATOM 3776 O ASP C 50 57.883 87.770 10.321 1.00 24.69 C ATOM 3777 N LYS C 51 58.247 86.664 8.386 1.00 26.19 C ATOM 3778 CA LYS C 51 56.948 86.006 8.319 1.00 23.97 C ATOM 3779 CB LYS C 51 56.717 85.091 9.526 1.00 31.09 C ATOM 3780 CG LYS C 51 57.749 84.021 9.749 1.00 32.84 C ATOM 3781 CD LYS C 51 57.625 82.919 8.769 1.00 44.41 C ATOM 3782 CE LYS C 51 58.505 81.752 9.179 1.00 52.55 C ATOM 3783 NZ LYS C 51 58.266 81.397 10.605 1.00 51.40 C ATOM 3784 C LYS C 51 55.791 86.996 8.241 1.00 25.78 C ATOM 3785 O LYS C 51 54.660 86.628 8.510 1.00 25.03 C ATOM 3786 N VAL C 52 56.048 88.252 7.896 1.00 25.78 C ATOM 3787 CA VAL C 52 54.937 89.195 7.758 1.00 23.31 C ATOM 3788 CB VAL C 52 54.976 90.286 8.894 1.00 30.82 C ATOM 3789 CG1 VAL C 52 53.786 91.197 8.802 1.00 27.39 C ATOM 3790 CG2 VAL C 52 54.946 89.611 10.264 1.00 33.79 C ATOM 3791 C VAL C 52 55.085 89.832 6.376 1.00 29.16 C ATOM 3792 O VAL C 52 54.193 89.764 5.537 1.00 25.28 C ATOM 3793 N ASP C 53 56.248 90.433 6.146 1.00 31.64 C ATOM 3794 CA ASP C 53 56.575 91.099 4.892 1.00 27.94 C ATOM 3795 CB ASP C 53 57.647 92.167 5.150 1.00 28.37 C ATOM 3796 CG ASP C 53 57.189 93.235 6.132 1.00 30.66 C ATOM 3797 OD1 ASP C 53 56.323 94.069 5.744 1.00 20.78 C ATOM 3798 OD2 ASP C 53 57.700 93.245 7.287 1.00 27.56 C ATOM 3799 C ASP C 53 57.112 90.126 3.837 1.00 23.86 C ATOM 3800 O ASP C 53 57.862 89.212 4.164 1.00 24.61 C ATOM 3801 N GLY C 54 56.735 90.327 2.573 1.00 26.63 C ATOM 3802 CA GLY C 54 57.253 89.489 1.476 1.00 20.87 C ATOM 3803 C GLY C 54 58.190 90.420 0.730 1.00 25.47 C ATOM 3804 O GLY C 54 57.814 91.563 0.435 1.00 19.97 C ATOM 3805 N THR C 55 59.422 89.999 0.459 1.00 22.42 C ATOM 3806 CA THR C 55 60.345 90.907 −0.247 1.00 21.92 C ATOM 3807 CB THR C 55 61.326 91.591 0.760 1.00 24.17 C ATOM 3808 OG1 THR C 55 61.999 92.669 0.106 1.00 24.68 C ATOM 3809 CG2 THR C 55 62.401 90.597 1.251 1.00 24.06 C ATOM 3810 C THR C 55 61.184 90.153 −1.284 1.00 22.33 C ATOM 3811 O THR C 55 61.298 88.929 −1.209 1.00 24.76 C ATOM 3812 N TRP C 56 61.767 90.882 −2.230 1.00 22.04 C ATOM 3813 CA TRP C 56 62.637 90.281 −3.226 1.00 21.23 C ATOM 3814 CB TRP C 56 62.689 91.142 −4.506 1.00 28.51 C ATOM 3815 CG TRP C 56 61.377 91.081 −5.223 1.00 25.63 C ATOM 3816 CD2 TRP C 56 60.853 89.962 −5.970 1.00 26.11 C ATOM 3817 CE2 TRP C 56 59.512 90.266 −6.287 1.00 23.40 C ATOM 3818 CE3 TRP C 56 61.384 88.723 −6.383 1.00 25.94 C ATOM 3819 CD1 TRP C 56 60.374 91.988 −5.141 1.00 23.59 C ATOM 3820 NE1 TRP C 56 59.249 91.513 −5.771 1.00 25.69 C ATOM 3821 CZ2 TRP C 56 58.679 89.384 −7.003 1.00 24.25 C ATOM 3822 CZ3 TRP C 56 60.555 87.832 −7.095 1.00 26.08 C ATOM 3823 CH2 TRP C 56 59.209 88.177 −7.398 1.00 29.68 C ATOM 3824 C TRP C 56 63.994 90.185 −2.504 1.00 22.58 C ATOM 3825 O TRP C 56 64.379 91.119 −1.805 1.00 23.17 C ATOM 3826 N ASP C 57 64.698 89.064 −2.660 1.00 24.44 C ATOM 3827 CA ASP C 57 65.949 88.838 −1.931 1.00 26.43 C ATOM 3828 CB ASP C 57 66.293 87.334 −1.894 1.00 26.66 C ATOM 3829 CG ASP C 57 66.722 86.762 −3.256 1.00 31.79 C ATOM 3830 OD1 ASP C 57 67.168 85.599 −3.268 1.00 36.29 C ATOM 3831 OD2 ASP C 57 66.613 87.435 −4.298 1.00 30.66 C ATOM 3832 C ASP C 57 67.173 89.647 −2.317 1.00 29.20 C ATOM 3833 O ASP C 57 68.161 89.651 −1.589 1.00 32.18 C ATOM 3834 N LYS C 58 67.084 90.363 −3.428 1.00 31.78 C ATOM 3835 CA LYS C 58 68.180 91.182 −3.928 1.00 31.51 C ATOM 3836 CB LYS C 58 69.081 90.366 −4.866 1.00 37.98 C ATOM 3837 CG LYS C 58 70.061 89.452 −4.166 1.00 49.29 C ATOM 3838 CD LYS C 58 69.648 87.987 −4.237 1.00 58.25 C ATOM 3839 CE LYS C 58 69.569 87.484 −5.686 1.00 55.39 C ATOM 3840 NZ LYS C 58 68.893 86.136 −5.803 1.00 46.73 C ATOM 3841 C LYS C 58 67.614 92.311 −4.741 1.00 29.28 C ATOM 3842 O LYS C 58 66.442 92.301 −5.106 1.00 29.16 C ATOM 3843 N PRO C 59 68.429 93.340 −4.958 1.00 32.29 C ATOM 3844 CD PRO C 59 69.835 93.582 −4.659 1.00 26.68 C ATOM 3845 CA PRO C 59 67.912 94.387 −5.841 1.00 24.28 C ATOM 3846 CB PRO C 59 68.919 95.530 −5.673 1.00 28.93 C ATOM 3847 CG PRO C 59 70.198 94.856 −5.368 1.00 30.90 C ATOM 3848 C PRO C 59 67.949 93.982 −7.321 1.00 29.24 C ATOM 3849 O PRO C 59 68.694 93.012 −7.627 1.00 23.42 C ATOM 3850 N ALA C 60 67.208 94.594 −8.172 1.00 28.57 C ATOM 3851 CA ALA C 60 67.247 94.196 −9.570 1.00 31.26 C ATOM 3852 CB ALA C 60 66.284 95.039 −10.363 1.00 24.31 C ATOM 3853 C ALA C 60 68.674 94.376 −10.126 1.00 32.02 C ATOM 3854 O ALA C 60 69.403 95.259 −9.700 1.00 29.35 C ATOM 3855 N PRO C 61 69.101 93.498 −11.046 1.00 29.11 C ATOM 3856 CD PRO C 61 68.453 92.245 −11.466 1.00 26.65 C ATOM 3857 CA PRO C 61 70.449 93.643 −11.625 1.00 26.17 C ATOM 3858 CB PRO C 61 70.690 92.296 −12.307 1.00 28.95 C ATOM 3859 CG PRO C 61 69.280 91.838 −12.676 1.00 27.22 C ATOM 3860 C PRO C 61 70.327 94.812 −12.632 1.00 26.90 C ATOM 3861 O PRO C 61 69.221 95.303 −12.859 1.00 22.51 C ATOM 3862 N LYS C 62 71.430 95.280 −13.208 1.00 21.80 C ATOM 3863 CA LYS C 62 71.379 96.409 −14.158 1.00 24.26 C ATOM 3864 CB LYS C 62 72.173 97.615 −13.637 1.00 26.24 C ATOM 3865 CG LYS C 62 71.776 98.107 −12.246 1.00 39.00 C ATOM 3866 CD LYS C 62 71.465 99.585 −12.222 1.00 41.85 C ATOM 3867 CE LYS C 62 71.357 100.084 −10.800 1.00 46.78 C ATOM 3868 NZ LYS C 62 72.692 100.117 −10.118 1.00 55.22 C ATOM 3869 C LYS C 62 71.955 96.043 −15.507 1.00 21.61 C ATOM 3870 O LYS C 62 72.735 95.097 −15.607 1.00 25.68 C ATOM 3871 N CYS C 63 71.585 96.790 −16.549 1.00 27.02 C ATOM 3872 CA CYS C 63 72.113 96.526 −17.903 1.00 27.02 C ATOM 3873 C CYS C 63 73.118 97.601 −18.302 1.00 30.37 C ATOM 3874 O CYS C 63 72.751 98.758 −18.416 1.00 32.00 C ATOM 3875 CB CYS C 63 70.989 96.504 −18.932 1.00 28.91 C ATOM 3876 SG CYS C 63 69.851 95.146 −18.602 1.00 29.20 C ATOM 3877 N GLU C 64 74.376 97.213 −18.514 1.00 23.24 C ATOM 3878 CA GLU C 64 75.417 98.167 −18.890 1.00 30.86 C ATOM 3879 CB GLU C 64 76.707 97.873 −18.098 1.00 31.31 C ATOM 3880 CG GLU C 64 77.231 99.028 −17.228 1.00 39.58 C ATOM 3881 CD GLU C 64 78.383 98.616 −16.287 1.00 40.40 C ATOM 3882 OE1 GLU C 64 79.134 97.679 −16.620 1.00 26.79 C ATOM 3883 OE2 GLU C 64 78.543 99.238 −15.208 1.00 48.25 C ATOM 3884 C GLU C 64 75.703 98.035 −20.380 1.00 25.87 C ATOM 3885 O GLU C 64 75.849 96.923 −20.882 1.00 19.45 C ATOM 3886 N TYR C 65 75.782 99.155 −21.093 1.00 25.32 C ATOM 3887 CA TYR C 65 76.106 99.110 −22.530 1.00 31.90 C ATOM 3888 CB TYR C 65 76.325 100.536 −23.061 1.00 36.00 C ATOM 3889 CG TYR C 65 76.254 100.650 −24.570 1.00 42.53 C ATOM 3890 CD1 TYR C 65 75.041 100.470 −25.238 1.00 42.78 C ATOM 3891 CE1 TYR C 65 74.951 100.568 −26.621 1.00 40.68 C ATOM 3892 CD2 TYR C 65 77.396 100.937 −25.331 1.00 48.40 C ATOM 3893 CE2 TYR C 65 77.321 101.040 −26.729 1.00 48.66 C ATOM 3894 CZ TYR C 65 76.086 100.848 −27.366 1.00 48.38 C ATOM 3895 OH TYR C 65 75.998 100.897 −28.750 1.00 49.96 C ATOM 3896 C TYR C 65 77.407 98.304 −22.704 1.00 26.60 C ATOM 3897 O TYR C 65 78.410 98.634 −22.101 1.00 27.68 C ATOM 3898 N PHE C 66 77.404 97.279 −23.541 1.00 24.63 C ATOM 3899 CA PHE C 66 78.583 96.428 −23.736 1.00 25.64 C ATOM 3900 CB PHE C 66 78.250 95.339 −24.776 1.00 30.86 C ATOM 3901 CG PHE C 66 79.408 94.427 −25.130 1.00 30.23 C ATOM 3902 CD1 PHE C 66 80.137 93.775 −24.143 1.00 25.24 C ATOM 3903 CD2 PHE C 66 79.753 94.208 −26.481 1.00 33.99 C ATOM 3904 CE1 PHE C 66 81.206 92.899 −24.478 1.00 28.31 C ATOM 3905 CE2 PHE C 66 80.822 93.329 −26.838 1.00 29.10 C ATOM 3906 CZ PHE C 66 81.550 92.672 −25.826 1.00 27.94 C ATOM 3907 C PHE C 66 79.896 97.121 −24.133 1.00 32.19 C ATOM 3908 O PHE C 66 79.931 97.955 −25.044 1.00 29.06 C ATOM 3909 N ASN C 67 80.977 96.766 −23.440 1.00 25.19 C ATOM 3910 CA ASN C 67 82.297 97.296 −23.754 1.00 27.44 C ATOM 3911 CE ASN C 67 82.845 98.203 −22.639 1.00 28.12 C ATOM 3912 CG ASN C 67 84.126 98.921 −23.066 1.00 33.33 C ATOM 3913 OD1 ASN C 67 84.904 98.390 −23.870 1.00 27.62 C ATOM 3914 ND2 ASN C 67 84.356 100.126 −22.528 1.00 28.36 C ATOM 3915 C ASN C 67 83.245 96.106 −23.942 1.00 30.05 C ATOM 3916 O ASN C 67 83.706 95.489 −22.967 1.00 18.34 C ATOM 3917 N LYS C 68 83.565 95.816 −25.199 1.00 24.67 C ATOM 3918 CA LYS C 68 84.428 94.686 −25.511 1.00 29.80 C ATOM 3919 CB LYS C 68 84.491 94.441 −27.024 1.00 29.48 C ATOM 3920 CG LYS C 68 85.095 95.574 −27.875 1.00 39.59 C ATOM 3921 CD LYS C 68 85.233 95.076 −29.326 1.00 45.75 C ATOM 3922 CE LYS C 68 85.993 96.016 −30.254 1.00 52.45 C ATOM 3923 NZ LYS C 68 85.111 96.916 −31.073 1.00 56.09 C ATOM 3924 C LYS C 68 85.821 94.831 −24.995 1.00 32.29 C ATOM 3925 O LYS C 68 86.541 93.833 −24.921 1.00 27.75 C ATOM 3926 N TYR C 69 86.237 96.059 −24.663 1.00 25.84 C ATOM 3927 CA TYR C 69 87.599 96.229 −24.153 1.00 24.63 C ATOM 3928 CB TYR C 69 88.147 97.625 −24.434 1.00 27.26 C ATOM 3929 CG TYR C 69 88.161 97.948 −25.876 1.00 31.88 C ATOM 3930 CD1 TYR C 69 87.105 98.635 −26.441 1.00 25.30 C ATOM 3931 CE1 TYR C 69 87.067 98.885 −27.791 1.00 33.19 C ATOM 3932 CD2 TYR C 69 89.213 97.503 −26.708 1.00 32.15 C ATOM 3933 CE2 TYR C 69 89.186 97.749 −28.079 1.00 32.52 C ATOM 3934 CZ TYR C 69 88.095 98.453 −28.614 1.00 34.98 C ATOM 3935 OH TYR C 69 88.031 98.764 −29.952 1.00 32.72 C ATOM 3936 C TYR C 69 87.687 95.997 −22.673 1.00 30.28 C ATOM 3937 O TYR C 69 88.777 95.781 −22.158 1.00 28.03 C ATOM 3938 N SER C 70 86.565 96.050 −21.967 1.00 29.29 C ATOM 3939 CA SER C 70 86.597 95.868 −20.505 1.00 23.26 C ATOM 3940 CB SER C 70 85.204 96.061 −19.871 1.00 25.19 C ATOM 3941 OG SER C 70 84.518 97.144 −20.277 1.00 30.67 C ATOM 3942 C SER C 70 87.175 94.504 −20.128 1.00 29.31 C ATOM 3943 O SER C 70 86.714 93.455 −20.641 1.00 33.25 C ATOM 3944 N SER C 71 88.113 94.596 −19.092 1.00 34.01 C ATOM 3945 CA SER C 71 88.825 93.422 −18.570 1.00 33.07 C ATOM 3946 CB SER C 71 90.139 93.197 −19.334 1.00 37.09 C ATOM 3947 OG SER C 71 90.774 91.992 −18.919 1.00 38.97 C ATOM 3948 C SER C 71 89.145 93.621 −17.099 1.00 31.37 C ATOM 3949 O SER C 71 89.965 94.464 −16.748 1.00 31.95 C ATOM 3950 N CYS C 72 88.518 92.836 −16.230 1.00 32.50 C ATOM 3951 CA CYS C 72 88.760 92.984 −14.803 1.00 31.24 C ATOM 3952 C CYS C 72 89.899 92.131 −14.294 1.00 32.97 C ATOM 3953 O CYS C 72 90.062 90.989 −14.695 1.00 37.51 C ATOM 3954 CB CYS C 72 87.479 92.670 −14.032 1.00 31.14 C ATOM 3955 SG CYS C 72 86.104 93.792 −14.488 1.00 35.33 C ATOM 3956 N PRO C 73 90.723 92.681 −13.401 1.00 31.28 C ATOM 3957 CD PRO C 73 90.688 94.015 −12.785 1.00 34.25 C ATOM 3958 CA PRO C 73 91.836 91.900 −12.875 1.00 37.83 C ATOM 3959 CB PRO C 73 92.700 92.953 −12.199 1.00 39.00 C ATOM 3960 CG PRO C 73 91.667 93.862 −11.635 1.00 36.58 C ATOM 3961 C PRO C 73 91.325 90.889 −11.872 1.00 40.84 C ATOM 3962 O PRO C 73 90.265 91.088 −11.284 1.00 40.57 C ATOM 3963 N GLU C 74 92.185 89.834 −11.599 1.00 44.75 C ATOM 3964 CA GLU C 74 91.750 88.788 −10.731 1.00 50.06 C ATOM 3965 CB GLU C 74 92.854 87.743 −10.680 1.00 55.68 C ATOM 3966 CG GLU C 74 93.109 86.845 −9.771 1.00 64.35 C ATOM 3967 CD GLU C 74 92.171 85.710 −10.135 1.00 67.16 C ATOM 3968 OE1 GLU C 74 92.147 85.315 −11.320 1.00 67.98 C ATOM 3969 OE2 GLU C 74 91.459 85.216 −9.236 1.00 69.43 C ATOM 3970 C GLU C 74 91.482 89.377 −9.347 1.00 45.69 C ATOM 3971 O GLU C 74 92.282 90.168 −8.832 1.00 43.16 C ATOM 3972 N PRO C 75 90.195 89.176 −8.898 1.00 45.27 C ATOM 3973 CD PRO C 75 89.118 88.373 −9.504 1.00 46.99 C ATOM 3974 CA PRO C 75 89.789 89.765 −7.622 1.00 46.84 C ATOM 3975 CB PRO C 75 88.278 89.575 −7.643 1.00 45.59 C ATOM 3976 CG PRO C 75 88.129 88.251 −8.380 1.00 43.10 C ATOM 3977 C PRO C 75 90.484 88.987 −6.471 1.00 46.31 C ATOM 3978 O PRO C 75 90.622 87.764 −6.533 1.00 43.58 C ATOM 3979 N ILE C 76 90.967 89.682 −5.452 1.00 44.06 C ATOM 3980 CA ILE C 76 91.585 88.961 −4.346 1.00 49.43 C ATOM 3981 CB ILE C 76 93.091 89.252 −4.220 1.00 50.66 C ATOM 3982 CG2 ILE C 76 93.648 88.589 −2.960 1.00 51.02 C ATOM 3983 CG1 ILE C 76 93.829 88.692 −5.433 1.00 53.97 C ATOM 3984 CD1 ILE C 76 95.327 88.938 −5.393 1.00 58.58 C ATOM 3985 C ILE C 76 90.910 89.320 −3.041 1.00 47.39 C ATOM 3986 O ILE C 76 90.663 90.496 −2.770 1.00 45.77 C ATOM 3987 N VAL C 77 90.596 88.303 −2.240 1.00 47.49 C ATOM 3988 CA VAL C 77 89.933 88.516 −0.949 1.00 47.30 C ATOM 3989 CB VAL C 77 88.466 87.930 −0.945 1.00 46.81 C ATOM 3990 CG1 VAL C 77 87.848 88.039 0.474 1.00 43.39 C ATOM 3991 CG2 VAL C 77 87.604 88.654 −1.986 1.00 42.04 C ATOM 3992 C VAL C 77 90.725 87.855 0.188 1.00 47.58 C ATOM 3993 O VAL C 77 90.823 86.620 0.263 1.00 45.09 C ATOM 3994 N PRO C 78 91.301 88.669 1.086 1.00 44.97 C ATOM 3995 CD PRO C 78 91.365 90.140 1.032 1.00 45.60 C ATOM 3996 CA PRO C 78 92.078 88.143 2.221 1.00 44.08 C ATOM 3997 CB PRO C 78 92.461 89.407 2.989 1.00 45.76 C ATOM 3998 CG PRO C 78 92.593 90.447 1.892 1.00 46.75 C ATOM 3999 C PRO C 78 91.208 87.217 3.065 1.00 43.84 C ATOM 4000 O PRO C 78 90.088 87.568 3.403 1.00 43.30 C ATOM 4001 N GLY C 79 91.705 86.035 3.395 1.00 44.86 C ATOM 4002 CA GLY C 79 90.913 85.126 4.204 1.00 43.45 C ATOM 4003 C GLY C 79 89.868 84.402 3.379 1.00 45.18 C ATOM 4004 O GLY C 79 89.025 83.667 3.914 1.00 43.18 C ATOM 4005 N GLY C 80 89.922 84.605 2.067 1.00 41.25 C ATOM 4006 CA GLY C 80 88.970 83.946 1.185 1.00 39.64 C ATOM 4007 C GLY C 80 89.622 83.287 −0.022 1.00 44.23 C ATOM 4008 O GLY C 80 90.827 83.420 −0.269 1.00 40.56 C ATOM 4009 N TYR C 81 88.829 82.545 −0.779 1.00 42.62 C ATOM 4010 CA TYR C 81 89.343 81.905 −1.973 1.00 46.24 C ATOM 4011 CB TYR C 81 89.908 80.496 −1.655 1.00 44.92 C ATOM 4012 CG TYR C 81 88.934 79.522 −1.020 1.00 46.64 C ATOM 4013 CD1 TYR C 81 88.405 78.463 −1.754 1.00 48.03 C ATOM 4014 CE1 TYR C 81 87.438 77.618 −1.221 1.00 48.43 C ATOM 4015 CD2 TYR C 81 88.478 79.709 0.281 1.00 47.96 C ATOM 4016 CE2 TYR C 81 87.503 78.871 0.826 1.00 50.43 C ATOM 4017 CZ TYR C 81 86.980 77.827 0.062 1.00 51.08 C ATOM 4018 OH TYR C 81 85.948 77.038 0.550 1.00 54.25 C ATOM 4019 C TYR C 81 88.233 81.854 −3.028 1.00 50.13 C ATOM 4020 O TYR C 81 87.039 81.840 −2.711 1.00 46.05 C ATOM 4021 N LYS C 82 88.643 81.853 −4.289 1.00 50.32 C ATOM 4022 CA LYS C 82 87.697 81.828 −5.380 1.00 53.74 C ATOM 4023 CB LYS C 82 88.393 82.238 −6.681 1.00 53.51 C ATOM 4024 CG LYS C 82 87.466 82.280 −7.884 1.00 54.66 C ATOM 4025 CD LYS C 82 88.182 82.779 −9.126 1.00 52.50 C ATOM 4026 CE LYS C 82 89.254 81.803 −9.563 1.00 53.91 C ATOM 4027 NZ LYS C 82 90.030 82.321 −10.718 1.00 52.48 C ATOM 4028 C LYS C 82 87.089 80.447 −5.528 1.00 54.39 C ATOM 4029 O LYS C 82 87.782 79.435 −5.429 1.00 54.15 C ATOM 4030 N ILE C 83 85.783 80.412 −5.740 1.00 53.36 C ATOM 4031 CA ILE C 83 85.083 79.157 −5.935 1.00 56.28 C ATOM 4032 CB ILE C 83 83.815 79.085 −5.070 1.00 57.52 C ATOM 4033 CG2 ILE C 83 82.803 78.186 −5.698 1.00 58.38 C ATOM 4034 CG1 ILE C 83 84.162 78.510 −3.702 1.00 59.41 C ATOM 4035 CD1 ILE C 83 85.312 79.203 −3.034 1.00 64.54 C ATOM 4036 C ILE C 83 84.698 79.018 −7.408 1.00 60.57 C ATOM 4037 O ILE C 83 84.790 77.926 −7.969 1.00 61.13 C ATOM 4038 N ARG C 84 84.274 80.125 −8.025 1.00 58.19 C ATOM 4039 CA ARG C 84 83.859 80.134 −9.432 1.00 55.53 C ATOM 4040 CB ARG C 84 82.340 80.259 −9.557 1.00 59.40 C ATOM 4041 CG ARG C 84 81.555 79.123 −8.937 1.00 66.78 C ATOM 4042 CD ARG C 84 80.080 79.471 −8.783 1.00 70.71 C ATOM 4043 NE ARG C 84 79.338 78.353 −8.204 1.00 78.82 C ATOM 4044 CZ ARG C 84 78.041 78.384 −7.902 1.00 82.83 C ATOM 4045 NH1 ARG C 84 77.331 79.487 −8.124 1.00 84.17 C ATOM 4046 NH2 ARG C 84 77.454 77.308 −7.378 1.00 84.81 C ATOM 4047 C ARG C 84 84.475 81.305 −10.156 1.00 54.25 C ATOM 4048 O ARG C 84 84.812 82.313 −9.543 1.00 52.78 C ATOM 4049 N GLY C 85 84.612 81.164 −11.468 1.00 51.61 C ATOM 4050 CA GLY C 85 85.166 82.234 −12.265 1.00 52.64 C ATOM 4051 C GLY C 85 86.542 81.935 −12.801 1.00 52.39 C ATOM 4052 O GLY C 85 87.400 81.412 −12.093 1.00 53.26 C ATOM 4053 N SER C 86 86.768 82.264 −14.063 1.00 56.65 C ATOM 4054 CA SER C 86 88.074 82.013 −14.636 1.00 60.26 C ATOM 4055 CB SER C 86 88.078 80.685 −15.393 1.00 63.40 C ATOM 4056 OG SER C 86 89.410 80.222 −15.570 1.00 73.69 C ATOM 4057 C SER C 86 88.482 83.126 −15.567 1.00 56.75 C ATOM 4058 O SER C 86 87.650 83.698 −16.257 1.00 55.15 C ATOM 4059 N THR C 87 89.775 83.428 −15.565 1.00 58.49 C ATOM 4060 CA THR C 87 90.343 84.457 −16.417 1.00 57.84 C ATOM 4061 CB THR C 87 91.816 84.711 −16.006 1.00 62.33 C ATOM 4062 OG1 THR C 87 91.873 85.892 −15.197 1.00 69.91 C ATOM 4063 CG2 THR C 87 92.724 84.863 −17.215 1.00 64.96 C ATOM 4064 C THR C 87 90.257 84.034 −17.886 1.00 55.75 C ATOM 4065 O THR C 87 90.241 82.842 −18.198 1.00 56.65 C ATOM 4066 N PRO C 88 90.134 85.007 −18.805 1.00 52.96 C ATOM 4067 CD PRO C 88 90.192 84.766 −20.259 1.00 53.18 C ATOM 4068 CA PRO C 88 90.069 86.442 −18.533 1.00 52.06 C ATOM 4069 CB PRO C 88 90.533 87.060 −19.849 1.00 50.34 C ATOM 4070 CG PRO C 88 89.909 86.162 −20.842 1.00 52.45 C ATOM 4071 C PRO C 88 88.630 86.844 −18.183 1.00 47.83 C ATOM 4072 O PRO C 88 87.666 86.219 −18.628 1.00 43.02 C ATOM 4073 N TYR C 89 88.502 87.903 −17.398 1.00 40.94 C ATOM 4074 CA TYR C 89 87.204 88.376 −16.977 1.00 40.87 C ATOM 4075 CB TYR C 89 87.276 88.839 −15.516 1.00 41.58 C ATOM 4076 CG TYR C 89 87.666 87.730 −14.570 1.00 47.21 C ATOM 4077 CD1 TYR C 89 88.886 87.759 −13.879 1.00 48.57 C ATOM 4078 CE1 TYR C 89 89.260 86.711 −13.043 1.00 52.12 C ATOM 4079 CD2 TYR C 89 86.835 86.625 −14.397 1.00 47.83 C ATOM 4080 CE2 TYR C 89 87.203 85.573 −13.567 1.00 52.56 C ATOM 4081 CZ TYR C 89 88.409 85.618 −12.892 1.00 52.86 C ATOM 4082 OH TYR C 89 88.734 84.568 −12.059 1.00 55.18 C ATOM 4083 C TYR C 89 86.775 89.516 −17.874 1.00 37.75 C ATOM 4084 O TYR C 89 87.368 90.582 −17.837 1.00 35.86 C ATOM 4085 N ARG C 90 85.742 89.282 −18.677 1.00 36.76 C ATOM 4086 CA ARG C 90 85.227 90.291 −19.591 1.00 31.74 C ATOM 4087 CB ARG C 90 84.956 89.672 −20.957 1.00 39.30 C ATOM 4088 CG ARG C 90 86.211 89.526 −21.808 1.00 51.87 C ATOM 4089 CD ARG C 90 86.620 88.085 −21.981 1.00 60.63 C ATOM 4090 NE ARG C 90 87.619 87.933 −23.048 1.00 68.24 C ATOM 4091 CZ ARG C 90 88.091 86.767 −23.501 1.00 68.54 C ATOM 4092 NH1 ARG C 90 87.673 85.604 −22.993 1.00 64.59 C ATOM 4093 NH2 ARG C 90 88.987 86.767 −24.479 1.00 70.32 C ATOM 4094 C ARG C 90 83.959 90.915 −19.048 1.00 31.15 C ATOM 4095 O ARG C 90 83.414 90.456 −18.040 1.00 24.92 C ATOM 4096 N HIS C 91 83.483 91.955 −19.725 1.00 23.82 C ATOM 4097 CA HIS C 91 82.285 92.674 −19.301 1.00 23.05 C ATOM 4098 CB HIS C 91 81.872 93.640 −20.406 1.00 26.29 C ATOM 4099 CG HIS C 91 80.849 94.665 −19.998 1.00 23.49 C ATOM 4100 CD2 HIS C 91 80.142 95.553 −20.744 1.00 20.45 C ATOM 4101 ND1 HIS C 91 80.515 94.920 −18.685 1.00 28.99 C ATOM 4102 CE1 HIS C 91 79.651 95.923 −18.637 1.00 19.30 C ATOM 4103 NE2 HIS C 91 79.412 96.325 −19.873 1.00 28.70 C ATOM 4104 C HIS C 91 81.142 91.717 −19.003 1.00 24.93 C ATOM 4105 O HIS C 91 80.771 90.926 −19.862 1.00 22.92 C ATOM 4106 N GLY C 92 80.575 91.808 −17.801 1.00 25.08 C ATOM 4107 CA GLY C 92 79.459 90.949 −17.435 1.00 25.83 C ATOM 4108 C GLY C 92 79.834 89.612 −16.803 1.00 26.66 C ATOM 4109 O GLY C 92 78.964 88.947 −16.233 1.00 30.96 C ATOM 4110 N ASP C 93 81.098 89.203 −16.913 1.00 24.69 C ATOM 4111 CA ASP C 93 81.558 87.940 −16.311 1.00 28.03 C ATOM 4112 CB ASP C 93 83.001 87.609 −16.749 1.00 26.26 C ATOM 4113 CG ASP C 93 83.101 87.123 −18.214 1.00 33.28 C ATOM 4114 OD1 ASP C 93 84.243 86.973 −18.725 1.00 35.30 C ATOM 4115 OD2 ASP C 93 82.056 86.885 −18.859 1.00 33.91 C ATOM 4116 C ASP C 93 81.535 88.080 −14.791 1.00 32.16 C ATOM 4117 O ASP C 93 81.641 89.197 −14.254 1.00 32.11 C ATOM 4118 N SER C 94 81.400 86.966 −14.082 1.00 27.90 C ATOM 4119 CA SER C 94 81.395 87.050 −12.632 1.00 37.96 C ATOM 4120 CB SER C 94 79.983 86.889 −12.104 1.00 35.76 C ATOM 4121 OG SER C 94 79.577 85.556 −12.314 1.00 39.23 C ATOM 4122 C SER C 94 82.287 85.986 −11.997 1.00 38.51 C ATOM 4123 O SER C 94 82.713 85.038 −12.655 1.00 36.22 C ATOM 4124 N VAL C 95 82.550 86.154 −10.706 1.00 38.03 C ATOM 4125 CA VAL C 95 83.373 85.221 −9.943 1.00 42.81 C ATOM 4126 CB VAL C 95 84.825 85.728 −9.743 1.00 41.37 C ATOM 4127 CG1 VAL C 95 85.454 86.006 −11.073 1.00 46.63 C ATOM 4128 CG2 VAL C 95 84.840 86.980 −8.916 1.00 36.92 C ATOM 4129 C VAL C 95 82.724 85.111 −8.587 1.00 43.66 C ATOM 4130 O VAL C 95 82.023 86.024 −8.155 1.00 43.47 C ATOM 4131 N THR C 96 82.939 83.988 −7.918 1.00 45.64 C ATOM 4132 CA THR C 96 82.356 83.806 −6.599 1.00 46.87 C ATOM 4133 CB THR C 96 81.258 82.736 −6.600 1.00 46.87 C ATOM 4134 OG1 THR C 96 80.233 83.101 −7.531 1.00 40.12 C ATOM 4135 CG2 THR C 96 80.635 82.635 −5.208 1.00 50.66 C ATOM 4136 C THR C 96 83.432 83.403 −5.612 1.00 43.20 C ATOM 4137 O THR C 96 84.363 82.686 −5.962 1.00 41.73 C ATOM 4138 N PHE C 97 83.302 83.886 −4.387 1.00 39.07 C ATOM 4139 CA PHE C 97 84.267 83.578 −3.349 1.00 43.95 C ATOM 4140 CB PHE C 97 84.898 84.854 −2.810 1.00 45.41 C ATOM 4141 CG PHE C 97 85.850 85.519 −3.750 1.00 46.14 C ATOM 4142 CD1 PHE C 97 85.422 86.543 −4.594 1.00 42.85 C ATOM 4143 CD2 PHE C 97 87.195 85.162 −3.749 1.00 45.67 C ATOM 4144 CE1 PHE C 97 86.320 87.194 −5.406 1.00 39.79 C ATOM 4145 CE2 PHE C 97 88.101 85.812 −4.562 1.00 42.72 C ATOM 4146 CZ PHE C 97 87.663 86.829 −5.390 1.00 41.65 C ATOM 4147 C PHE C 97 83.646 82.859 −2.158 1.00 46.38 C ATOM 4148 O PHE C 97 82.421 82.804 −1.988 1.00 39.27 C ATOM 4149 N ALA C 98 84.530 82.332 −1.318 1.00 48.32 C ATOM 4150 CA ALA C 98 84.155 81.664 −0.076 1.00 46.94 C ATOM 4151 CB ALA C 98 84.112 80.158 −0.277 1.00 46.22 C ATOM 4152 C ALA C 98 85.254 82.038 0.929 1.00 46.65 C ATOM 4153 O ALA C 98 86.394 82.293 0.536 1.00 44.10 C ATOM 4154 N CYS C 99 84.914 82.103 2.212 1.00 46.08 C ATOM 4155 CA CYS C 99 85.917 82.423 3.209 1.00 47.08 C ATOM 4156 C CYS C 99 86.590 81.156 3.711 1.00 46.05 C ATOM 4157 O CYS C 99 85.963 80.096 3.760 1.00 43.34 C ATOM 4158 CB CYS C 99 85.289 83.168 4.375 1.00 44.52 C ATOM 4159 SG CYS C 99 84.727 84.800 3.844 1.00 44.83 C ATOM 4160 N LYS C 100 87.874 81.273 4.056 1.00 47.36 C ATOM 4161 CA LYS C 100 88.645 80.147 4.574 1.00 48.81 C ATOM 4162 CB LYS C 100 90.135 80.489 4.594 1.00 49.39 C ATOM 4163 CG LYS C 100 90.750 80.658 3.219 1.00 54.21 C ATOM 4164 CD LYS C 100 92.190 81.114 3.317 1.00 54.87 C ATOM 4165 CE LYS C 100 92.806 81.267 1.942 1.00 57.13 C ATOM 4166 NZ LYS C 100 94.197 81.768 2.053 1.00 60.72 C ATOM 4167 C LYS C 100 88.165 79.861 5.997 1.00 49.95 C ATOM 4168 O LYS C 100 87.495 80.705 6.619 1.00 48.69 C ATOM 4169 N THR C 101 88.786 78.765 6.373 1.00 51.22 C ATOM 4170 CA THR C 101 88.580 78.229 7.709 1.00 55.29 C ATOM 4171 CB THR C 101 89.528 77.069 8.012 1.00 57.10 C ATOM 4172 OG1 THR C 101 89.306 76.008 7.077 1.00 64.35 C ATOM 4173 CG2 THR C 101 89.308 76.559 9.429 1.00 57.34 C ATOM 4174 C THR C 101 88.780 79.304 8.764 1.00 49.93 C ATOM 4175 O THR C 101 89.894 79.947 8.793 1.00 47.27 C ATOM 4176 N ASN C 102 88.004 79.652 9.763 1.00 46.86 C ATOM 4177 CA ASN C 102 88.149 80.670 10.780 1.00 48.18 C ATOM 4178 CB ASN C 102 89.557 80.629 11.363 1.00 46.95 C ATOM 4179 CG ASN C 102 89.845 79.289 12.014 1.00 48.40 C ATOM 4180 OD1 ASN C 102 88.985 78.720 12.693 1.00 41.35 C ATOM 4181 ND2 ASN C 102 91.051 78.775 11.810 1.00 49.40 C ATOM 4182 C ASN C 102 87.761 82.030 10.236 1.00 49.20 C ATOM 4183 O ASN C 102 88.252 83.052 10.922 1.00 46.49 C ATOM 4184 N PHE C 103 87.220 82.295 9.176 1.00 48.20 C ATOM 4185 CA PHE C 103 86.584 83.570 8.755 1.00 49.30 C ATOM 4186 CB PHE C 103 87.390 84.074 7.554 1.00 46.94 C ATOM 4187 CG PHE C 103 88.859 84.187 7.814 1.00 45.01 C ATOM 4188 CD1 PHE C 103 89.671 83.059 7.792 1.00 48.38 C ATOM 4189 CD2 PHE C 103 89.437 85.421 8.082 1.00 48.98 C ATOM 4190 CE1 PHE C 103 91.045 83.157 8.034 1.00 48.94 C ATOM 4191 CE2 PHE C 103 90.810 85.533 8.328 1.00 48.39 C ATOM 4192 CZ PHE C 103 91.616 84.400 8.302 1.00 46.82 C ATOM 4193 C PHE C 103 85.097 83.521 8.378 1.00 50.21 C ATOM 4194 O PHE C 103 84.570 82.478 7.968 1.00 49.82 C ATOM 4195 N SER C 104 84.414 84.647 8.565 1.00 48.66 C ATOM 4196 CA SER C 104 83.012 84.745 8.214 1.00 45.33 C ATOM 4197 CB SER C 104 82.165 85.191 9.417 1.00 46.37 C ATOM 4198 OG SER C 104 82.048 86.605 9.522 1.00 57.43 C ATOM 4199 C SER C 104 82.984 85.792 7.108 1.00 41.51 C ATOM 4200 O SER C 104 83.757 86.736 7.130 1.00 38.53 C ATOM 4201 N MET C 105 82.114 85.616 6.129 1.00 41.72 C ATOM 4202 CA MET C 105 82.036 86.573 5.038 1.00 43.60 C ATOM 4203 CB MET C 105 81.601 85.872 3.748 1.00 44.67 C ATOM 4204 CG MET C 105 81.330 86.830 2.579 1.00 40.80 C ATOM 4205 SD MET C 105 80.914 85.922 1.118 1.00 45.07 C ATOM 4206 CE MET C 105 82.489 85.186 0.675 1.00 39.55 C ATOM 4207 C MET C 105 81.077 87.722 5.308 1.00 46.26 C ATOM 4208 O MET C 105 79.972 87.519 5.816 1.00 44.17 C ATOM 4209 N ASN C 106 81.518 88.927 4.963 1.00 47.38 C ATOM 4210 CA ASN C 106 80.707 90.137 5.078 1.00 49.51 C ATOM 4211 CB ASN C 106 81.391 91.160 5.984 1.00 56.07 C ATOM 4212 CG ASN C 106 80.769 92.539 5.879 1.00 63.53 C ATOM 4213 OD1 ASN C 106 80.925 93.233 4.867 1.00 66.72 C ATOM 4214 ND2 ASN C 106 80.048 92.943 6.921 1.00 68.89 C ATOM 4215 C ASN C 106 80.572 90.688 3.645 1.00 49.28 C ATOM 4216 O ASN C 106 81.566 91.073 3.015 1.00 46.49 C ATOM 4217 N GLY C 107 79.344 90.700 3.130 1.00 50.96 C ATOM 4218 CA GLY C 107 79.102 91.178 1.776 1.00 47.29 C ATOM 4219 C GLY C 107 78.620 90.074 0.846 1.00 46.96 C ATOM 4220 O GLY C 107 78.421 88.940 1.275 1.00 48.97 C ATOM 4221 N ASN C 108 78.439 90.398 −0.434 1.00 50.83 C ATOM 4222 CA ASN C 108 77.974 89.429 −1.426 1.00 49.00 C ATOM 4223 CB ASN C 108 77.392 90.148 −2.635 1.00 56.26 C ATOM 4224 CG ASN C 108 76.392 91.180 −2.247 1.00 61.63 C ATOM 4225 OD1 ASN C 108 76.703 92.371 −2.168 1.00 67.56 C ATOM 4226 ND2 ASN C 108 75.176 90.735 −1.977 1.00 62.48 C ATOM 4227 C ASN C 108 79.125 88.561 −1.887 1.00 46.12 C ATOM 4228 O ASN C 108 80.217 89.064 −2.155 1.00 42.01 C ATOM 4229 N LYS C 109 78.858 87.266 −2.016 1.00 38.69 C ATOM 4230 CA LYS C 109 79.874 86.310 −2.407 1.00 41.12 C ATOM 4231 CB LYS C 109 79.444 84.897 −2.023 1.00 44.04 C ATOM 4232 CG LYS C 109 78.255 84.360 −2.804 1.00 45.47 C ATOM 4233 CD LYS C 109 77.585 83.222 −2.019 1.00 51.74 C ATOM 4234 CE LYS C 109 76.584 82.453 −2.865 1.00 59.58 C ATOM 4235 NZ LYS C 109 77.262 81.664 −3.956 1.00 64.18 C ATOM 4236 C LYS C 109 80.199 86.324 −3.874 1.00 40.75 C ATOM 4237 O LYS C 109 81.189 85.714 −4.307 1.00 41.19 C ATOM 4238 N SER C 110 79.358 86.988 −4.655 1.00 38.36 C ATOM 4239 CA SER C 110 79.578 87.024 −6.101 1.00 36.23 C ATOM 4240 CB SER C 110 78.437 86.305 −6.834 1.00 39.46 C ATOM 4241 OG SER C 110 78.481 84.918 −6.579 1.00 36.52 C ATOM 4242 C SER C 110 79.635 88.421 −6.581 1.00 29.42 C ATOM 4243 O SER C 110 78.876 89.247 −6.098 1.00 28.55 C ATOM 4244 N VAL C 111 80.560 88.692 −7.499 1.00 30.69 C ATOM 4245 CA VAL C 111 80.678 90.017 −8.105 1.00 29.50 C ATOM 4246 CB VAL C 111 81.934 90.782 −7.652 1.00 33.90 C ATOM 4247 CG1 VAL C 111 81.666 91.463 −6.325 1.00 32.11 C ATOM 4248 CG2 VAL C 111 83.135 89.825 −7.579 1.00 26.88 C ATOM 4249 C VAL C 111 80.718 89.916 −9.632 1.00 29.99 C ATOM 4250 O VAL C 111 80.996 88.853 −10.194 1.00 27.74 C ATOM 4251 N TRP C 112 80.448 91.034 −10.299 1.00 25.72 C ATOM 4252 CA TRP C 112 80.437 91.062 −11.756 1.00 25.20 C ATOM 4253 CB TRP C 112 79.020 91.411 −12.237 1.00 26.69 C ATOM 4254 CG TRP C 112 78.107 90.226 −12.146 1.00 33.34 C ATOM 4255 CD2 TRP C 112 77.481 89.706 −10.957 1.00 30.54 C ATOM 4256 CE2 TRP C 112 76.820 88.505 −11.322 1.00 33.04 C ATOM 4257 CE3 TRP C 112 77.421 90.133 −9.622 1.00 31.04 C ATOM 4258 CD1 TRP C 112 77.799 89.338 −13.158 1.00 37.78 C ATOM 4259 NE1 TRP C 112 77.029 88.309 −12.665 1.00 35.55 C ATOM 4260 CZ2 TRP C 112 76.110 87.729 −10.397 1.00 27.67 C ATOM 4261 CZ3 TRP C 112 76.713 89.357 −8.696 1.00 30.48 C ATOM 4262 CH2 TRP C 112 76.067 88.168 −9.092 1.00 26.73 C ATOM 4263 C TRP C 112 81.456 92.052 −12.307 1.00 27.63 C ATOM 4264 O TRP C 112 81.719 93.091 −11.701 1.00 22.47 C ATOM 4265 N CYS C 113 82.042 91.719 −13.455 1.00 26.10 C ATOM 4266 CA CYS C 113 83.025 92.593 −14.083 1.00 25.33 C ATOM 4267 C CYS C 113 82.313 93.725 −14.830 1.00 30.04 C ATOM 4268 O CYS C 113 81.611 93.488 −15.824 1.00 28.98 C ATOM 4269 CB CYS C 113 83.897 91.780 −15.029 1.00 26.64 C ATOM 4270 SG CYS C 113 85.096 92.793 −15.958 1.00 29.69 C ATOM 4271 N GLN C 114 82.478 94.951 −14.336 1.00 22.99 C ATOM 4272 CA GLN C 114 81.842 96.127 −14.927 1.00 25.16 C ATOM 4273 CB GLN C 114 81.597 97.177 −13.835 1.00 28.73 C ATOM 4274 CG GLN C 114 80.857 96.602 −12.630 1.00 36.89 C ATOM 4275 CD GLN C 114 80.727 97.569 −11.457 1.00 42.08 C ATOM 4276 OE1 GLN C 114 79.802 98.365 −11.382 1.00 49.79 C ATOM 4277 NE2 GLN C 114 81.665 97.493 −10.539 1.00 49.11 C ATOM 4278 C GLN C 114 82.630 96.739 −16.092 1.00 31.28 C ATOM 4279 O GLN C 114 83.827 96.444 −16.284 1.00 27.34 C ATOM 4280 N ALA C 115 81.956 97.594 −16.865 1.00 25.85 C ATOM 4281 CA ALA C 115 82.564 98.246 −18.031 1.00 28.40 C ATOM 4282 CB ALA C 115 81.577 99.211 −18.667 1.00 20.65 C ATOM 4283 C ALA C 115 83.844 98.990 −17.651 1.00 28.38 C ATOM 4284 O ALA C 115 84.797 99.004 −18.432 1.00 23.27 C ATOM 4285 N ASN C 116 83.873 99.587 −16.456 1.00 23.81 C ATOM 4286 CA ASN C 116 85.060 100.327 −16.002 1.00 28.02 C ATOM 4287 CB ASN C 116 84.663 101.425 −14.993 1.00 28.32 C ATOM 4288 CG ASN C 116 83.983 100.858 −13.746 1.00 27.71 C ATOM 4289 OD1 ASN C 116 84.129 99.674 −13.436 1.00 24.66 C ATOM 4290 ND2 ASN C 116 83.247 101.707 −13.020 1.00 23.76 C ATOM 4291 C ASN C 116 86.139 99.447 −15.378 1.00 27.65 C ATOM 4292 O ASN C 116 87.027 99.957 −14.695 1.00 31.18 C ATOM 4293 N ASN C 117 86.060 98.132 −15.593 1.00 27.61 C ATOM 4294 CA ASN C 117 87.030 97.189 −15.048 1.00 29.18 C ATOM 4295 CB ASN C 117 88.475 97.578 −15.449 1.00 27.03 C ATOM 4296 CG ASN C 117 88.724 97.389 −16.951 1.00 30.01 C ATOM 4297 OD1 ASN C 117 87.901 96.793 −17.638 1.00 27.30 C ATOM 4298 ND2 ASN C 117 89.853 97.883 −17.455 1.00 29.00 C ATOM 4299 C ASN C 117 86.958 96.986 −13.543 1.00 31.56 C ATOM 4300 O ASN C 117 87.748 96.230 −12.994 1.00 31.15 C ATOM 4301 N MET C 118 86.035 97.652 −12.860 1.00 33.87 C ATOM 4302 CA MET C 118 85.918 97.430 −11.421 1.00 38.31 C ATOM 4303 CB MET C 118 85.431 98.700 −10.723 1.00 43.16 C ATOM 4304 CG MET C 118 86.446 99.857 −10.744 1.00 53.52 C ATOM 4305 SD MET C 118 85.763 101.385 −10.037 1.00 58.36 C ATOM 4306 CE MET C 118 86.038 101.027 −8.271 1.00 63.17 C ATOM 4307 C MET C 118 84.937 96.281 −11.182 1.00 41.22 C ATOM 4308 O MET C 118 84.034 96.039 −12.001 1.00 39.23 C ATOM 4309 N TRP C 119 85.108 95.588 −10.058 1.00 39.36 C ATOM 4310 CA TRP C 119 84.276 94.458 −9.706 1.00 34.52 C ATOM 4311 CB TRP C 119 85.044 93.494 −8.830 1.00 37.83 C ATOM 4312 CG TRP C 119 85.916 92.608 −9.625 1.00 34.11 C ATOM 4313 CD2 TRP C 119 85.497 91.515 −10.449 1.00 33.34 C ATOM 4314 CE2 TRP C 119 86.652 90.975 −11.053 1.00 32.21 C ATOM 4315 CE3 TRP C 119 84.250 90.935 −10.741 1.00 29.94 C ATOM 4316 CD1 TRP C 119 87.264 92.691 −9.755 1.00 31.13 C ATOM 4317 NE1 TRP C 119 87.721 91.715 −10.608 1.00 36.90 C ATOM 4318 CZ2 TRP C 119 86.610 89.897 −11.919 1.00 29.11 C ATOM 4319 CZ3 TRP C 119 84.206 89.869 −11.594 1.00 31.88 C ATOM 4320 CH2 TRP C 119 85.384 89.352 −12.181 1.00 32.92 C ATOM 4321 C TRP C 119 82.930 94.725 −9.066 1.00 45.62 C ATOM 4322 O TRP C 119 82.742 95.703 −8.345 1.00 44.53 C ATOM 4323 N GLY C 120 82.022 93.799 −9.399 1.00 52.00 C ATOM 4324 CA GLY C 120 80.621 93.709 −8.986 1.00 49.90 C ATOM 4325 C GLY C 120 79.864 94.960 −8.669 1.00 50.22 C ATOM 4326 O GLY C 120 80.454 96.037 −8.703 1.00 53.01 C ATOM 4327 N PRO C 121 78.546 94.853 −8.388 1.00 42.28 C ATOM 4328 CD PRO C 121 77.760 93.635 −8.569 1.00 46.84 C ATOM 4329 CA PRO C 121 77.673 95.988 −8.042 1.00 46.16 C ATOM 4330 CB PRO C 121 76.263 95.395 −8.040 1.00 42.57 C ATOM 4331 CG PRO C 121 76.380 94.189 −8.846 1.00 45.38 C ATOM 4332 C PRO C 121 78.054 96.442 −6.637 1.00 48.97 C ATOM 4333 O PRO C 121 78.066 97.631 −6.340 1.00 49.57 C ATOM 4334 N THR C 122 78.361 95.485 −5.766 1.00 45.65 C ATOM 4335 CA THR C 122 78.735 95.807 −4.388 1.00 48.81 C ATOM 4336 CB THR C 122 78.209 94.712 −3.397 1.00 52.30 C ATOM 4337 OG1 THR C 122 76.777 94.615 −3.488 1.00 54.63 C ATOM 4338 CG2 THR C 122 78.563 95.064 −1.953 1.00 54.73 C ATOM 4339 C THR C 122 80.264 95.881 −4.287 1.00 51.31 C ATOM 4340 O THR C 122 80.964 95.769 −5.277 1.00 49.95 C ATOM 4341 N ARG C 123 80.792 96.106 −3.094 1.00 56.40 C ATOM 4342 CA ARG C 123 82.233 96.099 −2.936 1.00 54.17 C ATOM 4343 CB ARG C 123 82.628 96.777 −1.621 1.00 62.98 C ATOM 4344 CG ARG C 123 82.258 98.275 −1.561 1.00 73.33 C ATOM 4345 CD ARG C 123 82.868 98.987 −0.336 1.00 77.96 C ATOM 4346 NE ARG C 123 83.483 100.279 −0.674 1.00 80.89 C ATOM 4347 CZ ARG C 123 84.558 100.439 −1.458 1.00 80.79 C ATOM 4348 NH1 ARG C 123 85.166 99.392 −2.007 1.00 79.18 C ATOM 4349 NH2 ARG C 123 85.035 101.656 −1.696 1.00 81.16 C ATOM 4350 C ARG C 123 82.566 94.608 −2.890 1.00 52.07 C ATOM 4351 O ARG C 123 81.687 93.780 −2.609 1.00 51.24 C ATOM 4352 N LEU C 124 83.801 94.245 −3.210 1.00 46.24 C ATOM 4353 CA LEU C 124 84.175 92.836 −3.137 1.00 43.03 C ATOM 4354 CB LEU C 124 85.682 92.655 −3.342 1.00 38.28 C ATOM 4355 CG LEU C 124 86.181 92.386 −4.766 1.00 39.78 C ATOM 4356 CD1 LEU C 124 87.714 92.314 −4.721 1.00 41.84 C ATOM 4357 CD2 LEU C 124 85.591 91.090 −5.304 0.00 41.07 C ATOM 4358 C LEU C 124 83.785 92.371 −1.738 1.00 35.52 C ATOM 4359 O LEU C 124 83.740 93.175 −0.807 1.00 32.32 C ATOM 4360 N PRO C 125 83.473 91.080 −1.574 1.00 31.53 C ATOM 4361 CD PRO C 125 83.668 89.969 −2.523 1.00 35.48 C ATOM 4362 CA PRO C 125 83.093 90.568 −0.255 1.00 36.74 C ATOM 4363 CB PRO C 125 82.663 89.127 −0.554 1.00 32.42 C ATOM 4364 CG PRO C 125 83.629 88.741 −1.610 1.00 33.06 C ATOM 4365 C PRO C 125 84.328 90.593 0.623 1.00 36.97 C ATOM 4366 O PRO C 125 85.438 90.594 0.117 1.00 34.38 C ATOM 4367 N THR C 126 84.130 90.571 1.930 1.00 41.39 C ATOM 4368 CA THR C 126 85.239 90.584 2.857 1.00 44.67 C ATOM 4369 CB THR C 126 85.171 91.881 3.691 1.00 49.35 C ATOM 4370 OG1 THR C 126 86.470 92.211 4.174 1.00 58.86 C ATOM 4371 CG2 THR C 126 84.227 91.731 4.855 1.00 46.39 C ATOM 4372 C THR C 126 85.179 89.343 3.765 1.00 43.43 C ATOM 4373 O THR C 126 84.101 88.820 4.068 1.00 41.61 C ATOM 4374 N CYS C 127 86.333 88.832 4.164 1.00 46.42 C ATOM 4375 CA CYS C 127 86.348 87.679 5.068 1.00 46.58 C ATOM 4376 C CYS C 127 86.997 88.162 6.361 1.00 47.12 C ATOM 4377 O CYS C 127 88.182 88.490 6.384 1.00 44.98 C ATOM 4378 CB CYS C 127 87.153 86.515 4.485 1.00 41.09 C ATOM 4379 SG CYS C 127 86.397 85.641 3.072 1.00 36.94 C ATOM 4380 N VAL C 128 86.202 88.224 7.422 1.00 47.64 C ATOM 4381 CA VAL C 128 86.671 88.675 8.725 1.00 50.09 C ATOM 4382 CB VAL C 128 85.674 89.670 9.349 1.00 53.76 C ATOM 4383 CG1 VAL C 128 84.322 88.993 9.553 1.00 56.55 C ATOM 4384 CG2 VAL C 128 86.211 90.180 10.678 1.00 55.81 C ATOM 4385 C VAL C 128 86.860 87.494 9.696 1.00 50.97 C ATOM 4386 O VAL C 128 86.117 86.494 9.653 1.00 47.21 C ATOM 4387 N SER C 129 87.860 87.611 10.563 1.00 44.79 C ATOM 4388 CA SER C 129 88.146 86.561 11.534 1.00 41.23 C ATOM 4389 CB SER C 129 89.373 86.901 12.370 1.00 36.76 C ATOM 4390 OG SER C 129 89.483 85.955 13.423 1.00 38.45 C ATOM 4391 C SER C 129 87.020 86.289 12.506 1.00 42.12 C ATOM 4392 O SER C 129 86.396 87.214 13.030 1.00 38.42 C ATOM 4393 N VAL C 130 86.783 85.004 12.747 1.00 42.88 C ATOM 4394 CA VAL C 130 85.786 84.566 13.712 1.00 48.17 C ATOM 4395 CB VAL C 130 85.679 83.028 13.724 1.00 49.37 C ATOM 4396 CG1 VAL C 130 85.006 82.570 15.003 1.00 55.87 C ATOM 4397 CG2 VAL C 130 84.879 82.558 12.510 1.00 47.26 C ATOM 4398 C VAL C 130 86.191 85.042 15.124 1.00 47.25 C ATOM 4399 O VAL C 130 85.334 85.271 15.976 1.00 49.24 C ATOM 4400 N PHE C 131 87.495 85.202 15.360 1.00 42.64 C ATOM 4401 CA PHE C 131 87.979 85.639 16.665 1.00 43.25 C ATOM 4402 CB PHE C 131 89.429 85.174 16.873 1.00 37.67 C ATOM 4403 CG PHE C 131 89.608 83.691 16.666 1.00 36.56 C ATOM 4404 CD1 PHE C 131 90.324 83.218 15.589 1.00 30.51 C ATOM 4405 CD2 PHE C 131 88.927 82.770 17.461 1.00 32.59 C ATOM 4406 CE1 PHE C 131 90.357 81.848 15.278 1.00 32.11 C ATOM 4407 CE2 PHE C 131 88.955 81.399 17.157 1.00 37.78 C ATOM 4408 CZ PHE C 131 89.674 80.938 16.055 1.00 33.91 C ATOM 4409 C PHE C 131 87.849 87.146 16.797 1.00 45.03 C ATOM 4410 O PHE C 131 88.533 87.896 16.104 1.00 43.08 C ATOM 4411 N PRO C 132 86.980 87.606 17.719 1.00 49.31 C ATOM 4412 CD PRO C 132 86.384 86.810 18.806 1.00 48.64 C ATOM 4413 CA PRO C 132 86.730 89.029 17.954 1.00 51.76 C ATOM 4414 CB PRO C 132 85.882 89.026 19.227 1.00 51.00 C ATOM 4415 CG PRO C 132 86.345 87.802 19.927 1.00 49.99 C ATOM 4416 C PRO C 132 87.948 89.921 18.054 1.00 54.56 C ATOM 4417 O PRO C 132 88.018 90.941 17.371 1.00 59.16 C ATOM 4418 N LEU C 133 88.913 89.558 18.887 1.00 53.87 C ATOM 4419 CA LEU C 133 90.089 90.396 18.991 1.00 56.98 C ATOM 4420 CB LEU C 133 90.854 90.093 20.274 1.00 53.54 C ATOM 4421 CG LEU C 133 89.997 90.162 21.538 1.00 52.81 C ATOM 4422 CD1 LEU C 133 90.901 90.183 22.748 1.00 53.95 C ATOM 4423 CD2 LEU C 133 89.142 91.398 21.540 1.00 53.34 C ATOM 4424 C LEU C 133 90.958 90.156 17.772 1.00 58.59 C ATOM 4425 O LEU C 133 92.106 90.579 17.726 1.00 54.07 C ATOM 4426 N GLU C 134 91.054 89.741 16.857 1.00 60.78 C ATOM 4427 CA GLU C 134 91.010 89.158 15.522 1.00 70.26 C ATOM 4428 CB GLU C 134 91.448 90.184 14.475 1.00 72.39 C ATOM 4429 CG GLU C 134 90.575 91.428 14.421 1.00 75.60 C ATOM 4430 CD GLU C 134 89.133 91.113 14.077 1.00 78.38 C ATOM 4431 OE1 GLU C 134 88.819 89.923 13.866 1.00 80.20 C ATOM 4432 OE2 GLU C 134 88.317 92.057 14.018 1.00 80.22 C ATOM 4433 C GLU C 134 91.879 87.908 15.438 1.00 71.86 C ATOM 4434 O GLU C 134 92.143 87.521 16.835 1.00 73.34 C ATOM 4435 OXT GLU C 134 92.658 87.662 14.702 1.00 76.05 C ATOM 4436 C1 NAG D 1 91.022 77.190 13.373 1.00 39.02 D ATOM 4437 O1 NAG D 1 90.217 76.061 13.510 1.00 53.38 D ATOM 4438 C2 NAG D 1 92.379 76.764 12.861 1.00 36.79 D ATOM 4439 N2 NAG D 1 92.264 76.234 11.516 1.00 39.67 D ATOM 4440 C7 NAG D 1 92.851 76.904 10.527 1.00 40.49 D ATOM 4441 O7 NAG D 1 93.458 77.963 10.726 1.00 46.19 D ATOM 4442 C8 NAG D 1 92.771 76.338 9.115 1.00 36.88 D ATOM 4443 C3 NAG D 1 92.972 75.726 13.816 1.00 35.88 D ATOM 4444 O3 NAG D 1 94.293 75.444 13.394 1.00 40.30 D ATOM 4445 C4 NAG D 1 92.986 76.292 15.264 1.00 37.37 D ATOM 4446 O4 NAG D 1 93.308 75.255 16.169 1.00 36.52 D ATOM 4447 C5 NAG D 1 91.610 76.877 15.659 1.00 38.38 D ATOM 4448 O5 NAG D 1 91.167 77.818 14.663 1.00 39.81 D ATOM 4449 C6 NAG D 1 91.599 77.601 16.994 1.00 34.64 D ATOM 4450 O6 NAG D 1 92.510 78.695 16.984 1.00 35.80 D ATOM 4451 C1 NAG E 1 90.580 70.350 4.612 1.00 80.29 E ATOM 4452 O1 NAG E 1 90.608 71.734 4.755 1.00 82.28 E ATOM 4453 C2 NAG E 1 91.606 69.705 5.560 1.00 79.89 E ATOM 4454 N2 NAG E 1 91.383 70.221 6.901 1.00 79.48 E ATOM 4455 C7 NAG E 1 90.709 69.507 7.799 1.00 79.52 E ATOM 4456 O7 NAG E 1 89.865 68.652 7.495 1.00 78.01 E ATOM 4457 C8 NAG E 1 91.027 69.791 9.263 1.00 77.64 E ATOM 4458 C3 NAG E 1 93.061 70.018 5.141 1.00 79.82 E ATOM 4459 O3 NAG E 1 93.945 69.116 5.805 1.00 80.58 E ATOM 4460 C4 NAG E 1 93.291 69.924 3.618 1.00 80.30 E ATOM 4461 O4 NAG E 1 94.526 70.547 3.285 1.00 80.30 E ATOM 4462 C5 NAG E 1 92.148 70.607 2.853 1.00 80.10 E ATOM 4463 O5 NAG E 1 90.884 70.035 3.252 1.00 79.60 E ATOM 4464 C6 NAG E 1 92.253 70.476 1.341 1.00 80.36 E ATOM 4465 O6 NAG E 1 91.044 70.874 0.705 1.00 78.94 E END

While various embodiments of the present invention have been described in detail, it is apparent that modifications and adaptations of those embodiments will occur to those skilled in the art. It is to be expressly understood, however, that such modifications and adaptations are within the scope of the present invention, as set forth in the following claims.

                   #             SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 9 <210> SEQ ID NO 1 <211> LENGTH: 1033 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 1 Met Gly Ala Ala Gly Leu Leu Gly Val Phe Le #u Ala Leu Val Ala Pro 1               5    #                10   #                15 Gly Val Leu Gly Ile Ser Cys Gly Ser Pro Pr #o Pro Ile Leu Asn Gly             20       #            25       #            30 Arg Ile Ser Tyr Tyr Ser Thr Pro Ile Ala Va #l Gly Thr Val Ile Arg         35           #        40           #        45 Tyr Ser Cys Ser Gly Thr Phe Arg Leu Ile Gl #y Glu Lys Ser Leu Leu     50               #    55               #    60 Cys Ile Thr Lys Asp Lys Val Asp Gly Thr Tr #p Asp Lys Pro Ala Pro 65                   #70                   #75                   #80 Lys Cys Glu Tyr Phe Asn Lys Tyr Ser Ser Cy #s Pro Glu Pro Ile Val                 85   #                90   #                95 Pro Gly Gly Tyr Lys Ile Arg Gly Ser Thr Pr #o Tyr Arg His Gly Asp             100       #           105       #           110 Ser Val Thr Phe Ala Cys Lys Thr Asn Phe Se #r Met Asn Gly Asn Lys         115           #       120           #       125 Ser Val Trp Cys Gln Ala Asn Asn Met Trp Gl #y Pro Thr Arg Leu Pro     130               #   135               #   140 Thr Cys Val Ser Val Phe Pro Leu Glu Cys Pr #o Ala Leu Pro Met Ile 145                 1 #50                 1 #55                 1 #60 His Asn Gly His His Thr Ser Glu Asn Val Gl #y Ser Ile Ala Pro Gly                 165   #               170   #               175 Leu Ser Val Thr Tyr Ser Cys Glu Ser Gly Ty #r Leu Leu Val Gly Glu             180       #           185       #           190 Lys Ile Ile Asn Cys Leu Ser Ser Gly Lys Tr #p Ser Ala Val Pro Pro         195           #       200           #       205 Thr Cys Glu Glu Ala Arg Cys Lys Ser Leu Gl #y Arg Phe Pro Asn Gly     210               #   215               #   220 Lys Val Lys Glu Pro Pro Ile Leu Arg Val Gl #y Val Thr Ala Asn Phe 225                 2 #30                 2 #35                 2 #40 Phe Cys Asp Glu Gly Tyr Arg Leu Gln Gly Pr #o Pro Ser Ser Arg Cys                 245   #               250   #               255 Val Ile Ala Gly Gln Gly Val Ala Trp Thr Ly #s Met Pro Val Cys Glu             260       #           265       #           270 Glu Ile Phe Cys Pro Ser Pro Pro Pro Ile Le #u Asn Gly Arg His Ile         275           #       280           #       285 Gly Asn Ser Leu Ala Asn Val Ser Tyr Gly Se #r Ile Val Thr Tyr Thr     290               #   295               #   300 Cys Asp Pro Asp Pro Glu Glu Gly Val Asn Ph #e Ile Leu Ile Gly Glu 305                 3 #10                 3 #15                 3 #20 Ser Thr Leu Arg Cys Thr Val Asp Ser Gln Ly #s Thr Gly Thr Trp Ser                 325   #               330   #               335 Gly Pro Ala Pro Arg Cys Glu Leu Ser Thr Se #r Ala Val Gln Cys Pro             340       #           345       #           350 His Pro Gln Ile Leu Arg Gly Arg Met Val Se #r Gly Gln Lys Asp Arg         355           #       360           #       365 Tyr Thr Tyr Asn Asp Thr Val Ile Phe Ala Cy #s Met Phe Gly Phe Thr     370               #   375               #   380 Leu Lys Gly Ser Lys Gln Ile Arg Cys Asn Al #a Gln Gly Thr Trp Glu 385                 3 #90                 3 #95                 4 #00 Pro Ser Ala Pro Val Cys Glu Lys Glu Cys Gl #n Ala Pro Pro Asn Ile                 405   #               410   #               415 Leu Asn Gly Gln Lys Glu Asp Arg His Met Va #l Arg Phe Asp Pro Gly             420       #           425       #           430 Thr Ser Ile Lys Tyr Ser Cys Asn Pro Gly Ty #r Val Leu Val Gly Glu         435           #       440           #       445 Glu Ser Ile Gln Cys Thr Ser Glu Gly Val Tr #p Thr Pro Pro Val Pro     450               #   455               #   460 Gln Cys Lys Val Ala Ala Cys Glu Ala Thr Gl #y Arg Gln Leu Leu Thr 465                 4 #70                 4 #75                 4 #80 Lys Pro Gln His Gln Phe Val Arg Pro Asp Va #l Asn Ser Ser Cys Gly                 485   #               490   #               495 Glu Gly Tyr Lys Leu Ser Gly Ser Val Tyr Gl #n Glu Cys Gln Gly Thr             500       #           505       #           510 Ile Pro Trp Phe Met Glu Ile Arg Leu Cys Ly #s Glu Ile Thr Cys Pro         515           #       520           #       525 Pro Pro Pro Val Ile Tyr Asn Gly Ala His Th #r Gly Ser Ser Leu Glu     530               #   535               #   540 Asp Phe Pro Tyr Gly Thr Thr Val Thr Tyr Th #r Cys Asn Pro Gly Pro 545                 5 #50                 5 #55                 5 #60 Glu Arg Gly Val Glu Phe Ser Leu Ile Gly Gl #u Ser Thr Ile Arg Cys                 565   #               570   #               575 Thr Ser Asn Asp Gln Glu Arg Gly Thr Trp Se #r Gly Pro Ala Pro Leu             580       #           585       #           590 Cys Lys Leu Ser Leu Leu Ala Val Gln Cys Se #r His Val His Ile Ala         595           #       600           #       605 Asn Gly Tyr Lys Ile Ser Gly Lys Glu Ala Pr #o Tyr Phe Tyr Asn Asp     610               #   615               #   620 Thr Val Thr Phe Lys Cys Tyr Ser Gly Phe Th #r Leu Lys Gly Ser Ser 625                 6 #30                 6 #35                 6 #40 Gln Ile Arg Cys Lys Ala Asp Asn Thr Trp As #p Pro Glu Ile Pro Val                 645   #               650   #               655 Cys Glu Lys Glu Thr Cys Gln His Val Arg Gl #n Ser Leu Gln Glu Leu             660       #           665       #           670 Pro Ala Gly Ser Arg Val Glu Leu Val Asn Th #r Ser Cys Gln Asp Gly         675           #       680           #       685 Tyr Gln Leu Thr Gly His Ala Tyr Gln Met Cy #s Gln Asp Ala Glu Asn     690               #   695               #   700 Gly Ile Trp Phe Lys Lys Ile Pro Leu Cys Ly #s Val Ile His Cys His 705                 7 #10                 7 #15                 7 #20 Pro Pro Pro Val Ile Val Asn Gly Lys His Th #r Gly Met Met Ala Glu                 725   #               730   #               735 Asn Phe Leu Tyr Gly Asn Glu Val Ser Tyr Gl #u Cys Asp Gln Gly Phe             740       #           745       #           750 Tyr Leu Leu Gly Glu Lys Lys Leu Gln Cys Ar #g Ser Asp Ser Lys Gly         755           #       760           #       765 His Gly Ser Trp Ser Gly Pro Ser Pro Gln Cy #s Leu Arg Ser Pro Pro     770               #   775               #   780 Val Thr Arg Cys Pro Asn Pro Glu Val Lys Hi #s Gly Tyr Lys Leu Asn 785                 7 #90                 7 #95                 8 #00 Lys Thr His Ser Ala Tyr Ser His Asn Asp Il #e Val Tyr Val Asp Cys                 805   #               810   #               815 Asn Pro Gly Phe Ile Met Asn Gly Ser Arg Va #l Ile Arg Cys His Thr             820       #           825       #           830 Asp Asn Thr Trp Val Pro Gly Val Pro Thr Cy #s Met Lys Lys Ala Phe         835           #       840           #       845 Ile Gly Cys Pro Pro Pro Pro Lys Thr Pro As #n Gly Asn His Thr Gly     850               #   855               #   860 Gly Asn Ile Ala Arg Phe Ser Pro Gly Met Se #r Ile Leu Tyr Ser Cys 865                 8 #70                 8 #75                 8 #80 Asp Gln Gly Tyr Leu Leu Val Gly Glu Ala Le #u Leu Leu Cys Thr His                 885   #               890   #               895 Glu Gly Thr Trp Ser Gln Pro Ala Pro His Cy #s Lys Glu Val Asn Cys             900       #           905       #           910 Ser Ser Pro Ala Asp Met Asp Gly Ile Gln Ly #s Gly Leu Glu Pro Arg         915           #       920           #       925 Lys Met Tyr Gln Tyr Gly Ala Val Val Thr Le #u Glu Cys Glu Asp Gly     930               #   935               #   940 Tyr Met Leu Glu Gly Ser Pro Gln Ser Gln Cy #s Gln Ser Asp His Gln 945                 9 #50                 9 #55                 9 #60 Trp Asn Pro Pro Leu Ala Val Cys Arg Ser Ar #g Ser Leu Ala Pro Val                 965   #               970   #               975 Leu Cys Gly Ile Ala Ala Gly Leu Ile Leu Le #u Thr Phe Leu Ile Val             980       #           985       #           990 Ile Thr Leu Tyr Val Ile Ser Lys  His Arg  #Glu Arg Asn  Tyr Tyr Thr         995           #       1000           #       1005 Asp Thr  Ser Gln Lys Glu Ala  Phe His L #eu Glu Ala  Arg Glu Val     1010              #    1015              #    1020 Tyr Ser  Val Asp Pro Tyr Asn  Pro Ala S #er     1025              #    1030 <210> SEQ ID NO 2 <211> LENGTH: 60 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 2 Cys Gly Ser Pro Pro Pro Ile Leu Asn Gly Ar #g Ile Ser Tyr Tyr Ser 1               5    #                10   #                15 Thr Pro Ile Ala Val Gly Thr Val Ile Arg Ty #r Ser Cys Ser Gly Thr             20       #            25       #            30 Phe Arg Leu Ile Gly Glu Lys Ser Leu Leu Cy #s Ile Thr Lys Asp Lys         35           #        40           #        45 Val Asp Gly Thr Trp Asp Lys Pro Ala Pro Ly #s Cys     50               #    55               #    60 <210> SEQ ID NO 3 <211> LENGTH: 56 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 3 Cys Pro Glu Pro Ile Val Pro Gly Gly Tyr Ly #s Ile Arg Gly Ser Thr 1               5    #                10   #                15 Pro Tyr Arg His Gly Asp Ser Val Thr Phe Al #a Cys Lys Thr Asn Phe             20       #            25       #            30 Ser Met Asn Gly Asn Lys Ser Val Trp Cys Gl #n Ala Asn Asn Met Trp         35           #        40           #        45 Gly Pro Thr Arg Leu Pro Thr Cys     50               #    55 <210> SEQ ID NO 4 <211> LENGTH: 134 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 4 Gly Ile Ser Cys Gly Ser Pro Pro Pro Ile Le #u Asn Gly Arg Ile Ser 1               5    #                10   #                15 Tyr Tyr Ser Thr Pro Ile Ala Val Gly Thr Va #l Ile Arg Tyr Ser Cys             20       #            25       #            30 Ser Gly Thr Phe Arg Leu Ile Gly Glu Lys Se #r Leu Leu Cys Ile Thr         35           #        40           #        45 Lys Asp Lys Val Asp Gly Thr Trp Asp Lys Pr #o Ala Pro Lys Cys Glu     50               #    55               #    60 Tyr Phe Asn Lys Tyr Ser Ser Cys Pro Glu Pr #o Ile Val Pro Gly Gly 65                   #70                   #75                   #80 Tyr Lys Ile Arg Gly Ser Thr Pro Tyr Arg Hi #s Gly Asp Ser Val Thr                 85   #                90   #                95 Phe Ala Cys Lys Thr Asn Phe Ser Met Asn Gl #y Asn Lys Ser Val Trp             100       #           105       #           110 Cys Gln Ala Asn Asn Met Trp Gly Pro Thr Ar #g Leu Pro Thr Cys Val         115           #       120           #       125 Ser Val Phe Pro Leu Glu     130 <210> SEQ ID NO 5 <211> LENGTH: 1025 <212> TYPE: PRT <213> ORGANISM: Mus musculus <400> SEQUENCE: 5 Met Leu Thr Trp Phe Leu Phe Tyr Phe Ser Gl #u Ile Ser Cys Asp Pro 1               5    #                10   #                15 Pro Pro Glu Val Lys Asn Ala Arg Lys Pro Ty #r Tyr Ser Leu Pro Ile             20       #            25       #            30 Val Pro Gly Thr Val Leu Arg Tyr Thr Cys Se #r Pro Ser Tyr Arg Leu         35           #        40           #        45 Ile Gly Glu Lys Ala Ile Phe Cys Ile Ser Gl #u Asn Gln Val His Ala     50               #    55               #    60 Thr Trp Asp Lys Ala Pro Pro Ile Cys Glu Se #r Val Asn Lys Thr Ile 65                   #70                   #75                   #80 Ser Cys Ser Asp Pro Ile Val Pro Gly Gly Ph #e Met Asn Lys Gly Ser                 85   #                90   #                95 Lys Ala Pro Phe Arg His Gly Asp Ser Val Th #r Phe Thr Cys Lys Ala             100       #           105       #           110 Asn Phe Thr Met Lys Gly Ser Lys Thr Val Tr #p Cys Gln Ala Asn Glu         115           #       120           #       125 Met Trp Gly Pro Thr Ala Leu Pro Val Cys Gl #u Ser Asp Phe Pro Leu     130               #   135               #   140 Glu Cys Pro Ser Leu Pro Thr Ile His Asn Gl #y His His Thr Gly Gln 145                 1 #50                 1 #55                 1 #60 His Val Asp Gln Phe Val Ala Gly Leu Ser Va #l Thr Tyr Ser Cys Glu                 165   #               170   #               175 Pro Gly Tyr Leu Leu Thr Gly Lys Lys Thr Il #e Lys Cys Leu Ser Ser             180       #           185       #           190 Gly Asp Trp Asp Gly Val Ile Pro Thr Cys Ly #s Glu Ala Gln Cys Glu         195           #       200           #       205 His Pro Gly Lys Phe Pro Asn Gly Gln Val Ly #s Glu Pro Leu Ser Leu     210               #   215               #   220 Gln Val Gly Thr Thr Val Tyr Phe Ser Cys As #n Glu Gly Tyr Gln Leu 225                 2 #30                 2 #35                 2 #40 Gln Gly Gln Pro Ser Ser Gln Cys Val Ile Va #l Glu Gln Lys Ala Ile                 245   #               250   #               255 Trp Thr Lys Lys Pro Val Cys Lys Glu Ile Le #u Cys Pro Pro Pro Pro             260       #           265       #           270 Pro Val Arg Asn Gly Ser His Thr Gly Ser Ph #e Ser Glu Asn Val Pro         275           #       280           #       285 Tyr Gly Ser Thr Val Thr Tyr Thr Cys Asp Pr #o Ser Pro Glu Lys Gly     290               #   295               #   300 Val Ser Phe Thr Leu Ile Gly Glu Lys Thr Il #e Asn Cys Thr Thr Gly 305                 3 #10                 3 #15                 3 #20 Ser Gln Lys Thr Gly Ile Trp Ser Gly Pro Al #a Pro Tyr Cys Val Leu                 325   #               330   #               335 Ser Thr Ser Ala Val Leu Cys Leu Gln Pro Ly #s Ile Lys Arg Gly Gln             340       #           345       #           350 Ile Leu Ser Ile Leu Lys Asp Ser Tyr Ser Ty #r Asn Asp Thr Val Ala         355           #       360           #       365 Phe Ser Cys Glu Pro Gly Phe Thr Leu Lys Gl #y Asn Arg Ser Ile Arg     370               #   375               #   380 Cys Asn Ala His Gly Thr Trp Glu Pro Pro Va #l Pro Val Cys Glu Lys 385                 3 #90                 3 #95                 4 #00 Gly Cys Gln Ala Pro Pro Lys Ile Ile Asn Gl #y Gln Lys Glu Asp Ser                 405   #               410   #               415 Tyr Leu Leu Asn Phe Asp Pro Gly Thr Ser Il #e Arg Tyr Ser Cys Asp             420       #           425       #           430 Pro Gly Tyr Leu Leu Val Gly Glu Asp Thr Il #e His Cys Thr Pro Glu         435           #       440           #       445 Gly Lys Trp Thr Pro Ile Thr Pro Gln Cys Th #r Val Ala Glu Cys Lys     450               #   455               #   460 Pro Val Gly Pro His Leu Phe Lys Arg Pro Gl #n Asn Gln Phe Ile Arg 465                 4 #70                 4 #75                 4 #80 Thr Ala Val Asn Ser Ser Cys Asp Glu Gly Ph #e Gln Leu Ser Glu Ser                 485   #               490   #               495 Ala Tyr Gln Leu Cys Gln Gly Thr Ile Pro Tr #p Phe Ile Glu Ile Arg             500       #           505       #           510 Leu Cys Lys Glu Ile Thr Cys Pro Pro Pro Pr #o Val Ile His Asn Gly         515           #       520           #       525 Thr His Thr Trp Ser Ser Ser Glu Asp Val Pr #o Tyr Gly Thr Val Val     530               #   535               #   540 Thr Tyr Met Cys Tyr Pro Gly Pro Glu Glu Gl #y Val Lys Phe Lys Leu 545                 5 #50                 5 #55                 5 #60 Ile Gly Glu Gln Thr Ile His Cys Thr Ser As #p Ser Arg Gly Arg Gly                 565   #               570   #               575 Ser Trp Ser Ser Pro Ala Pro Leu Cys Lys Le #u Ser Leu Pro Ala Val             580       #           585       #           590 Gln Cys Thr Asp Val His Val Glu Asn Gly Va #l Lys Leu Thr Asp Asn         595           #       600           #       605 Lys Ala Pro Tyr Phe Tyr Asn Asp Ser Val Me #t Phe Lys Cys Asp Asp     610               #   615               #   620 Gly Tyr Ile Leu Ser Gly Ser Ser Gln Ile Ar #g Cys Lys Ala Asn Asn 625                 6 #30                 6 #35                 6 #40 Thr Trp Asp Pro Glu Lys Pro Leu Cys Lys Ly #s Glu Gly Cys Glu Pro                 645   #               650   #               655 Met Arg Val His Gly Leu Pro Asp Asp Ser Hi #s Ile Lys Leu Val Lys             660       #           665       #           670 Arg Thr Cys Gln Asn Gly Tyr Gln Leu Thr Gl #y Tyr Thr Tyr Glu Lys         675           #       680           #       685 Cys Gln Asn Ala Glu Asn Gly Thr Trp Phe Ly #s Lys Ile Glu Val Cys     690               #   695               #   700 Thr Val Ile Leu Cys Gln Pro Pro Pro Lys Il #e Ala Asn Gly Gly His 705                 7 #10                 7 #15                 7 #20 Thr Gly Met Met Ala Lys His Phe Leu Tyr Gl #y Asn Glu Val Ser Tyr                 725   #               730   #               735 Glu Cys Asp Glu Gly Phe Tyr Leu Leu Gly Gl #u Lys Ser Leu Gln Cys             740       #           745       #           750 Val Asn Asp Ser Lys Gly His Gly Ser Trp Se #r Gly Pro Pro Pro Gln         755           #       760           #       765 Cys Leu Gln Ser Ser Pro Leu Thr His Cys Pr #o Asp Pro Glu Val Lys     770               #   775               #   780 His Gly Tyr Lys Leu Asn Lys Thr His Ser Al #a Phe Ser His Asn Asp 785                 7 #90                 7 #95                 8 #00 Ile Val His Phe Val Cys Asn Gln Gly Phe Il #e Met Asn Gly Ser His                 805   #               810   #               815 Leu Ile Arg Cys His Thr Asn Asn Thr Trp Le #u Pro Gly Val Pro Thr             820       #           825       #           830 Cys Ile Arg Lys Ala Ser Leu Gly Cys Gln Se #r Pro Ser Thr Ile Pro         835           #       840           #       845 Asn Gly Asn His Thr Gly Gly Ser Ile Ala Ar #g Phe Pro Pro Gly Met     850               #   855               #   860 Ser Val Met Tyr Ser Cys Tyr Gln Gly Phe Le #u Met Ala Gly Glu Ala 865                 8 #70                 8 #75                 8 #80 Arg Leu Ile Cys Thr His Glu Gly Thr Trp Se #r Gln Pro Pro Pro Phe                 885   #               890   #               895 Cys Lys Glu Val Asn Cys Ser Phe Pro Glu As #p Thr Asn Gly Ile Gln             900       #           905       #           910 Lys Gly Phe Gln Pro Gly Lys Thr Tyr Arg Ph #e Gly Ala Thr Val Thr         915           #       920           #       925 Leu Glu Cys Glu Asp Gly Tyr Thr Leu Glu Gl #y Ser Pro Gln Ser Gln     930               #   935               #   940 Cys Gln Asp Asp Ser Gln Trp Asn Pro Pro Le #u Ala Leu Cys Lys Tyr 945                 9 #50                 9 #55                 9 #60 Arg Arg Trp Ser Thr Ile Pro Leu Ile Cys Gl #y Ile Ser Val Gly Ser                 965   #               970   #               975 Ala Leu Ile Ile Leu Met Ser Val Gly Phe Cy #s Met Ile Leu Lys His             980       #           985       #           990 Arg Glu Ser Asn Tyr Tyr Thr Lys  Thr Arg  #Pro Lys Glu  Gly Ala Leu         995           #       1000           #       1005 His Leu  Glu Thr Arg Glu Val  Tyr Ser I #le Asp Pro  Tyr Asn Pro     1010              #    1015              #    1020 Ala Ser     1025 <210> SEQ ID NO 6 <211> LENGTH: 135 <212> TYPE: PRT <213> ORGANISM: Mus musculus <400> SEQUENCE: 6 Glu Ile Ser Cys Asp Pro Pro Pro Glu Val Ly #s Asn Ala Arg Lys Pro 1               5    #                10   #                15 Tyr Tyr Ser Leu Pro Ile Val Pro Gly Thr Va #l Leu Arg Tyr Thr Cys             20       #            25       #            30 Ser Pro Ser Tyr Arg Leu Ile Gly Glu Lys Al #a Ile Phe Cys Ile Ser         35           #        40           #        45 Glu Asn Gln Val His Ala Thr Trp Asp Lys Al #a Pro Pro Ile Cys Glu     50               #    55               #    60 Ser Val Asn Lys Thr Ile Ser Cys Ser Asp Pr #o Ile Val Pro Gly Gly 65                   #70                   #75                   #80 Phe Met Asn Lys Gly Ser Lys Ala Pro Phe Ar #g His Gly Asp Ser Val                 85   #                90   #                95 Thr Phe Thr Cys Lys Ala Asn Phe Thr Met Ly #s Gly Ser Lys Thr Val             100       #           105       #           110 Trp Cys Gln Ala Asn Glu Met Trp Gly Pro Th #r Ala Leu Pro Val Cys         115           #       120           #       125 Glu Ser Asp Phe Pro Leu Glu     130               #   135 <210> SEQ ID NO 7 <211> LENGTH: 310 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 7 Met Leu Asp Ala Glu Arg Leu Lys His Leu Il #e Val Thr Pro Ser Gly 1               5    #                10   #                15 Ala Gly Glu Gln Asn Met Ile Gly Met Thr Pr #o Thr Val Ile Ala Val             20       #            25       #            30 His Tyr Leu Asp Glu Thr Glu Gln Trp Glu Ly #s Phe Gly Leu Glu Lys         35           #        40           #        45 Arg Gln Gly Ala Leu Glu Leu Ile Lys Lys Gl #y Tyr Thr Gln Gln Leu     50               #    55               #    60 Ala Phe Arg Gln Pro Ser Ser Ala Phe Ala Al #a Phe Val Lys Arg Ala 65                   #70                   #75                   #80 Pro Ser Thr Trp Leu Thr Ala Tyr Val Val Ly #s Val Phe Ser Leu Ala                 85   #                90   #                95 Val Asn Leu Ile Ala Ile Asp Ser Gln Val Le #u Cys Gly Ala Val Lys             100       #           105       #           110 Trp Leu Ile Leu Glu Lys Gln Lys Pro Asp Gl #y Val Phe Gln Glu Asp         115           #       120           #       125 Ala Pro Val Ile His Gln Glu Met Ile Gly Gl #y Leu Arg Asn Asn Asn     130               #   135               #   140 Glu Lys Asp Met Ala Leu Thr Ala Phe Val Le #u Ile Ser Leu Gln Glu 145                 1 #50                 1 #55                 1 #60 Ala Lys Asp Ile Cys Glu Glu Gln Val Asn Se #r Leu Pro Gly Ser Ile                 165   #               170   #               175 Thr Lys Ala Gly Asp Phe Leu Glu Ala Asn Ty #r Met Asn Leu Gln Arg             180       #           185       #           190 Ser Tyr Thr Val Ala Ile Ala Gly Tyr Ala Le #u Ala Gln Met Gly Arg         195           #       200           #       205 Leu Lys Gly Pro Leu Leu Asn Lys Phe Leu Th #r Thr Ala Lys Asp Lys     210               #   215               #   220 Asn Arg Trp Glu Asp Pro Gly Lys Gln Leu Ty #r Asn Val Glu Ala Thr 225                 2 #30                 2 #35                 2 #40 Ser Tyr Ala Leu Leu Ala Leu Leu Gln Leu Ly #s Asp Phe Asp Phe Val                 245   #               250   #               255 Pro Pro Val Val Arg Trp Leu Asn Glu Gln Ar #g Tyr Tyr Gly Gly Gly             260       #           265       #           270 Tyr Gly Ser Thr Gln Ala Thr Phe Met Val Ph #e Gln Ala Leu Ala Gln         275           #       280           #       285 Tyr Gln Lys Asp Ala Pro Asp His Gln Glu Le #u Asn Leu Asp Val Ser     290               #   295               #   300 Leu Gln Leu Pro Ser Arg 305                 3 #10 <210> SEQ ID NO 8 <211> LENGTH: 310 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 8 Met Leu Asp Ala Glu Arg Leu Lys His Leu Il #e Val Thr Pro Ser Gly 1               5    #                10   #                15 Ala Gly Glu Gln Asn Met Ile Gly Met Thr Pr #o Thr Val Ile Ala Val             20       #            25       #            30 His Tyr Leu Asp Glu Thr Glu Gln Trp Glu Ly #s Phe Gly Leu Glu Lys         35           #        40           #        45 Arg Gln Gly Ala Leu Glu Leu Ile Lys Lys Gl #y Tyr Thr Gln Gln Leu     50               #    55               #    60 Ala Phe Arg Gln Pro Ser Ser Ala Phe Ala Al #a Phe Val Lys Arg Ala 65                   #70                   #75                   #80 Pro Ser Thr Trp Leu Thr Ala Tyr Val Val Ly #s Val Phe Ser Leu Ala                 85   #                90   #                95 Val Asn Leu Ile Ala Ile Asp Ser Gln Val Le #u Cys Gly Ala Val Lys             100       #           105       #           110 Trp Leu Ile Leu Glu Lys Gln Lys Pro Asp Gl #y Val Phe Gln Glu Asp         115           #       120           #       125 Ala Pro Val Ile His Gln Glu Met Ile Gly Gl #y Leu Arg Asn Asn Asn     130               #   135               #   140 Glu Lys Asp Met Ala Leu Thr Ala Phe Val Le #u Ile Ser Leu Gln Glu 145                 1 #50                 1 #55                 1 #60 Ala Lys Asp Ile Cys Glu Glu Gln Val Arg Se #r Leu Pro Gly Ser Ile                 165   #               170   #               175 Thr Lys Ala Gly Asp Phe Leu Glu Ala Asn Ty #r Met Asn Leu Gln Arg             180       #           185       #           190 Ser Tyr Thr Val Ala Ile Ala Gly Tyr Ala Le #u Ala Gln Met Gly Arg         195           #       200           #       205 Leu Lys Gly Pro Leu Leu Asn Lys Phe Leu Th #r Thr Ala Lys Asp Lys     210               #   215               #   220 Asn Arg Trp Glu Asp Pro Gly Lys Gln Leu Ty #r Asn Val Glu Ala Thr 225                 2 #30                 2 #35                 2 #40 Ser Tyr Ala Leu Leu Ala Leu Leu Gln Leu Ly #s Asp Phe Asp Phe Val                 245   #               250   #               255 Pro Pro Val Val Arg Trp Leu Asn Glu Gln Ar #g Tyr Tyr Gly Gly Gly             260       #           265       #           270 Tyr Gly Ser Thr Gln Ala Thr Phe Met Val Ph #e Gln Ala Leu Ala Gln         275           #       280           #       285 Tyr Gln Lys Asp Ala Pro Asp His Gln Glu Le #u Asn Leu Asp Val Ser     290               #   295               #   300 Leu Gln Leu Pro Ser Arg 305                 3 #10 <210> SEQ ID NO 9 <211> LENGTH: 310 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 9 Met Leu Asp Ala Glu Arg Leu Lys His Leu Il #e Val Thr Pro Ser Gly 1               5    #                10   #                15 Ala Gly Glu Gln Asn Met Ile Gly Met Thr Pr #o Thr Val Ile Ala Val             20       #            25       #            30 His Tyr Leu Asp Glu Thr Glu Gln Trp Glu Ly #s Phe Gly Leu Glu Lys         35           #        40           #        45 Arg Gln Gly Ala Leu Glu Leu Ile Lys Lys Gl #y Tyr Thr Gln Gln Leu     50               #    55               #    60 Ala Phe Arg Gln Pro Ser Ser Ala Phe Ala Al #a Phe Val Lys Arg Ala 65                   #70                   #75                   #80 Pro Ser Thr Trp Leu Thr Ala Tyr Val Val Ly #s Val Phe Ser Leu Ala                 85   #                90   #                95 Val Asn Leu Ile Ala Ile Asp Ser Gln Val Le #u Cys Gly Ala Val Lys             100       #           105       #           110 Trp Leu Arg Arg Glu Lys Gln Lys Pro Asp Gl #y Val Phe Gln Glu Asp         115           #       120           #       125 Ala Pro Val Ile His Gln Glu Met Ile Gly Gl #y Leu Arg Asn Asn Asn     130               #   135               #   140 Glu Lys Asp Met Ala Leu Thr Ala Phe Val Le #u Ile Ser Leu Gln Glu 145                 1 #50                 1 #55                 1 #60 Ala Lys Asp Ile Cys Glu Glu Gln Val Ala Se #r Leu Pro Gly Ser Ile                 165   #               170   #               175 Thr Lys Ala Gly Asp Phe Leu Glu Ala Asn Ty #r Met Asn Leu Gln Arg             180       #           185       #           190 Ser Tyr Thr Val Ala Ile Ala Gly Tyr Ala Le #u Ala Gln Met Gly Arg         195           #       200           #       205 Leu Lys Gly Pro Leu Leu Asn Lys Phe Leu Th #r Thr Ala Lys Asp Lys     210               #   215               #   220 Asn Arg Trp Glu Asp Pro Gly Lys Gln Leu Ty #r Asn Val Glu Ala Thr 225                 2 #30                 2 #35                 2 #40 Ser Tyr Ala Leu Leu Ala Leu Leu Gln Leu Ly #s Asp Phe Asp Phe Val                 245   #               250   #               255 Pro Pro Val Val Arg Trp Leu Asn Glu Gln Ar #g Tyr Tyr Gly Gly Gly             260       #           265       #           270 Tyr Gly Ser Thr Gln Ala Thr Phe Met Val Ph #e Gln Ala Leu Ala Gln         275           #       280           #       285 Tyr Gln Lys Asp Ala Pro Asp His Gln Glu Le #u Asn Leu Asp Val Ser     290               #   295               #   300 Leu Gln Leu Pro Ser Arg 305                 3 #10 

What is claimed is:
 1. A method of structure-based identification of candidate compounds for binding to complement receptor type 2 (CR2) proteins or to a complex of CR2 and its ligand, comprising: a. providing a three dimensional structure of a CR2 short consensus repeat (SCR) 1-2 region selected from the group consisting of: i. a structure defined by atomic coordinates of a three dimensional structure of a crystalline CR2 SCR1-2 region in complex with C3d; ii. a structure defined by atomic coordinates selected from the group consisting of: (1) atomic coordinates represented in a table selected from the group consisting of Table 2 (CR2-C3d) and Table 3 (CR2 only); and, (2) atomic coordinates that define a three dimensional structure, wherein at least 50% of said structure has an average root-mean-square deviation (RMSD) from backbone atoms in secondary structure elements in at least one domain of a three dimensional structure represented by said atomic coordinates of (1) of equal to or less than about 1.0 Å; and iii. a structure defined by atomic coordinates derived from CR2 protein molecules arranged in a crystalline manner in a space group R32 so as to form a unit cell of dimensions a=b=170.5 Å, c173.8 Å; b. identifying a candidate compound for binding to said CR2 SCR 1-2 region by performing structure based drug design with said structure of (a); c. synthesizing said candidate compound identified in step (b); and d. selecting candidate compounds from step (c) that bind to CR2.
 2. The method of claim 1, wherein said step of selecting comprises selecting candidate compounds that bind to and activate CR2.
 3. The method of claim 1, wherein said method further comprises: e. selecting candidate compounds that inhibit the binding of CR2 to its ligand.
 4. The method of claim 3, wherein said step (e) of selecting comprises: i. contacting said candidate compound synthesized in step (c) with CR2 or a fragment thereof and a CR2 ligand or a fragment thereof under conditions in which a CR2-CR2 ligand complex can form in the absence of said candidate compound; and ii. measuring the binding affinity of said CR2 or fragment thereof to said CR2 ligand or fragment thereof; wherein a candidate inhibitor compound is selected as a compound that inhibits the binding of CR2 to its ligand when there is a decrease in the binding affinity of said CR2 or fragment thereof for said CR2 ligand or fragment thereof, as compared to in the absence of said candidate inhibitor compound.
 5. The method of claim 3, wherein said ligand is selected from the group consisting of C3d, CD23, and Epstein Barr Virus (EBV) gp350/220, or CR2-binding fragments thereof.
 6. The method of claim 3, wherein said ligand is a gp350/220 viral membrane protein from EBV or a CR2-binding fragment thereof.
 7. The method of claim 3, wherein said CR2 protein or fragment thereof comprises an amino acid sequence selected from the group consisting of SEQ ID NO:4 and SEQ ID NO:6.
 8. The method of claim 1, wherein said method further comprises: e. selecting candidate compounds that stabilizes a complex of CR2 with its ligand.
 9. The method of claim 8, wherein step (e) of selecting comprises: i. contacting said candidate compound synthesized in step (c) with a CR2-CR2 ligand complex, wherein said CR2-CR2 ligand complex comprises CR2 or a fragment thereof and a CR2 ligand, or a fragment thereof; ii. measuring the stability of said CR2-CR2 ligand complex of (i), wherein a,candidate stabilizer compound is selected as a compound that stabilizes the CR2-CR2 ligand complex when there is an increase in the stability of the said complex as compared to in the absence of said candidate stabilizer compound.
 10. The method of claim 8, wherein said ligand is selected from the group consisting of C3d and CD23.
 11. The method of claim 8, wherein said CR2 protein or fragment thereof comprises an amino acid sequence selected from the group consisting of SEQ ID NO:4 and SEQ ID NO:6.
 12. The method of claim 1, wherein said step of identifying comprises identifying candidate compounds for binding to the SCR2 domain of said CR2.
 13. The method of claim 1, wherein said step of identifying comprises identifying candidate compounds for binding to the interface between the SCR1 and SCR2 domains of CR2.
 14. The method of claim 1, wherein said step of identifying comprises identifying candidate compounds for binding to the dimer interface between two CR2 proteins.
 15. The method of claim 1, wherein said step of identifying comprises identifying candidate compounds for binding to the interface between CR2 and C3d, C3, a CR2-binding fragment of C3 containing C3d, or a fragment thereof.
 16. The method of claim 1, wherein said step of identifying comprises identifying candidate compounds for binding to the B strand and the B-C loop of CR2 SCR2 comprising the segment: G79-G80-Y81-K82-183-R84-G85-S86-T87-P88-Y89.
 17. The method of claim 1, wherein said step of identifying comprises identifying candidate compounds for binding to a site on the B strand of CR2 SCR2 comprising position K100.
 18. The method of claim 1, wherein said step of identifying comprises identifying candidate compounds for binding to a segment of CR2 SCR2 comprising V130-F131-P132-L133.
 19. The method of claim 1, wherein said step of identifying comprises identifying candidate compounds for binding to a segment of CR2 SCR2 comprising the fragment T 101-N102-F103.
 20. The method of claim 1, wherein said step of identifying comprises identifying candidate compounds for binding to the loop between helix 2-3 of C3d comprising the segment Q68-P69-S70-S71.
 21. The method of claim 1, wherein said step of identifying comprises identifying candidate compounds for binding to Helix 5 of C3d comprising the segment S104-Q105-V106-L107-C108-G109-A110-V111-K112-W113-L114-I115-L116-E117-K118-Q119-K120-P121-D122.
 22. The method of claim 1, wherein said step of identifying comprises identifying candidate compounds for binding to Helix 7of C3d comprising the segment N170-S171-L172-P173-G174-S175-1176-T177-K178-A179-G180-D181-F182-L183-E184-A185.
 23. The method of claim 1, wherein said step of identifying comprises identifying candidate compounds for binding to amino acid residues at positions 84 and 86 of an amino acid sequence selected from the group consisting of SEQ ID NO:4 and SEQ ID NO:6.
 24. The method of claim 1, wherein said step of identifying comprises directed drug design.
 25. The method of claim 1, wherein said step of identifying comprises random drug design.
 26. The method of claim 1, wherein said step of identifying comprises grid-based drug design.
 27. The method of claim 1, wherein said step of identifying comprises computational screening of one or more databases of chemical compounds. 